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Abstract  
 
Tetraspanins are a superfamily of membrane proteins which span the membrane four times; 
they are found predominantly at the cell surface but are also located on intracellular vesicles. 
Tetraspanins (with a few exceptions) do not have conventional receptor ligand functionality 
and instead form lateral associations with other molecules within the membrane. Binding 
partners include, but are not limited to, MHC proteins, integrins, signalling proteins and other 
members of the tetraspanin superfamily. This large network of interactions has led to the idea 
of tetraspanin enriched microdomains (TEMs) or the tetraspanin web, in which tetraspanins 
function by bringing together proteins to form functional clusters which allow processes (such 
as signal transduction or adhesion) to take place more efficiently. Due to the numerous diverse 
binding partners, tetraspanins have been implicated in a number of cellular and pathological 
processes. 
Despite tetraspanins being involved in fundamental physiological processes, relatively little is 
known about the function of individual members. Difficulties arise as only a few monoclonal 
antibodies are available to the native proteins and mouse knock outs often show only a mild 
phenotypic change. Our group and others have used recombinant human EC2 domains in the 
form of GST fusion proteins to assess tetraspanin involvement in several processes. This region 
is thought to attribute specificity to individual tetraspanin members and when recombinant 
versions are added to cells exogenously, they have been shown to modulate different cellular 
events including adhesion, migration and fusion. 
Due to a number of inherent drawbacks associated with bacterially expressed recombinant 
EC2 domains (such as LPS contamination and inferior folding), the initial aim of this work was 
to express the recombinant proteins in a mammalian host. Despite multiple attempts to 
express the proteins in mammalian or insect cells using different vector systems, this was not 
successful, although it was demonstrated that DNA was integrated into the host genome and 
that EC2 encoding mRNA was expressed. Following this, it was decided to focus on bacterial 
expression and use the EC2 domains generated to further our understanding of tetraspanin 
involvement in IgE mediated degranulation this is a critical first step in Type I Hypersensitivity 
and although several tetraspanin family members have been implicated in this pathway, their 
exact involvement is not yet clear. Here, recombinant EC2 domains of tetraspanins CD9, CD63, 
CD81 and CD151 were used for the first time in conjunction with RBL-2H3 cells (a cell line 
commonly used as a model for mast cell degranulation) to examine tetraspanin involvement in 
IgE mediated degranulation. These particular tetraspanins were selected because past studies 
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have implicated these members in mast cell activation, but dispite an anti-CD63 antibody 
being able to down regulate degranulation, in this instance the EC2 domains did not exhibit 
any modulating effect on this form of degranulation in RBL-2H3 cells. The activity of these 
particular recombinant proteins was demonstrated in two other functional assays; bacterial 
adhesion to endothelial cells and bacterial induced giant cell formation. 
Later work sought to characterise the EC2 proteins in terms of their secondary structure, LPS 
content and their ability to bind to cells, with the hope of elucidating their mechanism of 
action. The binding of each EC2 domains to two cell lines was examined: RBL-2H3 where EC2 
domains show no effect on degranulation, and HEC-1B cells, where EC2 domains were 
previously shown exhibit biological activity by reducing bacterial adhesion. At highest 
concentrations utilised, the EC2 domains were shown to bind to both cell lines significantly 
more than the GST control protein, but attempts to examine the specificity of the EC2 
interaction with the cells by competitive inhibition gave inconclusive results. Whilst this may 
have been due to technical issues it is tempting to speculate that this indicates cellular 
interactions that do not follow conventional binding mechanisms. The LPS content of the EC2 
domains was shown not to correlate with their ability to modulate bacterial-induced cell 
fusion. Finally, to facilitate structural and future functional studies, attempts were made to 
optimise the removal of the GST tag from the fusion proteins. CD spectroscopy was then 
performed and attributed the EC2 domains of CD9 and CD81 with 50% and 52% α-helical 
structure, respectively, as expected for these proteins. 
Although initial aims of producing mammalian EC2 domains were not fulfilled, they were 
successfully produced in bacteria and used in RBL degranulation assays. later work indicated 
that LPS contamination was not the causative component of EC2 preparations and confirmed 
some level of secondary structure. Furthermore, the apparent lack of effect of recombinant 
EC2 domains in RBL-2H3 activation may shed light on tetraspanin interaction with the high 
affinity IgE receptor. 
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Chapter 1: Introduction 
1.1 The Tetraspanin superfamily 
1.1.1 The history, evolution and distribution of tetraspanins 
Tetraspanins are a superfamily of membrane proteins which span the membrane four times 
and the main focus of this project was to express recombinant proteins corresponding to 
specific extracellular sections of tetraspanin proteins, with the aim of using these proteins to 
find out more about how tetraspanins function. This is important because despite tetraspanins 
being involved in many fundamental processes, relatively few functions have been ascribed to 
individual tetraspanin members. The superfamily first came to light in 1990 when similarities 
were discovered between TAPA-1 (CD81), CD37, the melanoma antigen ME491 (CD63) and 
Sm23 (Oren et al., 1990; Wright et al., 1990). Since then, tetraspanins have been identified in 
all metazoan, fungi (although not unicellular fungi), plants and protozoa; to date 33 human 
members have been identified (Table 1.1) along with 20 in Caenorhabditis. elegans and 36 in 
Drosophila. melanogaster (Huang et al., 2005). In addition to the four membrane spanning 
alpha helices true tetraspanins also contain a number of key defining features including short 
intracellular N and C terminal domains, a short extracellular loop (EC1), a large extracellular 
loop (EC2) and specific conserved residues within the EC2  (Section 1.1.2) (Hemler, 2008; 
Wright et al., 2000) Conservation of tetraspanins across such a diverse range of species 
indicates an ancient evolutionary origin, and their expression in early multicellular eukaryotes 
along with amoeba has led to speculation of involvement in initial cell-cell interactions (Huang 
et al., 2010). In addition, conservation of the gene structure itself lead to the suggestion of 
evolution from a common ancestor by duplication (Boucheix and Rubinstein, 2001). 
Tetraspanins are mainly thought to play an organisational role in which they interact laterally 
with one another and other partner proteins within cell membranes which enables clustering 
of functionally related proteins. Tetraspanins are found on all human cells both on intracellular 
membranes and the plasma membrane, with the majority of tetraspanins found 
predominantly at the cell surface, with the exception of CD63 which is mainly localised to the 
surface of intracellular vesicles (Boucheix and Rubinstein, 2001; Charrin et al., 2009; Hemler, 
2003). Different family members exhibit different patterns of expression, for example some 
members are widely distributed such as CD9, CD63 and CD81, whilst others show more 
restricted levels of tissue distribution, for instance Tspan25 and 26 which are found solely on 
immune cells (van Spriel and Figdor, 2010). Furthermore, there are more specialised 
Chapter 1: Introduction 
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tetraspanins, such as RDS/peripherin and ROM1 and the uroplakins UP1a and UP1b which are 
expressed exclusively in the retina and bladder epithelium respectively (Wu et al., 1995, 2009). 
The breadth of tetraspanin expression and diversity in the proteins which they associate with 
has led to them being implicated in a range of cellular and pathological processes, some of 
which have been discussed later (Section 1.1.3). 
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Tetraspanin 
name/ alternate 
name 
Protein 
accession 
Size 
(amino 
acids) 
Known Functions and additional information 
TSPAN1 / NET-1, 
TM4-C 
O60635 241 Increased expression in several cancers suggests a 
role in tumour progression (Scholz et al., 2009) 
TSPAN2 / NET-3 O60636 221  
TSPAN3 / TM4-A  O60637 253  
TSPAN4 /  NAG-2 O14817 238  
TSPAN5 /  NET-4 P62079 232 RNAi suggest positive regulatory role in 
osteoclsatogenesis (Iwai et al., 2007). Member of 
the TspanC8 family which Regulates trafficking 
and activity of ADAM10 (Dornier et al., 2012) 
TSPAN6 /  T245, 
A15 homologue, 
TM4-D 
O43657 245 Regulates retinoic acid-inducible gene I-like 
receptors (Wang et al., 2012) 
TSPAN7 /  A15, 
TALLA-1, CD231 
P41732 249 Highly expressed in areas of the brain, mutation 
leads to mental retardation (Zemni et al., 2000) 
TSPAN8 /  CO-029 P19075 237 Regulated cancer progression (Charrin et al., 
2014) 
TSPAN9 / NET-5 O75954 239 May regulate platelet function (Protty et al., 2009) 
TSPAN10 / 
Oculospanin 
Q9H1Z9 355 Largest tetraspanin. Member of the TspanC8 
family which Regulates trafficking and activity of 
ADAM10 (Dornier et al., 2012) 
TSPAN11 A1L157 253  
TSPAN12 / NET-2 O95859 305 Mutation may be linked to exudative 
vitreoretinopathy (Junge et al., 2009) 
TSPAN13 / NET-6 O95857 204 RNAi suggests a negative regulatory role in 
osteoclastogensis (Iwai et al., 2007). Smallest 
tetraspanin 
TSPAN14 / DC-
TM4F2 
Q8NG11 270 Member of the TspanC8 family which Regulates 
trafficking and activity of ADAM10 (Dornier et al., 
2012) 
TSPAN15 / NET-7 O95858 294 Member of the TspanC8 family which Regulates 
trafficking and activity of ADAM10 (Dornier et al., 
2012) 
TSPAN16 / TM4-B Q9UKR8 245  
TSPAN17 / F-box 
only protein 23, 
SB134 
Q96FV3 270 Member of the TspanC8 family which Regulates 
trafficking and activity of ADAM10 (Dornier et al., 
2012) 
TSPAN18  Q96SJ8 248  
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TSPAN19  P0C672 248  
TSPAN20 / UP1b O75841 260 In complex with Tspan21 and two non-tetraspanin 
proteins this tetraspanins help establish a 
permeability barrier in the bladder (Min et al., 
2002) 
TSPAN21 / UP1a O00322 258 In complex with Tspan20 and two non-tetraspanin 
proteins this tetraspanins help establish a 
permeability barrier in the bladder (Min et al., 
2002) 
TSPAN22 / PRPH2, 
RDS 
P23942 346 Required for photoreceptor morphology and 
function, mutation leads to retinal dystrophy 
(Clarke et al., 2000).  
TSPAN23 / ROSP1, 
ROM-1 
Q03395 351 Required for photoreceptor morphology and 
function (Clarke et al., 2000) 
TSPAN24 / CD151 P48509 253 Mutation leads to skin blistering and kidney 
disease (Crew et al., 2004). Mutation led to 
reduced adhesion strengthening in vitro 
(Lammerding et al., 2003). 
TSPAN25 / CD53 P19397 219 Regulation of TNFα production  
May promote cell survival (Beckwith et al., 2015) 
TSPAN26 / CD37 P11049 281 Involved in B-cell function and B-cell  T-cell 
interaction (Hemler, 2001). Target of therapeutic 
antibody for NHL treatment(Pagel et al., 2014) 
TSPAN27 / CD82 P27701 267 Potential suppressor of metastasis (Ono et al., 
1999) 
TSPAN28 / CD81, 
TAPA-1  
P60033 236 Required for surface expression and function of 
CD19 on B cells and complete B cell function 
(Hemler, 2001). Co-receptor for HCV entry 
(Moseley, 2005). Mutation led to reduced 
adhesion strengthening in vitro (Feigelson et al., 
2003) 
TSPAN29 / CD9, 
H59, MIC2, MRP-
1, P24 
P21926 228 Required for sperm egg fusion (Le Naour et al., 
2000; Zhu et al., 2002) 
TSPAN30 / CD63, 
MLA1 
P08962 238 Selectively Incorporates into HIV virions (von 
Lindern et al., 2003). Marker for granulocyte  and 
platelet activation 
TSPAN31 / SAS Q12999 210 Amplified from a subset of human sarcomas 
(Jankowski et al., 1994) 
TSPAN32 / 
PHEMX, TSSC6 
Q96QS1 320  
TSPAN33 / 
Penumbra 
Q86UF1 283 Member of the TspanC8 family which Regulates 
trafficking and activity of ADAM10 (Dornier et al., 
2012) 
Table 1.1 Alternate name, accession number and function of all 33 human tetraspanins. 
Accession number alternate names and amino acid size were sourced from Uniprot 
http://www.uniprot.org/  
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1.1.2 Tetraspanin Structure 
Tetraspanins range in size from 204-355 amino acids (Boucheix and Rubinstein, 2001) and 
consist of four membrane spanning helices separated by a short extracellular loop (EC1), an 
intracellular loop and a large extracellular loop (EC2) with short intracellular N- and C- terminal 
regions (Figure 1.1a). To be classed as a bona fide tetraspanin, four-span membrane proteins 
must also contain a number of conserved residues within transmembrane helix two, the 
intracellular loop and transmembrane helix three (Seigneuret et al., 2001) and must also 
contain four to eight conserved cysteine residues within the EC2 domain, one of which resides 
in the absolutely conserved CCG motif (Seigneuret et al., 2001; Wright et al., 2000). The only 
available tetraspanin crystal structure is of the CD81 large extracellular domain (Figure 1.1b) 
(discussed in section 1.1.2.4), however, CD spectroscopy has also been employed to analyse 
full length CD81 and attributed it with a predominantly (77.1%) α-helical content (Jamshad et 
al., 2008). Cryo-electron microscopy (EM) studies on the specialised uroplakin tetraspanins 
have also aided our understanding of how tetraspanins function (1.1.3.1) (Min et al., 2006). 
Here the four different regions of the tetraspanin protein will be considered (namely the 
intracellular regions, membrane spanning region, EC1 and EC2) with respect their structure 
and function. An alignment has been generated to demonstrate the level of conservation 
between the 33 different mammalian members.  It is also clear from this figure that the level 
of conservation varies depending on which region of the tetraspanin is considered for instance 
the TM domains show a high degree of similarity whilst the EC2 domains of more varied. 
1.1.2.1 Intracellular regions 
The cytoplasmic portion of tetraspanin proteins consist of short N- and C- termini which are 
generally under 20 amino acids long and a small linker region between transmembrane helices 
two and three (Charrin et al., 2009). Relatively few functions have been assigned to the 
tetraspanin amino terminal sequence, although Lineberry et al. (2008) have demonstrated 
that in CD151 this region is the target of ubiquitination which leads to its degradation at the 
proteasome. It has also been demonstrated that the amino terminal region of CD81 is required 
for efficient N-linked glycosylation of its partner molecule CD19 (Shoham et al., 2006) 
The C-terminus on the other hand, has been implicated in a number of tetraspanin properties 
and associated processes. For instance, the C-terminal tail of CD63 contains a tyrosine based 
lysosomal targeting motif (GYEVM) (Berditchevski and Odintsova, 2007) and interacts with the 
adaptor protein AP-3 to enable CD63 lysosomal targeting (Rous et al., 2002). This sorting motif 
is not unique to CD63 as twelve other members have been shown to have a similar sequence; 
however, in these members the sorting motifs proximity to the transmembrane region may 
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preclude interaction with AP-3 (Berditchevski and Odintsova, 2007). Another signalling motif in 
the C-terminal tail of CD151 (YXXφ, where φ is an amino acid with a bulky side chain) is 
responsible not only for CD151 trafficking to intracellular vesicles, but trafficking of CD151 
integrin partner proteins also (Liu et al., 2007). Mutation of this motif did not alter CD151-
integrin association but did have an effect on cell motility, adhesion and spreading (Zhang et 
al., 2002). Similarly mutation of the EMV residues in the CD9 C-terminal region also led to 
reduced spreading and had the added effect of abolishing CD9-dependent microvilli formation 
(Wang et al., 2011). The C-terminus may also be involved in tetraspanin interaction with other 
membrane protein, as this region in CD63 and CD81 interacts with PDZ domains in syntenin-1, 
Sap97 and EPB-50; it is yet to be determined if this type of interaction is responsible for other 
protein-protein interactions within tetraspanin microdomains however (Latysheva et al., 2006; 
Pan et al., 2007). The C-terminus may also provide a link between tetraspanins and the actin 
cytoskeleton, as the CD81 C-terminal tail has been shown to interact with Rac GTPase, and 
EZRIN which are suggested to enable interaction with the actin cytoskeleton through ERM 
proteins (Charrin et al., 2014; Sala-Valdés et al., 2006; Tejera et al., 2013). Deletion of the C-
terminus in CD151 also implicated this region in partner protein signalling as it led to reduced 
α6β1 dependent cell spreading and impaired adhesion strengthening to laminin-1 
(Lammerding et al., 2003; Zhang et al., 2002) 
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Figure 1.1: (a) Diagrammatic representation of a tetraspanin showing key structural features. Transmembrane helices 1-4 form a coiled coil structure within 
the membrane. The large extracellular region consisting of helices A, B and E and the more variable region (shown in red) is stabilised by disulphide bonds 
between conserved cysteine residues which vary in number depending on the tetraspanin member (4-8). Intracellular membrane proximal palmatoylation is 
thought to enable interaction with other membrane proteins (Taken from (Hemler, 2013)).  (b) Crystal structure of the human CD81 EC2 domain. This crystal 
structure represents helices A, B and E of Figure 1.1a and shows an additional 2 helices (C and D) which may not be a conserved feature across the entire 
tetraspanin family. The stalk region is comprised of helices A and E whilst the head domain is made up of helices B, C and D. Disulphide bridges are depicted in 
yellow (modified from (Kitadokoro et al., 2001)). 
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BAD AVG GOOD -  strength of residue alignment 
Tspan1    MQC------------------------------------------------------------------------FSFIKTMMILFNLLIFLCGAALLAVGIWVSIDGASFLKIFGP---LSSSA------- 
Tspan2    MGR--FR------------------------------------------------------------------GGLRCIKYLLLGFNLLFWLAGSAVIAFGLWFRFGG-AIKELSSE---DK-SP------- 
TSPAN3    MGQ--C--------------------------------------------------------------------GITSSKTVLVFLNLIFWGAAGILCYVGAYVFITYDDYDHFFED--------------- 
TSPAN4    MAR--AC--------------------------------------------------------------------LQAVKYLMFAFNLLFWLGGCGVLGVGIWLAATQGSFATLSSS--------------- 
TSPAN5    MSG--KHY-------------------KGPEV-------------------------------------------SCCIKYFIFGFNVIFWFLGITFLGIGLWAWNEKGVLSNISSI------TD------- 
TSPAN6    MAS--PSRRL-----------------QTKPV-------------------------------------------ITCFKSVLLIYTFIFWITGVILLAVGIWGKVSLENYFSLLNE--------------- 
TSPAN7    MAS--RRM-------------------ETKPV-------------------------------------------ITCLKTLLIIYSFVFWITGVILLAVGVWGKLTLGTYISLIAE--------------- 
TSPAN8    MAG--V---------------------------------------------------------------------SACIKYSMFTFNFLFWLCGILILALAIWVRVSNDSQAIFGSE----D-VG------- 
TSPAN9    MAR--GC--------------------------------------------------------------------LCCLKYMMFLFNLIFWLCGCGLLGVGIWLSVSQGNFATFSPS--------------- 
TSPAN10   MEE--GERSPLLSQETAGQKPLSVHRPPTSGC-LGPVPREDQAEAWGCSCCPPETKHQALSGTPKKGPAPSLSPGSSCVKYLIFLSNFPFSLLGLLALAIGLWGLAVKGSLGSDLGG--------------- 
TSPAN11   MAHY--KTEQ------------------DDW-------------------------------------------LIIYLKYLLFVFNFFFWVGGAAVLAVGIWTLVEKSGYLSVLAS------S-------- 
TSPAN12   MAR--ED------------------------S-------------------------------------------VKCLRCLLYALNLLFWLMSISVLAVSAWMRDYLNNVLTLTAE------TRVEEAVIL 
TSPAN13   MVC--GG--------------------------------------------------------------------FACSKNCLCALNLLYTLVSLLLIGIAAWGIGFG--------L---ISS--------- 
TSPAN14   MHY--YRY-------------------SNAKV-------------------------------------------SCWYKYLLFSYNIIFWLAGVVFLGVGLWAWSEKGVLSDLTKV------TR------- 
TSPAN15   MPRG--DSEQ------------------VRYCAR---------------------------------------FSYLWLKFSLIIYSTVFWLIGALVLSVGIYAEVERQKYKTLE--------S-------- 
TSPAN16   MAE--IH-----------------------TP-------------------------------------------YSSLKKLLSLLNGFVAVSGIILVGLGIGGKCGGASLTNVLGL------SS------- 
TSPAN17   MPG--KHQHF-----------------QEPEV-------------------------------------------GCCGKYFLFGFNIVFWVLGALFLAIGLWAWGEKGVLSNISAL------TD------- 
TSPAN18   MEG--D--------------------------------------------------------------------CLSCMKYLMFVFNFFIFLGGACLLAIGIWVMVDPTGFREIVAA-------N------- 
TSPAN19   MLR--NN------------------------K-------------------------------------------TIIIKYFLNLINGAFLVLGLLFMGFGAWLLLDRNNFLTAFDE------NN------- 
TSPAN20   MAK--DNS------------------------------------------------------------------TVRCFQGLLIFGNVIIGCCGIALTAECIFFVSDQHSLYPLLEA---TDN--------- 
TSPAN21   MAS--AAAAE------------------AEK-------------------------------------------GSPVVVGLLVVGNIIILLSGLSLFAETIWVTADQYRVYPLMGV---SGK--------- 
TSPAN22   MALL--KVKF------------------DQK-------------------------------------------KRVKLAQGLWLMNWFSVLAGIIIFSLGLFLKIELRKRSDVMNN------S-------- 
TSPAN23   MAPV--LPLV-----------------LPLQ-------------------------------------------PRIRLAQGLWLLSWLLALAGGVILLCSGHLLVQLRHLGTFLAP------S-------- 
TSPAN24   MGEF--NEKK------------------TTC-------------------------------------------GTVCLKYLLFTYNCCFWLAGLAVMAVGIWTLALKSDYISLLAS------G-------- 
TSPAN25   MGM--SS--------------------------------------------------------------------LKLLKYVLFFFNLLFWICGCCILGFGIYLLIHN-NFGVLFHN--------------- 
TSPAN26   MSAQESC--------------------------------------------------------------------LSLIKYFLFVFNLFFFVLGSLIFCFGIWILIDKTSFVSFVGL------A-------- 
TSPAN27   MGS--AC--------------------------------------------------------------------IKVTKYFLFLFNLIFFILGAVILGFGVWILADKSSFISVLQT------S-------- 
TSPAN28   MGV--E-------------------------------------------------------------------GCTKCIKYLLFVFNFVFWLAGGVILGVALWLRHDPQTTNLLYLELGDKP-AP------- 
TSPAN29   MPV--K-------------------------------------------------------------------GGTKCIKYLLFGFNFIFWLAGIAVLAIGLWLRFDSQTKSIFEQET--NN-NN------- 
TSPAN30   MAV--E-------------------------------------------------------------------GGMKCVKFLLYVLLLAFCACAVGLIAVGVGAQLVLSQTIIQGAT--------------- 
TSPAN31   MVC--GG--------------------------------------------------------------------FACSKNALCALNVVYMLVSLLLIGVAAWGKGLG--------L---VSS--------- 
TSPAN32   MGP--WSR-------------------------------------------------------------------VRVAKCQMLVTCFFILLLGLSVATMVTL-TYFGAHFAVIRRAS--LEK--------- 
Tspan33   MAR--RPRAPAASGE------------EFSFV-------------------------------------------SPLVKYLLFFFNMLFWVISMVMVAVGVYARLMKHAEAALAC---------------- 
  N-Terminus TM1 EC1 
  
9
 
Tspan1    MQF-VNVGY-----FLIAA-GVVVFALGFL-G--CYGAKTES-----KCALV-TFFFILLLIFIAEVA-------AA-VVALVYTTMAEHF----LTLL--VVPAIKKDYGSQ------------EDFTQVW 
Tspan2    EYF-YVGLY-----VLVGA-GALMMAVGFF-G--CCGAMRES-----QCVLG-SFFTCLLVIFAAEVT-------TG-VFAFIGKGVAIRH----VQTM--YEEAYN-DYLKD--R-------GKG--NGTL 
TSPAN3    VYT-LIPAV-----VIIAV-GALLFIIGLI-G--CCATIRES-----RCGLA-TFVIILLLVFVTEVV-------VV-VLGYVYRAKVENE----VDRS--IQKVYK-TYNGT--N--------PDAASRAI 
TSPAN4    FPS-LSAAN-----LLIIT-GAFVMAIGFV-G--CLGAIKEN-----KCLLL-TFFLLLLLVFLLEAT-------IA-ILFFAYTDKIDRY----AQQD--LKKGLH-LYGTQ----------GNVGLTNAW 
TSPAN5    LGG-FDPVW-----LFLVV-GGVMFILGFA-G--CIGALREN-----TFLLK-FFSVFLGIIFFLELT-------AG-VLAFVFKDWIKDQ----LYFF--INNNIR-AYRDD------------IDLQNLI 
TSPAN6    -KA-TNVPF-----VLIAT-GTVIILLGTF-G--CFATCRAS-----AWMLK-LYAMFLTLVFLVELV-------AA-IVGFVFRHEIKNS----FKNN--YEKALK-QYNST----------GD-YRSHAV 
TSPAN7    -NS-TNAPY-----VLIGT-GTTIVVFGLF-G--CFATCRGS-----PWMLK-LYAMFLSLVFLAELV-------AG-ISGFVFRHEIKDT----FLRT--YTDAMQ-TYNGN----------DE--RSRAV 
TSPAN8    SSS-YVAVD-----ILIAV-GAIIMILGFL-G--CCGAIKES-----RCMLL-LFFIGLLLILLLQVA-------TG-ILGAVFKSKSDRI----VNET--LYENTK-LLSAT--G------ESEKQFQEAI 
TSPAN9    FPS-LSAAN-----LVIAI-GTIVMVTGFL-G--CLGAIKEN-----KCLLL-SFFIVLLVILLAELI-------LL-ILFFVYMDKVNEN----AKKD--LKEGLL-LYHTE----------NNVGLKNAW 
TSPAN10   PLP-TD-PM-----LGLALGGLVVSAASLA-G--CLGALCEN-----TCLLR-GFSGGILAFLVLEAV-------AG-ALVVALWGPLQDS----LEHT--LRVAIA-HYQDD--P----------DLRFLL 
TSPAN11   TF--AASAY-----ILIFA-GVLVMVTGFL-G--FGAILWER-----KGCLS-TYFCLLLVIFLVELV-------AG-VLAHVYYQRLSDE----LKQH--LNRTLAENYGQP----------GATQITASV 
TSPAN12   TYF-PVVHP-----VMIAV-CCFLIIVGML-G--YCGTVKRN-----LLLLA-WYFGSLLVIFCVELA-------CG-VWTYEQELMVPVQ----WSDMVTLKARMT-NYGL---P-------RYRWLTHAW 
TSPAN13   ----LRVVG-----VVIAV-GIFLFLIALV-G--LIGAVKHH-----QVLLF-FYMIILLLVFIVQFS-------VS-CACLALNQEQQGQ----LLEV--GW----------------------NNTASAR 
TSPAN14   MHG-IDPVV-----LVLMV-GVVMFTLGFA-G--CVGALREN-----ICLLN-FFCGTIVLIFFLELA-------VA-VLAFLFQDWVRDR----FREF--FESNIK-SYRDD------------IDLQNLI 
TSPAN15   AF--LAPAI-----ILILL-GVVMFMVSFI-G--VLASLRDN-----LYLLQ-AFMYILGICLIMEL-------IGG-VVALTFRNQTIDF----LNDN--IRRGIE-NYYD------------DLDFKNIM 
TSPAN16   AYL-LHVGN-----LCLVM-GCITVLLGCA-G--WYGATKES-----RGTLL-FCILSMVIVLIMEVT-------AA-TVVLLFFPIVGDVALEHTFVT--LRKNYR-GYNEP----------DD--YSTQW 
TSPAN17   LGG-LDPVW-----LFVVV-GGVMSVLGFA-G--CIGALREN-----TFLLK-FFSVFLGLIFFLELA-------TG-ILAFVFKDWIRDQ----LNLF--INNNVK-AYRDD------------IDLQNLI 
TSPAN18   PLL-LTGAY-----ILLAM-GGLLFLLGFL-G--CCGAVREN-----KCLLL-FFFLFILIIFLAELS-------AA-ILAFIFRENLTRE----FF----TKELTK-HYQGN--N-------DTDVFSATW 
TSPAN19   HFI-VPISQ-----ILIGM-GSSTVLFCLL-G--YIGIHNEI-----RWLLI-VYAVLITWTFAVQVV-------LS-AFIITKKEEVQQL----WHDK--IDFVIS-EYGSKDKP-------EDITKWTIL 
TSPAN20   DDI-YGAAW-----IGIFV-GICLFCLSVL-G--IVGIMKSS-----RKILL-AYFILMFIVYAFEVA-------SC-ITAATQQDFFTPN------LF--LKQMLE-RYQNNS-PPNNDDQWKNNGVTKTW 
TSPAN21   DDV-FAGAW-----IAIFC-GFSFFMVASF-G--VGAALCRR-----RSMVL-TYLVLMLIVYIFECA-------SC-ITSYTHRDYMVSN----PSLI--TKQMLT-FYSADT-D-------QGQELTRLW 
TSPAN22   ES--HFVPN-----SLIGM-GVLSCVFNSLAGKICYDALDPAKYARWKPWLK-PYLAICVLFNIILF-------LVA-LCCFLLRGSLENT----LGQG--LKNGMK-YYRDTDTP-------GRCFMKKTI 
TSPAN23   CQF-PVLPQ-----AALAA-GAVALGTGLV-G--V-GASRAS----LNAALYPPWRGVLGPLLVAGTAGGGGLLVVGLGLALALPGSLDEA----LEEG--LVTALA-HYKDTEVP-------GHCQAKRLV 
TSPAN24   TY--LATAY-----ILVVA-GTVVMVTGVL-G--CCATFKER-----RNLLR-LYFILLLIIFLLEII-------AG-ILAYAYYQQLNTE----LKEN--LKDTMTKRYHQP----------GHEAVTSAV 
TSPAN25   LPS-LTLGN-----VFVIV-GSIIMVVAFL-G--CMGSIKEN-----KCLLM-SFFILLLIILLAEVT-------LA-ILLFVYEQKLNEY----VAKG--LTDSIH-RYHSD------------NSTKAAW 
TSPAN26   FVPLQIWSK-----VLAIS-GIFTMGIALL-G--CVGALKEL-----RCLLG-LYFGMLLLLFATQIT-------LG-ILISTQRAQLERS----LRDV--VEKTIQ-KYGTN--P-------EETAAEESW 
TSPAN27   SSSLRMGAY-----VFIGV-GAVTMLMGFL-G--CIGAVNEV-----RCLLG-LYFAFLLLILIAQVT-------AG-ALFYFNMGKLKQE----MGGI--VTELIR-DYNSS----------REDSLQDAW 
TSPAN28   NTF-YVGIY-----ILIAV-GAVMMFVGFL-G--CYGAIQES-----QCLLG-TFFTCLVILFACEVA-------AG-IWGFVNKDQIAKD----VKQF--YDQALQ-QAVVD--D-------DANNAKAVV 
TSPAN29   SSF-YTGVY-----ILIGA-GALMMLVGFL-G--CCGAVQES-----QCMLG-LFFGFLLVIFAIEIA-------AA-IWGYSHKDEVIKE----VQEF--YKDTYN-KLKTK--D-------EPQ--RETL 
TSPAN30   PGS-LL-PV-----VIIAV-GVFLFLVAFV-G--CCGACKEN-----YCLMI-TFAIFLSLIMLVEVA-------AA-IAGYVFRDKVMSE----FNNN--FRQQME-NYPKN--N----------HTASIL 
TSPAN31   ----IHIIG-----GVIAV-GVFLLLIAVA-G--LVGAVNHH-----QVLLF-FYMIILGLVFIFQFV-------IS-CSCLAINRSKQTD----VINA--SWW---------------------VMSNKTR 
TSPAN32   NPY-QAVHQWAFSAGLSLV-G-LLTLGAVL-S--AAATVREA-----QGLMA-GGFLCFSLAFCAQVQ-------VV-FWRLHSPTQVEDA----MLDT--YDLVYEQAMKGT-----------SHVRRQEL 
Tspan33   -LA-VDPAI-----LLIVV-GVLMFLLTFC-G--CIGSLREN-----ICLLQ-TFSLCLTAVFLLQLA-------AG-ILGFVFSDKARGK----VSEI--INNAIV-HYRDD------------LDLQNLI 
  EC1 TM2 IC TM3 EC2 
  
1
0 
Tspan1    NTTMKGLKCCGFT-NYTDFEDSPYF-KE-----------------------NSAFPPFC-CNDNVTN--TAN-------------------------ETCT------------KQKAHDQK--VEGCFNQLL 
Tspan2    ITFHSTFQCCGKE-SSEQVQP------------------------------------TC-P-------------------------------------------------------KELLG--HKNCIDEIE 
TSPAN3    DYVQRQLHCCGIH-NYSDWENTDWF-KET---------------------KNQSVPLSC-CRETAS--------------------------------NCN-G---------SLAHPSDLY--AEGCEALVV 
TSPAN4    SIIQTDFRCCGVS-NYTDWFEVYN---------------------------ATRVPDSC-CLEFSES--------------------------------CG-L-----------HAPGTWW--KAPCYETVK 
TSPAN5    DFTQEYWQCCGAF-GADDWNLNIYF-NCTDSNA---------------SRERCGVPFSC-CTKDPAE-DVIN-------------------------TQCG-Y-DA-R-QKPEVDQQIVIY--TKGCVPQFE 
TSPAN6    DKIQNTLHCCGVT-DYRDWTDTNYY-S------------------------EKGFPKSC-CKLED----------------------------------CT-P----------QRDADKVN--NEGCFIKVM 
TSPAN7    DHVQRSLSCCGVQ-NYTNWSTSPYF-L------------------------EHGIPPSC-CMNET---------------------------------DCN-P-QD-L-H-NLTVAATKVN--QKGCYDLVT 
TSPAN8    IVFQEEFKCCGLVNGAADWGNNF-----------------------------QHYPELCACLDKQR--------------------------------PC------------QSYNGKQVY--KETCISFIK 
TSPAN9    NIIQAEMRCCGVT-DYTDWYPVLG---------------------------ENTVPDRC-CMENSQG--------------------------------CG-R-----------NATTPLW--RTGCYEKVK 
TSPAN10   DQVQLGLRCCGAA-SYQDWQQNLYF-NCSS--P---------------GVQACSLPASC-CIDPREDGASVN-------------------------DQCG-F-GV-L-RLDADAAQRVVY--LEGCGPPLR 
TSPAN11   DRLQQDFKCCGSN-SSADWQHSTYI-LLRE-------------------AEGRQVPDSC-CKTVVVR--CG-----------------------------------------QRAHPSNIYKVEGGCLTKLE 
TSPAN12   NFFQREFKCCGVV-YFTDWLEMTE---------------------------MDWPPDSC-CVREFP--------------------------------GCS-K-Q------AHQEDLSDLY--QEGCGKKMY 
TSPAN13   NDIQRNLNCCGFR-SVNPN-DT---------------------------------CLAS-CVKSD------------------------------------------------------HS--CSPCAPIIG 
TSPAN14   DSLQKANQCCGAY-GPEDWDLNVYF-NCSGASY---------------SREKCGVPFSC-CVPDPAQ-KVVN-------------------------TQCG-Y-DV-R-IQLKSKWDESIF--TKGCIQALE 
TSPAN15   DFVQKKFKCCGGE-DYRDWSKNQYH-DCSAPG-----------------PLACGVPYTC-CIRNTTE--VVN-------------------------TMCG-Y-KT-I-DKERFSVQDVIY--VRGCTNAVI 
TSPAN16   NLVMEKLKCCGVN-NYTDFSGSSFE-MT----------------------TGHTYPRSC-CKSIGSV-------------------------------SCD-G-R--------DVSPNVIH--QKGCFHKLL 
TSPAN17   DFAQEYWSCCGAR-GPNDWNLNIYF-NCTDLNP---------------SRERCGVPFSC-CVRDPAE-DVLN-------------------------TQCG-Y-DV-R-LKLELEQQGFIH--TKGCVGQFE 
TSPAN18   NSVMITFGCCGVN-GPEDFKFASVF-RLLT-------------------LDSEEVPEAC-CRREPQ--------------------------------SRD-GVLLSR-EECLLGRSLFLN--KQGCYTVIL 
TSPAN19   NALQKTLQCCGQH-NYTDWIKNKNK-EN-----------------------SGQVPCSC-TKSTLR--------------------------------K-----W------FCDEPLNATY--LEGCENKIS 
TSPAN20   DRLMLQDNCCGVN-GPSDWQKYTSAFRTEN------------------NDADYPWPRQC-CVMNNLK-EPLNL------------------------EACK------------LGVPGFYH--NQGCYELIS 
TSPAN21   DRVMIEQECCGTS-GPMDWVNFTSAFRAAT------------------PEVVFPWPPLC-CRRTGNF-IPLNE------------------------EGCR------------LGHMDYLF--TKGCFEHIG 
TSPAN22   DMLQIEFKCCGNN-GFRDWFEIQWI-SNRYLDFSSKEVKDRIKSNVDGRYLVDGVPFSC-CNPSSPR-PCIQ-------------------------YQITNN-SA-HYSYDHQTEELNLW--VRGCRAALL 
TSPAN23   DELQLRYHCCGRH-GYKDWFGVQWV-SSRYLDPGDRDVADRIQSNVEGLYLTDGVPFSC-CNPHSPR-PCLQ-------------------------NRLSDS-YA-HPLFDPRQPNQNLW--AQGCHEVLL 
TSPAN24   DQLQQEFHCCGSN-NSQDWRDSEWI-RSQE-------------------AGGRVVPDSC-CKTVVAL--CG-----------------------------------------QRDHASNIYKVEGGCITKLE 
TSPAN25   DSIQSFLQCCGIN-GTSDWTSG--------------------------------PPASC-PS--------------------------------------------------------DRK--VEGCYAKAR 
TSPAN26   DYVQFQLRCCGWH-YPQDWFQVLIL-RGNG-------------------SEAHRVPCSC-YNLSATN-DSTILDKVILPQLSRL---GHLARSRHSADICA-V-----------PAESHIY--REGCAQGLQ 
TSPAN27   DYVQAQVKCCGWV-SFYNWTDNAEL-MNR---------------------PEVTYPCSC-EVKGEED-NSLSVRK------GFCEAPGNR------TQSGN-H-----------PEDWPVY--QEGCMEKVQ 
TSPAN28   KTFHETLDCCGSS-TLTALTTSVLK---------------------------N---NLC-PS--------------------------------------------------GSNIISNLF--KEDCHQKID 
TSPAN29   KAIHYALNCCGLA-GGVEQFIS----------------------------------DIC-PK---------------------------------------------------KDVLETFT--VKSCPDAIK 
TSPAN30   DRMQADFKCCGAA-NYTDWEKIPSM-------------------------SKNRVPDSC-CINVTV--------------------------------GCG-I----------NFNEKAIH--KEGCVEKIG 
TSPAN31   DELERSFDCCGLF-NLTTLYQQDYD-F----------------------------CTAI-CKSQS------------------------------------------------------PT--CQMCGEKFL 
TSPAN32   AAIQDVFLCCGKK-SPFSRLGSTEA--------------------------------DL-CQGE------------------------------------------------------EAA--REDCLQGIR 
Tspan33   DFGQKKFSCCGGI-SYKDWSQNMYF-NCSEDNP---------------SRERCSVPYSC-CLPTPDQ-AVIN-------------------------TMCG-Q-GM-Q-AFDYLEASKVIY—TNGCIDKLV 
  
EC2 
  
1
1 
Tspan1    YDIRT--NAVTVGGV-AAGIGGLELAAMIVSMYLYCNL---------------------------------------------------------------------------------------------- 
Tspan2    TIISV--KLQLIGIV-GIGIAGLTIFGMIFSMVLCCAIR------NSRD-----V----------------------------------------------------------------------------- 
TSPAN3    KKLQE--IMMHVIWA-ALAFAAIQLLGMLCACIVLCRRS------RDPA---YEL-----------------L-----ITG-------------------------GTY----------------------- 
TSPAN4    VWLQE--NLLAVGIF-GLCTALVQILGLTFAMTMYCQVV------KAD----TY-------------------------------C---------------------------------------------- 
TSPAN5    KWLQD--NLTIVAGI-FIGIALLQIFGICLAQNLVSDIE------AVRA---S------------------------------------------------------------------------------- 
TSPAN6    TIIES--EMGVVAGI-SFGVACFQLIGIFLAYCLSRAIT------NN------------------------------------------------------------------------------------- 
TSPAN7    SFMET--NMGIIAGV-AFGIAFSQLIGMLLACCLSRFIT------AN------------------------------------------------------------------------------------- 
TSPAN8    DFLAK--NLIIVIGI-SFGLAVIEILGLVFSMVLYCQIG------NK------------------------------------------------------------------------------------- 
TSPAN9    MWFDD--NKHVLGTV-GMCILIMQILGMAFSMTLFQHIH------RTGK---KY-------------------------------D---------------------------------------------- 
TSPAN10   RWLRA--NLAASGGY-AIAVVLLQGAELLLAARLLGALA------ARSG---AAY-----------------G---PGAHGEDRAG--------------------PQS-----PSPG-------AP--PA- 
TSPAN11   QFLAD--HLLLMGAV-GIGVACLQICGMVLTCCLHQRLQ------RHFY----------------------------------------------------------------------------------- 
TSPAN12   SFLRGTKQLQVLRFL-GISIGVTQILAMILTITLLWALY------YDRR---EP-----------------------G---TDQMM----------------------SLKNDNSQHL-------SC--PS- 
TSPAN13   EYAGE--VLRFVGGI-GLFFSFTEILGVWLTYRYRNQK------DPRAN---PSA----------------------------------------------------------------------------F 
TSPAN14   SWLPR--NIYIVAGV-FIAISLLQIFGIFLARTLISDIE------AVKA---G----------------------------------------------------------------------------HH- 
TSPAN15   IWFMD--NYTIMAGI-LLGILLPQFLGVLLTLLYITRVE------DIIM---EHS-------------VTDGLL-----------------------------------------GPGAKPSVEAAG--TG- 
TSPAN16   KITKT--QSFTLSGS-SLGAAVIQRWGSRYVAQAGLELL--------------------------------------------------------------------------------------------- 
TSPAN17   KWLQD--NLIVVAGV-FMGIALLQIFGICLAQNLVSDIK------AVKA---N------------------------------------------------------------------------------- 
TSPAN18   NTFET--YVYLAGAL-AIGVLAIELFAMIFAMCLFRGIQ--------------------------------------------------------------------------------------------- 
TSPAN19   AWYNV--NVLTLIGI-NFGLLTSEVFQVSLTVCFFKNIK------NIIH---AE------------------------------------------------------------------------------ 
TSPAN20   GPMNR--HAWGVAWF-GFAILCWTFWVLLGTMFYWSRI------E--------------------------------------------------------------------------------------- 
TSPAN21   HAIDS--YTWGISWF-GFAILMWTLPVMLIAMYFYTM----------------------------------------------------------------------------------------------- 
TSPAN22   SYYSS--LMNSMGVV-TLLIWLFEVTITIGLRYLQTSLD------GVSNPEESES-------------ESEGWLLEKSVPETWK-A---------------------FLESVKKLGKGNQVEAEGAG--AG- 
TSPAN23   EHLQD--LAGTLGSM-LAVTFLLQALVLLGLRYLQTALE------GLGGVIDAGG-------------ETQGYLFPSGLKDMLKTA---------------------WL----QGGVACRPAPEEAP--PG- 
TSPAN24   TFIQE--HLRVIGAV-GIGIACVQVFGMIFTCCLYRSLK------LEHY----------------------------------------------------------------------------------- 
TSPAN25   LWFHS--NFLYIGII-TICVCVIEVLGMSFALTLNCQID------KTSQ---TI-------------------------------G---------------------------------------------- 
TSPAN26   KWLHN--NLISIVGI-CLGVGLLELGFMTLSIFLCRNLD------HV-Y---NR-------------------------------L-------------------------------------------AR- 
TSPAN27   AWLQE--NLGIILGV-GVGVAIIELLGMVLSICLCRHVH------SEDY---SK-------------------------------V-------------------------------------------PK- 
TSPAN28   DLFSG--KLYLIGIA-AIVVAVIMIFEMILSMVLCCGIR------NSSV----------------------------------------------------------------------------------- 
TSPAN29   EVFDN--KFHIIGAV-GIGIAVVMIFGMIFSMILCCAIR------RNRE-----M----------------------------------------------------------------------------- 
TSPAN30   GWLRK--NVLVVAAA-ALGIAFVEVLGIVFACCLVKSIR------SGYE---VM------------------------------------------------------------------------------ 
TSPAN31   KHSDE--ALKILGGV-GLFFSFTEILGVWLAMRFRNQK------DPRAN---PSA----------------------------------------------------------------------------F 
TSPAN32   SFLRT--HQQVASSLTSIGLA-LTVSALLFSSFLWFAIRCGCSLDRKGK---YTLTPRACGRQPQEPSLLRCSQGGPTHCLHSEAVAIGPRGCSGSLRWLQESDAAPLPLSCHLAAHR-------ALQGRSR 
Tspan33   NWIHS--NLFLLGGV-ALGLAIPQLVGILLSQILVNQIK------DQIK---LQ-------------------------------L--------------------------YNQQHR-------AD--PW- 
  EC2 TM4 C-Terminus 
  
1
2 
Tspan1    Q-------------------------------------- 
Tspan2    --------------------------------------I 
TSPAN3    --------------------------------------A 
TSPAN4    --------------------------------------A 
TSPAN5    --------------------------------------W 
TSPAN6    --------------------------------QYE--IV 
TSPAN7    --------------------------------QYE--MV 
TSPAN8    --------------------------------------- 
TSPAN9    --------------------------------------A 
TSPAN10   ----AK--------------------------PAR---G 
TSPAN11   --------------------------------------- 
TSPAN12   ----VELLKPSLSRIFEHTSMANSFNT-----HFEMEEL 
TSPAN13   L-------------------------------------- 
TSPAN14   --------------------------------------F 
TSPAN15   ----C---------------------CLCYPN------- 
TSPAN16   --------------------------------------A 
TSPAN17   --------------------------------------W 
TSPAN18   --------------------------------------- 
TSPAN19   --------------------------------------M 
TSPAN20   Y-------------------------------------- 
TSPAN21   L-------------------------------------- 
TSPAN22   ----Q---------------------AP-EA-------G 
TSPAN23   ----E---------------------APPKEDLSE---A 
TSPAN24   --------------------------------------- 
TSPAN25   --------------------------------------L 
TSPAN26   ---------------------------------Y----R 
TSPAN27   --------------------------------------Y 
TSPAN28   --------------------------------------Y 
TSPAN29   --------------------------------------V 
TSPAN30   --------------------------------------- 
TSPAN31   L-------------------------------------- 
TSPAN32   GGLSG---------------------CPE-----RGLSD 
Tspan33   --------------------------------------Y 
 
 
Figure 1.2.  Alignment of the primary amino acid sequence of all 33 human tetraspanins.  Full length tetraspanin amino acid sequences were attained from 
www.uniprot.org and aligned using the online software T-coffee simple multiple sequence alignment http://tcoffee.crg.cat/. Tetraspanin names are labelled using 
the Tspan nomenclature but alternate name can be found in Table 1.1  
C-Terminus 
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1.1.2.2 Transmembrane domains 
The four transmembrane domains range in size from 21-25 amino acids (Kovalenko et al., 
2005) and are the areas of highest homology between the superfamily members (Stipp et al., 
2003). Alignment and analysis of multiple tetraspanin transmembrane sequences by 
Kovalenko et al. (2005) revealed a conserved heptad repeat motif in TMs one to three 
indicative of a coiled coil structure found in many membrane proteins. In the same study, a 
model was proposed in which TM1 and TM2 are able form intermolecular associations via 
packing of bulky hydrophobic residues; this is suggested to result in tetraspanin dimerization 
(Kovalenko et al., 2005). The authors also identify a second potential intermolecular interface 
between TM3 and TM4 which may enable the formation of higher order structures. Unusually, 
there are a number of polar residues within membrane spanning helices one, three and four, 
which have also been suggested as possible areas of interaction between tetraspanins (Stipp 
et al., 2003). More recently it has been suggested that they are involved in intramolecular 
interactions between the transmembrane domains which help maintain the conformation 
stability of tetraspanin CD81 within the membrane, enabling its interaction with CD9 and 
CD151 (Bari et al., 2009) 
Transmembrane regions are not only required for packing of separate tetraspanin molecules, 
but for efficient expression of tetraspanins at the cell surface too. CD82 lacking the initial 
transmembrane region was retained within the endoplasmic reticulum (ER) but its expression 
was restored by separate co-expression of the missing TM1 region (Cannon and Cresswell, 
2001). CD82 lacking the TM1 region was not recognised by an anti-CD81 mAb indicating 
incorrect EC2 folding. This led the authors to suggest that retention at the ER is a means of 
quality control imposed by the cell to ensure that only fully formed, correctly folded 
tetraspanins are transported to the surface. Berditchevski et al. (2001) also found that deletion 
of any of the initial three transmembrane domains of CD151 resulted in its distribution to 
intracellular vesicles, indicating a requirement of the four-span structure for efficient surface 
expression. Work by Shoham et al. (2006) suggested a role for transmembrane domains in 
partner protein interactions too. They found that the expression of CD81 binding partner CD19 
was much reduced in CD81 knockout B-lymphopoietic cells and through transfection of various 
CD9/CD81 chimeras demonstrated that only the first transmembrane region of CD81 was 
required to restore expression levels of CD19 (Section 1.1.3.2). 
1.1.2.3 EC1 region 
The smaller of the extracellular loops, EC1, is composed of under 30 amino acids (Charrin et 
al., 2009; Seigneuret, 2006). Relatively few functions have been assigned to this region but 
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Masciopinto et al. (2001) found that although the EC1 was not required for CD81-partner 
interactions, removal of the EC1 led to CD81 retention within the cell, suggesting requirement 
of this region for efficient translocation. Similarly deletion of the EC1 in CD151 did not affect its 
association with integrin α3β1 but did prohibit its cell surface expression (Berditchevski et al., 
2001). Bioinformatic analysis of CD81 also identified a hydrophobic patch within the EC2 which 
has been proposed as a “docking site” for the EC1 domain (Seigneuret, 2006); this is thought 
to aid in EC2 stability and cryo-EM studies of urpolakins have suggested a similar phenomenon 
(Min et al., 2006). The EC1-EC2 interaction is relatively ambiguous however, because CD81 EC2 
crystallised as a homodimer which blocked the proposed EC1 binding site and would therefore 
prevent this interaction (Kitadokoro et al., 2001; Rajesh et al., 2012). 
1.1.2.4 EC2 domain 
The EC2 domain makes up a large proportion of the tetraspanin protein accounting for 76-131 
amino acids (Boucheix and Rubinstein, 2001; Charrin et al., 2009), and is targeted by many of 
the available anti-tetraspanin monoclonal antibodies. To date, the only tetraspanin crystal 
structure available is that of the EC2 domain of human CD81. This particular structure consists 
of a five helix bundle stabilised by disulphide bonds that the authors describe as having a 
“mushroom-like” shape comprised of a stalk and head region (Figure 1.1b (Kitadokoro et al., 
2001). Kitadokoro et al. speculated that this structure is conserved across the tetraspanin 
family, however later work suggested this is only partly true (Seigneuret et al., 2001). Through 
sequence alignment, analysis of secondary structures and homology modelling, Seigneuret et 
al. (2006) proposed that the EC2 domain is in fact made of two sub-domains. The more 
constant of the two subdomains comprises three helices (helices A, B and E) which are thought 
to be a consistent feature across the family. On the other hand, the hyper-variable subdomain 
(composed of helices C and D in the CD81 structure) is suggested to have a more varied 
structure (Seigneuret et al., 2001). Indeed, later NMR analysis by Rajesh et al (2012) indicated 
that the originally dubbed “Helix D” in CD81 may actually have a more dynamic loop structure.  
There are four to eight conserved cysteine residues within the EC2 with the majority of 
members having six, one of which is found within an absolutely conserved CCG motif. These 
cysteines are thought to take part in di-sulphide bridge formation which is essential for 
maintaining the structure of the EC2. Interestingly, the specialised tetraspanins 
perphearin/RDS and ROM-1, located in the photoreceptor outer segment of the eye, have a 
seventh cysteine involved in intermolecular bonding (Charrin et al., 2009; Loewen and Molday, 
2000). Similarly, plant tetraspanins have an uneven number of cysteines (nine), one of which is 
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located within the EC1 domain and has also been suggested to enable cross-molecule linkage 
(DeSalle et al., 2010) 
The EC2 domain is the most varied region of the tetraspanin proteins and is thought to 
contribute specificity to different tetraspanin members and as such is primarily considered as 
the site of partner protein interaction. A number of studies have provided further evidence 
towards this, for example chimeras of CD151/CD9 showed the EC2 domain was essential for 
the interaction of CD151 with its binding partner integrin α3β1. Moreover Kazarov et al. (2002) 
were able to show that residues 194-196 within the EC2 are required for this association 
(Berditchevski et al., 2001; Yaucht et al., 2000). Point mutations at two of the conserved 
cysteines within the EC2 abrogated interaction with partner proteins, therefore also indicating 
a requirement of disulphide bonds for partner protein associations (Berditchevski et al., 2001). 
These mutations did not affect interaction with other tetraspanin family members but 
mutation of the CCG motif did prevent CD151-CD151 interactions, perhaps suggesting 
different regional requirements for homodimer and heterodimer formation.  
The EC2 domain is also responsible for several receptor ligand interactions, for instance the 
site of CD81 association with the Hepatitis C virus protein E2 has been mapped to the hyper-
variable region (Higginbottom et al., 2000b). Binding of the uropathogenic E. coli (UPEC)  
fimbriael protein, FimH, to the uroplakin tetraspanin, UP1a, takes place within the EC2 domain 
and CD9 interaction with its ligand, PSG17, similarly requires the EC2 domain (Ellerman et al., 
2003; Zhou et al., 2001). 
Many of the mutations which lead to disease in humans are mutations of residues within the 
EC2 domains again demonstrating the importance of this particular region. For instance 
mutation of residue 172 within the hypervariable region of tetraspanin TM4SF2 leads to 
mental retardation (Zemni et al., 2000). Furthermore, mutations in perpharin/RDS (a 
tetraspanin found in photoreceptor cells within the eye) leads to severe retinal disease and 
70% of mutations that display this phenotype are located within the EC2, many being within 
the hypervariable region (Stipp et al., 2003). 
1.1.2.5 Post translational modification 
All tetraspanins undergo post-translational modification with the vast majority of the family 
being N-glycosylated within the EC2 domain at a classical Asn-X-Thr/Ser motif (Martin et al., 
2005). The exceptions to this are CD9, which is glycosylated within the EC1 domain, and CD81 
and NET-2 which are not glycosylated at all (Boucheix et al., 1991; Maecker et al., 1997). The 
exact function of glycosylation is unknown however it is required for normal tetraspanin 
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function in several processes. Glycosylation of CD82 and CD9 is required for their ability to 
impose a pro-apoptotic anti-metastatic effect in Krieger’s ldlD 14 (D14) cells, therefore 
suggesting a role of tetraspanin glycosylation in cancer suppression (Ono et al., 1999). Point 
mutation of glycosylation sites in CD82 also resulted in a systematic increase in α5 integrin 
association and a concurrent decrease in cell motility (Ono et al., 2000). This demonstrates an 
inhibitory role of tetraspanin glycosylation in partner protein association and a physiological 
downstream consequence (Ono et al., 2000). Binding and subsequent infection of UPEC is 
mediated through FimH interaction with the uroplakin UPaI. Interestingly, this binding requires 
UPaI glycosylation, and the non-mannose residues used in UP1b glycosylation mean that this 
related tetraspanin is not amenable to FimH binding. This not only demonstrates a role for 
tetraspanin glycosylation in ligand binding but also shows a level of specificity towards 
glycosylation patterns (Xie et al., 2006). 
Palmitoylation is the covalent attachment of a palmitate group to a cysteine residue (or less 
commonly a serine/threonine residue) and in contrast to glycosylation, all of the tetraspanins 
family members without exception undergo this form of modification (Yang et al., 2002). In 
tetraspanins, palmitoylation takes place on cytoplasmic juxtamembrane cysteines (the number 
of which vary between members) and several reports have shown the importance of this 
modification in tetraspanin interactions and trafficking. Although palmitoylation deficient CD9 
was still found in the detergent resistant fraction of sucrose gradients (indicating its inclusion 
within a TEM), its interaction with other tetraspanins was diminished (Charrin et al., 2002). 
Similarly, abolition of CD151 palmitoylation prohibited its interaction with other tetraspanins 
(CD63 and CD81) and also reduced its interaction with palmitoylated integrin α3β1 
(Berditchevski et al., 2002). Yang et al. (2002) also suggest a contribution of palmitoylation to 
cellular distribution of CD151, however Berditchevski et al. (2002) did not see the same effect 
and suggest this may be instead due to the C-terminal GFP tag affecting a targeting motif. 
Interestingly, elimination of palmitoylation in CD81 had no effect on its binding to HCV protein 
EW2 but did lead to a decrease in HCV susceptibility. Because this mutation led to a decrease 
in CD81 association with other tetraspanins, the apparent resistance to HCV infection is 
thought to arise from palmitoylation deficient CD81s inability to exist within TEM (section 
1.1.3.1) (Zhu et al., 2012). Additionally, analysis of palmitoylation deficient CD9 indicated that 
palmitoylation is required for confinement of CD9 into tetraspanin enriched areas (Espenel et 
al., 2008). Overall, this data would suggest a role for palmitoylation in tetraspanin 
microdomain formation and interaction with other palmitoylated proteins including other 
tetraspanin family members. A small number of tetraspanins have also been shown to be 
ubiquitinated, for example, ubiquitination of CD82 by the ubiquitin ligase gp78 targets it for 
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degradation (Tsai et al., 2007) and similarly ubiquitination of CD151 promotes its degradation 
(Lineberry et al., 2008) 
1.1.3 Tetraspanin function 
1.1.3.1 TEMs 
Tetraspanins are primarily thought to function as “molecular facilitators”, a role in which they 
organise proteins within the plasma membrane to form functional clusters which can for 
example, increase efficiency of signal transduction or increase receptor avidity within a specific 
area (Kropshofer et al., 2002; Maecker et al., 1997; Yáñez-Mó et al., 2009). Tetraspanins 
capacity to organise other membrane proteins comes as a result of a number of tetraspanin-
partner and tetraspanin-tetraspanin interactions which form a network of proteins at the cell 
surface often referred to as the tetraspanin web, which includes discreet tetraspanin enriched 
microdomains (TEM) (Figure 1.2) (Hemler, 2003; Rubinstein et al., 1996). Evidence for the 
tetraspanin web first came from biochemical studies in which co-immunoprecipitation 
revealed a plethora of proteins to which tetraspanins associate. Partner proteins include 
adhesion molecules such as integins, receptor proteins, Ig domain containing proteins and 
ectro-enzymes, amongst others. Moreover, many of the tetraspanins were found to associate 
with one another (for an extensive list of binding partners see (Yáñez-Mó et al., 2009)). There 
is also some evidence for association with intracellular signalling molecules, however it is not 
clear is this is a direct interaction (Charrin et al., 2014). By varying the strength of detergent 
used for extraction, it was found that the degree of interaction varied (Rubinstein et al., 1996). 
Primary interactions refer to those that are retained under the most stringent detergents 
when tetraspanin-tetraspanin interactions have been abolished; these include specific highly 
stoichiometric associations between tetraspanins and partner molecules. Weaker detergents 
maintain secondary interactions (including those between tetraspanins) which are thought to 
represent association of two proteins through an intermediary tetraspanin-tetraspanin 
interaction. For example, the metalloproteinase MT1-MMP will co-immunoprecipitate with 
CD9 but is only in Förster resonance energy transfer (FRET) distance of CD151 (Yanez-Mó et al., 
2008). Tertiary interactions include a broad array of proteins and are only found when using 
the mildest of detergents (such as CHAPS) for lysis. Little is known about the nature of these 
interactions, although the physical proximity of interacting proteins has been confirmed 
(Szöllósi et al., 1996; Yáñez-Mó et al., 2009).  
Tetraspanin-tetraspanin interactions are thought to initiate in the Golgi resulting in homo and 
heterodimers which are then transported to the cell surface (perhaps by aid of a 
transmembrane chaperone) where they act as TEM building blocks 
  
1
8 
Figure 1.3 Diagrammatic representation of proposed TEM architecture. Robust highly stoichiometric primary interactions are followed by secondary 
interactions (including those between tetraspanins) which enable the coalescence of tetraspanin-partner complexes and interaction of different primary 
partners. The coming together of multiple tetraspanin-partner units through tetraspanin-tetraspanin interactions results in the formation of a large multi-
molecular complex with tertiary interactions resulting from this higher order structure. The depicted hexagon structure is based on those found in urothelial 
plaques composed of the specialised uroplakin tetraspanins. Taken from (Martin et al., 2005) 
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(Berditchevski and Odintsova, 2007; Kovalenko et al., 2004). Several tetraspanin-partner 
interactions have also been shown to take place in early biosynthesis with tetraspanins 
proposed to aid in partner protein trafficking (section 1.1.3.2). Partner proteins have been 
shown to vary depending on the cell type, for example CD81 associates with CD19 in B cells 
whilst in T cells it associates with CD4 (Charrin et al., 2009). Moreover, partner protein have 
even been shown to change during tumour progression (Le Naour et al., 2006).  
Co-immunoprecipitation after extraction in mild detergents can result in incomplete 
membrane solubilisation which may give rise to a number of false positives when determining 
tetraspanin binding partners (Claas et al., 2001). However, more advanced techniques have 
since corroborated the existence of such associations. For instance, CD9 and CD151 
association with the adhesion molecules ICAM-1 and VCAM-1 has been evidenced by FRET 
(Barreiro et al., 2008) as was the association of CD151 with the metalloproteinase MT1-MMP 
(Yanez-Mó et al., 2008). A lack of mAbs towards many tetraspanin members made confirming 
tetraspanin-tetraspanin association difficult also; but these have similarly been proven using 
various alternative methods. For example, chemical cross linking of CD9 showed homodimers 
formed in the Golgi (Kovalenko et al., 2004) and FRET analysis demonstrated the existence of 
CD9-CD151 heterodimers along with CD9-CD9 homodimers at the cell surface (Barreiro et al., 
2008). A number of studies have evidenced secondary associations which take place via a 
tetraspanin intermediary. For instance, the CD9 binding partner, CD9P-1, only interacts with 
CD81 when CD9 is also expressed (Charrin et al., 2003a) and interaction of the CD151 binding 
partner, integrin α1β3, with other tetraspanins is abrogated in the absence of CD151 (Takeda 
et al., 2007) . 
The existence of TEMs has also been proven using advanced microscopy techniques. For 
instance the diffusion patterns of a single CD9 molecule were monitored using total internal 
reflection fluorescence (TIRF) microscopy (Espenel et al., 2008). In the study, regions of the 
membrane were identified which were enriched in both CD9 and CD81 and the stability of 
these tetraspanin enriched areas (TEAs) was unaffected by cholesterol depletion or 
cytoskeletal elements and was therefore suggested to be dependent on protein-protein 
interaction. CD9 molecules outside of TEAs displayed Brownian motion and were thought to 
form transient homodimers due to the propensity of two CD9 molecules to co-diffuse for short 
intervals. Unusually the increased size of the co-diffusing molecules did not reduce their rate 
of diffusion (which would normally be expected). This led the authors to suggest their 
existence within a cluster of other tetraspanins and partner proteins. Inside the TEAs, CD9 
showed a more restricted , lower diffusion rate than in the rest of the cell, indicating an area 
of confinement (Espenel et al., 2008). Fluorescence recovery after photo bleaching (FRAP) by 
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Barreiro et al. (2008) also demonstrated that tetraspanins and other members of TEMs 
diffused at much slower rates than the lipid raft marker GPI-EGFP. 
The web phenomenon is perhaps best exemplified in the bladder urothelium, in which the 
specialised tetraspanins UPIa and UPIb interact with partner protein UPII and UPIII 
respectively. Interaction of these proteins leads to the formation of 16nm urothelial plaques 
which cover the bladder surface and help to maintain a permeability barrier (Wu et al., 2009). 
Cryo-EM studies and cross linking analysis on these naturally forming 16nm particles 
demonstrated that tetraspanin partner interaction is facilitated through both transmembrane 
and extracellular regions and varying levels of protein-protein interactions lead to the 
formation of a distinct microdomain (Min et al., 2006; Wu et al., 1995) 
The discovery of membrane microdomains has seen the original fluid mosaic model of the 
plasma membrane somewhat disregarded/altered in favour of one in which related proteins 
are grouped to carry out functions more efficiently. However the idea of membrane protein 
organisation is not unique to TEMs. In 1997 Simons et al (1997) proposed the idea of distinct 
platforms enriched in sphingolipids and cholesterol which contain mostly saturated 
phospholipids. These platforms are now known as lipid rafts and are thought to form a liquid 
ordered phase within a liquid disordered environment, leading to protein segregation and 
clustering. Other membrane microdomains also exist, such as caveolae which appear as flask 
shaped invaginations in the cell membrane. These micromdomains are linked to endocytosis, 
and as well as being enriched in glycosphingolipids and cholesterol, they also contain the 
membrane proteins caveolin (Thomsen et al., 2002).  
There are a number of common features between TEMs and lipid rafts, for instance both 
contain cholesterol, gangliosides and glycosphingolipids. Lipid rafts partition into the detergent 
resistant fraction of density gradients and in some circumstances tetraspanins do also. 
Palmitoylation is required for the partitioning of proteins into lipid rafts and is also required for 
many tetraspanin-tetraspanin interactions (Charrin et al., 2002, 2003a; Claas et al., 2001; Yang 
et al., 2004). However, a number of physical and molecular differences reveal TEMs as a 
distinct type of microdomain. Firstly in their composition; there has been no reported 
associations of tetraspanins with GPI-linked proteins or caveolin (which are used as markers 
for lipid rafts and caveoli) and proteomics of lipid raft-resident proteins has not identified any 
tetraspanin family members (Foster et al., 2003; Le Naour et al., 2006) a number of G-protein 
subunits have been identified in both lipid rafts and TEMs however (Le Naour et al., 2006). 
Their physical properties also differ, in contrast to lipid rafts, TEMs are disrupted with Triton X-
100 at 4ᵒC but are maintained at 37ᵒC under milder detergents (Le Naour et al., 2006). 
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Moreover, TEMS are more resistant to cholesterol depletion than lipid rafts (although are still 
partially disrupted) (Charrin et al., 2003b; Hemler, 2005). Finally, FRAP analysis by Barreiro et 
al. (2008) revealed that TEM associated proteins diffused at much slower rates than a 
commonly used lipid raft marker. 
This organising potential of TEMs along with the multitude of partner proteins has led to their 
implication in a plethora of different processes both in normal physiology and also in disease, 
some of which will be discussed here. 
1.1.3.2 Protein trafficking  
In addition to their organising capacity at the cell surface, tetraspanins have also been shown 
to aid trafficking of their associated protein partners, with just a few instances being discussed 
here. 
The immunoglobulin family member CD19 is the molecular partner of tetraspanin CD81 in B 
lymphocytes and its surface expression is significantly reduced in CD81 knockout mice 
(Tsitsikov et al., 1997). CD19 mRNA levels were unaffected in CD81-/- cells indicating a 
posttranscriptional involvement of CD81; which was also suggested due to CD19s significantly 
slower transit from the ER to the Golgi in these cells (Shoham et al., 2003). Gene knockouts of 
other tetraspanins had no such effect and the use of CD9/CD81 chimeras demonstrated that 
the CD81 EC2 domain was not required for CD19 expression. Surprisingly the first 
transmembrane domain (TM1) alone was sufficient to restore CD19 surface expression; this is 
suggested to be because this region can facilitate the release of CD19 from a transmembrane 
chaperone (Shoham et al., 2006). 
In contrast to CD81, CD151 knockout cells did not show diminished expression of CD151 
integrin partners, α3β1 or α6β4, at the cell surface (Winterwood et al., 2006). However, RNAi 
mediated silencing of CD151 in carcinoma cells led to reduced motility on certain surfaces, due 
to the loss of CD151 not only preventing integrin association with TEMs, but also significantly 
reducing their internalisation rate, leading to persistence at the surface and increased 
adhesive contacts. CD151 trafficking is suggested to involve the C-terminal YXXφ motif 
previously mentioned (section 1.1.2.1), thought to enable selection for clathrin dependent 
endocytosis by interaction with adaptor complexes (Winterwood et al., 2006) 
Some of the less well characterised tetraspanins which contain eight cysteine residues 
(TspanC8) also aid in the trafficking of their partner proteins, specifically a surface 
metalloproteinase, ADAM10, which cleaves and activates the transcription factor Notch. In this 
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instance the TspanC8 proteins regulate ADAM10 release from the ER and in doing so are able 
to regulate its cleavage ability and subsequent notch signalling (Dornier et al., 2012) 
1.1.3.3 Migration and adhesion  
Integrins are a family of membrane proteins composed of αβ heterodimers, through 
interaction with other cells and extracellular matrix components, they can alter cellular 
adhesion and migratory properties (Hemler, 1990). Integrins are prime examples of primary 
tetraspanin partner proteins which exhibit strong tetraspanin interactions that are stable in a 
variety of detergents. It is perhaps unsurprising then that tetraspanins have been implicated in 
a number of adhesion and migratory processes. 
Tetraspanin-integrin associations are known to take place early in their biosynthesis and 
tetraspanins have been shown to regulate integrin trafficking and turnover. CD151 is perhaps 
most well-known for its interaction with integrins and, as previously mentioned, CD151 
mediated endocytosis of α3β1 and α6β4 has pronounced effects on cellular migration (Liu et 
al., 2007). A role of CD151 in adhesion strengthening has also been shown using fibroblasts 
expressing mutant CD151 which lacks the C-terminal tail. Although initial adhesion was 
unaffected in these mutant cells, the strength of adhesion to laminin did not increase over 
time (in contrast to cells expressing wild-type CD151) (Lammerding et al., 2003). This is 
thought to result from loss of CD151 C-terminus interaction with unidentified membrane 
proximal elements following integrin α6β1 attachment which would normally result in 
adhesion strengthening. CD81 has also been shown to affect adhesion strengthening although 
in different cell types (monocytes and B cells). Interestingly CD81 also enhanced initial capture 
events of α4β1 to VCAM-1 (Feigelson et al., 2003). 
In addition to integrins, tetraspanins also associate with the integrin receptors ICAM-1 and 
VCAM-1, which enables another means by which they are able to regulate adhesion and 
migration. Barreiro et al. (2005) showed that treatment of endothelial cells with recombinant 
CD9 or CD151 EC2 domains, or siRNA knockdown of CD9 and CD151 resulted in reduced 
lymphocyte transmigration and increased detachment under shear stress. This is thought to 
happen due to the disruption of TEMs (also called endothelial adhesive platforms (EAPs)) 
which result from co-recruitment of tetraspanins and adhesion molecules to specific 
lymphocyte engagement sites. These form a docking structures on endothelial cells, clustering 
adhesion molecules and in so doing enable more efficient capture and transmigration (Barreiro 
et al., 2008).  
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1.1.3.4 Cell fusion 
One of the most well documented tetraspanin roles is that of CD9 in sperm-egg fusion. From 
the first observation in 2000 that CD9-/- oocytes were unable to fuse with sperm cells, it has 
since been discovered that treatment of oocytes with recombinant CD9-EC2 domains or anti-
tetraspanin monoclonal antibodies is also sufficient to inhibit fusion (Miller et al., 2000; Le 
Naour et al., 2000; Zhu et al., 2002). Interestingly, pre-incubation of sperm with CD9-EC2 
domains has no effect on fusion and male CD9 knock-out mice do not exhibit reduced fertility, 
thus indicating an in-cis effect of CD9 at the oocyte surface (Kaji et al., 2000). CD9 has since 
been suggested to coordinate the formation of adhesion sites at the egg surface, resulting in a 
tight interface between the gametes, enabling cell fusion (Jegou et al., 2011). 
This is not the only instance of tetraspanins being involved in cellar fusion; they have also been 
implicated in fusion of muscle cells to form myotubes, renewal of photoreceptor outer discs 
and monocyte fusion (Boesze-Battaglia et al., 2003; Tachibana and Hemler, 1999). Monocytes 
do not traditionally undergo fusion and instead circulate in the blood before differentiating in 
the tissues to form mononucleate macrophages. In the rare event of monocyte fusion, the 
resultant cells are known as osteoclasts when found in the bone and multinucleated giant cells 
(MNGCs) when found in cases of chronic inflammation (Chen et al., 2007). Monocytes are 
thought to form these larger entities to enable more efficient resorption of bone, or for the 
extracellular killing of microbes. Given that this is not the traditional route of monocyte 
progression it is a tightly regulated process and investigation into tetraspanin involvement has 
displayed varied effects for different members. Antibodies towards CD9 and CD81 were shown 
to enhance Con-A induced MNGC formation whereas anti-CD63 antibodies had the inverse 
affect and CD151 had no significant affect (Parthasarathy et al., 2009; Takeda et al., 2003). The 
inhibitory role for CD9 and CD81 was also exhibited by CD9-/- and CD81-/- monocytes which 
showed enhanced fusion individually and spontaneous fusion when knocked-out together 
(Takeda et al., 2003). Interestingly, the EC2 domain of CD9 and CD63 when added exogenously 
to the cells as a recombinant GST fusion proteins also inhibited cell fusion whereas CD81 EC2 
had no significant effect suggesting a more direct role of CD9 in this type of fusion 
(Parthasarathy et al., 2009; Takeda et al., 2003) 
Tetraspanins have also been linked to viral induced cell fusion that results in multinucleated 
giant cells known as syncytium, proposed to aid in viral dissemination in an infected host. For 
instance, overexpression of CD9 or CD63 in HeLa or Jurkat cells results in a significant decrease 
in HIV induced syncytium formation and the reciprocal effect is seen when expression of these 
proteins was knocked down (Weng et al., 2009). It is not known exactly how this happens but 
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the recruitment of viral proteins GAG and ENV into TEMs has been implicated. In contrast to 
CD9 and CD63, a positive regulatory role has been described for CD81 in HTLV-1 syncytium 
formation as anti-CD81 antibodies have been shown to reduce syncytium formation and CD81 
associates with a number of viral proteins on the plasma membrane and on intracellular 
vesicles (Fanaei et al., 2011). 
1.1.3.5 Immune function 
T helper cells (Th) are activated by interaction with class II major histocompatibility complexes 
(MHC) on the surface of antigen presenting cells (APCs). A single signal in isolation is not 
sufficient for T cell activation and instead there is a requirement for T-cell receptors to engage 
multiple, peptide primed MHC molecules on the opposing cell. Clustering of MHC molecules 
on APCs at the point of T-cell engagement (also known as the immunological synapse) is 
crucial for activation and is now known to involve TEMs (Kropshofer et al., 2002). Interestingly, 
lipid rafts have also been shown to cluster MHC molecules, however far more MHC complexes 
can be isolated from TEMs and their peptide composition is more restricted than those 
isolated from rafts, indicated another physiological difference between the two microdomains. 
(Kropshofer et al., 2002). Disruption of the membrane microdomains using the glycoside, 
saponin, significantly reduced T cell activation. Similarly Unternaehrer et al. (2007) found that 
knocking out CD9 led to disruption of heterologous MHC molecules dimers, also suggesting a 
role for tetraspanins in enhancing T cell stimulation. It is therefore surprising that knocking out 
tetraspanins CD37 and CD151 in dendritic cells led to a hyperstimulatory phenotype (Sheng et 
al., 2009). Investigation into this response found that these two tetraspanins have differing 
roles in T-cell activation with CD37 being involved in MHC clustering and CD151 regulating co-
stimulation. The authors suggest that the unexpected phenotype is a result of tetraspanin 
members having differing functions in T-cell activation some stimulatory and some inhibitory. 
CD81 was original found as the target of an anti-proliferative antibody towards B cells and has 
since been linked to a number of immune functions (Oren et al., 1990). Along with its 
requirement for efficient glycosylation, transport and activation of CD19 in B cells, CD81 is also 
thought to act as a co-stimulatory molecule in T cells (Witherden et al., 2000). Its activity was 
akin to that of another co-stimulatory molecule, CD28, although the two pathways are distinct 
and lead to differing cytokine profiles. Additionally, antibody cross linking of CD81 and CD63 
on natural killer (NK) cells leads to increased migration towards various cytokines, an effect 
thought to be mediated through increase phosphorylation of ERM proteins (a family of 
proteins which link the membrane to the actin cytoskeleton (Arpin et al., 2011; Krämer et al., 
2009).  
Chapter 1: Introduction 
25 
 
1.1.3.6 Disease 
Tetraspanins are linked to a number of pathologies, perhaps most evidently to those which are 
a direct result of mutations within the tetraspanin genes. For instance, mutation of tetraspanin 
Tspan7 results in X-linked mental retardation (Abidi, 2002) and mutation of CD81 EC2 leads to 
severe immune deficiency from an inability to mount an antibody mediated immune response 
(Van Zelm et al., 2010). A premature stop codon in CD151 results in renal failure, skin blistering 
and deafness which reflects this proteins importance in basement membrane formation in the 
kidney and skin and mirrors the effect seen of various integrin mutants (Crew et al., 2004). 
Finally mutation in the EC2 domain of Tspan 12 leads to progression vision loss in the form of 
familial exudative vitreoretinopathy (FEVR)(Yang et al., 2011). This is thought to arise from 
developmental issues and subsequent deficiencies in signalling through norrin/β-catenin 
(Junge et al., 2009) 
Tetraspanins involvement in cancer was initially as markers for cancer type, progression and 
prognosis, for instance CD63 (initially known as melanoma associated antigen) is highly 
expressed in early melanoma stages and is much reduced in later phases (Hotta et al., 1988). 
Tetraspanins are now known to regulate cell behaviour at multiple cancer stages, for instance, 
although they are not as strongly linked to initial tumour formation, ablation of CD151 in 
breast cancer xenograft models reduced tumour initiation through integrin redistribution 
(Yang et al., 2008). Many reports using anti-CD9 antibodies or genetic knockdown of CD9 have 
demonstrated its ability to inhibit cancer metastasis (Powner et al., 2011). Similarly CD82 is 
also able to reduce metastasis and low expression levels of both CD9 and CD82 is linked to a 
poor prognosis (Boucheix and Rubinstein, 2001). On the other hand introduction of CD151 or 
Tspan8 results in enhanced metastasis (Zöller, 2009), again exhibiting the contrasting role 
which tetraspanins can display. The exact mechanism by which tetraspanins modulate cancer 
activity is in the most part unknown, but is most likely due to their association with integrins 
and proteinases which can themselves alter cellular migration.  
Tetraspanins have been identified as the initial pathogen binding partners (enabling 
subsequent infection) in several infectious diseases. One of the most prominent is hepatitis C 
(HCV) infection of hepatocytes mediated through viral protein E2 binding of tetraspanin CD81 
(Pileri et al., 1998). CD81 not only enables entry of HCV but is also involved in downstream 
processes. For example, in CD81 negative cells, the viral protein E1E2 was retained in the ER, 
whilst in those which were transfected with human CD81, E1E2 was transported through the 
Golgi and found within exosomes which are suggested to fuse to and infect other cells 
(Masciopinto et al., 2004). Tetraspanins are also indirectly linked to HIV entry, as recombinant 
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EC2 domains of several tetraspanins along with an anti-CD63 mAb block macrophage infection 
by HIV (Ho et al., 2006; von Lindern et al., 2003). CD63 silencing also inhibited HIV reverse 
transcription and CD63 is suggested to exhibit these pro-infectious properties due to its 
trafficking of CXCR4 (a GPCR which acts as a HIV co-receptor) (Yoshida et al., 2008). These are 
just two examples of tetraspanin involvement in viral infection; however there are a number 
of other instances (Hassuna et al., 2009; Martin et al., 2005; Monk and Partridge, 2012) 
Tetraspanins are also linked to bacterial infection with the most well characterised interaction 
being between the uroplakin UP1a and uropathogenic E. Coli (UPEC). Similarly to CD81-HCV 
interaction, the UP1a-FimH association acts as an initial point of pathogen binding and enables 
subsequent infection of the bladder epithelium (Wu et al., 1996). Interestingly, it was more 
recently shown that following initial binding of FimH to a mannose moiety on UP1, a global 
conformation change takes place across the uroplakin complex both extracellularly and in the 
transmembrane regions (Wang et al., 2009). Despite this being the only documented direct 
interaction of tetraspanins with bacteria, they have been linked indirectly to many other 
bacterial infections also. For instance CD81 knockout HeLa cells exhibited its importance in 
listeria internalisation and work by our group showed several anti-tetraspanin antibodies and 
recombinant EC2 were able to prohibited meningococcal adhesion to endothelial cells (Green 
et al., 2011; Tham et al., 2010). Moreover, tetraspanins have also been implicated in a number 
of fungal and even plasmodium infections (Monk and Partridge, 2012) 
1.1.3.7 Trans associations and specialised functions 
Although tetraspanins are mainly known for their lateral associations within the membrane 
there are a number of instances of trans associations, for example with a specific ligand or a 
surface protein on another cell. The first identified tetraspanin ligand was pregnancy specific 
glycoproteins 17 (PSG17) and the use of blocking antibodies and knockouts exhibited its 
specificity for CD9 (Waterhouse et al., 2002). Later results showed that PSG17 binding requires 
SFQ residues within the CD9 EC2 domain which are also those required to enable sperm-egg 
fusion (Ellerman et al., 2003). Yeast-two-hybrid screening identified CD63 as the binding 
partner of the matrix metalloproteinase inhibitor TIMP-1, (which was later confirmed using 
shRNA knockdown of CD63) (Jung et al., 2006). TIMP-1 binding of CD63 is required for its cell 
surface association and intergrin co-localisation. The same study also showed that CD63 is 
required for several TIMP-1 functions for instance promoting cell survival through inhibition of 
the caspase pathway. Finally two instances of tetraspanin ligand interaction were discussed In 
the previous section (1.1.3.5) with CD81 binding HCV protein E2 and UPIa binding UPEC 
adhesin Fim-H. 
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Although the tetraspanins UP1a and UP1b in the bladder and ROM-1 and peripherin/RDS in 
the eye act in the more convention manner of forming lateral interactions, their specialised 
functions are distinct from traditional tetraspanins. As previously mentioned (section 1.1.3.1) 
the two uroplakins UPIa and UPIb form heterodimers with their respective partner protein 
UPII and UPIII and a network of these hetrodimers results in a plaque which help form a 
permeability barrier (Min et al., 2006). Peripherin/RDS and Rom-1 are located in the rim 
membrane of the disc structures found in the outer segment of photoreceptor cells. 
Peripherin/RDS is required for morphogenesis and stabilisation of the rim, evidenced by the 
lack of outer segment in homozygous negative mice and disordered structure found in 
heterozygous mutants (Sanyal and Hawkins, 1981). On the other hand knock-outs of Rom-1 led 
to larger more disordered discs and mutants have a far less serious phenotype than that of 
Peripherin/RDS mutants indicating a more supportive role for this protein(Boon et al., 2008; 
Clarke et al., 2000). As may be expected from tetraspanin family members, these proteins are 
thought to form multi protein complexes (tetramers) which in turn form larger oligomer 
structures which are required for disc formation (although in contrast to traditional 
tetraspanins heterodimers are thought to be stabilised by intermolecular disulphide bonds) 
(Boon et al., 2008; Loewen and Molday, 2000)  
1.1.3.8 Studying tetraspanin 
Despite tetraspanins being involved in a multitude of processes, relatively little is known about 
the effects of individual members. Many different methods have been used to assay their 
function with varying levels of success. For example, knockout mice frequently display mild 
phenotypes probably because of a level of redundancy within the tetraspanin web (Charrin et 
al., 2009; Hemler, 2005; Weng et al., 2009). The occasional phenotypes which are displayed 
have shed some light on the activities of certain tetraspanins. For instance, the previously 
mentioned CD9 knock-out mice displayed CD9s importance in fertility, and CD9, CD81 double 
knockout monocytes exhibited spontaneous fusion (Section 1.1.3.3) (Miller et al., 2000; 
Takeda et al., 2003). Additionally, further cellular examination of knock-out mice previously 
considered “normal”, has identified subtle defects such as CD37-/- dendritic cells which have 
impaired in vivo migration, adhesion and spreading and altered T-cell stimulation (Gartlan et 
al., 2013; Sheng et al., 2009). Anti-tetraspanin monoclonal antibodies have also been shown to 
modulate tetraspanin function and are often used in collaboration with other techniques to 
corroborate results. For instance studies have shown that anti-CD151 antibodies inhibit CD151 
association with α3β1 and in doing so, greatly reduced the integrins ligand binding capability 
thus suggesting CD151 stabilises α3β1 in an active conformation (Nishiuchi et al., 2005). 
Monoclonal antibodies do however have drawbacks: they are difficult to raise against some 
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tetraspanins due to poor immunogenicity, they may cause remote unrelated results because 
of their inherent ability to interact with fragment crystallisable (Fc) receptors and they may 
cross-link both tetraspanins and partner molecules within TEMs due to their divalent nature 
(Hassuna et al., 2009; Wright et al., 2004) 
As mentioned previously (section 1.1.2.4), the high level of variability between EC2 domains of 
different family members has led to the suggestion that they are responsible for some specific 
functions of individual tetraspanins. Furthermore, the CD81 crystal structure, NMR and 
conformationally sensitive antibodies have shown that EC2s domain can be correctly folded 
when expressed alone (Higginbottom et al., 2003; Kitadokoro et al., 2001; Rajesh et al., 2012). 
These factors, along with recombinant EC2 domains ability to bind to other tetraspanins and 
partner proteins has led to the use of these proteins in a number of functional studies 
(Parthasarathy et al., 2009, Ho et al., 2006, Barreiro et al., 2005), some of which will be 
discussed here, along with their proposed mechanism of action. 
To examine the involvement of TEMs in the adhesion of leukocytes to endothelial cells, 
Barreiro et al. (2005) treated endothelial cells with recombinant CD9-EC2-GST fusion proteins. 
Electron microscopy revealed that when endothelial cells were treated CD9-EC2-GST the 
spacing of the reported TEM associated receptors ICAM-1 and VCAM-1 was increased over the 
untreated counterparts. Furthermore, the pattern of distribution of these two receptors was 
also altered and this trend was not seen in cells treated with heat inactivated CD9-EC2-GST. 
Moreover, treatment of the endothelial cells with CD9 EC2 not only decreased CD9 diffusion 
but also decreased diffusion of CD151, therefore indicating that modulation of one tetraspanin 
may affect the TEM as a whole. The authors suggest that this occurs due to exogenous CD9-
EC2-GST competing with endogenous CD9 for both homotypic interactions with other native 
CD9 molecules and heterotypic interaction with partner proteins, which in turn disrupts the 
TEM (Barreiro et al., 2008). In an earlier study by Zhu et al. (2002), recombinant CD9 EC2 
domains were also used, in this case to study their effects on sperm-egg fusion. When eggs 
were pre-incubated with CD9-EC2 their rate of fusion was lowered, however, a similar affect 
was not seen when sperm were pre-incubated. This showed that the EC2 domains were acting 
in cis, leading the authors to again speculate that exogenous CD9 competes with endogenous 
CD9; however, they did add that the inability of recombinant CD9 EC2 to display the complete 
function of CD9 is most likely due to the lack of transmembrane regions. Higginbottom et al. 
(2003) similarly used recombinant EC2 domains to study sperm-egg fusion and demonstrated 
an inhibitory effect with CD81 EC2 (albeit a less dramatic inhibition than CD9 EC2). In this study 
mutation of specific residues displayed the functional importance of several conserved 
cysteines within the EC2.  
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As previously discussed, the use anti-CD9 and anti-CD81 mAbs along with and CD9/CD81 
knockout mice led Takeda et al. (Takeda et al., 2003) to reported a negative regulatory role for 
these tetraspanins in monocyte fusion. In addition to these methods, the authors also used 
recombinant EC2 domains corresponding to CD9. Interestingly anti-CD9 mAbs and GST-CD9 
showed opposing effects on cell fusion, with EC2 domains inhibiting monocyte fusion in a dose 
dependent manner and anti-CD9 mAbs enhancing fusion. This emphasised the different modes 
of action between mAbs and EC2 domains. In a similar experiment, Parthasarathy et al. (2009) 
showed recombinant EC2 domains of tetraspanin CD63 were also able to inhibit fusion 
whereas CD81-EC2 and mouse CD9-EC2 had no effect. Not only does this show EC2 domains 
from different family members have specific interactions (and therefore different outcomes) 
but also exhibits the variation between EC2 domains originating from different species.  
Kelid et al. (2001) were able to show specific binding of CD81-EC2-GST to neurones and not 
astrocytes, despite endogenous expression of CD81 on both cell types. This suggested the 
existence of a CD81 ligand on neurons, additionally, recombinant CD81 was thought to 
compete with native CD81 for receptors on the neurone and in doing so block neuron-induced 
astrocyte proliferative arrest.  
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1.2 Mast cells  
1.2.1 History  
Multiple studies have linked tetraspanins to mast cells, with a specific focus on tetraspanins 
role in the activation of mast cells in response to specific stimuli (Fleming et al., 1997; Köberle 
et al., 2012; Kraft et al., 2005; Peng et al., 2011). Despite these investigations being able to 
show tetraspanins involvement in activation there is still no definitive answer as to their 
specific role, the aim herein was to develop our understanding or tetraspanin involvment in 
mast cell activation by IgE.  
Granulated cells within tissue were first described in 1863 by Friedrich von Recklinghausen, 
however it was not until 1879 when these cells were first called “Maztzellen” or “Mast cells” 
(meaning well-fed cells) by Paul Ehrlich (Blank et al., 2013; Ehrlich, 1879). Mast cells have since 
become known as key players in both immunity and disease and it has been established that 
they are of the myeloid lineage, originating in the bone marrow and circulating in the blood, 
before migrating to the tissues where they undergo maturation (Gurish and Boyce, 2006). 
They have a common morphology with distinct electron dense granules within the cytoplasm. 
These granules contain cytokines, proteases, histamine and serotonin and in response to 
certain stimuli these components can be rapidly released to the surroundings. In addition, 
mast cells are able to release de novo synthesised cytokines along with several lipid based 
signalling molecules (Plaut et al., 1989).  
Despite a common morphology, mast cells are a heterogeneous population, which have been 
divided into a number of groups. The first groups to be established were based on staining 
differences in mast cells isolated from the rat gastrointestinal mucosa and were entitled 
mucosal mast cells (MMCs) and connective tissue mast cells (CTMC). Human mast cells were 
later divided based on their protease content with one group containing only tryptase (MCT) 
and the other group containing both tryptase and chymase (MCTC) (Irani et al., 1986). A third 
group also exists which express chymase and capthesin G (MCc), although these are much less 
prevalent (Metcalfe, 2008). Further subdivisions have since been made based on differences in 
granular content, response to stimuli, drug inhibition, histamine content and proteoglycan 
composition amongst other factors (Metcalfe et al., 1997). Differences in mast cell properties 
are suggested to stem from requirements for residing in various tissues or for responding to 
different pathogens (Abraham and St John, 2010).  
The primary function of mast cells was initially unknown, however, the finding that their 
granules contain histamine along with the prior knowledge that this substance could cause 
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smooth muscle contraction led to the suggestion of mast cells involvement in anaphylaxis 
(Riley and West, 1953). Later work recognised the association of mast cells with IgE, a subtype 
of antibodies initially known as the serum factor, able to transfer hypersensitivity from one 
animal to another (Ishizaka et al., 1967; Kulczycki et al., 1974). It was not until years later that 
the beneficial effects of mast cells were hinted upon when it was discovered that they are able 
to synthesise cytokines, specifically IL-4, opening the possibility for a role beyond allergic 
effectors (Brown et al., 1987). This possibility was solidified when mast cell activity was 
exhibited in parasitic (specifically nematode) expulsion and In the following years various 
studies have shown their ability to phagocytose microbes, process and present antigen and 
produce vasoactive substances and cytokines (Metcalfe et al., 1997; Woodbury et al., 1984).  
Mast cells are now seen as an important player in the host immune response, acting as 
sentries to announce the presence of pathogens, effector cells able to themselves destroy 
invading microorganisms and signalling cells modulating both innate and adaptive immune 
responses (Galli et al., 2005).  
1.2.3 Mast cells in immunity  
1.2.2.1 Pathogen detection 
As mast cells are predominantly found in the mucosal tissues at the boundary with the outside 
environment, they are often one of the first immune cells to encounter infection and so it may 
not be surprising that mast cells are well equipped for pathogen detection. Similarly to 
dendritic cells, neutrophils, epithelial and endothelial cells, mast cells are also able to detect 
pathogens through Toll-like receptors (TLRs) which recognise pathogen associated molecular 
patterns (PAMPs)(Trinchieri and Sher, 2007). In addition, mast cells contain a number of other 
non-toll like receptors which are able to recognise features specific to certain pathogens, for 
example CD48 is able to recognise fimbriated E. coli (Malaviya et al., 1999). Furthermore, mast 
cells also express a number of Fc receptors which enable them to bind to antibodies directed 
against pathogens. This allows mast cell activation with exquisite specificity against a limitless 
amount of pathogens to which the host has previously been exposed (Kawakami and Galli, 
2002). Moreover, Fc receptors have the added effect of enabling activation towards bacterial 
“super antigens” which are able to bind to various antibody subclasses indiscriminately thus 
causing Fc receptor crosslinking and degranulation (Genovese et al., 2000). Interestingly, mast 
cells can also be activated by substances such as snake and bee venom (Metz et al., 2006). 
Mast cells are not only activated by external pathogen related sources but can also be 
activated by endogenous signalling molecules. These include complement components 
signalling through the C5a receptor, Endothelin-I, substance P, neurotensin, SCF and of course 
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cytokines (Kulka et al., 2008; Nilsson et al., 1996) (for a comprehensive list of receptors and 
the signalling molecules by which and receptors see table 2 in (Galli et al., 2005)) 
1.2.2.2 Signalling  
Like other immune cells, mast cells are able to produce a multitude of cytokines, chemokines 
and growth factors which affect cells in the surrounding area (Table 1.2). Unlike many immune 
cells, mast cells contain these mediators within granules in their cytoplasm. The ability to 
immediately release these preformed mediators instead of synthesising molecules upon 
stimulation, allows a more rapid response to stimulus. The granules are predominantly 
insoluble structures within the cytoplasm, a proportion of which, once released, will become 
soluble allowing for signalling within the immediate area. However, thanks to interaction of 
positively charged proteins with negatively charged carbohydrate molecules, the majority of 
the granular content will remain in an insoluble form (Metcalfe et al., 1997; Schwartz et al., 
1981). Kunder et al. (2009) have demonstrated that when TNFα is parcelled in these insoluble 
heparin containing particles, it is protected from degradation and dilution and is therefore able 
to signal over long distances to draining lymph nodes (resulting in hypertrophy). This 
demonstrates the ability of mast cells to signal over large distances using the circulatory 
system, analogous to the endocrine system but using a smaller amount of signalling molecule.  
As previously mentioned, in addition to the release of preformed mediators upon stimulation, 
mast cells also synthesise molecules de novo. These come in the form of lipid based mediators 
which can be produced rapidly and cytokines and chemokines which have a more delayed 
production. The lipid mediators are collectively known as eicosanoids and the two subfamilies 
produced in mast cells are called prostaglandins and leukotrienes (Beaven, 2009). The speed 
by which they are produced is a result of them being synthesised from arachidonic acid which 
can be cleaved from the phospholipid bilayer by phospholipase A2. Arachidonic acid then 
follows two pathways initiated by the either cyclooxygenase in the case of the prostaglandins 
or lipoxygenase for leukotrienes. These mediators cause increased vascular permeability and 
lead to bronchoconstriction in the lungs and “wheal and flare” reactions in the skin (Beaven, 
2009) 
MHC class I is expressed on the surface of all mast cell subclasses and It has been shown that 
following enterobacteria phagocytosis, mast cells are able to present processed antigen to T 
cells (Malaviya et al., 1996). Interaction in this manner was more recently shown to activate 
and induce proliferation of CD8+ cytotoxic T cells (Stelekati et al., 2009). The case for mast cell 
involvement in MHC class II signalling is less clear because resting mast cells often show low or 
no expression of MHC class II; however in several groups its expression is drastically increased 
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following LPS of IFN-γ exposure (Henz et al., 2001). On the other hand, mast cells isolated from 
sites of inflammation caused by various diseases were shown not to express MHC class II 
suggesting a requirement for specific activation and/or maturation (Henz et al., 2001; Lipski et 
al., 1996). Mast cells are able to attract T cells, for example through secretion of lymphotactin 
a chemokine with restricted CD8+ specificity and they have also been shown to migrate to the 
lymph nodes after induced hypersensitivity, demonstrating that they can influence T-cell 
distally as well as locally (Henz et al., 2001; Wang et al., 1998).  
 
  
Class Mediators Physiological effect 
Cytokines TNF-α, TGF-β, IFN-α, IFN-β,  IFN-γ, IL-1α, 
IL-1β, 
 IL-2, IL-4, IL-5, IL-10, IL-12, IL-6, IL-13, IL-
16, IL-17, IL-18 
Inflammation, leukocyte 
migration/proliferation 
 
Chemokines IL-8 (CXCL8), I-309 (CCL1), MCP-1 (CCL2), 
MIP-1αS (CCL3), MIP1β (CCL4), MCP-3 
(CCL7), RANTES (CCL5), eotaxin (CCL11), 
MCAF (MCP-1) 
Chemoattraction and tissue 
infiltration of leukocytes 
Growth 
factors 
SCF, M-CSF, GM-CSF, bFGF, VEGF, NGF, 
PDGF 
Growth of various cell types, 
vasodilation, neovascularization, 
angiogenesis 
Table 1.2 Cytokines, chemokines and growth factors produced by mast cells, list is not 
exhaustive and some produced in vitro may not be found in vivo. Adapted from “Mast 
cells and mastocytosis” (Metcalfe, 2008) with additions from “Targetting mast cells in 
inflamtory disease” (Reber and Frossard, 2014). 
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Mast cells are adaptive and able to alter their mediator production based on the pathogens 
that they encounter and signals they receive; furthermore, they are also able to alter the 
extent of their response. For instance when encountering LPS through TLR-4 they produce IL-4 
but will not degranulate, but when stimulated by peptidoglycan through TLR-2 they will both 
produce IL-4 and degranulate (Supajatura et al., 2002). They not only alter their mediator 
synthesis but can also change the components they store within granules and because they 
are able to replenish these granules following infection, this has been considered as a type of 
immunological memory which allows a more specific response in subsequent infection 
(Abraham and St John, 2010; Toru et al., 1998). Even the protease content of granules is not a 
predetermined factor and can be altered based on their surrounding environment for instance 
IL-10 is able to stimulate the production of the mouse mast cell serine protease MMCP-2 
(Ghildyal et al., 1992). 
1.2.2.3 Mast cell as effectors  
One of the most prominent effects of mast cell activation is inflammation. Oftentimes this is 
viewed in the unfavourable context of allergy, for instance during anaphylaxis or asthma; 
however this process is also crucial to the recruitment of immune cells to sites of infection. 
The first inflammatory mediator to be identified was histamine, a small amine which is 
produced from decarboxylation of the amino acid L-histidine. It acts through G protein-
coupled receptors H1R-H4R on target cells resulting in increased vascular permeability and 
smooth muscle contraction (O’Mahony et al., 2011). Although histamine is perhaps the most 
studied contributor to mast cell induced inflammation, it is just one of a number of 
inflammatory mediators including several cytokines and leukotrienes.  
Several proteases have also been shown to modulate inflammation, for instance through 
degradation of extracellular matrix components (Caughey, 2007). The proteases are stored 
within the acidic granules in an inactive form complexed with proteoglycans, and once 
released can act on a variety of substrates. They not only contribute to inflammation but can 
also degrade potentially harmful endogenous signalling molecules attributing them a 
protective role in certain instances. For example, in mouse sepsis models, expression of the 
peptidase neurolysin leads to decrease mortality though reduction of neurotensin levels 
(which is known to promote hypertension during sepsis) (Piliponsky et al., 2008). Endothelein-
1 (ET-1) is similarly harmful during sepsis and mast cells have been show to produce, detect 
and, following activation, reduce ET-1 levels and associated pathology suggesting a 
homeostatic role for mast cells. Protease activity is not limited to endogenous products as in 
contrast to the commonly held misbelieve that mast cells contribute to snake and bee venom 
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mortality, it has now been shown that they actually reduce pathology though production of 
proteases which breakdown these harmful toxins (Metz et al., 2006) 
In addition to microbial killing via phagocytosis, mast cells also constitutively express 
antimicrobial peptides (AMPs) called cathelicidins (Abraham and Malaviya, 1997; Di Nardo et 
al., 2003). These small amphipathic α-helical molecules induce microbial killing through 
intercalation into the membrane. AMPs effect many pathogens including bacteria, fungi 
enveloped viruses and protozoa and AMP deficient mast cells demonstrated significantly 
reduced ability to kill streptococci (Di Nardo et al., 2008) 
1.2.4 Mast cells in disease  
The term anaphylaxis was first coined in 1901 by Paul Portier and Charles Richet when they 
observed that injecting dogs with Physalia tentacle extract for a second time killed them, 
despite the same dose not doing so in an initial injection. This was counter to the idea at the 
time that exposure led to protection, and although the mechanism of how it happened was 
unknown it was deemed anaphylaxis (ana= against, phylaxis = protection) (Blank et al., 2013). 
Subsequent studies showed that repeat injection of serum led to serum sickness and 
transferring the serum of someone who suffered from allergy also led to sensitivity in the 
recipient (Blank et al., 2013). We now know that the transferred serum factor which was 
responsible for sensitisation is IgE; moreover, this class of allergy is now called type I 
hypersensitivity and is one of four different classes of allergy proposed by Robin Coombs and 
Philip Gell in 1963 (Rajan, 2003). Type II hypersensitivity is a result of complement activation 
initiated through IgG or IgM binding to the cell surface. Type III hypersensitivity occurs when 
antibodies bind to soluble target antigens in the blood and are deposited on the basement 
membrane leading to tissue damage. Finally type IV (also known as delayed type) 
hypersensitivity is not mediated by antibodies but instead by T cells, both through recruitment 
of macrophages by CD4+ T cells and cell killing by CD8+ T cells (Rajan, 2003). 
In 1911 it was observed that histamine was able to cause smooth muscle contraction 
analogous to anaphylaxis, and years later it was shown that mast cells contained histamine, 
thus an initial link between mast cells and hypersensitivity was established (Riley and West, 
1953). Later work (following the identification of IgE) by Ishizaka et al., identified IgE binding 
sites on mast cells and showed that IgE could cause histamine release, therefore linking both 
mast cells and IgE to Type I hypersensitivity (Ishizaka et al., 1967, 1970) 
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1.2.4.1 IgE receptor signalling 
Despite current knowledge of mast cells beneficial roles, much of the work on them still 
focuses on their involvement in allergy specifically as the main effector cells in Type-1 
hypersensitivity. Also known as immediate type hypersensitivity (due to the quick appearance 
of symptoms), this form of allergy is now known to be instigated by IgE antibodies produced 
towards an otherwise innocuous multivalent antigen. These antibodies bind to the high affinity 
IgE receptor (FcεRI) on mast cells and upon subsequent antigen exposure they are cross linked 
and a signalling pathway is initiated which leads to degranulation and synthesis and release of 
various mediators (Roberts et al., 1979). Although the focus of this section will be IgE mediated 
degranulation, there are a number of other pathways by which degranulation can take place. 
For example, in response to pathogen associated molecular pattern (PAMP) activation of toll 
like receptors (TLRs), Complement components binding to their respective receptors, stem cell 
factor binding to c-KIT, and even specific venoms have been shown to stimulate degranulation 
(Reber and Frossard, 2014)  
The high affinity IgE receptor (FcεRI) is a member of the multichain immune recognition 
receptor (MIRR) protein family. The receptor is made up of four subunits, one IgE binding α 
domain, a single β domain involved in signal amplification and two di-sulphide linked γ 
domains where the signalling initiates (Garman et al., 1998; Lin et al., 1996). High-affinity 
binding of IgE takes place through two Ig-like domains in the extracellular region of the α 
subunit, which was shown to be essential in mast cell activation in mice (Dombrowicz et al., 
1993). Interestingly, binding of IgE to FcεRI is no longer solely thought as a sensitisation step 
before degranulation, since monomeric binding of IgE has been shown in itself to promote 
mast cell survival (Asai et al., 2001; Kalesnikoff et al., 2001). β and γ subunits both contain 
immunoreceptor tyrosine-based activating motifs (ITAMs) within the cytoplasmic tails; 
however FcεRI lacks intrinsic kinase activity so initial activation require phosphorylation by one 
of a number kinases belonging to the Src tyrosine kinase family. Downstream signalling is 
complex, involving multiple pathways which are usually defined by the separate Src proteins 
which are used to initiate them (Figure 1.3). Although each pathway is distinct in terms of its 
signal transduction, each of the Src proteins are simultaneously activated by the receptor 
leading to large protein complexes called signalosomes which are primarily made up of 
adaptor proteins and kinases (Draber et al., 2012). In the primary pathway (Figure1.3a), upon 
activation of the receptor, the constitutively associated protein Lyn (a member of the SRC 
family) phosphorylates intracellular ITAM motifs on γ and β subunits (Pribluda et al., 1994). 
Signalling molecules which contain SH2 domains are then recruited, including the kinase Syk 
(another member of the Src family). The adaptor proteins LAT is one of several Syk targets and 
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once phosphorylated it recruits a number of cytosolic adapter proteins, GTP exchangers and 
signalling enzymes which results in the formation of the aforementioned signalasome. One 
such signalling enzyme PLCγ, cleaves PIP2, yielding inositol trisphosphate (IP3) and 
diacylglycerol (DAG). These lead to activation of protein kinase C (PKC) and an increase in 
intracellular calcium levels which are both required for mast cell degranulation and eicosanoid 
formation (reviewed in (Metcalfe et al., 2009)). The discovery that Lyn deficient mast cells 
were able to degranulate to a normal extent (Nishizumi and Yamamoto, 1997) led to the 
identification of a second pathway (Figure 1.3b) which functions though an alternate Src 
Kinase Fyn and the adaptor protein GAB-2 (Parravicini et al., 2002). These activate PI3K which 
in turn activates Akt leading to the phosphorylation of PIP2. This enabling recruitment of Btk 
and PLCγ which can function as previously mentioned (Sibilano et al., 2014). More recently a 
third pathway has also been identified (Figure 1.3c) which utilises the Src proteins Fgr and Hck. 
Although this is less well characterised, it is known that Fgr and Hck are positive regulators of 
degranulation and cytokine production (Hong et al., 2007; Lee et al., 2011). Down regulation of 
degranulation signals is important for fine tuning and prevention aberrant activation and as 
such there are a number of negative regulators include SHIP1 and SHIP 2 (Src homologue 
containing inositol phosphatase), PKCδ, allergin-1 and RabGEF-1 (Reber and Frossard, 2014).  
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Figure 1.4 Pathways involved in IgE mediated degranulation. (A, B, C) show early steps in 
mast cell activation pathway following FcεRI crosslinking by antigen. Each panel represents 
initiration by a differing Src Kinase family member (D) molecular pathway of mast cell 
desensitisation arrows indicate positive signals and red bars show inhibitory signals. 
Activation pathways are split based on the Src kinase which initiates signalling (either Lyn in 
(A) Fyn in (B) or Fgr in (C)) taken from from (Sibilano et al., 2014).  
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1.2.5 Tetraspanins and mast cells 
 Tetraspanin expression on mast cells and basophils and their involvement in said cells 
activation is as yet not fully understood. However, a number of studies have shown an 
association of various tetraspanin family members with Fc receptors (including FcεRI) or have 
described a functional involvement of tetraspanins in degranulation. CD9, CD63 and CD81 
have all been functionally associated with degranulation, CD151 on the other hand has been 
shown to be expressed on a number of mast cell subtypes but to date its only functional effect 
has been on cytokine production (Table 1.2.). Here, some of the previous studies of 
tetraspanins in mast cells will be discussed along with the proposed means in which they are 
involved. 
 
Tspan 
Splice 
variants 
Binding partners 
Link to mast cell function 
CD9 13 CD9P-1/EWI-F/FPRP 
EWI-2/PGRL 
EpCAM 
Pro-HB-EGF 
ICAM-1 
Claudin-1 
Interacts with FcγRII in plate lets (Huang et al., 
1992) 
Antibodies towards human CD9 were able to 
inhibit degranulation in  (Higginbottom et al., 
2000a) 
Co-localises with FcγRI in dendritic cells (Peng 
et al., 2011) 
Cross-linking of CD9 during activation increases 
degranulation (Peng et al., 2011) 
Possible alternative IL-16 receptor (Yadav et 
al., 2010) 
CD63 16 H+/K+-ATPase Anti-CD63 antibodies inhibited mast cell 
degranulation (Kitani et al., 1991) 
CD63 knockout BMCCs display inhibited 
degranulation (Kraft et al., 2005) 
Anti-CD63 antibody inhibited degranulation in 
rats 
Antibodies towards a CD63 granular variant 
inhibit  degranulation after a first activation 
(Schäfer et al., 2010) 
CD81 18 CD19 
Integrin α4β1 
CD9P-1/EWI-F/FPRP 
EWI-2/PGRL 
Claudin-1 
Anti-CD81 antibodies  inhibited RBL cell 
degranulation 
Anti-CD81 antibodies reduced passive 
cutaneous anaphylaxis in rats (Fleming et al., 
1997) 
CD151 21 Integrin α3β1 
Integrin α6β1 
Integrin α6β4 
Integrin αIIbβ3 
VCAM-1 
MT1-MMP 
CD151 deficient mast cells give a different 
cytokine profile after activation (Abdala-
Valencia et al., 2015) 
Table 1.3 Tetraspanin involvement in degranulation and mast cell function. Binding partners taken 
from (Charrin et al., 2009), number of splice variants from www.ensembl.org. 
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1.2.5.1 CD9 
CD9 is expressed on a number of mast cell subtypes and basophils and was shown to interact 
with FcγRII in platelets and FcεRI in monocytes (Peng et al., 2011; Qi et al., 1996). RBL-2H3 cells 
transfected with human CD9 were used to investigate its involvement in IgE mediated 
degranulation. In said study, three out of four mAbs towards human CD9 were able to 
stimulate degranulation (Higginbottom et al., 2000a). Upon further investigation it was found 
that F(ab’)2 fragments alone could not induce this effect and required the addition of an anti-
F(ab’) antibody to restored this function. This led the authors to suggest CD9 cross linking was 
not sufficient to stimulate degranulation and required Fc receptor interaction. Indeed, this 
degranulation was later inhibited via co-incubation with monomeric IgE (and not IgG1) which 
indicated an involvement of the high-affinity IgE receptor; this was also corroborated via co-
immunoprecipitation. Subsequently two models were suggested for CD9 involvement; in the 
first, CD9 monomers are brought together in complex with FcεRI resulting in its activation. In 
the second, dimers or multimers of CD9 are connected by antibody binding and FcεRI 
receptors are “enmeshed” by involvement through their Fc receptor domains with 
degranulation resulting from FcεRI immobilisation. More recently Peng et al. (2011) observed 
a relationship between expression patterns of CD9, CD81 and FcεRI on monocytes, which 
prompted them to evaluate a possible molecular association. Using both immunoprecipitation 
and fluorescence microscopy they were able to show an association of both tetraspanins and 
FcεRI. Further experiments by the same group also showed that CD9 antibodies were able to 
unregulated IL-10 production following FcεRI crosslinking.  
CD9 has also been implicated in other forms of mast cell signalling, specifically as an alternate 
IL-16 receptor. Mast cells respond to IL-16; however some subtypes do not express the 
primary IL-16 receptor CD4. The suggestion of CD9 as an alternate receptor arose from 
observations that anti-CD9 antibodies were able to inhibit the chemotactic response to, and 
BMMC activation by, IL-16 (Qi et al., 2006). More recently, however, this observation has been 
questioned due to the inability of anti-CD9 antibodies to alter the cytotoxic effects of IL-16 on 
CD4- A549 cells and the suggestion that its capacity to modulate the chemotactic effect is in 
fact an artefact (Yadav et al., 2010) 
1.2.5.2 CD63 
One of the first studies to associate tetraspanins with FcεRI showed that high concentration of 
a mAb towards (the then unidentified) CD63 was able to inhibit degranulation in RBL-2H3 cells 
(Kitani et al., 1991). It was shown that the inhibition was not due to impeding IgE binding to its 
receptor; however antibodies directed towards FcεRI could stop anti-CD63 binding, indicating 
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a close proximity to FcεRI. Later work has shown CD63 also localised to a number of secretory 
granules in a range of different cells and has subsequently been used as an activation marker 
for basophils and mast cells (Knol et al., 1991; Nishikata et al., 1992). Work by Smith et al. 
(1995) used human CD63 transfected RBL-2H3 cells to investigated human CD63 (hCD63) 
involvement in degranulation. In these experiments a number of antibodies directed towards 
hCD63 were able to induce degranulation without further stimulus. Furthermore, one 
antibody was able to partially inhibit degranulation caused by IgE crosslinking. The differing 
responses to various anti-CD63 mAbs indicated that crosslinking is not sufficient to induce 
activation and the authors suggest mAbs are acting in place of a natural hCD63 ligand. 
However, later work by the same group suggests that the results may be at least partly 
explained by interaction of the anti-CD63 antibodies with FcεRI as described above 
(Higginbottom et al., 2000a). 
More recent work by Kraft et al. (2005) also used an anti-CD63 monoclonal antibody to further 
examine the role of CD63 in degranulation. In this study the mAb was again able to inhibit IgE 
mediated RBL-2H3 degranulation, however it was shown to only affect adherent cells. Tyrosine 
phosphorylation and calcium mobilisation (early stages in the IgE primary activation pathway) 
were not affected by the mAb however it did exhibit a capacity to reduce adhesion to 
fibronectin and vitronectin. These results led to the suggestion that CD63 was acting through a 
common pathway which is able to modulate both adhesion and degranulation. CD63’s known 
interaction with α chain of β1 integrins (which bind to the aforementioned ECM components) 
revealed a possible mechanism, and further analysis led to the identification of changes within 
the PI3K, GAB-2 degranulation pathway. The authors concluded with three possible 
mechanisms. Firstly, anti-CD63 could sterically hinder integrin binding to ECM thus stopping 
positive degranulation signals. Secondly, a similar reduction in positive degranulation signals 
could result from general disruption of CD63 containing complexes which uncouple integrins 
and signalling partners. Finally, anti-CD63 could be sequestering CD63 along with associated 
signalling molecules. More recently work by Kraft et al. (2013) favoured the latter hypothesis 
and suggested that the treatment may have been affecting endocytosis (being as CD63 is 
predominantly found on intracellular membranes). They also showed that mast cells from 
CD63 knockout mice exhibited significantly reduced degranulation, and indicated a possible 
link between CD63 and t-SNARE activity (a protein required for membrane fusion)(Südhof and 
Rothman, 2009). Interestingly, being as BMMC grow in suspension, in this instance the 
reduction in degranulation was not reliant on the cells being adhered to a surface which was 
suggested to be a “particularity” of the RBL-2H3 cells originally used. 
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Schafer et al. (Schäfer et al., 2010) demonstrated the existence a distinct variant of CD63 
expressed on intracellular granules of cord blood human mast cells (CBHMCs). This variant is 
distinct from the surface expressed CD63, it is thought to be a different glycoform resulting 
from an alternative synthesis pathway or due to a different environment. Single amino acid 
mutation identified specific variation at residues C170 and N172. A mAb which bound only to 
the so called “granular variant” of CD63 was not only shown to be a useful as a marker of 
degranulation, but was also able to inhibit subsequent rounds of degranulation. The authors 
indicate a potential therapeutic application in which primary mast cell degranulation can 
function as normal but repeat degranulation is impeded.  
1.2.5.3 CD81 
Similarly to CD63, a mAb towards CD81 has also been shown to inhibit IgE mediated 
degranulation in RBL cells (Fleming et al., 1997). This antibody did not affect calcium 
mobilization or tyrosine phosphorylation either and was shown to affect degranulation in vivo 
also. The authors did not speculate as to a possible mode of action, however a similar 
modulation of mast cell signalling was shown in CD81-/- mice which exhibited reduced allergen 
induced airway hyperactivity (Deng et al., 2000). Köberle et al. (2012) suggest that these 
phenotypes may result from disruption of CD81-FcεRI interactions which regulates signaling.  
1.2.5.4 CD151 
Although evidence for CD151 involvement in degranulation is limited, in a recent study 
BMMCs from CD151 knockout mice displayed increased expression of pro-inflammatory 
cytokines following FcεRI stimulation. Although no affect was seen on FcεRI mediated 
degranulation in these cells, the authors suggest a negative regulatory role for CD151 in FcεRI 
mediated cytokine production (Abdala-Valencia et al., 2015) 
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1.3 Hosts for recombinant protein expression 
Recombinant proteins are those which are produced from recombinant DNA technology, for 
instance molecular cloning, which brings together DNA which would not conventionally be 
found (in most instances a coding gene and a vector). Since its discovery in the 1970s the field 
of recombinant protein production has developed vastly both in terms of large scale 
production of therapeutics and industrial enzymes and in small scale protein production which 
is common practice in many research laboratories (Demain and Vaishnav, 2009). Recombinant 
protein production still follows the common pathway of generation of an expression construct, 
introduction into the desired host, expression and downstream processing, but improved 
understanding of genetics and protein production has seen refinement and variation in each 
area to suit the needs of the user. Variables are primarily altered based on the desired 
properties of the final protein product, but one must also consider the ease of use, cost and 
time associated with the different systems. One of the primary considerations which must be 
made is the choice of host for expression, as each one has its own benefits and downsides 
(Wurm, 2004) 
1.3.1 Bacteria 
The Gram-negative bacteria Escherichia coli was the one of the first, and is still one of the most 
used, host for recombinant protein expression; this stems from its ease of use, quick growth 
and high yields (Terpe, 2006). Furthermore, its long standing use in research has led to 
excellent genetic characterisation thus enabling easy manipulation (Baneyx, 1999). Many 
strains of E. coli are available commercially, which are tailored for different requirements 
through the inclusion or deletion of different genetic elements. To name just a few; the 
frequently used stain BL21 is deficient in certain cellular proteases thus reducing breakdown of 
the desired product, Rosetta contain tRNA for codons which are rarely seen in E. coli 
facilitating the expression of proteins from other organisms and Origami cells have mutated 
reductases, resulting in an oxidising environment in the cytoplasm which is beneficial for 
disulphide bond formation (Demain and Vaishnav, 2009).  
Although E. coli is a common first choice for protein expression, other bacterial species have 
proven useful for different applications. Perhaps the most used (after E. coli) are the Gram-
positive class of bacterial Bacillus. These do not contain LPS within the cell wall therefore 
resultant product will not contain endotoxin contamination and Bacillus are thus favoured for 
the production of food stuffs (Westers et al., 2004). Moreover, they naturally have high 
efficiency of secretion and transport many enzymes to the growth media which enables easier 
downstream purification (Westers et al., 2004). Traditionally, high levels of protease secretion 
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into surrounding growth media meant certain Bacilli species were not amenable to 
recombinant protein expression but mutant stains are now available which show drastically 
reduced protease activity (Wu et al., 1991). 
Recombinant proteins are frequently expressed into E. coli cytoplasm due to the potentially 
higher yields (Terpe, 2006); however it is also possible for expressed proteins to be 
transported to the periplasmic space or secreted into the growth media. Expression into the 
periplasm is often favoured for proteins which contain disulphide bonds because it (a) 
removes them from the reducing environment of the cytoplasm which is detrimental to 
disulphide bond formation and (b) contains disulphide bond isomerase chaperones such as 
DsbA which aid in disulphide formation (Joly and Swartz, 1994). Expression into the periplasm 
or growth media also offers the advantage of simplified downstream purification due to there 
being fewer unwanted proteins here than the cytoplasm (the expressed protein can be 
released from the periplasm by osmotic shock or permiabilisation of the cell wall). 
Additionally, fewer proteases in the periplasm or growth media means there is less chance of 
unwanted proteolysis of the protein product (Shokri et al., 2003). Transport to the periplasm 
or indeed secretion from the cell is achieved through inclusion of a leader sequence at the 
proteins N-terminus. There are multiple secretions sequences to select from, with the choice 
often determined on a trial and error basis (Choi and Lee, 2004). Once synthesised in the 
cytoplasm, proteins commonly enter the periplasm in an unfolded state through the Sec 
pathway before being exported through a type II secretion system (if applicable) with the 
leader sequence being cleaved by membrane bound proteases once the protein has been 
successfully translocated (Choi and Lee, 2004). Consideration must be given to the ability of 
the cells to translocate the protein as this must be equal to, or greater than, their capacity to 
produce said proteins or it may retained within the cytoplasm where they will likely form 
inclusion bodies (Choi and Lee, 2004). 
Inclusion bodies are intracellular insoluble protein aggregates formed from unfolded or 
partially folded proteins. These are often viewed as an unwanted consequence of 
heterologous protein overexpression, arising due to insufficient amounts of chaperones, thus 
allowing hydrophobic surfaces of proteins to form intermolecular associations before the 
proteins can fold correctly (Carrió and Villaverde, 2002; Terpe, 2003). Co-expression of 
chaperones has been shown to help in the folding of over- expressed protein (Levy et al., 
2001), However, inclusion bodies are not always undesirable because it is possible to recover 
soluble, functional protein from these insoluble aggregates (Buchner and Rudolph, 1991). The 
aggregates must first be solubilised (usually using a strong denaturing agents) and reduced 
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before the proteins are refolded (Demain and Vaishnav, 2009); however this is a timely 
process and on average refolding is only 10%-50% efficient (Carrió and Villaverde, 2002) 
Despite the advantages discussed, there are a number of drawbacks to the use of a bacteria 
host for expression. Firstly, most bacterial species are unable to glycosylate their proteins and 
although this is not always required, it can mean that the resultant proteins behave differently 
than their glycosylated counterparts (Demain and Vaishnav, 2009). For instance, they may 
exhibit reduced half-life or solubility and may not display full biological activity. Furthermore, 
antibodies raised against a non-glycosylated recombinant protein may not recognise the 
native mammalian protein (Jenkins and Curling, 1994). Proteins produced In Gram-negative 
bacteria also contain endotoxin contamination meaning they cannot be used for therapeutic 
application and are unsuitable for many research-based applications where LPS may elicit a 
response (unless the LPS is removed during downstream purification) (Terpe, 2006). Finally 
bacteria are not equipped to cope with the folding of larger proteins >100 kDa with more 
complex folding patterns often resulting in their aggregation (Demain and Vaishnav, 2009) 
1.3.2 Mammalian cell lines  
The first protein to be produced from recombinant mammalian cells was human tissue 
plasminogen activator in 1986, an enzymes which breaks down blood clots and is thus used to 
treat stroke patients (Kim et al., 2012). Since then, mammalian cells have become the principle 
host for production of therapeutic agents. Although there are many different cell types 
available for the production of recombinant proteins, as of 2007, 70% of therapeutics 
produced in mammalian cells were produced in Chinese hamster ovary (CHO) cells (Jayapal et 
al., 2007). This is in part because past products have shown that CHO cells are safe for 
therapeutic production, making approval from regulatory agencies easier to attain. 
Additionally, they produce proteins with glycosylation patterns which make them active in 
humans, and systems have been developed which enable high specific productivity from these 
cells (Kim et al., 2012). HEK-293 cells are often used in research laboratories because they are 
readily transfected by a number of means and can be easily adapted to serum-free suspension 
growth. COS-1 cells are also frequently utilised, however this cell line is predominantly used 
for transient expression because they express the SV40 large T-antigen which enables vector 
replication through the SV40 origin of replication leading to increase in gene copy number and 
higher expression (Dalton and Barton, 2014).  
DNA is usually introduced into mammalian cells by non-viral means, for instance using 
lipofectamine, electroporation, calcium phosphate or a polymer based method, and the DNA is 
normally integrated into the host genome through non-homologous recombination (Finn et 
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al., 1989). The site of integration is often random and can impact on protein expression levels 
(position effect variegation), for instance if the gene integrates in euchromatin then it should 
be expressed, whilst integration into heterochromatin can result in little to no expression 
(Wurm, 2004). Several methods have been developed to stop these effects such as blocking 
histone deacetylation (which promotes euchromatin formation) (Gorman et al., 1983) and 
including flanking regions in the DNA which stop the effects of the chromatin structure (Zahn-
Zabal et al., 2001). A more recent development is the use of a specific recombinase enzyme 
such as the phage protein Cre or yeast derived Flp recombinase. These enzymes catalyse 
recombination at pre-defined sites leading to integration at a transcriptionally active location 
(Wurm, 2004). Transient gene expression can also be utilised, in which the gene is expressed 
from an extrachromosomal plasmid; this offers the advantages of quicker time from 
transfections to purified protein but it requires a far greater amount of both transfection 
reagent and recombinant DNA which may be prohibitively expensive (Dalton and Barton, 
2014) 
Proteins which are produced in mammalian cells are usually correctly folded with glycosylation 
patterns which are most like those found in vivo. Additionally, proteins produced in 
mammalian cells have relatively homogenous glycosylation patterns and once a stable cell 
lines has been established it can be stored indefinitely in liquid nitrogen (Dalton and Barton, 
2014). However, cell culture is expensive due to the high price of media and disposable plastic 
ware and specialist facilities are required for mammalian cell culture. Moreover the time 
commitment for mammalian expression is far greater than for prokaryotic expression (weeks 
to months to establish a stable cell line). 
1.3.3 Other hosts 
Insect cells can carry out post-translational modification and are well equipped for producing 
proteins with complex folding patterns (Britain et al., 1991). The most commonly used insect 
cells are Sf9 cells, originating from the fall army worm Spodoptera frugiperda. These cells grow 
in suspension culture which enables high cell densities to be achieved along with easy scale-up 
of production. Insect cells are commonly transfected using baculovirus DNA vectors with the 
gene of interest under the control of the polyhedron promoter. This strong promoter enables 
high expression of the desired protein during the very late phase of the viral lifecycle (Altmann 
et al., 1999). The main advantage of insect cells is their ability to cope with proteins containing 
complex folding patterns and di-sulphide bonds, and their capacity to post translationally 
modify their expressed proteins. However, as with each expression system, insect cells also 
have a number of shortcomings. For instance, the lytic lifestyle of the baculovirus means that 
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cellular contents are released during expression, this can comprise protease enzymes resulting 
in degradation of the desired proteins. Furthermore, baculovirus infection leads to the 
inevitable death of the host cells meaning cells must be re-infected for subsequent round of 
expression (and viral stocks cannot be stored indefinitely) (Dalton and Barton, 2014). One of 
the foremost problems with insect cells is the manner in which they glycosylate their proteins. 
They often utilise N-glycans which are less complex than those found in mammalian cells and 
proteins can be underglycosylated also (Altmann et al., 1999; Demain and Vaishnav, 2009). 
Due to the high culture cost of insect cells they frequently overlooked in favour of mammalian 
expression which can produce higher protein yields at a similar cost with the added benefit of 
being able to produce more complex glycosylation patterns (Dalton and Barton, 2014). 
The single celled eukaryotes yeast (usually in the form of S. cerevisiae or P. pastoris) offer 
similar advantages to E. coli, they too give high protein yields, grow rapidly and are cost 
effective due to inexpensive media and reusable glass culture vessels (Dalton and Barton, 
2014). However, in contrast to E. coli, yeast are able to cope with proteins containing 
disulphide bonds and more complex folding patterns and are also able to glycosylate the 
proteins they produce (Demain and Vaishnav, 2009). However, glycosylation patterns 
produced by yeast vary significantly to those found in mammalian host. For instance, through 
inclusion of high-mannose sugar moieties and over glycosylation of N-glycosylation sites the 
produced protein can exhibit reduced activity and half-life (Wildt and Gerngross, 2005). 
Furthermore, yeast express a number of extracellular and cell bound proteases which can 
degrade or truncate the produced proteins (Macauley-Patrick et al., 2005). 
Although not readily applicable for production of recombinant protein for many research 
groups, transgenic animals have been used to produce large amounts of recombinant proteins 
for industrial and therapeutic applications. Proteins are normally expressed into the milk of 
the transgenic animal because of the large volumes produced and easy collection methods. 
“Biofarming” has the potential to produce large amounts of proteins (100s of Kgs) at low 
production costs; however, it does come with a number of issues. The length of time required 
in order to assess protein production in transgenic animals can be extremely long, ranging 
from 3.5 months to 32 months depending on the organism used (Demain and Vaishnav, 2009), 
with high prices of keeping animals this can represent a large financial investment. Moreover, 
the likelihood of successful protein production following this lengthy initial phase is low and 
there is a possibility of animal viruses and prions contaminating the final protein products 
(Larrick and Thomas, 2001). Transgenic plants have similarly been used and have some distinct 
benefits over the other hosts. For instance, they are able to produce oligomeric proteins such 
as antibodies whilst microbes cannot, and large scale production of proteins in plants is 
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suggested to be far more cost effective than when using large microbial or mammalian 
bioreactors. Unlike transgenic animals, plant products do not contain human pathogens such 
as viruses and prions. Plants are able to carry out post translational modifications, however 
inclusion of noval glycan structure and production of many different protein glycoforms means 
the resultant protein may not have use therapeutically (Larrick and Thomas, 2001). 
 
Table 1.4 Summary of advantages and disadvantages of expression systems. (Demain and 
Vaishnav, 2009) 
  
Expression 
System 
Advantages Disadvantages 
Bacterial  Rapid expression 
 High yields 
 Inexpensive 
 Cost effective 
 Proteins containing disulphide 
bonds are difficult to express 
 Proteins are not glycosylated 
 Protein preparations contain 
endotoxins 
 Proteins can be expressed in 
inactive inclusion bodies 
Yeast  High yield 
 Cost effective  
 Can produce isotope labelled 
proteins  
 Fast growth  
 Can produce disulphide 
containing proteins 
 Can express glycosylated 
proteins  
 Proteases may break down 
expressed proteins 
 Glycosylate proteins with high 
mannose sugars 
Insect  cells  Post translationally modify 
their proteins  
 Easy scale up of production 
 Safe to work with  
 
 Unusual glycosylation patterns with 
many protein being over 
glycosylated 
 Unable keep cryogenic stocks 
Mammalian 
cells 
 Post translationally modify 
proteins 
 Most like in vivo protein when 
expression mammalian targets 
 Expensive 
 Specialist facilities required 
  
Plants  Cost effective  
 Can accumulate protein in 
plant tissue 
 Wont contain animal 
pathogens 
 Post translationally modify 
their proteins 
 Unusual glycosylation patterns 
 Can express complex oligomeric 
proteins 
Transgenic 
animals 
 Cost effective for large scale 
protein production 
 May contain pathogens  
 Low chance of selecting stable cell 
lines 
 Large time and money investment 
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1.4 Project aims 
As discussed throughout section 1.1.3, tetraspanin EC2 domains have proven useful in 
dissecting the roles of various tetraspanins in a range of different processes. Our group has 
traditionally used these recombinant domains in the form of GST fusion proteins produced in 
E. coli. Unfortunately, proteins made in such a manner inherently contain bacterial 
contaminants which render them unusable in certain circumstances. Moreover, antibodies 
raised against these recombinant proteins were unable to recognise their native counterpart, 
which is suggested to arise because the recombinant preparations contain both folded and 
unfolded proteins. To address some of the issues found in recombinant protein expressed in 
bacteria, the initial aim of this project was to clone and express the EC2 domains using 
mammalian or insect cells as a host for expression. The next aim was to use the purified 
recombinant proteins for functional studies or for raising monoclonal antibodies that were 
specific to the native protein(s). As discussed in section 1.3 mammalian and insect cells are 
better equipped for the complex folding patterns resulting from multiple disulphide bonds and 
would produce products free from endotoxin contamination therefore suitable for a wider 
range of applications (Wakelin et al., 2006). Additionally, both mammalian and insect cells are 
able to glycosylate their expressed proteins, therefore the produced EC2 domains may be able 
to shed more light on the involvement of glycosylation in tetraspanin function. Initial efforts 
aimed to express three tetraspanin EC2 domains (CD9, CD151 and Tspan5) so that the 
increasing complexcity of the EC2 domains could provide some indication as to how well 
mammalian systems could cope with the folding patterns.  
After efforts to produce recombinant EC2 domains in eukaryotic systems were unsuccessful, it 
was decided to instead focus on expression in E. coli which was already an established means 
of producing recombinant EC2 proteins. Although these bacterially expressed proteins are in 
limited by possible contamination and incorrect folding, they can be produced in relatively 
high amounts, are suitable for a number of applications, and have proven useful in a number 
of functional assays by our group and others (Barreiro et al., 2008; Green et al., 2011; 
Parthasarathy et al., 2009; Zhu et al., 2002). Four tetraspanins have been linked to mast cell 
degranulation (Table 1.2) however it is not clear exactly what their involvement in this process 
is, so in an effort to shed more light on their function the EC2 domains of CD9, CD63 CD81 and 
CD151 were expressed as recombinant GST fusion proteins in E. coli. Following initial 
purification and characterisation via Western blot, the expression and purification procedures 
for these proteins were optimised. It was hypothesised that the IgE receptor responsible for 
initial steps in mast cell activation may be organised by tetraspanins so the recombinant 
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proteins were used in conjunction with RBL-2H3 cells to determine if they were able to 
modulate IgE-mediated degranulation.  
In initial attempts to dissect their mode of action, the binding of the recombinant tetraspanin 
EC2 binding to the surface of different mammalian cell types was investigated. Work was also 
undertaken to assess the possible effects of LPS contamination of the EC2 proteins in a cell:cell 
fusion assay. Finally cleavage of the GST tag from the recombinant EC2 domains was optimised 
prior to CD spectroscopy analysis, which was carried out to further characterise the EC2 
domains in terms of their secondary structure.  
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Chapter 2: Materials and Methods 
2.1 Materials 
2.1.1 Prepared Reagents and Buffers  
Reagent Preparation 
Acid ethanol (1%) 1ml HCl, 99ml ethanol 
Agar plates 10g tryptone, 5g yeast extract, 10g NaCL, 15g 
agar made up to 1L with dH2O 
Agarose gel (1%) 1g of MetaPhor agarose (Lonza) in 100ml 1x 
TAE buffer, heat until dissolved 
BBN 1g BSA, 0.5g sodium azide add to 500ml HBSS 
(with divalents)  
Blocking buffer 5g milk powder, 10ml 10x TBS, 90ml dH2O, 
150µl tween 20 
Blotting buffer 10x 20.23g Tris, 144g glycine made up to 1L with 
dH2O 
Blotting buffer 1x 100ml 10x blotting buffer, 200ml methanol, 
700ml dH20 
Carbonate-bicarbonate buffer (100mM) 3.03g Na2CO3, 6g NaHCO3 made up to 1L with 
dH2O, pH adjusted to 9.6 with HCl 
Citrate buffer (200mM) 5.85 citric acid, 6.47g sodium citrate 
Coomassie blue stain 500ml methanol, 2.5g Coomassie Brilliant 
Blue R-250 (BioRad), 100ml acetic acid made 
up to 1L with dH2O 
Coomassie de-stain 400ml methanol, 100ml acetic acid, 500ml 
dH2O 
EDTA 500mM 18.6g EDTA, 90ml dH2O, adjust pH to 7.0 with 
HCl, make up to 1L with dH2O 
Freezing solution 9ml FCS, 1ml DMSO 
Glutathione elution buffer (25mM) 30.8mg reduced glutathione, 60.6mg Tris, 
made to 10ml with dH2O pH 8.0 
Glycerol 60% 12ml 100% glycerol, 6ml dH20. Sterile filtered 
through a 0.22µm filter 
Imidazole binding buffer (10mM)  6.9g NaH2PO4, 17.54 g NaCl, 0.68g imidazole 
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make up to 1L with dH2O adjusted pH to 8.0 
with HCl 
Imidazole Elution buffer (500mM) 6.9g NaH2PO4, 17.54 g NaCl, 34g imidazole 
make up to 1L with dH2O adjusted pH to 8.0 
with HCl 
LB (Lysogeny broth) 10g tryptone, 5g, yeast extract, 10g NaCl 
made up to 1L with dH2O 
Nitrocellulose membrane stripping buffer 15g glycine, 1g SDS, 10ml tween20, pH to 2.2 
with HCl made up to 1L with dH2O 
PBST 1x 100ml 10x PBS, 900ml dH20, 250µl tween20 
Phosphate buffered saline (PBS) 10x 80g NaCL, 2g KCL, 14.4g Na2HPO4, 2.4g 
KH2PO4 Made up to 1L with dH2O 
Release buffer  500ml HBSS (with divalents) with 0.1%BSA 
(0.5g) 
SDS-PAGE loading buffer (non-reducing) 4x 5ml 0.5M Tris adjust pH to 6.8 with HCl, 2ml 
20%SDS, 4ml glycerol, 1ml 2mg/ml 
bromophenol blue 
SDS-PAGE Loading buffer (reducing) 2x 5ml 0.5M Tris adjust pH to 6.8, 2ml 10% SDS, 
2ml 60% Glycerol, 1ml β-mercaptoethanol, 
0.5ml 2mg/ml bromophenol blue  
SDS-PAGE Running buffer 10x 30g Tris, 144g glycine, 10g SDS made up to 1L 
with dH2O 
Separating gel (12.5%) 2.5ml H2O, 3ml 30% acrylamide, 1.9ml 4x 
separating buffer, 112μl 10% APS, 5μl TEMED 
Separating gel buffer (4x) 18.7g Tris base, 4ml 10% SDS, pH adjusted to 
8.8 with HCl, made up to 100ml with dH2O 
Sodium bicarbonate (1M) 840mg NaHCO3 dissolved in 10ml dH2O, pH 
adjusted to pH 8.3 with NaOH 
Sodium phosphate buffer 100mM (pH7.4) 77.4ml 1M sodium phosphate dibasic, 22.6ml 
sodium phosphate monobasic, made up to 1L 
with dH2O 
Sodium phosphate dibasic (1M) 142g Na2HPO4 made up to 1L with dH2O 
Sodium phosphate monobasic (1M) 138g NaH2PO4.H2O made to 1L with dH2O 
Stacking gel (5%) 1ml H2O, 300μl 30% acrylamide, 444μl 4x 
stacking buffer, 25μl 10% APS, 5μl TEMED  
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Stacking gel buffer (4x) 6.06g Tris, 4ml 10%SDS, pH to 6.8 with HCl, 
made up to 100ml with dH2O 
Sulforhodamine B 0.4% 400mg sulforhodamine B sodium salt (Sigma) 
dissolved in 100ml 1% acetic acid 
TAE buffer 50x 242g Tris, 700ml dH2O, 57.1ml acetic acid, 
100ml 500mM EDTA (pH8) made up to 1L 
with dH2O 
TBST 1x 100ml 10x TBS, 900ml dH2O, 250µl tween20 
Tris 1M (pH9.0) 121.14g of Tris dissolved in 800ml dH20, 
adjust to 9.0 with HCl and make up  to 1Litre  
Tris buffered saline (TBS) 10x 24.2g Tris, 87.66g NaCl pH to 7.6 with HCl 
made up to 1L with dH2O 
Tris HCl 18.171g Tris dissolved in 100ml dH2O, pH 
adjusted to 8.8 with NaOH 
Tris unbuffered (50mM) 6.06g Tris in 1L dH2O 
Β-Hexosaminidase substrate solution Naphthol AS-BI N-acetyl-β-D-glucosaminide 
diluted to 50mM stock in DMSO 
Table 2.1: Recipes for prepared buffers and reagents. 
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2.1.2 Antibodies 
Antigen Target 
Species 
Clone Isotype Label Source 
GST - Polyclonal IgG HRP Sigma 
GST - Polyclonal IgG FITC Abcam 
CD9 Human 602.29 IgG1 - Prepared in house from 
hyridoma 
(Andrews et al., 1981) 
CD9 Rat RPM7 IgG3, κ - BD biosciences 
CD81 Mouse EAT2 IgG1 - AbD serotec 
CD81 Human 1.3.3.22 IgG1, κ - Thermo fisher 
CD151 Human 14A2 IgG1 - L. Ashman, Aus 
CD151 Human 11G5a IgG1 - Thermofisher 
CD63 Human H5C6 IgG1 - Prepared in house from 
hyridoma 
(Azorsa et al., 1991) 
CD63 Rat AD1 IgG1 - AbD serotec 
Rat IgE Rat LO-ME-3 IgG1 FITC AbD serotec 
DNP - Polyclonal IgE - Prepared in house from 
hyridoma 
(Eshhar et al., 1980) 
Mouse IgG Mouse Polyclonal IgG HRP Sigma 
Mouse IgG Mouse Polyclonal - FITC Sigma 
Mouse IgE Mouse 23G3 IgG1 - Southern biotech 
Hamster IgG Hamster Polyclonal - FITC Abcam 
Isotype IgG3 Mouse J606 IgG3, κ - BD biosciences 
Isotype IgG1 Mouse JC1 IgG1 - Prepared in house from 
hyridoma 
(Muranova et al., 2003) 
Isotype 
Hamster 
Hamster eBio299Arm IgG - Affymetrix 
Table 2.2 Concentration, specificities, isotype and suppliers of various antibodies.  
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2.1.3 Restriction enzymes 
Name Used for 
HindIII Mammalian EC2 cloning, Flp-in/ Rat CD63 expression 
AgeI Mammalian EC2 cloning, Flp-in 
NheI Mammalian EC2 cloning, Flp-in 
XbaI Mammalian EC2 cloning, pCINEO 
EcoRV Mammalian EC2 cloning, pCINEO 
BamHI Cloning for insect cells 
NotI Cloning for insect cells 
EcoRI Rat-CD63 cloning 
Table 2.3 Endonuclease restriction enzymes and their application. All restriction enzymes 
were purchased from Promega and used with Multi-coreTM buffer where applicable.  
 
 
 
2.1.4 Bacterial strains 
E. coli Strain  Characteristics Souce 
Rosetta-gami F– ompT hsdSB(rB–mB– ) gal dcm 
lacY1 aphC (DE3) gor522::Tn10 
trxB pRARE2 (CamR , KanR , TetR ) 
Novagen  
DH5α F- Φ80lacZΔM15 Δ(lacZYA-argF) 
U169 recA1 endA1 hsdR17(rk-, 
mk+) phoAsup E44 thi-
1 gyrA96 relA1 λ- 
Life technologies 
Table 2.4 Bacterial strains and their characteristics  
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2.1.5 Antibiotics 
Carbenicillin Stock preparation 
(mg/ml) 
Diluted in Working 
concentration 
(ug/ml) 
Chloramphenicol 34 100% ethanol 34 
Tetracycline 12.5 70% ethanol 12.5 
Kanamycin 15 water 15 
Carbenicillin 50 water 50 
Hygromycin 50 - 1000 
Zeocin 100 - 300 
Geneticin (G418) 250 DMEM 300/1000 
Penicillin/Streptomycin 10000 units/ 10mg/ml Growth media 10 units/ml / 100 
Amikacin  50 water 500 
Table 2.5 Antibiotic stock and working concentrations.  
2.1.6 Cell lines 
Name Source  Culture medium  Used for 
CHO Chinese hamster ovary (ECACC) DMEM + 10%FCS Expression of EC2 
domains 
HEK-293 Human embryonic kidney (ECACC) DMEM + 10%FCS Expression of EC2 
domains 
HEC-1B Human endothelial carcinoma 
(ECACC) 
EMEM + 10%FCS Binding of EC2 domains, 
bacterial adhesion 
studies 
KM3 Rat (kind gift from Peter Hersey, 
Newcastle Hospital, Newcastle, 
Australia (Moseley et al., 2003)) 
DMEM + 10%FCS Positive control for 
tetraspanin CD9 
expression 
RBL-2H3 Rat basophil leukaemia (kind gift 
from Dr Birgit Helm, MBB, 
University of Sheffield) 
DMEM + 10%FCS 
+P/S 
Binding of EC2 domains, 
degranulation assays 
SF9 Spodoptera frugiperda (insect cells) 
(ECACC) 
SF900, Insect Xpress Expression of EC2 
domains 
J774 Mouse macrophage (ECACC) EMEM + 10%FCS Giant cell formation assay 
Table 2.6 Cell lines, growth media used and their application. 
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2.1.7 Plasmids 
Plasmid name Application Origin 
pGEX-KG Expression of GST tag for use as negative 
control, cloned tetraspanin EC2 domains 
into 
(Guan and Dixon, 1991) 
pGEX-CD9 Expression of tetraspanin CD9 EC2 domain 
in Rosetta-gami B(DE3) cells 
Previously produced by our group 
pGEX-CD63 Expression of tetraspanin CD63 EC2 
domain in Rosetta-gami B(DE3) cells 
Previously produced by our group 
pGEX-CD81 Expression of tetraspanin CD81 EC2 
domain in Rosetta-gami B(DE3) cells 
Previously produced by our group 
pGEX-CD151 Expression of tetraspanin CD81 EC2 
domain in Rosetta-gami B(DE3 cells 
Previously produced by our group 
pGEX-RCD63 Expression of rat tetraspanin CD63 EC2 
domain in Rosetta-gami B(DE3) cells 
This work 
pCI-neo Genes encoding EC2 domains of 
tetraspanins CD9 and CD151 cloned into 
this vector for expression in CHO and HEK-
293 cells 
Promega 
pCI-neo-CD63 Used in a previous study for expression of 
human CD63 in HEK-293 cells 
Previously produced by our group 
pSecTag-link Modified vector of the Flp-in system, use 
to express EC2 domains in CHO and HEK 
cells 
Modification of pSecTag/FRT/V5-
His by I. Wilkinson University of 
Sheffield, Medical School 
pSecTag-
GHstop 
Template for expression of IgGκ leader 
sequence 
I. Wilkinson, University of 
Sheffield, Medical School 
pOG44 Expresses Flp-recombinanse, co-
transfected in pSecTag to insert EC2 
encoding genes into the genome 
Life Technologies 
pVL1393 Expression of full length tspans in insect 
cells 
Life Technologies 
pAcSec1 Expression of EC2 domains in insect cells Allele Biotechnology 
pEGFP-N2 Reporter of transfection efficiency Clonetech 
Table 2.7 Plasmids used in this work and their origin. For vector maps see appendix  
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2.2 Methods 
2.2.1 Cell culture methods 
2.2.1.1 Passage of adherent mammalian cells 
Cells were routinely cultured in a humid atmosphere at 37:C and 8% CO2. Once cells became 
confluent they were sub-cultured for later use. To split cells in a T75 flask (Nunc), media was 
removed from the flask and cells were washed with 10ml HBSS without divalents (Lonza). Cells 
were dissociated from the flask by adding 4ml of Trypsin/EDTA (Sigma) or cell dissociation 
solution (Millipore) and incubating for 10 minutes. Following incubation, 6ml of DMEM 
containing 10%FCS (Lonza) was added and cells were removed by repeatedly pipetting up and 
down. Cells were transferred into a sterile falcon tube and the flask was washed again with 
10ml of HBSS to remove any remaining cells which were then also added to the falcon. Cells 
were centrifuged at 200g for 5 minutes before being resuspended in the required volume of 
DMEM and transferred to another plate. (Penicillin/streptomycin (Sigma) was routinely added 
to growth media for culture of RBL cells) 
2.2.1.2 Counting mammalian cells 
Cell numbers for experiments were determined using an Improved Neubauer 
haemocytometer with a counting chamber of 0.1mm depth. If viability of the cells was 
required the cell suspension was mixed 1:1 with trypan blue before counting, dead cells took 
up the dye whilst viable cells did not. 
2.2.1.3 Freezing mammalian cells 
Cells were passaged at least once before being frozen. Once cells reached 90% confluence they 
were dissociated using trypsin, centrifuged at 400g for 5 minutes and resuspended in freezing 
solution (Table 2.1) at a cell density of 1x106 per ml. 1ml of cell suspension was transferred to 
each cryovial, vials were transferred to a feezing plug (Jencons) and suspended in the vapour 
phase of a liquid nitrogen dewar to cool slowly for 90 minutes before transfer into the liquid 
nitrogen. 
2.2.1.4 Thawing mammalian cells 
Cryovials were removed from nitrogen and transferred to a water bath at 37ᵒC until most of 
the frozen pellet had thawed. The 1ml of cell suspension was then transferred to 9ml of 
growth media and centrifuged for 5 minutes at 200g. After centrifugation, growth media 
containing freezing solution was discarded and the cell pellet was resuspended in 10ml of 
fresh growth media and transferred to a 10cm dish or T75 flask. 
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2.2.1.5 RBL cell degranulation/release assay 
The amount of degranulation taking place in treated RBL cells was monitored using an 
enzymatic assay which produces a quantifiable colour changed based on the amount of β-
hexosaminidase released by the cells (Ortega et al., 1991). RBL cells were dissociated using cell 
dissociation solution (CDS, Sigma) and plated at a density of 5x104 per 100µl per well in a flat 
bottomed 96-well plate (Corning). After incubating at 37ᵒC for one hour, 100μl of DNP-specific 
IgE (diluted 1 in 500 with growth media) was added to each well and cells were cultured 
overnight. 
The following day, cells were inspected to ensure confluence, then the growth media was 
removed by flicking into Virkon and cells were washed twice with 50μl of HBSS with divalents 
(Lonza). Cells were incubated for 10 minutes in 30µl HBSS at 37ᵒC, 8% CO2. After incubation, 
10μl antibody or recombinant protein (at 4x final concentration) or HBSS was added to the 
cells and they were incubated for a further hour. Cells were then stimulated to degranulate by 
incubating with 10μl of DNP-BSA at varying concentrations for 15 minutes. After 15 minutes, 
40μl of cell supernatant was transferred to another flat-bottom 96-well plate containing 40μl 
of β-hexosaminidase substrate (Sigma) (diluted 1/25 in 0.2M citrate buffer) which was then 
incubated for 2 hours. The reaction was stopped by addition of 120μl 1M Tris (pH9.0) and the 
absorbance was measured using a LabTech-LT4000 plate reader at 405nm. Background 
absorbance values (from cells to which no DNP was added) were subtracted from test values 
and these were normalised to the maximum value attained from cells incubated with antigen 
and HBSS alone. Data points are shown mean ± standard error of the mean (SEM) unless 
otherwise stated. 
2.2.1.6 Indirect flow cytometry binding assay 
Cells were harvested by incubating for 15 minutes with cell dissociation solution, during which 
time recombinant proteins were diluted with BBN (Table 2.1) in a U bottom 96-well plate and 
stored on ice. Harvested cells were centrifuged for 5 minutes at 400g then resuspended in 
growth medium and transferred to a U bottomed 96-well plate (100μl per well, 1x105 cells per 
well). The cells were washed twice by centrifuging the plate at 400g for 2 minutes and 
resuspending the cells in 100μl of BBN. The cell pellets were then resuspended in 50µl of BBN 
only or the appropriate concentration of recombinant protein and incubated for 45 minutes 
on ice. Cells were washed twice (as above) and fixed by resuspending in 100µl of 2% PFA and 
incubating for 15 minutes. After fixation, cells were washed twice and resuspended in 25µl of 
FITC conjugated anti-GST antibody (Table 2.2) and incubated in the dark on ice for 45 minutes. 
Cells were again washed twice (as above) and resuspended in 150µl of BBN and analysed using 
an Attune Autosampler flow cytometer (LifeTechnologies). 
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2.2.1.7 Direct flow cytometry binding assay 
Cells were harvested, plated in U bottom 96-well plates and washed as described previously 
whilst dilutions of labelled recombinant proteins were prepared in BBN and stored on ice. Cell 
pellets were resuspended in the 50µl of the appropriate concentrations of labelled protein and 
incubated for 45 minutes in the dark on ice. The cells were washed twice more, resuspended 
in 150µl of BBN and analysed on an Attune Autosampler. 
2.2.1.8 Immunofluorescent protein labelling  
22mm diameter cover slips (SLS) were carefully added to the bottom of a sterile 24-well plate 
(Corning) using sterile forceps. Cells were harvested and seeded atop the coverslips at a 
density of 5x104 per 500µl per well, cells were then incubated overnight. The following day 
cells were inspected to check even distribution, growth media was removed and cells were 
washed by addition and removal of 500µl PBS. Labelled proteins were added at varying 
concentrations and incubated for 45 minutes. Following incubation the proteins were 
aspirated from the wells and cells washed twice with PBS before being fixed by addition of 
500µl 2% PFA for 10 minutes. Once fixed the cells were again washed twice with PBS before 
the coverslips were carefully removed from the 24 well plate with a needle. Cover slips were 
affixed to microscope slides using Vectashield mountant (VectorLabs) and sealed with nail 
varnish to prevent slides drying out. 
2.2.1.9 Immunological staining of mammalian cells 
Cells were harvested and seeded in each chamber of an 8-chamber Lab-TekTM slide (Nunc) at a 
density of 5x104 per chamber in 500µl then incubated overnight. The following day, cells were 
inspected to ensure an even distribution, growth media was removed and cells were washed 
by addition of 500µl PBS. PBS was removed and cells were fixed by incubating with 500µl of 
acetone. Acetone was removed and each well washed twice with PBS before submerging in 
PBS for 5 minutes. After incubation, PBS was removed and 150µl of primary antibody 
(10µg/ml), isotype control (10µg/ml) or PBS only was added to each well at an appropriate 
dilution, plates were then incubated for 1 hour on ice. After incubation, cells were washed 
twice with PBS and submerged in PBS for 5 minutes. Once washed, cells were incubated with 
150µl of FITC labelled secondary antibody (5µg/ml) for one hour in the dark, on ice. Secondary 
antibody was removed and the cells were washed twice with PBS and submerged in PBS for 5 
minutes. To stain the cell nuclei 150µl of propidium idodide was added to each well for 3 
minutes and the cells were again washed. The Lab-Tek chambers were removed from the slide 
with the provided tool and cells were carefully aspirated to remove and residual PBS. 5µl of 
Vectorshield mountant was added to each chamber and a cover slip was carefully lowered 
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over the slide. Sides of the chamber were sealed with nail varnish, which was allowed to set 
for one hour. Slides were stored at 4:C in the dark until needed. 
2.2.1.10 Fluorescent imaging of mammalian cells 
Slides were imaged using a Nikon A1 confocal microscope, random fields from each sample 
were selected and images were taken in both the FITC and DAPI channel for expression studies 
and FITC and brightfield channel for binding assays. Images were processed using the Fiji 
software (http://fiji.sc/Fiji). 
2.2.1.11 Antibiotic sensitivity testing 
The cells under investigation were harvested, counted and plated in each well of a 6-well plate 
(Corning) at a cell density of 1x105 per 3ml per well and grown overnight. The following day 
the cells were inspected to ensure they were healthy and around 50% confluent, the growth 
media was removed and replaced with growth media supplemented with a range of 
concentrations of antibiotic. In each experiment one well was replaced with growth media 
containing no antibiotics (as a negative control) and one with growth media containing an 
excess of antibiotic (positive control). Media was changed every two days and growth of cells 
monitored visually over the course of two weeks. A concentration of antibiotic for transfection 
was selected that successfully killed all cells after two weeks.  
2.2.1.12 Mammalian cell transfection via electroporation 
A 90% confluent T175 flask of cells was harvested using trypsin, counted, centrifuged (500g, 5 
minutes) and resuspended in serum free growth media at a density of 1x107ml-1. 0.8ml of the 
cell suspension was transferred to a pre-chilled electroporation cuvette (Biorad, 0.2cm gap 
width) on ice. 10µg of plasmid DNA was added to the cuvette (for the Flp-in system both pOG-
44 and the expression vector were mixed in an eppendorf in a 1:9 ratio before being 
transferred to the cuvette). The cuvettes were gently tapped to distribute the cells they were 
then incubated on ice for 10minutes. Following incubation, cuvettes were transferred to the 
electroporator (BioRad Gene Pulser II with capacitance extender) and pulsed at 250V (CHO) 
350V (HEK-293) and 975µF. After electroporation, cells were incubated on ice for a further 30 
minutes before being plated on 4 10cm dishes in growth media supplemented with FCS. The 
following day, growth media was replaced with one containing selective antibiotics. Cells were 
grown for two weeks with media being replaced every 2 days; after two weeks resistant cells 
were transferred to a fresh growth vessel. 
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2.2.1.13 Mammalian cell transfection via TurbofectTM 
Cells were plated in a 6-well plate at a density of 1x105 per well in 3ml of growth media and 
cultured overnight. The following day the cells were checked to ensure they were healthy and 
at a sufficient confluencey (40-60%). 3µg of DNA was mixed with 6µl of Turbofect transfection 
reagent (Life Technologies) in 400µl of serum free DMEM per well and left to incubate for 20 
minutes at room temperature (with intermittent mixing). 400µl of the DNA-Turbofect dilution 
was added in a drop-wise fashion to the top of each well, the plate was gently rocked before 
returning to the incubator overnight. Controls were included in each transfection, one without 
DNA and one without DNA and Turbofect. The following day the growth media was aspirated 
from the cells and replaced with growth media containing selective agent, media was replaced 
every other day for 2 weeks before assessing expression. 
2.2.1.14 Insect cell transfection 
Insect cells were routinely cultured in a shaking incubator at 27:C in SF-900 media 
(LifeTechnologies). 3.5x105 SF9 cells were plated in each well of a 6-well plate and grown 
overnight. The following day 1µg of baculovirus DNA (Saphire, Allelebiotech) was mixed 1:1 
with DNA expression plasmid and in a separate tube 10µl Cellfectin (Life Technologies) reagent 
was added to 100µl serum free SF-900 media. The diluted Cellfectin was added to the DNA 
mixture and incubated at room temperature for 20 minutes. During incubation the cells were 
gently washed with 2ml of serum free media three times. After washing the cells the DNA 
Cellfectin mixture was added in a drop wise fashion to the top of each well. Each plate was 
carefully wrapped in clingfilm and incubated at 27ᵒC for 6 hours with gentle shaking every 30 
minutes for the first 2 hours. After 6 hours, media was replaced with serum supplemented 
media and cells were left to grow for 5 days. After 5 days the cell media (containing primary 
viral isolate) was removed and centrifuged 500g for 5 minutes. Fresh SF9 cells were seeded at 
a density of 1x106 per ml in a 5ml volume and the primary viral isolate added atop the cells at a 
1:1000 dilution. After five days of growth the secondary viral isolate was harvested in the same 
fashion as the first. Fresh SF9 cells were seeded in a new flask in Insect-XpressTM media 
(Lonza); once the cells had reached a density of 2.5x106ml-1 the secondary viral isolate was 
added at a 1:200 dilution. Cells were grown for 2 weeks after which time protein expression 
was analysed. 
2.2.1.15 Detergent based mammalian cell lysis 
CHO and HEK-293 cells were lysed using CellLytic M Cell Lysis Reagent (Sigma) according to 
manufacturer’s instructions. Briefly; cells were grown and harvested from a T175 flask, 
counted and centrifuged at 200g for 5 minutes. Cells were washed with HBSS and then 
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resuspended in CelLytic M Cell Lysis Reagent (125µl per 1x106 cells) and protease inhibitor 
cocktail (Sigma)(1µl per 1x106 cells). Cells were incubated for 30 minutes on ice with vortexing 
every 5 minutes. Finally, lysates were centrifuged at 12000g for 15 minutes after which the 
protein containing supernatant was transferred to a chilled Eppendorf and stored at -80:C for 
later use. 
2.2.1.16 Burkholderia thailandensis – induced mammalian cell fusion 
assay 
J774.2 cells were harvested using a cell scraper and seeded in a 96-well plate at a density of 
2x104. The following day cells where washed twice with sterile PBS then incubated for one 
hour with PBS only, 500 nM of tetraspanin EC2-GST or GST alone as a control. After one hour 
cells were again washed twice with PBS and infected with Burkholderia thailandensis at an 
MOI of 3:1 for 2 hours. After infection, cells were washed as previously then incubated in 
growth medium supplemented with 500 µg/ml kanamycin and amikacin for 14 hours. The 
following day, cells were fixed with acid ethanol (Table 2.1) at room temperature for 10 
minutes after which time they were washed as previous and stained by incubation with of 
0.1% Giemsa solution for 10 minutes at room temperature. Finally cells were washed with 
dH2O and allowed to air dry before being visualised. 10 random fields were taken for each well 
and results are displayed as:               
                          
                        
    
          Or              
                       
               
 
2.2.1.17 Sulforhodamine B (SRB) assay 
A colorimetric assay was employed to determine the amount of cellular protein  remaining in 
wells following treatment with EC2 domains and thorough washing (Vichai and Kirtikara, 
2006).  RBL-2H3 cells were plated in a 96-well plate at 2x105 per 50 µl per well. EC2 proteins or 
GST were diluted to 2x concentration in 50µl of growth media and added atop the cells and 
incubated overnight. If necessary, the cells were washed by removing growth media and 
adding 100µl of pre-warmed media then rocking for 5 minutes before the growth media was 
replaced. Cells were then fixed by adding 50µl TCA to each well and incubating for one hour at 
4:C. TCA was removed and wells were washed five times by adding dH2O to each well and 
flicking the plate into Virkon. The plate was left inverted on a paper towel at room 
temperature until dry and cellular protein was then stained by adding 100 µl of 0.4% (Table 
2.1). The plate was incubated for 30 minutes and excess stain was then removed by flicking 
into Virkon, wells were then washed four times with 1% acetic acid. The plate was again dried 
on a paper towel at room temperature and then dye was solubilised by adding 50 µl of 10mM 
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unbuffered tris (Table 2.1) to each well. The plate was incubated for 5 minutes with gentle 
agitation before its absorbance was read at 570nm. 
2.2.1.18 Flow cytometry  
Cells were harvested and seeded in a 96-well plate at a density of 1x105 per well in 100µl 
volume. After centrifugation at 200 g, growth media was removed and cells were washed 
twice with 100µl HBSS. HBSS was removed and 100µl of primary antibody (10µg/ml) , isotype 
control (10µg/ml) or PBS only was added to each well at an appropriate dilution, plates were 
then incubated for one hour on ice. After incubation, cells were washed twice with HBSS and 
were incubated with 100µl of FITC labelled secondary antibody (5µg/ml) for one hour in the 
dark, on ice. Secondary antibody was removed and the cells were washed twice with HBSS 
before being resuspended in 150µl BBN and analysed using an Attune Autosampler flow 
cytometer. 
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2.2.2 Molecular biology methods 
2.2.2.1 Primer design 
The boundaries of the EC2 domain encoding genes where initially defined according to 
previous work from our group based on hydrophobicity analysis to determine the position of 
the TM domains (Higginbottom et al., 2000b) along with a number of publications which 
aligned various EC2 domains. EC2 encoding sequences were analysed using the NEB cutter 
software to identify any potential restriction sites and appropriate restriction enzymes for 
cloning were determined. Restriction sites were added to the sequence along with several GC 
base pairs to accommodate the restriction enzymes themselves, keep coding sequences in 
frame and add a GC clamp to the primer ends. For overlap extension PCR, Primers were 
designed corresponding to the 5’ and 3’ end of the tetraspanin EC2 domains and contained a 
leader sequence overlap and a restriction site respectively. Primers were also designed to 
anneal to the 5’ and 3’ end of the leader sequence and contained a restriction site and EC2 
overlap respectively. Leader sequence forward primers also contained a start codon and a 
Kozak sequence. Once potential primer pairs were designed the Tm values were checked and 
primers were adjusted accordingly, cloning was then simulated using Clone manager suite 7. 
The EC2 domains amplified along with their amino acid position can be seen in Table 2.8 
TSpan EC2 domain 
boundaries 
Amino acid sequence 
CD9 113-192 HKDEVIKEVQEFYKDTYNKLKTKDEPQRETLKAIHYALNCCGLAGGVEQFISD
ICPKKDVLETFTVKSCPDAIKEVFDNK 
CD63 107-202 FRDKVMSEFNNNFRQQMENYPKNNHTASILDRMQADFKCCGAANYTDW
EKIPSMSKNRVPDSCCINVTVGCGINFNEKAIHKEGCVEKIGGWLRKN 
CD81 115-199 NKDQIAKDVKQFYDQALQQAVVDDDANNAKAVVKTFHETLDCCGSSTLTA
LTTSVLKNNLCPSGSNIISNLFKEDCHQKIDDLFSGKLY 
CD151 114-219 YYQQLNTELKENLKDTMTKRYHQPGHEAVTSAVDQLQQEFHCCGSNNSQ
DWRDSEWIRSQEAGGRVVPDSCCKTVVALCGQRDHASNIYKVEGGCITKLE
TFIQEH 
Tspan5 115-232 FKDWIKDQLYFFINNNIRAYRDDIDLQNLIDFTQEYWQCCGAFGADDWNL
NIYFNCTDSNASRERCGVPFSCCTKDPAEDVINTQCGYDARQKPEVDQQIVI
YTKGCVPQFEKWLQDN 
Table 2.8 EC2 domain boundaries and amino acid sequence.  
2.2.2.2 Touchdown PCR 
Touchdown PCRs were utilised which start with a high initial annealing temperature which is 
thought to reduce the amount of nonspecific priming. Annealing temperature is gradually 
decreased in subsequent rounds of amplification when the specific target has been amplified 
(Don et al., 1991). Reactions were carried out in a 20µl reaction volume which consisted of 
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Component Volume/ Final concentration 
Water 10µl 
10x HF Buffer 2µl 
dNTPS 200µM 
Forward primer 200nM 
Reverse primer 200nM 
Template 500ng 
Phusion DNA pol 1.25units/50µl 
Table 2.9 PCR components Phusion DNA polymerase and buffer HF were purchased from NEB, 
10mM dNTPS from Sigma. Primers were used from a 1:10 dilution of the initial 100pmol stock 
supplied by eurofins. Template DNA was initially diluted to 100ng/ml before inclusion.  
For amplification the thermocycler (Techne Genius) was programmed for an initial 
denaturation step of 95:C for 5 minutes followed by 35 rounds of: 
 95⁰C for 30 seconds 
 X⁰C for 30 seconds  
 72⁰C for 45 seconds 
After this, a final extension took place at 72:C for 10 minutes before the reaction was held at 
4:C. The annealing temperature (X) was determined based on the Tm values of primer pairs 
2.2.2.3 Overlap extension PCR 
Overlap extension PCRs were utilised to combine two pieces of DNA (the EC2 encoding gene 
and leader sequence) (Ho et al., 1989). Primers used in this PCR included an overhang which 
corresponded to the gene to be added (for example a forward primer for an EC2 domain 
included a leader sequence overhang see Figure 2.1). For this kind of amplification 
“Touchdown PCR” was used (Don et al., 1991) in which a high initial annealing temperature 
reduces nonspecific primer binding and is reduced in subsequent rounds which reduces the 
stringency of the reaction. The Themocycler program was as in the previous section (2.2.2.2). 
However the annealing temperature (X) started at the primer Tm value + 2:C and after every 5 
round of amplification was dropped by 2:C for a total of 35 rounds. 
2.2.2.4 Small scale plasmid purification 
Small scale plasmid purifications were carried out using a Qiagen Plasmid Mini Kit according to 
manufacturer’s instructions. Briefly, single colonies were picked using a sterile cocktail stick 
and inoculated into 5ml of LB containing selective antibiotics. Cultures were grown overnight 
(37:C, 225 rpm) after which time they were centrifuged at 5500g for 10 minutes. Pellets were 
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resuspended in 250µl of buffer P1, vortexed and transferred to Eppendorf tubes, 250µl of 
buffer P2 was added and the solutions mixed by inversion. 350µl of buffer P3 was added and 
the tubes were again mixed thoroughly by inversion after which they were centrifuged at 13k 
rpm for 10 minutes to pellet the cell debris. Supernatant was decanted into to a Qiagen spin 
column which was then centrifuged again at 13k rpm in a microfuge for 1 minute; columns 
were then washed with 750µl of buffer PE and centrifuged again as above. After washing, the 
DNA was eluted in 50µl of RNase free water or elution buffer. 
2.2.2.5 Large scale plasmid purification 
Larger plasmid purifications were carried out using a Qiagen HiSpeed Plasmid Midi kit 
according to manufacturer’s instructions. In short, single bacterial colonies were picked from 
an agar plate using a sterile cocktail stick/pipette tip and inoculated into 5ml of LB containing 
selective antibiotics and cultured overnight (37:C, 225 rpm). The following day 1ml of bacterial 
culture was added to 50ml of LB containing selective antibiotics, which was again cultured 
overnight. 50ml cultures were centrifuged at 5500g for 30 minutes and supernatant discarded. 
Bacterial pellets were resuspended in 4ml of buffer P1, 4ml of buffer P2 was added and 
samples mixed by inversion then incubated on ice for 15 minutes. 4ml of buffer P3 was added 
and the samples were again mixed thoroughly by inversion then centrifuged for 30 minutes at 
5500g. Supernatant was then passed through a previously equilibrated QIAGEN-tip then the 
tip was washed with 10ml of buffer QC twice. DNA was eluted from the tip into a sterile falcon 
tube using 5ml of buffer QF and then precipitated with 3.5ml of isopropanol. Precipitated DNA 
was added to a QIA precipitator module and washed with 2ml of 70% ethanol. DNA was eluted 
from the precipitator module using 1ml of buffer TE or RNAse free DNase free water. 
2.2.2.6 Transformation of competent cells 
20µl of Rosetta-gami or DH5α competent cells were thawed on ice for 10 minutes. 1ul of 
expression plasmid at 100ng/µl or ligation mixture was added and cells were incubated for a 
further 20 minutes. Following incubation cells were heat shocked at 42ᵒC for 45 seconds and 
then incubated on ice for a further 2 minutes. 250 µl of SOC buffer was added to the bacteria 
and they were then transferred to 37ᵒC to recover for 45 minutes. Cells were then plated on 
agar plates containing selective agent and grown overnight. 
2.2.2.7 DNA sequencing 
DNA sequencing was carried out at The University of Sheffield Core Genomic Facility. Results 
were read using the software FinchTV and aligned using EMBOSS NEEDLE Pairwise Sequence 
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Alignment (http://www.ebi.ac.uk/Tools/psa/emboss_needle/). For primer sequences see 
Appendix.  
2.2.2.8 Preparation of glycerol stocks 
A single colony of transformed bacteria was transferred into 5ml of LB containing appropriate 
antibiotics, which was then grown overnight (37:C, 250 rpm). The following day 750 ml of the 
bacterial culture was transferred to a cryovial (Nunc) along with 250µl of 60% glycerol (Table 
2.1), vials were immediately transferred to a -80:C freezer until further use. To thaw cells from 
glycerol stocks some of the frozen pellet was scraped from the vial using a pipette tip and 
transferred to LB containing antibiotics. 
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Figure 2.1: Schematic diagram depicting the different steps in overlap extension PCR. Short arrows represent primers and long lines either products or 
templates. Initial PCRs incorporate restriction sites and overlaps onto either the leader sequence or EC2 encoding sequence. Products from the first PCRs are able 
to anneal and are used as a template in a second PCR which combines both leader sequence and EC2 encoding gene. 
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2.2.2.9 Agarose gel electrophoresis 
1g of agarose was heated with 100ml of TAE buffer (Table 2.1) and once cooled sufficiently, 
3µl of 10mg/ml ethidium bromide was added and the gel was poured into a DNA gel tank with 
comb. DNA samples were diluted with 6x DNA loading dye (Bioline). Once the gel had set, the 
comb was removed and 15µl of each diluted DNA sample was loaded into each well, 5µl of the 
DNA ladder Hyperladder I (Bioline) was included with each gel. Gels were run at 100 volts for 
50 minutes and then imaged using a gel imaging system (UVP gel doc).  
2.2.2.10 Gel extraction 
Gel extraction was carried out using QIAquick Gel Extraction Kit according to manufacturer’s 
instructions. In short, after conducting DNA electrophoresis (Section 2.2.2.9) samples were 
briefly illuminated using a UV block. Gel bands corresponding to the required DNA fragment 
were removed from the gel with a sterile scalpel and transferred to an Eppendorf tube. After 
weighing each gel slice, 3 volumes of buffer QG was added to 1 volume of gel, samples were 
then dissolved in a 60:C heat block with intermittent vortexing. After the gel slice had 
completely dissolved the solution was added to a spin column and centrifuged at 13k rpm in a 
benchtop centrifuge (Eppendorf minispin) for 1 minute. The column was washed with 750µl of 
buffer PE and after washing the column was again centrifuged at max speed for 1 minute to 
remove and residual wash buffer. DNA was eluted using 40µl of RNase free water into a clean 
Eppendorf tube. 
2.2.2.11 PCR purification 
PCR purifications were carried out using a QIAquick PCR Purification Kit according to 
manufacturer’s instructions. In brief, PCR samples were diluted with 5 volumes of buffer PB 
and added to a QIAquick spin column then centrifuged at 13k rpm for 1 minute in a microfuge. 
750µl of buffer PE was added and the columns were again centrifuged for 1 minute. After an 
additional centrifuge step to remove any residual wash buffer DNA was eluted from the 
column using 50µl of RNAse free DNAse free water. 
2.2.2.12 Restriction digest 
Digestion of inserts was carried out using ~ 400ng of PCR product (Section 2.2.2.2), 4µl of 
multicore buffer (Promega), 4µl of BSA (1ng/ml) and 1.5µl of each enzyme, made up to 40μl 
with RNase incubated at 37ᵒC for 3 hours. Digestion of vector was achieved through two 
individual single digests, which were then combined into one double digest. Single digests 
comprised 400ng of vector DNA, 2µl multicore-buffer, 2µl BSA and 1µl of the required enzyme 
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made up to 20µL using RNase free water. Single enzyme digests of the vector were incubated 
at 37:C for 1.5 hours after which time they were pooled and incubated for another 1.5hours.  
2.2.2.13 Ligation 
Ligations were set up using a 3:1molar ratio of insert to vector according to the equation: 
                                    
                   
                           
                       
Ligations were carried out in a 20µl reaction volume which consisted of: 
Component Volume 
Water Made up to 20µl 
Buffer 2µl 
Insert Xµl (See equation) 
Digested vector Xµl (50ng) 
T4 DNA Ligase 1unit/50µl 
Table 2.10 Ligation reaction components: buffer and ligase were both part of the T4 DNA 
ligase kit (NEB) vector and insert volume was determined based on DNA concentration volume 
using the equation above 
The ligation mix was incubated for 3 hours at 37:C after which 1µl of the ligation mix was used 
for transformation of DH5α competent cells (Section 2.2.2.6).  
2.2.2.14 Genomic DNA extraction from mammalian cells 
Genomic DNA was extracted using the PureLink genomic DNA extraction kit (Invitrogen) as per 
the manufacturer’s instructions. Briefly, cells were harvested and 3x106 cells were 
resuspended in 200µl of HBSS. The cell suspension was added to 20µl of proteinase K to which 
20µl of RNase A was added, the sample was then vortexed and incubated for 2 minutes at 
room temperature. 200µl of PureLink Lysis/binding buffer was added and the mixture was 
again vortexed and incubated for 10 minutes at 55:C. 200µl of absolute ethanol was then 
added and the solution was vortexed. This sample was added to a spin column which was 
centrifuged at 13k rpm in a micofuge for 1 minute, then the column was washed with 500µl 
Wash buffer 1 and 2 and finally the DNA was eluted in 100µl elution buffer. 
2.2.2.15 Preparation of cDNA from mammalian cells 
To assess the presence of specific RNA within mammalian cells cDNA was first prepared from 
whole cell extracts. Total nucleic acid was isolated using a Qiagen RNeasy Mini Kit according to 
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manufacturer’s instructions. Briefly, cells were harvested and 3x106 cells were resuspended in 
350µl buffer RLT, 350µl of 70% ethanol was added and the sample was mixed thoroughly by 
pipetting. The lysate was transferred to an RNeasy mini column and centrifuged for 15 seconds 
at 13k rpm, then the column was washed with 700µl RW1 and 500µl RPE. After washing, the 
nucleic acid was eluted in 30µl of elution buffer.  
 An Ambion DNA-free kit was used to remove DNA from the sample. A mixture consisting of 
2µl 10x buffer, 2µg of nucleic acid and 1µl of DNase was made up to 10µl with RNase-free 
water. Samples were incubated for 20 minutes at room temperature before 2µl of inactivation 
reagent was added and the sample vortexed. After a further 2 minute incubation (with 
intermittent mixing) the samples were centrifuged for 10 minutes at 13k rpm in a microfuge 
and the RNA containing supernatant removed. 
 RT-PCR was carried out using a High-Capacity RNA-to-cDNA kit (Applied Biosystems). A 2x 
master mix was made for each reaction consisting of: 
 
Component Volume 
Water 3.2µl 
10x RT Buffer 2µl 
25x dNTP mix (100mM) 0.8µl 
10x RT Random primers 2µl 
MultiScribe Reverse transcriptase 1µl 
RNase inhibitor 1µl 
Table 2.11 Components of the reverse transcription master mix. Random primers, reverse 
transcriptase, dNTPs and RNase inhibitor were all from the High Capacity RNA-to-cDNA kit (Life 
technologies). 
10µl of this master mix along with 10µl of the previously produced RNA were added to a PCR 
tube and run in a thermocycler for: 10 minutes at 25:C, 120minutes at 73:C and 5 minutes at 
85:C. Once produced the cDNA was stored at 4:C for later use or -20:C for long term storage. 
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2.2.3 Protein biochemistry methods 
2.2.3.1 SDS-PAGE 
Protein gels consisting of a 12% separating gel and 8% stacking gel were prepared according to 
Table 2.1. Once gels were set they were removed from the casting apparatus and transferred 
to a Biorad mini-protean tetra cell. Protein samples were diluted with either non-reducing 
protein loading dye (Table 2.1), for Western blots using conformationally sensitive antibodies, 
or reducing protein loading dye (Table 2.1). The gel tank was filled with SDS running buffer 
(Table 2.1) and gels were run at constant voltage of 160v for around 2 hours before being 
removed from the tank 
2.2.3.2 Coomassie staining and de-staining 
Gels were carefully removed from the glass plates, transferred to a container and then 
incubated with Coomassie brilliant blue stain (Table 2.1) for one hour with gentle rocking. 
Once stained, the gel was briefly washed with dH2O and transferred to de-stain (Table 2.1) for 
4 hours or until sufficiently de-stained. Gels were then imaged using a UVP gel doc. 
2.2.3.3 Western blot 
Once gels had finished running (Section 2.2.3.1) they were carefully removed from glass plates 
and transferred to a Western blot “sandwich” consisting of cassette, sponge, blotting paper, 
PAGE gel, high bond ECL nitrocellulose membrane (Amersham), blotting paper and finally 
sponge. This sandwich was assembled under blotting buffer (Table 2.1) and any air bubbles 
were removed with a roller. Once assembled, the sandwich was loaded into the blotting 
apparatus along with 1L of blotting buffer (Table 2.1). Blotting was carried out for 1 hour at 
100 volts or overnight at 10 volts then the membranes were transferred to blocking buffer 
(Table 2.1) for one hour. Membranes were then washed by incubating twice in TBST (Table 
2.1) for 10 minutes then transferred to a universal tube containing 5ml of primary antibody 
diluted in blocking buffer to 1µg/ml. Membranes were incubated for one hour on a rotary 
mixer, washed twice as before then transferred to a second universal tube containing HRP-
linked secondary antibody, also diluted in blocking buffer. Membranes were incubated in 
secondary for one hour then washed before being incubated with SuperSignal West Pico 
Chemiluminescent Substrate (Life Technologies) for 5 minutes with gentle rocking. 
Membranes were transferred to a Western blot cassette and incubated with X-ray film (Pierce) 
for varying lengths of time. Finally the films were removed from the cassette and immersed in 
developing solution, washed with tap water then immersed in fixing solution.  
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2.2.3.4 Expression of tetraspanin EC2 domains in E. coil 
After Rosetta-gami cells had been transformed with pGEX-KG plasmids (Section 2.1.7) a single 
colony was picked from an agar plate using a sterile pipette tip and transferred to 5ml of LB 
containing the appropriate antibiotics (Table 2.1.5). Starter cultures were grown for 8 hours at 
37:C 250rpm, then the 5ml culture was added to a larger 200ml flask of LB (also containing 
antibiotics) which was grown overnight (37:C 250rpm). The overnight culture was then added 
to 500ml flasks of LB containing antibiotics at a 1/25 dilution. The cultures were grown at 37:C 
250rpm until an OD600 of 0.6 was achieved at which point expression was induced using 
0.1mM IPTG and cultures were incubated for 4 hours. Bacteria were harvested by centrifuging 
at 4500g for 20 minutes, supernatant was decanted into Virkon and bacterial pellets were 
weighed and frozen until lysis and purification 
2.2.3.5 Cell lysis by sonication 
Bacterial cell pellets collected previously (Section 2.2.3.4) were thawed on ice and 
resuspended in lysis buffer consisting of 1x PBS (Table 2.1) and Halt protease inhibitor cocktail 
(Lifetechnologies) diluted 1/100 (5ml lysis buffer per 1g of bacterial pellet). Resuspended 
cultures were lysed by sonicating at 15 microns for two 15 second rounds, at which point there 
were mixed and sonicated again for a further 3 rounds (5 round in total). Tubes were then 
balanced using PBS and centrifuged at 24000g for 20 minutes to pellet unwanted cell debris. 
Cell lysates were transferred to fresh universal tubes for downstream purification and cell 
pellets containing the insoluble protein fraction were frozen for later analysis. 
2.2.3.6 Affinity purification of GST tagged proteins –Batch method 
An appropriate volume of GST Sepharose beads (GE Healthcare) (100µl of beads for every 
gram of bacterial pellet) were transferred to a 1.5ml Eppendorf tube, centrifuged (500g, 5 
minutes) and the head volume (containing ethanol) discarded. The beads were resuspended in 
5 bed volumes of PBS centrifuged again and the head volume discarded, this wash process was 
repeated twice more for a total of 3 washes. Washed beads were incubated at room 
temperature with cell lysates for 2 hours on a rotary mixer. Beads were then centrifuged and 
the head volume containing unbound protein was removed, (the final 100-200µl of 
supernatant was removed using a gel loading tip to prevent unwanted transfer of beads). The 
beads were washed with 5 bed volumes of PBS, centrifuged and the head volume was once 
again removed (wash 1). This process was repeated twice more yielding the Wash 2 and Wash 
3 fractions, after which the beads were incubated for 15 minutes with 25mM reduced 
glutathione (Table 2.1) (0.5ml of elution buffer for each gram of bacterial pellet). After 
incubation the beads were pelleted and the head volume (eluate 1) was transferred to a pre-
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chilled Eppendorf for later dialysis. The elution process was carried out once more using half 
the initial volume to remove any protein which may have remained on the beads (eluate 2). 
2.2.3.7 Affinity purification of GST tagged proteins – Column method 
An appropriate volume of GST Sepharose beads ) (100µl of beads for every gram of bacterial 
pellet) were added to a Poly-Prep chromatography column (BioRad) and left to settle. To 
remove the 70% ethanol the beads are supplied in, 2 bed volumes of PBS were added to the 
top of the column and allowed to pass though – this was repeated until 5 bed volumes had 
passed through the column. The column was then capped, cell lysates were added and the lid 
was securely fitted. Lysates were incubated with the beads for 2 hours with end-over-end 
rotation at room temperature. After incubation the column was allowed to settle for 5 
minutes before both caps were removed and the lysate was allowed to flow through and 
collected (unbound fraction). The beads were washed three times by adding 5 bed volumes of 
PBS to the top of the column and allowing it to empty under gravity then the beads were 
incubated with 25mM reduced glutathione for 20 minutes with end over end rotation (0.5ml 
per gram of bacterial pellet). After incubation, the eluate was passed through the column and 
collected; any residual liquid was forced through the column using a syringe (eluate 1). To 
remove any remaining protein the column was again incubated with 25mM reduced 
glutathione (0.25ml per gram of bacterial pellet) for 20 minutes and the eluate collected 
(eluate 2)  
2.2.3.8 Nickel affinity chromatography 
Cell supernatant or lysate samples containing His tagged proteins were concentrated to a 
volume less than 10ml and simultaneously buffer exchanged into 10mM Imidazole binding 
buffer (Table 2.1) using centristrat columns (section 2.2.3.8). Once samples had buffer 
exchanged, samples were added to a Ni-NTA agarose column (approximately 20mg of protein 
per 1ml of resin) and incubated for 2 hours at room temperature with on a rotary mixer. 
Following incubation the column was uncapped and unbound protein was eluted and 
collected. The column was washed with 5 bed volumes of 10mM imidazole before the bound 
proteins were eluted. Initial elution was carried out with 500µl of 500mM imidazole elution 
buffer (Table 2.1) and subsequent elutions with a two-fold lower concentration for a total of 3 
elutes. Eluted proteins were stored at 4:C for immediate use or -80:C for later analysis 
2.2.3.9 Dialysis 
16mm snakeskin dialysis tubing with 3.5kDa molecular weight cut-off (Life Technologies) was 
soaked in 1x PBS and one end of the tubing was tied and clipped. Proteins eluates were 
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pipetted into the tubing, the tubing was gently pressed to remove any air and the open end 
was tied and clipped. Proteins were incubated in 5 litres of PBS overnight at 4:C with gentle 
agitation. The PBS was then replaced and proteins were incubated for a further 6 hours before 
they were transferred to an Eppendorf on Ice. Protein was then quantified and aliquots were 
stored at -80:C 
2.2.3.10 Bradford assay protein quantification 
A Bradford assay was used to quantify proteins in a sample by comparing aborbance to 
samples of known protein concentration (Bradford, 1976)   12 BSA standards spanning a range 
of concentrations were generated by serially diluting a stock of BSA in PBS. 10µl of these 
standards along with 10µl of test proteins were added in triplicate to a 96-well plate. Protein 
Assay Dye Reagent Concentrate (BioRad) was diluted 1:5 with dH2O and 200µl of this diluted 
dye was added to each sample. The plate was gently rocked to distribute the dye and then 
incubated for 5 minutes to ensure a complete colour change. The absorbance was read on a 
plate reader at a wavelength of 595nm. A standard curve was generated using the absorbance 
values of the proteins standards from which the unknown protein concentrations could be 
determined. 
2.2.3.11 Protein concentration using molecular weight cut-off columns 
EC2-GST fusion proteins were concentrated using Centrisart I Concentrator columns with 5kDa 
molecular weight cut off (Sigma). Protein was added to the column to the 2.5ml mark and then 
the inner tube was inserted and left to stand for 5 minutes. Columns were then centrifuged at 
2500g for 30-45 minutes. After centrifugation the filtrate was removed and the outer tube was 
again filled to the 2.5ml mark. This process was repeated until samples were sufficiently 
concentrated. 
2.2.3.12 LPS quantification 
LPS levels were quantified using a LAL Chromogenic Endotoxin Quantitation Kit (Pierce) 
according to manufacturer’s instructions. Briefly, standards were prepared using provided LPS 
and endotoxin free water and protein samples were diluted with endotoxin free water to fit 
within range of LPS standards. 50µl of recombinant protein or LPS standards were added in 
duplicate to a 96-well plate and incubated for 5 minutes at 37:C. After incubation 50µl of LAL 
(Limulus amebocyte lysate) was added to each well, the plate was gently shaken and then 
incubated for a further 10 minutes at 37:C. Exactly 10 minutes following incubation 100µl of 
substrate solution was added to each well, again the plate was gently shaken and incubated 
for an additional 6 minutes. Finally 50µl of 25% acetic acid was added to stop the reaction and 
  Chapter 2: Materials and Methods 
77 
 
absorbance was read at 410nm on LT-4000 Labtech plate reader. Background values were 
subtracted before a standard curve was established to determine LPS levels in test proteins. 
2.2.3.13 GST cleavage –batch method 
Recombinant GST tagged proteins were incubated with prewashed glutathione Sepharose 
beads with end-over-end rotation for 2 hours in a protein LoBind tube (Eppendorf) (10mg of 
protein per 1ml of glutathione Sepharose). Beads were then centrifuged for 5 minutes at 500g 
and the head volume (containing any non-bound protein) was removed. Beads were then 
washed 3 times with 5 bed-volumes of PBS to ensure any residual unbound protein was 
removed. An appropriate amount of Thrombin (GE healthcare) was diluted in PBS/phosphate 
buffer (1.5 units per 100µg of protein) and was then used to re-suspend the GST-Sepharose 
beads, which were then incubated for 16 hours with end-over-end rotation at room 
temperature. Samples were then centrifuged at 500g for 5 minutes and the head volume 
containing cleaved protein was removed using a gel loading tip to avoid transfer of any GST-
beads. Cleaved protein was incubated with washed p-aminobenzimade agarose (Sigma)(2µl 
per unit of thrombin) for 30 minutes after which samples were centrifuged at 13k rpm 5 
minutes. The head volume containing cleaved protein was then transferred to another LoBind 
tube using a gel loading tip and cleaved protein was then stored at 4:C for immediate use or -
80:C for later use.  
2.2.3.14 GST cleavage – column method 
Recombinant GST tagged proteins were incubated with washed glutathione sepharose beads 
with end-over-end rotation for 2 hours in a BioRad Polyprep chromatography column (10mg of 
protein per 1ml of glutathione Sepharose). The beads were then allowed to settle for 5 
minutes before the column was uncapped and unbound proteins allowed to flow through and 
collected. The beads were washed 3 times with 5 bed volumes of PBS before thrombin diluted 
in PBS was added to the column. The column was sealed and incubated overnight with end-
over-end rotation at room temperature. The column was then uncapped and cleaved protein 
was collected in a LoBind tube. To remove any residual protein from the column, additional 
PBS was added and pushed through the column with a syringe. Cleaved protein was incubated 
with washed p-aminobenzimade-agarose (Sigma) (2µl per unit of thrombin) for 30 minutes 
after which, samples were centrifuged at 13k rpm on a microfuge for 5 minutes. The head 
volume containing cleaved protein was then transferred to another LoBind tube using a gel 
loading tip and the cleaved protein was then stored at 4:C for immediate use or -80:C for later 
use. 
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2.2.3.15 CD spectroscopy 
CD spectroscopy was utilised to estimate the secondary structures of proteins. All circular 
dichroism experiments were carried out using a Jasco J-810 spectrophotometer with a cell of 
pathlength of 0.02cm. Data were obtained at 15:C with start and end points of 350 and 190nm 
respectively. A data pitch of 1nm, response time of 8 seconds and scan speed of 20nm/min 
were used and readings were averaged over 5 accumulations. To allow for more direct 
comparison results are displayed as mean residue elipticity *Θ+MRW (deg∙cm2 dmol-1) which 
was calculated using the following equation. 
[ ]     
          
 0        
  
where MRW is mean residue weight, P is the path length in cm and C is the concentration in 
mg/ml. Absorbance values were read in an environment of nitrogen gas and if required, 
recombinant proteins were buffer exchanged into 20mM sodium phosphate buffer before 
being analysed. 115µl of protein sample was added to the recess on one glass slide then the 
second slide was placed on top and excess protein removed with a lens wipe. The filled slides 
were placed in the spectrophotometer and the program parameters used were as previously 
described. If assessing effects of temperature on circular dichroism the spectra was measured 
at a constant 222nm and a temperature gradient from 10:C-90:C was used with responses 
every 2:C. Spectra were deconvoluted using the online software Dichroweb (Whitmore and 
Wallace, 2004)  
2.2.3.16 Alexa488 Protein labelling  
Alexa488 dye (Life Technologies) was dissolved in 100µl of DMSO to generate a 10mg/ml stock 
which was stored in aliquots at -20:C. The quantity of Alexa488, NaHCO3 and Tris-HCL to use 
were determined based on the number of moles of protein to be labelled, using a molar excess 
of 20 (as suggested by the manufacturer). A minimum of 200µg of recombinant protein was 
added to a 0.5ml Eppendorf wrapped in foil and appropriate volumes of Alexa488 and NaHCO3 
were added then incubated for 2 hours with end over end rotation at room temperature. 
During incubation PD-SpinTrap G-25 columns (GE healthcare) were prepared by removing 
storage buffer and washing the column 5 times with 300µl of PBS. After the 2 hours incubation 
free succinyl groups were quenched with Tris-HCL and the samples were added to the 
previously prepared columns (one column could accommodate 130µl sample). Columns were 
centrifuged at 13k rpm on a microfuge for 3 minutes and flow through containing labelled 
protein was collected. The OD280 and OD494 of the resulting samples were read on a Nanodrop 
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(Nanodrop 1000 Thermo) and used to determine the degree of labelling using the following 
equation. 
    
  494                  
7 000                            
 
2.2.3.17 Enzyme linked immuno assay (ELISA)  
 100µl of cell supernatant or recombinant protein at appropriate initial concentrations were 
serially diluted in carbonate-bicarbonate buffer (Table 2.1) across a 96-well ELISA plate (Nunc). 
Plates were wrapped in cling-film and incubated overnight at 4:C. Excess protein samples were 
discarded from the wells and the plate was washed twice with PBST and patted dry on paper 
towels. 150µl of blocking buffer (Table 2.1) was added to the wells and the plate was 
incubated again for 2 hours at 37:C. The blocking buffer was then discarded and the plate was 
again washed twice with PBST and patted dry. 50µl of primary antibody diluted in blocking 
buffer to 10 µg/ml was added to each well and the plate was incubated at 37:C for 1 hour. The 
primary antibody was then discarded and the plate was washed and dried as previously, 50µl 
of secondary HRP-linked antibody was added to each well and the plate was again incubated 
for 1 hour at 37:C. The plate was washed twice with PBST and twice with dH2O after which 
50µl of TMB substrate (Sigma) was added to each well. The colour was allowed to develop for 
15 minutes before the reaction was stopped by addition of 50µl of 2M H2SO4, The absorbance 
was read on a plate reader a 450nm. 
2.2.3.17 Statistical analysis 
Data was analysed using tools within the GraphPad Prism 6 software. To reduce variation 
between experiments, degranulation values are normalised to those seen when no treatment 
were used in conjunctions with the highest concentration of DNP-HSA (this value was fixed to 
100%). Unless otherwise stated, data are presented as mean +/- SEM. Significance was 
determined by one way ANOVA using Bonferroni post hoc multiple comparison.  
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Chapter 3: Production and analysis of 
tetraspanin EC2 domains 
3.1 Introduction 
Despite tetraspanin proteins being almost ubiquitous in the human body, and involved in a 
multitude of important cellular and pathological processes (see section 1.1.3), relatively little is 
known about the functions of individual members. This is in part due to the limited availability 
of monoclonal antibodies and the mild phenotypes observed in a number of tetraspanin 
knock-out mutants (probably due to a level of redundancy) (Hemler, 2005). Our group and 
others have previously had success in dissecting individual tetraspanin functions using 
recombinant tetraspanin EC2 domains (Section 1.1.4); however, these bacterially expressed 
recombinant proteins lack post-translational modifications, specifically glycosylation, so may 
not exhibit a tetraspanins full function. Furthermore, due to the complex folding patterns of 
tetraspanin EC2 domains and a lack of specific chaperones in E. coli, which help with this 
folding, it has been suggested that a heterogeneous group of both folded and unfolded 
proteins may be expressed. Additionally, previous work by our group (Fanaei, 2013) has also 
considered the effects of contaminating LPS resulting from the use of bacteria as a host for 
recombinant protein expression.  
The initial aim of this chapter was to express the EC2 domains of the human tetraspanins: CD9, 
CD151 and Tspan5, in a mammalian or insect host. These specific tetraspanins were selected 
as candidates for mammalian expression as they contain a varied number of theoretical di-
sulphide bonds (2, 3 and 4 respectively). This is thought to contribute to a more complex 
protein structure and could give an indication as to how well these systems can express more 
“difficult” proteins. As both mammalian and insect cells are able to carry out post translational 
modifications (albeit with different patterns of glycosylation) it was hypothesised that the 
resultant proteins could shed light on the contribution of glycosylation in the function of 
tetraspanin EC2 domains. Additionally, due to the more sophisticated cellular machinery 
present in both cell types, it was thought that these systems may be better equipped to handle 
the complex folding of the EC2 domains, resulting in a more homologous, higher quality end 
product (Section 1.3.1). Moreover, using a non-bacterial host for protein expression eliminates 
the possibility of LPS contamination in the proteins produced, which would enable the use of 
these proteins in LPS sensitive assays.  
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Later aims were to express recombinant EC2 domains of the human versions of tetraspanins 
CD9, CD63 and CD151 in bacteria. These specific family members were selected based on their 
association with mast cell degranulation, with the later view to using them in furthering our 
understanding of tetraspanin involvement in this area. The EC2 domain on Rat CD63 was also 
expressed to enable a comparison between the effects of EC2 domains originating from 
different species. Following this, work was carried out to optimise the expression of said 
proteins to enable studies that require higher protein concentrations.  
3.2 Results 
3.2.1 Cloning of tetraspanin EC2 domains for mammalian 
expression  
Boundaries for the tetraspanin EC2 domains had previously been defined by our group based 
on hydrophobicity analysis and alignment of the primary amino acid sequence of multiple 
human tetraspanin EC2 domains, in addition to work carried out by Todd et al. (1998) and Rob 
et al. (2001). To allow for easier downstream purifications it is desirable to have the products 
secreted into the surrounding growth media; this was achieved through the inclusion of a 
leader (or secretion) sequence at the 5’ end of the gene sequence (here the leader sequence 
of the IgGκ light chain was used (Young et al., 1995)) . DNA sequences for the tetraspanin EC2 
domains, each containing an IgGκ leader sequence, were generated by overlap extension PCR 
(Section 2.2.2.3) using the gene specific primers displayed in the Appendix (Table 7.1). PCR 
reactions were carried out using Phusion high fidelity polymerase (NEB) with initial rounds of 
PCR resulting in products ranging from ~260-380bp for the EC2 domains and ~90bp for the 
leader sequences (Figure 3.1a). Subsequent rounds of amplification (overlap extension) 
combined the leader sequences with the EC2 genes, resulting in products ranging from 330bp-
450bp (Figure 3.1b). PCR products prior to and following overlap extension were run adjacent 
to one another and the increased size after the second round of amplification also indicated 
successful combination of leader sequence and EC2 encoding gene. 
The resultant fragments were cloned into the plasmid pSec-Tag-link, a modified version of the 
pSecTag/FRT/V5-His plasmid from the Flp-in system (Life Technologies). In this particular 
vector the multiple cloning site was altered to remove the V5 epitope to make the resulting 
recombinant protein more representative of its native counterpart. The Flp-in system was 
selected as it had been used for transfections of other (non-tetraspanin) genes by our group 
and offers a number of advantages over traditional transfection systems. It involves the 
insertion of a coding gene from one plasmid (pSecTag/FRT/V5-His) into a Flp recombinase 
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target (FRT) site in the host genome using a Flp-recombinase encoded on a second plasmid 
(pOG44) (O’Gorman et al., 1991). Integration at a predefined site ensures that the gene will 
not be inserted at an inactive region of the chromosome, therefore overcoming position effect 
variegation (Barnes et al., 2003). Furthermore, this method results in a clonal population 
following transfection, eliminating the need for downstream cloning. In this instance AgeI or 
HindIII were used as a 3’ restriction site allowing for the inclusion or omission of a C-terminal 
His-tag on the recombinant protein produced.  
PCR fragments were purified and digested with the relevant restriction enzymes (as was the 
vector pSecTag-link). The digested EC2-encoding inserts and vector were ligated according to 
section 2.2.2.13 and transformed into chemically competent E. coli DH5α cells. Overnight 
cultures were created from the resulting transformants and the plasmid DNA was then 
isolated via a plasmid miniprep. Plasmid DNA was quantified and an analytical restriction 
digest was carried out using the restriction sites either side of the multiple cloning site. 
Digestion products were run on a 1% agarose gel and the presence of an excised fragment 
indicated a successful ligation (Figure 3.2). Bands in the 350 to 400 bp region of Figure 3.2 are 
visible in lanes 1, 3, 5 and 8, and indicate successful ligations (their faint appearance is due to 
the small size in relation to the larger plasmid, 450 bp vs 5000 bp). Successful ligations were 
then sequenced to confirm the presence of the correct EC2 domain. DNA sequencing was 
carried out using CMV forward primers and BHG reverse primers (Appendix Table 7.1) to show 
that the vectors aligned with desired sequence, were in frame and contained no mutations. 
Once the sequences had been confirmed, fresh transformations were made, scaled up and 
midi-preps carried out to generate more DNA for subsequent transfections. 
Chapter 3: Production and analysis of tetraspanin EC2 domains 
 
83 
  
 
 
 
 
 
 
 
 
Figure 3.1: PCR amplification of human CD9 and CD151 EC2 genes to generate EC2-leader 
sequence constructs for cloning into mammalian expression vector. (a) EC2 encoding genes 
from pGEX bacterial expression vectors and leader sequences from pSec-GHstop plasmid were 
amplified by PCR. Samples were run on a 1% agarose gel. L: Hyperladder 1kb (Bioline), 1: 151 
AgeI, 2: Tspan5 Age1, 3: CD9 HindIII, 4: Tspan5 HindIII, 5: Leader CD9, 6: Leader CD151, 7: 
Leader Tspan5. (b) Following overlap extension PCR products were run on a 1% agarose gel 
alongside the fragments without addition of a leader sequence. A shows the original PCR and 
B shows the fragment with addition of a leader sequence. Both gels show 4 of the 6 inserts 
that were eventually cloned. 
  
a) 
b) 
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Figure 3.2: Restriction digest analysis of EC2- encoding constructs to confirm ligation.  
Analytical restriction digests were carried out on potential pSecTAG constructs to check 
for the presence of the desired tetraspanin EC2 domains inserts Products of digestion 
were run on a 1% agarose gel and arrows denote insert fragments in lanes 1, 3, 5 and 7. 
1-2: CD9-his, 3-6: CD151-his, 7: Tspan5-his, 8: Digested vector 10: Uncut plasmid DNA.  
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3.2.2 Expression of recombinant EC2 domains in mammalian 
cells. 
CHO and HEK-293 mammalian cell lines were used as hosts for mammalian expression, both of 
which have been used extensively in industry for recombinant protein expression (Jayapal et 
al., 2007). CHO cells are very amenable to genetic manipulation and can reach high cell 
densities in suspension culture allowing for greater protein yields per litre (Jayapal et al., 
2007); whilst HEK293 cells, being of human origin, are able produce human patterns of 
glycosylation so proteins produced may better reflect native tetraspanins in terms of function. 
Both HEK-293 and CHO cells already containing FRT (Flp recombinanse target) sites were 
available to us (a kind gift from I. Wilkinson, University of Sheffield, Medical School). These 
cells were co-transfected via electroporation (Section 2.2.1.12) with an EC2-encoding pSecTag 
plasmid and the recombinase-encoding plasmid pOG44; some samples were also mock 
transfected with the pOG44 plasmid alone as a negative control. After selection in hygromycin, 
supernatant from confluent resistant cells was analysed for tetraspanin protein content. 
Supernatants from transfected and non-transfected cells were analysed by Western blot and 
ELIS using relevant antibodies (as no anti-Tspan5 antibodies are available an anti-his antibody 
was used instead, figure not shown). Recombinant EC2 proteins previously produced from 
bacteria were included as a positive control (Figure 3.3). Although positive controls were clear 
in all blots and ELISA experiments (data not shown), no tetraspanin proteins could be detected 
in the cell supernatant samples from either transfected CHO or HEK-293 cells when probing 
with anti-CD9, anti-CD151 or anti-his antibodies. In Figure 3.3(a) and 3.3(b) bands representing 
CD9 and CD151 respectively are clear in the 27-35kDa region of the positive control lanes 
along with higher molecular weight bands which are perhaps due to higher order oligomers. 
However, bands which would be expected at 10 kDa and 13 kDa are absent from lanes 
containing supernatant from CD9 or CD151 transfected cells respectively.  
It was considered that low protein expression levels may have resulted in tetraspanin 
concentrations in the supernatant being insufficient for detection; therefore efforts were 
made to increase the amount of protein in each sample. Cells were allowed to grow until 100% 
confluent before supernatant was again collected and concentrated tenfold as described in 
2.2.3.11. Samples were again analysed by Western blot and ELISA. In Figure 3.3(C) and 3.3(d) 
intense bands are clear in the 37-25 kDa region for positive controls; however there was still 
no detectable protein in the supernatant of transfected cells and ELISA absorbance values 
were  
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a) 
Figure 3.3: Attempts to detect soluble tetraspanin EC2 production in transfected cell supernatants. (a 
+b) Supernatants from CD9 and CD151 transfected and non-transfected HEK-293 (-ve) cells were 
analysed via Western blot using relevant specific monoclonal antibodies. Recombinant CD9 EC2 or CD151 
EC2 produced in bacteria (~25ug/ml) was included as a positive control (+ve). (c + d) as in a+b but 
supernatant samples were concentrated 10x using Centrisart columns (5kDa cut off) and X-ray films were 
incubated with membrane overnight rather than the traditional five minutes. 
b) 
d) c) 
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zero (data not shown). A similar result was also seen for CHO transfections and anti-His 
Western blots used to detect Tspan5 were also negative (data not shown). 
The anti-CD9 antibody 602.29 appeared to be the more sensitive of the two anti-tetraspanin 
antibodies, giving more intense bands with equal amounts of recombinant protein. To 
determine the limits of detection, bacterially expressed recombinant CD9 was serially diluted 
and probed with 602.29 in Western blotting. Bands were visible across the membrane down to 
a minimum of 6µg/ml (Figure 3.4 (a)). A similar approach was taken to determine the 
sensitivity of an anti-CD9 ELISA with figure 3.4(b) showing an absorbance reading in wells with 
protein quantities as low as ~80ng/ml.   
It was next considered that the protein may be being retained within the cells, if for example 
the leader sequence was not functioning as intended. To check this, lysates were prepared 
from, both transfected and non-transfected cells (Section 2.2.1.15) and were then analysed by 
Western blot and ELISA. An anti-actin Western blot was included to ensure lysis had been 
successful. Lanes 2 and 3 of figure 3.5(a) show no CD9 protein could be detected in the lysate 
samples from either transfected or non-transfected CHO cells while bands just below 50 kDa in 
figure 3.5(b) represent actin, indicating successful lysis. Western blots of HEK-293 cell lysates 
(data not shown) also displayed endogenous full-length CD9 which further suggests successful 
lysis and also acts as an additional positive control. As no protein could be detected in intra or 
extracellular samples, it was speculated that the protein was not being expressed at all (i.e. as 
a result of problems in translation or transcription). It was considered that the transfection 
efficiency may be low resulting in very few cells containing the required DNA, but which are 
able to give passive resistance to the rest of the population. 
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a) 
Figure 3.4: Determination of the sensitivity of CD9 EC2 detection in Western blots and ELISA. 
(a) Recombinant CD9 EC2 protein produced in bacteria was diluted with non-reducing loading 
dye (concentration indicated in the table), run on an SDS-PAGE gel and blotted. Membranes 
were probed with anti-CD9 antibody, 602.29 (the blot was developed for 5 minutes). (b) From 
a starting concentration of 20 µg/ml recombinant CD9 EC2 was serially double-diluted down 
and across the wells of a 96-well ELISA plate. Antigen was detected using 602.29 antibody as 
described in 2.2.3.18. Absorbance readings at 410nm are shown 
b) 
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Figure 3.5 Analysis of Lysates of transfected CHO cells by Western blotting. (a) Transfected and non-
transfected CHO cells (5x106) were lysed as in section 2.2.1.15. Lysates (lanes 2 and 3) were run on an 
SDS PAGE gel under reducing conditions along with Recombinant CD9 EC2 from bacteria (25 µg/ml) 
which was included as a positive control. Following transfer, membranes were probed with anti-CD9 
antibody. 1: bacterially expressed positive control, 2: transfected cell lysate, 3: non-transfected cell 
lysate (b) Cell lysates were also probed with an anti-actin antibody. 1: transfected cell lysate, 2: non-
transfected cell lysate 
Figure 3.6 Analysis of supernatant and lysates from CHO cells transfected with CD9 encoding plasmid 
via Turbofect. Supernatant from transfected and non-transfected CHO cells were concentrated tenfold 
as described in Figure 3.3 and lysates were collected according to section 2.2.1.15. Samples (along with 
bacterially expressed CD9 as a positive control) were probed by Western blot using an anti-CD9 
antibody as described previously. 1: non-transfected cell supernatant, 2: CD9 transfected cell 
supernatant, 3: non-transfected cell lysate, 4: CD9 transfected cell lysate. 
a) b) 
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TurbofectTM transfection reagent (Life Technologies) reportedly results in a greater efficiently 
of transfection than electroporation (I. Yaseen, unpublished data). The reagent consists of a 
cationic polymer which forms a positively charged complex with DNA in order to deliver DNA 
to the cell (Oba and Tanaka, 2012). To compare the transfection efficiencies of both methods 
and to ensure that the methods of transfection were working, CHO cells were initially 
transfected with a GFP expression vector (pEGFP-N1). Three days following transfection there 
was a marked difference in the appearance of cells transfected by different the methods, with 
electroporation initially giving fewer viable cells which were able to adhere. Once cells 
transfected by both methods had become confluent they were viewed using a Nikon A1 
fluorescent microscope. Both methods did yield transfected, fluorescent cells, indicating that 
the experimental procedures used were sufficient to successfully deliver DNA. However, 
Turbofect TM transfection gave a greater proportion of fluorescent cells (approximately 90% vs 
60% (Data not shown)). With this apparent increase in transfection efficiency, CHO and HEK 
cells were once again transfected with the EC2 expression vectors using TurbofectTM. However, 
despite improved initial viability compared to electroporation, still no protein could be 
detected in concentrated supernatant or lysate samples by Western blot (Figure 3.6) or ELISA 
(data not shown) 
After a number of unsuccessful attempts to detect EC2 protein following transfections with 
two different cell lines, five expression constructs (CD9, CD151 with and without His and 
Tspan5) and two transfection methods it was decided to try a different system for expression 
which forgoes the need for co-transfection. This system uses the expression vector pCI-neo 
and has previously been used successfully by our group for expression of human CD63 in HEK-
293 cells (Jirvairiyakul, 2010). Being as the CD63 pCI-neo construct was already available, 
cloning into the vector did not require overlap extension PCR and instead the CD9 and CD151 
encoding inserts were cloned down-stream of the existing leader sequence. Tspan5 was not 
cloned into this particular vector because no anti-Tspan5 mAbs are available, making its 
detection more difficult. Concentrations of G418 to use for selection were established prior to 
transfection and TurbofectTM was again used for these transfections. Two weeks following 
transfection, resistant colonies were clear (Figure 3.7). However, upon testing lysate and 
concentrated supernatant samples of CD9 transfected cells, these proteins still could not be 
detected by Western blot (Figure 3.8) or ELISA analysis (data not shown) (the same results 
were seen for CD151 transfection and when using HEK-293 cells, data not shown). 
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Figure 3.8: Analysis of Supernatant and Lysates from CD9 pCI-neo transfected CHO cells. Supernatant 
and lysates from CHO cells transfected with CD9 pCI-neo and non-transfected CHO cells were collected. 
After SDS-PAGE and blotting, membranes were probed using an anti-cd9 antibody as described previously, 
using bacterially expressed CD9 as a positive control. 1: Bacterially expressed positive control, 2: non-
transfected cell supernatant, 3: CD9 transfected cell supernatant, 4: non-transfected cell lysate, 5: CD9 
transfected cell lysate. 
Figure 3.7 Images of CD9 pCI-neo transfected CHO and HEK-293 cells following selection using 
G418.  Following transfection, cells were grown in DMEM containing G418 (1mg/ml CHO, 500µg/ml 
HEK-293) for two weeks (a) non transfected (b) mock transfected (c) CD9 pCI-neo transfected. 
Random fields were captured using a Nikon Diaphot brightfield microscope using a 10x objective. 
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3.2.2.1 Analysis of mammalian transfection 
To determine if the initial stages of transfection had been successful, attempts were made to 
check if the CD9 EC2 encoding DNA has been stably introduced into the cells. Genomic DNA 
was isolated from CD9 transfected HEK-293 FLP-in cells from pCI-neo transfected CHO cells, 
along with their non-transfected counterparts. The isolated nucleic acid was used as a PCR 
template to detect if the encoding DNA for CD9 EC2 was present (Figure 3.9). In both instances 
positive controls bands are clear, as are bands in the transfected cell samples, with no 
amplification product in non-transfected negative controls. This demonstrates that the coding 
DNA is present in the cells; however, it is possible that the DNA is not being transcribed.  
To address the possibility that the gene encoding CD9 EC2 was not being transcribed, levels of 
cellular RNA were investigated. Total cellular nucleic acid was firstly isolated from the CD9 EC2 
transfected HEK-293 and CHO cells as described in section 2.2.2.14. DNA in the samples was 
digested to leave only the RNA fraction and reverse transcription was carried out on each 
sample to produce cDNA (Section 2.2.2.15), in some cases the reverse transcriptase was 
omitted to give negative control samples for contaminating cellular DNA. The cDNA samples 
were used as PCR templates to amplify either the β-actin RNA as a positive control or CD9 EC2 
encoding RNA (Figure 3.10). Actin control bands can be seen in each sample with the reverse 
transcriptase and are not present in those without it, thus indicating that the only DNA present 
in the samples results from reverse transcription of RNA. CD9 EC2 bands can be seen in 
transfected cells but not in the non-transfected negative control lanes (Figure 3.10b), 
indicating that the CD9 encoding DNA being transcribed.  
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Figure 3.9: PCR analysis of Flp-in and pCI-neo transfected cells to check for incorporation of 
expression gene. (a) Genomic DNA was isolated from pSecTag-CD9 transfected HEK-293 cells and 
non-transfected HEK-293 cells according to section 2.2.2.14. Purified expression vector DNA from 
bacteria or genomic DNA from non-transfected or transfected cells was used as a template for PCR 
using leader sequence forward and  CD9 reverse primers for amplification (Appendix Table 7.1) 1: 
Positive control (expression vector DNA purified from bacteria), 2: Genomic DNA from non-
transfected cells, 3: Genomic DNA from transfected cells. (b) Genomic DNA was isolated from CD9-
pCI-neo transfected CHO cells and non-transfected CHO cells. Purified expression vector from 
bacteria or genomic DNA from non-transfected or transfected cells was used as a template for PCR 
using CD9F and CD9R primers (Appendix table7.1) 1: Positive control (expression vector DNA purified 
from bacteria), 2: Genomic DNA from non-transfected cells, 3: Genomic DNA from transfected cells. 
a) 
b) 
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a) 
b) 
Figure 3.10: PCR analysis to check for CD9 EC2 encoding mRNA in transfected CHO and HEK-293 
cells. Total nucleic acid was isolated from transfected and non-transfected CHO and HEK cells and 
DNA was digested using DNase. In A samples reverse transciptase was added to make cDNA, in B 
samples reverse transcriptase was omitted. cDNA was used as a template for PCR using (a) actin 
primers (Appendix table 7.1) (b) CD9 EC2 primers described in Figure 3.9. amplification is specific for 
recombinant DNA and not for endogenous CD9 encoding DNA. 
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3.2.3 Expression of recombinant EC2 domains in insect cells 
Since numerous attempts to produce recombinant EC2 domains from mammalian cells using 
different approaches were unsuccessful, it was proposed that insect cells, specifically Sf9 cells, 
might be a suitable alternative for protein expression. Insect cells are able to perform post-
translational modifications so would produce glycosylated EC2 domains, and their ability to 
produce correctly folded proteins is second only to mammalian cells (Altmann et al., 1999). 
Furthermore, as they grow in suspension, high cell densities are more easily attained, which 
could lead to higher protein yields. 
CD9 and Tspan5 were selected as initial candidates for insect expression as the different 
numbers of theoretical disulphide bonds (2 and 4 respectively) should give an indication as to 
how well this system can cope with the tetraspanin EC2 domain folding patterns. Genes for 
both the EC2 domains and full-length versions of CD9 and Tspan5 were amplified with the 
view to later structural studies. Primers were designed to introduce his-tags at either the N- or 
C- terminal ends of the tetraspanin proteins. The tetraspanin genes were amplified from 
constructs corresponding to the EC2 regions in the p-GEX vectors (Higginbottom et al., 2003) 
or full length tetraspanins in pEE6 vectors (Higginbottom et al., 2000a) that had previously 
been generated in the laboratory, and amplification products were run on a 1% agarose gel 
(Figure 3.11). Bands at ~250 bp in lanes 1, 2, 5 and 6 are the correct size for the EC2 domain 
encoding regions, whilst products at 650 bp in lanes 3, 4, 7 and 8 are the correct size for full 
length tetraspanin genes. PCR products were digested and ligated into either pACSEC1 (which 
contains a gp64 leader sequence) for EC2 expression or pVL1393 for the full length protein. 
The ligation products were used to transform E. coli DH5α competent cells as described in 
2.2.2.6. 
Once the tetraspanin-encoding sequences had been confirmed as correct, the plasmids were 
mixed with baculovirus DNA as described in section 2.2.1.14. During incubation, homologous 
recombination takes place which incorporates the gene of interest into the viral genome. The 
gene of interest is under the control of the polyhedron promotor, a strong very late stage 
promotor at its maximum during the lytic phase of the virus cycle. The baculovirus 
expression/DNA mixture was combined with the cationic lipid, Cellfectin (Life Technologies), 
which results in the formation of a cationic lipid-DNA complex. This complex was incubated 
with the cells where it fuses with the cell membrane and enters via subsequent endocytosis. 
After culturing the cells for five days, primary viral isolates were harvested and used to infect a 
larger volume of cells; secondary viral isolates were subsequently used to infect further cells.  
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Figure 3.11 PCR amplification of full length CD9 and Tspan5 and EC2 domains CD9 and Tspan5 for 
cloning into insect expression vectors. DNA encoding CD9 and Tspan5 EC2 domains and full length 
protein were PCR amplified from pGEX and pEE6 expression vectors respectively. PCR products were 
run on a 1% agarose gel. 1 = CD9 EC2 5’His, 2= CD9 EC2 3’ His, 3= CD9 full length 5’ His, 4 = CD9 full 
length 3’His, 5 = Tspan5 EC2 5’ His, 6 =Tspan5 EC2 3’ His, 7 = Tspan5 full length 5’ His, 8 = Tspan5 full 
length 3’His. 
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Once these insect cell cultures had reached the desired density, cells were harvested and 
frozen at -80ᵒC whilst supernatants were subjected to nickel affinity chromatography (Section 
2.2.3.8) in an attempt to isolate his tagged protein. Samples were taken at each step of the 
purification and run on a polyacrylamide gel along with the eluted protein. Recombinant CD9 
EC2 protein produced in bacteria was used as a positive control for the anti-CD9 Western blots 
as described in previous sections. 
An absence of bands in lanes 1-4 and lanes 6-9 of Figure 3.12a show that no CD9 EC2 protein 
could be detected in the column flow through, wash or fractions eluted with imidazole from 
the attempted purification of CD9 EC2 His-tagged at the N- or C- terminal ends. Again it was 
considered that protein could be being retained within the cells, so cell pellets were thawed 
and lysed by sonication as described in 2.2.3.5. Cell lysates also underwent nickel affinity 
chromatography; flow-through, wash and eluted samples were again subjected to Western 
blot analysis. Lanes 2-9 of Figure3.12 (b) again show that no CD9 protein could be detected in 
any fractions of the purification. Further attempts were made using different titres of 
secondary viral isolates for the infection of more cultures; however similar results were 
observed with no tetraspanin EC2 proteins being detected (data not shown). 
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b) 
a) 
Figure 3.12 Attempted purification of His-tagged CD9 EC2 protein from insect cell supernatants using 
nickel affinity chromatography. (a) Supernatants collected from transfected insect cells (2.2.1.14) were 
subjected to nickel affinity chromatography (2.2.3.8). Samples from each step of purification were run on a 
SDS-PAGE polyacrylamide gel, blotted and the membranes probed with anti-CD9 antibody. 1= Initial flow 
through, 2= Wash, 3= 500mM imidazole elutate 1, 4= 250mM imidazole eluate, +ve: CD9 EC2 control. (b) 
Cell lysates from transfected cells were also subjected to nickel affinity chromatography and were 
analysed as described in (a) 1= Flow through, 2= Wash, 3= 500mM imidazole eluate, 4= 250mM imidazole 
eluate, +ve= Positive control. 
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3.2.4 Expression of recombinant EC2 domains in bacteria 
3.2.4.1 Rationale for bacterial expression 
Although the recombinant EC2-GST fusion protein expressed in E. coli have some limitations 
(e.g. lack of glycosylation and possible contamination with LPS) they have shown biological 
activity in a number of functional studies and have proven useful in finding out more about 
tetraspanins as a whole (Green et al., 2011; Ho et al., 2006; Parthasarathy et al., 2009; Takeda 
et al., 2003; Zhu et al., 2002). Because of the problems encountered in trying to express 
soluble EC2 proteins in the eukaryotic systems described above, the EC2 domains of CD9, 
CD63, CD81 and CD151 were subsequently expressed in E. coli to provide protein for use in 
later functional studies (Chapters 4 and 5). 
Expression of disulphide containing proteins in bacteria is challenging due to the reducing 
environment of the cytoplasm. This issue can be circumvented in a number of ways, for 
example by expressing the proteins into the periplasmic space where Dsb enzymes facilitate 
the formation of disulphide bonds (Baneyx and Mujacic, 2004; Qiu et al., 1998). Here, 
however, a strain of E. coli called Rosetta-gamiB(DE3) (Novagen) were used, which have 
mutations making them amenable to the expression of di-sulphide containing protein in the 
cytoplasm. For di-sulphide bonds to form, enzymes must be present to oxidise amino acid thiol 
groups. In the E. coli cytoplasm thioredoxins TrxA and TrxC along with the three glutaradoxins, 
are capable of doing this, but are kept in a reduced state by a thioredoxin reductase (TrxB) and 
Glutathione (Gor) respectively. In Rosetta-gami cells trxB and gor mutations result in the 
oxidised form of the thioredoxins and glutaradoxins, thus enabling disulphide bond formation 
(Bessette et al., 1999). Rosetta-gami also contain a pRARE plasmid which encodes the tRNA for 
codons rarely seen in E. coli, enabling the expression of human proteins more efficiently 
(Brinkmann et al., 1989) 
The proteins were expressed as GST-fusion proteins via the use of the vector, pGEX-KG. This 
enables simple one-step purification through glutathione chromatography, and in some cases 
the GST tag has been suggested to aid in the solubility of the tagged protein (Shih et al., 2002). 
This particular vector includes a thrombin cleavage site for downstream removal of the GST 
tag along with a flexible glycine rich linker region to improve cleavage efficiency (Guan and 
Dixon, 1991).  
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3.2.4.2 Bacterial expression of EC2 domains and subsequent purification 
Previously generated pGEX-KG expression vectors encoding N-terminal GST tagged EC2 
domains were used to transform Rosetta-gami competent cells (Section 2.2.2.6). After 
induction with IPTG, cultures were harvested and bacteria lysed as described in 2.2.3.5 and 
GST tagged proteins were then purified by affinity chromatography as described in 2.2.3.6. 
Samples from each step of the purification were run on a SDS PAGE gel and subsequently 
stained with Coomassie blue (Figure 3.13).  
The eluted protein from each purification (shown in lanes 6 and 7) was largely composed of 
the full length tetraspanin EC2-GST fusion protein (indicated by a red arrow); however there 
are a number of contaminating bands also. Lower MW bands are most likely products of 
truncation or proteolytic cleavage of the GST tag, indeed a band indicative of free GST can be 
seen at ~25 kDa. An anti-GST Western blot of the eluted proteins (Figure 3.14a) shows GST 
containing products at intervals below the expected full length fusion protein; this further 
indicates that bands of lower molecular weights are indeed a result of degraded full length 
protein or truncated expression.  
The insoluble protein fraction was resuspended in loading dye and run alongside the samples 
from affinity purification (Figure 3.13 lane 1) and in each case a band can be seen at positions 
corresponding to the respective tetraspanin EC2 fusion proteins. Interestingly the size of the 
band seems to inversely correlate with the final protein yield (shown in table 3.2); this 
suggests that lower yields of soluble protein (e.g. for CD63 and CD151 purifications) are a 
result of the protein forming insoluble protein aggregates. Additionally, small amounts of 
tetraspanin protein can be seen in the wash steps (lanes 3, 4 and 5) of CD9 and CD81 
purifications; this is probably due to oversaturation of beads as these bands cannot be seen in 
CD63 and CD151 purification. Eluate protein concentration was quantified using absorption at 
280 nm and the proportion of correctly folded material (indicated by a red arrow) determined 
by densitometry using the software ImageJ. 
The EC2-GST fusion proteins were recognised via Western blotting using anti-tetraspanin 
antibodies, with bands being detected at the expected molecular weights in the non-reduced 
lanes of Figure3.14 (b). Higher molecular weight bands can also be at ~75 kDa and are thought 
to represent oligomers or protein aggregates. As these larger bands are not observed in 
Coomassie stained polyacrylamide gels of proteins under reducing conditions, it may be that 
these higher order structures are reliant on the correct folding of the proteins or that they are 
a result of some aberrant disulphide bond formation. Additionally, GST contains four solvent  
   
1
0
1 
Figure 3.13: Glutathione affinity purification of GST and four tetraspanin EC2 domains from Rosetta-gami cells. Rosetta-gami B(DE3) E. coli cells  
transformed with tetraspanin EC2 encoding pGEX vectors were used to express GST-tagged proteins as described in 2.2.3.4.. Lysates underwent 
glutathione affinity chromatography (Section 2.2.3.6) and samples taken at each stage of the purification, (and the insoluble fraction which was retained 
after lysis and resuspended in 1x reducing loading buffer) were run on a polyacrylamide gel and stained with Coomassie blue. 1 = insoluble fraction, 2 = Not 
bound to beads, 3 = 1st wash, 4 = 2nd wash, 5 = 3rd wash, 6 = Eluate 1, 7 = Eluate 2. 
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Protein Yield per gram of bacteria (mg) 
GST 3.529 
CD9 1.979 
CD63 0.255 
CD81 2.532 
CD151 0.964 
b) 
a) 
Table 3.1: Tetraspanin EC2 protein produced per gram of bacterial pellet as determined 
by absorbance at 280 nm. Purified proteins were quantified using a nanodrop. 
Figure 3.14 Western blot analyses of purified tetraspanin EC2 domains. (a) Purified Proteins (50 
µg/ml) were run under reducing conditions on a polyacrylamide gel, blotted and probed with an anti-
GST antibody. 1 = GST, 2 = CD9 EC2, 3 = CD63 EC2, 4 = CD81 EC2, 5 = CD151 EC2 (b) Purified 
tetraspanin proteins (50 µg/ml) were run under reducing (R) or non- reducing (NR) conditions on a 
polyacrylamide, blotted and probed with the relevant anti-tetraspanin antibodies. 
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exposed cysteine residues which can contribute to the formation of protein aggregates upon 
oxidation (Kaplan et al., 1997). Western blotting (Figure 3.14 (b)) also demonstrates that 
recognition of the tetraspanin EC2 proteins by their respective antibodies is abolished under 
reducing conditions. This indicates that the monoclonal antibodies used are conformationally 
sensitive and exhibits a requirement of di-sulphide bonds for the correct folding of the EC2 
domains. 
3.2.4.3 Optimisation of bacterial EC2 domain expression 
Visual inspection of Coomassie-stained polyacrylamide gels (Figure 3.13), along with the data 
presented in Table 3.2, indicates the relative protein yield from the expression and purification 
of each EC2 domain. Although only small amounts of EC2-GST fusion proteins are generally 
required for functional assays, it is desirable to optimise protein yields to reduce additionally 
rounds of expression and facilitate experiments which require higher quantities of protein (e.g. 
structural studies). Furthermore, alternative methods of purification might reduce 
contaminants in the final product. In an attempt to increase the amount of soluble protein 
from the purification a number of parameters were altered. 
IPTG is used as an inducer of the Lac promoter (or derivatives thereof) but at high 
concentrations can inhibit cell growth (Marbach and Bettenbrock, 2012). The effect of varied 
IPTG levels on CD63 expression by pGEX-CD63 transformed Rosetta-gami cells was 
investigated. Western blot analysis (Figure 3.15) showed a decrease in the band intensity with 
increasing levels of IPTG indicating that lower concentrations of IPTG favour higher amounts of 
correctly folded CD63 EC2-GST but that this effect plateaus at a concentration of 0.1 mM 
(indicated by the small difference between 0.1 and 0.25mM IPTG). As the entire cellular 
contents were loaded here, these results reflect total protein production and not levels of 
soluble protein. 
Rajesh and co-workers (2012) also expressed EC2 domains in E. coli and favour longer 
incubation (12hours) at lower temperatures (18:C) post induction. To determine the effects of 
prolonged incubation on EC2 expression, cells transformed with pGEX-CD81 were incubated 
for varying lengths of time after IPTG induction. GST tagged proteins were purified from the 
soluble fraction as described previously (Section 2.2.3.6) and samples were analysed on 
polyacrylamide gels. As shown in Figure 3.16, there is a decrease in full length protein 
(indicated by a red arrow) as soon as six hours after induction and a simultaneous increase in a 
band at 25 kDa indicative of free GST. These results suggest that prolonged incubation leads to 
far greater occurrence of aberrant proteolytic cleavage of the GST tag.   
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IPTG used (mM) Density, relative to 0.1mM Lane 
0.1 1.00 1 
0.25 0.98 2 
0.5 0.73 3 
0.75 0.44 4 
1 0.21 5 
 Figure 3.15: Effect of increasing concentration of IPTG on CD63 expression. E. coli transformed 
with p-GEX encoding CD63 EC2 were grown to an OD600 of 0.6 before being induced with varying 
concentrations of IPTG. After four hours, bacteria were harvested by centrifugation and 
resuspended in 1x non-reducing SDS loading buffer, boiled and run on an polyacrylamide gel. After 
blotting membranes were probed with an anti-CD63 antibody.  
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 Figure 3.16: Effect of prolonged incubation (post IPTG induction) and temperature on CD81-
EC2 expression. (a) E. coli transformed with pGEX-CD81 were grown to an OD600 of 0.6, induced 
with 0.1mM IPTG, incubated for varying lengths of time then harvested by centrifugation and 
frozen. Cell pellets were subsequently resuspended lysed and lysates were used for glutathione 
affinity purification (2.2.3.6). Samples from each stage of the purification were run on a 
polyacrylamide gel and stained with coomassie blue. 1= 1st wash , 2= 2nd wash 2, 3= eluate 1, 4= 
Protein remaining on GST beads (b) As in (a) but cells were incubated at the temperatures shown 
for 16 hours post induction.  
a) 
b) 
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Decreasing the temperature used for prolonged incubation after induction (Figure 3.16) 
reduces the amount of cleavage taking place but yields are still lower than those attained from 
the four hour expression period. Column and batch methods of affinity purification of GST-
tagged tetraspanin EC2s were also compared. Our group has recently favoured the use of a 
batch method of glutathione affinity purification over the previously used column method 
(sections 2.2.3.6 and 2.2.3.7 respectively). This is mostly due to the increased control over 
elution volumes in the batch method; if for example a higher concentration of protein is 
required, a lower elution volume can be used. However, it is conceivable that different 
methods of purification may result in slightly different end products, with one concern being 
that EC2 proteins purified by the batch method might contain higher levels of contaminants, 
such as LPS. Both methods were compared using Rosetta-gami cells transformed pGEX-CD9. 
Following expression and lysis, half of the lysate was used in a batch method of purification 
and half in the column method (Figure 3.17a and 3.17b). Similar yields of protein were 
recovered from each purification method, eluted proteins (lanes 5 and 6) have a similar 
appearance in terms of lower molecular weight bands and the amount of full length protein 
(determined by densitometry) was almost identical (~48% for the batch method and ~47% for 
column). The second and third wash steps (lanes 3 and 4) of the column method contain more 
protein, however the weight of the proteins suggest that it is CD9 EC2 eluting from the column 
rather than contaminating protein so may not be indicative of more thorough washing. LPS 
levels in recombinant CD9 EC2 proteins resulting from both methods of purification were also 
similar (displayed figure 3.16c) and would indicate that, with respect to endotoxin 
contamination, neither method is favourable.  
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Figure 3.17: Comparison of batch and column purification methods. E. coli transformed with 
pGEX-CD9 were grown, harvested and lysed as described in 2.2.3.4 and 2.2.3.5. GST-tagged 
proteins purified by glutathione affinity purification according to (a) batch method (2.2.3.6) or (b) 
column method (2.2.3.7). Samples from each step of the purifications were run on a 
polyacrylamide gel which was stained with Coomassie blue. 1= Non-bound protein, 2= 1st wash, 
3= 2nd wash, 4 = 3rd wash, 5= eluate 1, 6 = eluate 2 (c) LPS levels in a 500nM solution of CD9 EC2 
(eluted 1, lane 5) from each method of purification were quantified using a Pierce LAL endotoxin 
quantitation kit (2.2.3.13) data is representative of two repeats. 
c) 
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3.2.5 Cloning and expression of rat CD63 EC2 domain 
The majority of recombinant EC2 domains used by our group are those corresponding to 
human tetraspanins, however, previous reports have suggested that EC2 domains originating 
from different species can have significantly different effects in functional assays (Ho et al., 
2006; Parthasarathy et al., 2009). For use in functional assays involving rat cells (described in 
Chapter 4), rat CD63 was chosen to be expressed (becuase of the tetraspanins investigated 
here, this member shows the most variation between rat and human orthologues (see 
Appendix).  
A plasmid containing the full-length rat CD63 cDNA was purchased from OriGene. Primers 
were designed to amplify the EC2 domain (Appendix Table 7.1) and included restrictions sites 
to allow incorporation in the pEX-KG plasmid. Once amplified (Figure 3.18a), the PCR product 
corresponding to the EC2 domain and the pGEX-KG vector were digested and ligated (2.2.2.12 
and 2.2.2.13). E coli DH5α cells were transformed with the ligation product used to isolate and 
amplify vector DNA. An analytical digest was carried out to check for the presence of an insert 
(Figure 3.18b) (shown by fragments within the red box) and the construct was sequenced. 
Once the correct rat-CD63 EC2 sequence was confirmed, rat CD63 p-GEX plasmid was used to 
transform Rosetta-gami cells and GST-tagged protein was express and purified as described 
previously (Sections 2.2.3.4 and 2.2.3.6). As shown in Figure 13.19a the eluate (lane 5) contains 
a predominant band at the correct molecular weight for rat CD63. Samples of the eluate and 
previously generated human CD63 EC2 were compared Western blots probed with antibodies 
towards either rat CD63 (AD1) or human CD63 (H5C6) and the results are shown in Figure 
3.19b. The rat and human CD63 EC2 proteins only show reactivity with their respective 
antibodies (which are species specific) indicating that expression of rat CD63 had been 
successful (although yields were relatively low).  
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Figure 3.18: PCR of rat CD63 EC2 and analytical digest of rat CD63 EC2 expression vector to 
check for EC2 encoding insert. (a) PCR amplification products of rat CD63 EC2 from full length 
rat CD63 in the pCMV6-Entry vector were run on a 1% agarose gel (b) Restriction digest of pGEX-
ratCD63 (using EcoRI and HindIII) DNA from transformed DH5α E. Coli cells. Digestion products 
were run on a 1% agarose gels, each lane represents different tranformants insert fragments 
can be seen at 290 bp.  
a) 
b) 
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Figure 3.19: Steps in the glutathione purification of rat CD63-EC2 from bacterial lysates. (a) 
Transformed E. coli were cultured and lysed as described previously and GST-tagged proteins 
purified by affinity purification. Samples were run on a polyacrylamide gel under reducing 
conditions and stained with Coomassie blue 1= insoluble fraction, 2= Non-bound protein, 3= 1st 
wash, 4 = 2nd wash, 5 = eluate 1, 6 = eluate 2. (b) Samples of purified rat and human CD63 EC2 were 
run on a polyacrylamide gel and blotted; each membrane was probed with either anti-rat CD63 
(AD1) or anti-human CD63 (H5C6) monoclonal antibodies.  
a) 
b) 
1 2 3 4 5 6 
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3.3 Discussion 
Mammalian and insect cells are more able to cope with complex folding patterns than bacteria 
and produce proteins which are glycosylated and free of endotoxin contamination (Section 
1.3), therefore many attempts were made at producing recombinant EC2 domains in both 
systems. For mammalian expression, two cell lines were transfected by two separate methods 
using seven different vectors (Five for the Flp-in system and two for pCI-neo). Resistant cells 
were clear, yet no protein could be detected in supernatant samples or cell lysates by Western 
blot or ELISA. Similarly for insect cells, multiple vectors yielded no protein. This was surprising 
because the pCI-neo expression vector has been used by our group previously for CD63 EC2 
expression in HEK-293 and the Flp-in systems offers a number of benefits over this vector 
(Jiraviryakul, 2010). One of the most apparent advantages of the Flp-in system is the use of site 
specific recombination which stops the possibility of gene incorporation into a transcriptionally 
inactive site (Barnes et al., 2003). Although this improvement has not led to production of the 
desired protein in this instance, it has at least enabled this issue to be ruled out as the reason 
for the absence of protein. There are a number of other possible explanations for the lack of 
detectable protein, some of which will be discussed here. 
Firstly, DNA constructs were all sequenced and found to be in frame with no mutations 
indicating that the coding DNA was not at fault. With both HEK-293 and CHO transfections 
resistant colonies were apparent when comparing transfected cells with mock transfected 
cells. The presence of the CD9 coding DNA in genomic extractions from both FLP-in or pCI-neo 
transfected cells (Figure 3.9) indicates that there was no issue with introducing the DNA to the 
cells. Reverse transcription PCR (Figure 3.10) demonstrated that the CD9 transfected CHO and 
HEK-293 cells were producing CD9 encoding mRNA also. In both instances it is unlikely that the 
PCR products are a result of amplification of endogenous CD9 DNA/RNA, in CHO cells (which 
are hamster in origin) a forward primer corresponding to human CD9 was used and in the 
human HEK-293 cells an IgGκ forward primer (corresponding to the secretion tag) was used. 
These results show that the DNA is being transcribed and has therefore been introduced into 
the desired site. This therefore suggests an issue with translation of the mRNA into the desired 
protein product, or a problem with the produced protein, which renders it undetectable.  
Expression of CD9 encoding mRNA had been confirmed through RT-PCR on cellular RNA, 
however random primers were used for amplification leading to the amplification of all the 
cellular RNA, including that which is not processed (where as poly dT primers would amplify 
only polyadenylated RNA). It is possible that the small size of the RNA means it is poorly 
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processed (for example not polyadenylated), which could result in it not being translated (Ntini 
et al., 2013). In future, poly dT primers could be used for RT-PCR to assess whether the CD9 
encoding RNA is polyadenylated, it may also be beneficial to use longer DNA constructs for 
expression; for instance by including a streptavidin tag or V5 epitope which were omitted in 
this work with the hopes of expressing products closer to the native proteins.  
Mammalian cells traditionally produce less protein than E. coli expression systems, therefore 
initial thoughts were that the proteins were expressed but were at concentrations too low to 
be detected. However, analysis of Western blot and ELISA detection limits indicated that the 
methods used here should be sufficiently sensitive to detect proteins even with modest 
estimates of protein expression. For example, Western blots to determine the detection limits 
of the anti-CD9 antibody (Figure3.4a) were able to detect a protein concentration as low as 6 
µg/ml. In a supernatant sample concentrated 10x, as little as 0.6 µg/ml or 600µg/litre in the 
original sample would be detected via Western blot analysis, and ELISA experiments have 
proven even more sensitive, with absorbance readings being detected in wells with CD9 
quantities as low as 80 ng/ml, therefore theoretically requiring transfected cells to produce as 
little as 80 µg/litre. It is still possible that the recombinant proteins were being produced at 
lower than detectable quantities, however if this was the case, then these yields would be too 
low to make these hosts feasible for expression.  
An alternative explanation for lack of detectable EC2 protein is once the proteins are 
expressed they are rapidly degraded prior to detection. This could happen non-specifically by 
cellular proteases or via the unfolded protein response, in which proteins are broken-down in 
response to accumulation of unfolded protein within the ER (Cao and Kaufman, 2012).  If the 
EC2 domains are not broken down there is also the possibility that they are forming insoluble 
protein aggregates as a result of non-native interactions between protein folding 
intermediates (Kopito, 2000). This may have led to the loss of conformational epitopes 
required for the anti-tetraspanin antibody to bind, however it is likely that His-tagged variants 
would still be detected with anti-His antibodies. Finally there is the potential that the 
expressed tetraspanin EC2 domains are toxic for the host cells and therefore production of the 
EC2 domains is lost over time.  
Expression of EC2 domains by other groups is predominantly undertaken using E. coli as a host 
for expression (Barreiro et al., 2005; Kitadokoro et al., 2001; Petracca et al., 2000; Takeda et 
al., 2003; Zhu et al., 2002) with one instance of a yeast (Pichia pink) expression system being 
utilised (Curti et al., 2013), and another where mammalian cells (HEK-293) are used (Rajesh et 
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al., 2012). The group which used a cell line for EC2 expression favoured transient transfection 
(Rajesh et al., 2012), in which a large volume of cells are transfected and express protein for a 
short amount of time before the protein is harvested. It is possible that the expression from a 
high copy number plasmid could lead to more protein (Balbás, 2001). Additionally, with 
regards toxic proteins, transient transfection or inducible expression may be favourable 
because the cells are not subjected to the negative selection for a long period of time and cell 
viability is less of an issue over the short expression period. 
One instance where stable cell lines have been successfully used for expression of tetraspanin 
EC2 domains was by our group for the expression of CD63 in HEK-293 cells (Jiraviryakul, 2010). 
However, there are a number of properties of the CD63 construct that may make it more 
amenable to this method of expression. Firstly, the construct used contained a streptavidin 
tag, glycine linker and thrombin cleavage site and is therefore larger than the ones produced 
here. This will result in longer RNA which could be more readily processed. Furthermore, of 
the proteins which we have attempted to express in mammalian cells (CD9, CD63, CD151 and 
Tspan5) CD63 has a much lower theoretical stability index (Table 3.3). This value is based on 
the presence of specific dipeptides within the protein which have been correlated to its half-
life, proteins with values below 40 are considered stable, so CD63 with a stability index of 
28.83 may remain in solution for longer periods of time (Guruprasad et al., 1990). 
Furthermore, CD63 is unusual within the tetraspanin family as it is often found in intracellular 
vesicles and in some cases, lysosomes. With this localisation it is possible that CD63 has 
adaptations to prevent proteolytic degradation, for example, being heavily glycosylated as 
evidenced by the smear it shows as on Western blots (Jiraviryakul, 2010(Russell et al., 2009). 
Finally, CD63 has a much higher PI than the other members discussed here (Table 3.3). The 
mammalian cell lines used for expression are cultured in DMEM medium (pH of 7.4); however 
once cells reach a high density the pH does drop (indicated by changes phenol red indicator). 
This could favour the solubility of CD63 with a high pI and but negatively impact the solubility 
of the other tetraspanin protein with lower pI values. 
The EC2 domains of the four tetraspanins under investigation (CD9 CD63, CD81, CD151) and a 
GST control were successfully produced and purified from Rosetta-gami E. coli cells (Figure 
3.13) and the final purified products were effectively recognised by their respective antibodies 
(Figure 3.14b). Since these antibodies are conformationally sensitive and reliant upon the 
presence of disulphide bonds, this indicates that the resultant proteins are (at least in part) 
correctly folded. For the majority of the EC2 domains produced, over 50% of the final product 
was composed of the full length protein with much of the remainder being lower molecular 
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weight products. An anti-GST Western blot (Figure 3.14a) shows that the lower molecular 
weight bands are GST containing proteins; it is therefore likely that they are a result of 
premature termination of protein translation or degradation of the full length product 
(perhaps from aberrant proteolysis following cell lysis). The lowest band appears at ~ 26kDa 
and represents free GST from cleavage of the tag from the EC2 domain, however high bands 
also suggest that proteolysis is not just taking place at the GST cleavage site.  This 
phenomenon has been observed by other groups expressing GST tagged EC2 domains (Azorsa 
et al., 1999; Barreiro et al., 2005; Petracca et al., 2000), with some opting for the inclusion of a 
second affinity tag (usually a His-tag) at the opposing end of the protein (Petracca et al., 2000). 
This secondary tag enables an additional round of purification, which can purify the full length 
His containing products from the truncated proteins that do not include the 3’ His-tag. Not 
only would this method result in an end product with fewer unwanted protein contaminants 
but could also be beneficial when cleaving the bulky GST tag from the proteins (Section 5.3.3). 
Some groups have also utilised more rigorous methods of protein purification to remove the 
unwanted contaminating protein, such as reverse phase HPLC (Parthasarathy et al., 2009; Zhu 
et al., 2002) 
Coomassie staining of the insoluble protein fraction indicates that a relatively large amount of 
the desired protein is ending up in an insoluble form. This is more apparent in the low yielding 
purifications of CD63 and CD151, both of which contain six disulphide bonds. The relatively 
low yields of these EC2 domains, along with the increased proportion of insoluble protein is 
thought to result from an inability of the host E. coli cells to cope with the increased 
complexity of folding caused by a greater number of putative di-sulphide bonds. Reducing the 
level of recombinant protein expression (i.e. by using a lower concentration of IPTG) results in 
decreased a metabolic load on the cells which can lead to a lower incidence of protein 
aggregation and degradation (Baneyx and Mujacic, 2004). The results here would suggest that 
decreasing the concentration of IPTG does favour a higher incidence of soluble protein.  
When expressing CD81 EC2, Rajesh et al. (2012) utilised longer (12 hour) periods of expression 
at a lower temperature of 18:C. These same conditions were mimicked for expression of our 
pGEX-CD81 vector. However, Figure 3.16 indicates that incubations longer than 4 hours result 
in a decrease in the 35 kDa full length protein, and a simultaneous increase of 27 kDa free GST. 
Cleavage of the tag from the EC2 protein does not seem to be entirely responsible for the 
reduction in full length protein as there is no substantial increase in the 10 kDa band indicative 
of untagged EC2 protein. This suggests that there is a greater incidence of degradation when 
using longer incubations post induction. It is possible that the slight difference in the defined 
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EC2 boundaries (residues 112-202 for Rajesh et al. vs residues 114-203 for our construct) could 
impact on the expression and folding of the resultant protein. Alternately, the flexible glycine 
linker within the pGEX-KG vector used by our group may have the unintended effect of 
increasing the likelihood of unwanted proteolytic degradation of the EC2 domains. Using lower 
temperatures for expression increased the proportion of full length EC2 protein, with ~9% of 
the final protein being full length at 18:C incubation, whereas less than 1% was full length at 
37:C. However, the proportion of full length protein was still lower than traditional expression 
for four hours, where ~70% of the protein was the desired full length CD81-GST. Experiments 
were attempted using lower temperatures for shorter periods of expression however 
extremely low amounts of bacteria were harvested after 4 hours. Simultaneous expression of 
chaperones from psychrophilic bacteria has been reported to enable high E. coli growth rates 
when using temperatures as low as 4:C for recombinant protein expression (Ferrer et al., 
2004). What’s more these low temperatures facilitated a higher degree of protein folding and 
would presumably limit the activity of cellular proteases. Although principally for the 
expression of heat liable proteins this “pCold” system may be beneficial for the expression of 
protein with complex folding patterns such as the tetraspanin EC2 domains. 
Changing the purification method seemed to have little effect on the final protein product with 
coomassie profiles and LPS content appearing very similar (Figure 3.17). This enables more 
direct comparison between results gained from EC2 domains produced by either method and 
enables a choice of methods based on application. Column purification was the quicker of the 
two as there was no need for multiple centrifugation steps and was more suited to larger 
purification. However considerably more elution buffer had to be used to pass through the 
column which when producing low yield proteins may be an issue.  
EC2 domains from different species sometime exhibit differing functional effects, for example 
the EC2 domain of human CD9 but not mouse CD9 was able to inhibit multinucleated giant cell 
formation (Parthasarathy et al., 2009). In other instances they function similarly, for example 
injecting either mouse or human CD9 mRNA into CD9 -/- ooyctes restored their fusogenic 
ability to equal extents (Zhu et al., 2002). In terms of the EC2 domains under investigation 
here, Rat and Human CD63 show the most variation in amino acid sequence (Appendix Figure 
7.2). It was therefore decided to express rat CD63, for later studies on the effects of EC2 
domains from different species on degranulation. Figure 3.19 shows that this recombinant 
protein was successfully expressed and shows good reactivity with its respective antibody. 
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CD Name Tspan 
name 
Amino 
acid size 
(kDa) 
Amino acid 
size of EC2 
(kDa) 
Number of 
cysteine 
Amount of 
glycosylation 
(within EC2) 
Theoretical  
pI 
Hydrophobicity Stability 
index 
CD9 Tspan29 228aa 
(25.4) 
80 
(9.195) 
 
4 2/1 (0) 5.65 -0.64 46.18 
CD63 Tspan30 238aa 
(25.6) 
96 
(11.037) 
6 3 (3) 8.59 -0.745 28.84 
 
CD81 Tspan28 236aa 
(25.8) 
89 
(9.797) 
4 0 (0) 5.09 -0.371 37.31 
 
CD151 Tspan 24 253aa 
(28.3) 
106 
(12.12) 
6 1 (1) 5.67 -0.837 47.22 
 
- Tspan5 268aa 
(30.3) 
118 
(13.9) 
8 4 (3) 4.31 
 
-0.631 39.64 
 
Table 3.2: Physical properties of the tetraspanins under investigations. EC2 sizes were determined by multiple sequence alignment. 
Theoretical pI, hydrophobicity and stability index were all resourced from http://web.expasy.org/protparam/ and are for the EC2 domain 
alone. Stability index is based on the presence of specific dipeptides within the protein which have been correlated to its half-life, proteins 
with values below 40 are considered stable 
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Chapter 4: Effects of tetraspanin EC2 
domains on RBL-2H3 cell degranulation 
4.1 Introduction 
4.1.1 Degranulation and allergy 
The beneficial role of Mast cells in immunity is becoming more appreciated, such as their 
numerous methods of pathogen detection, ability to phagocytose microorganisms and signal 
locally as well as over long distances (Section 1.3). However, chronic or systemic activation of 
mast cells along with aberrant activation, towards an otherwise innocuous antigen for 
example, can result in a number of diseases such as arthritis and allergy (Brandt et al., 2003; 
Reber and Frossard, 2014). For this reason it is becoming increasingly important to understand 
the molecular mechanisms involved in mast cell activation which may enable the development 
of more treatments for mast cell associated diseases. 
Mast cell prevalence in allergy and autoimmunity has led to a number of therapeutic agents 
which stop or down regulate their activation. Some such agents prevent activation by 
stabilising the mast cell membrane, for example, cromolyn sodium and nedocromil sodium 
which are used to treat asthma amongst other diseases (Reber and Frossard, 2014). Other 
treatments stop specific means of activation, for instance, tyrosine kinase inhibitors prevent 
mast cell stimulation by inhibiting the tyrosine kinase growth factor receptor c-Kit, which is 
essential for mast cell activation (El-Agamy, 2012). One of the first tyrosine kinase inhibitors to 
be used medically, Imatanib, acts by blocking an ATP binding site on the c-Kit receptor, 
maintaining it in an inhibited state (Mol et al., 2004). Some therapeutics seek to minimise the 
effects of mast cell derived products, such as anti-histamines which function as reverse 
agonists of G protein coupled receptors (GPCR) targeted by histamine. However, reverse 
agonists for therapeutic use are currently only available towards two of the four histamine 
targeted GPCRs (H1-4R) (Simons and Simons, 2011). One of the main goals of allergy treatment 
is to prevent mast cell activation through the high affinity IgE receptor; one such method uses 
an anti-IgE antibody known as Omalizumab. This binds to IgE at the same site where 
interaction with the high affinity IgE receptor would take place, thereby stopping this 
association thus preventing activation (Chang, 2000). Although other strategies are currently in 
development (Borriello et al., 2014), Omalizumab is currently the only means to prevent IgE 
activation directly and its high price limits its use (Harvima et al., 2014). 
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A number of tetraspanins have been linked with mast cells and the process of degranulation, 
either through association with the FcεRI receptor or through the modulating effects exhibited 
by various anti-tetraspanin monoclonal antibodies and tetraspanin gene knockouts (Section 
1.2.5). For instance, It was previously shown that incubating RBL-2H3 cells with antibodies 
towards either CD63 or CD81 prior to degranulation was able down-regulate the degranulation 
response (Fleming et al., 1997; Kitani et al., 1991; Kraft et al., 2005). Some of the authors 
propose mechanisms by which these mAbs may affect degranulation but the specifics of 
tetraspanin involvement in IgE signalling are currently unknown, however the association of 
FcεRI with several tetraspanins could indicate its inclusion in TEMs. Recombinant forms of 
tetraspanin EC2 domains have previously shown biologically activity in a number of functional 
studies (Section 1.1.4), and what is more they do not inherently interact with the Fc receptors 
or cross link target proteins so their alternate mode of action to mAbs may shed more light on 
tetraspanins function. In this chapter, EC2-GST fusion proteins corresponding to four 
tetraspanins which have been implicated in IgE signalling (CD9, CD63, CD81 and CD151) are 
used in conjunction with RBL-2H3 cells in an attempt to further our understanding of 
tetraspanins involvement in degranulation and act as a preliminary investigation into any 
potential therapeutic application. RBL-2H3 cells do not express endogenous CD9, however it is 
unclear if homotypic interactions are required in order for EC2 domains to impart an effect so 
this EC2 domain was still used on in conjunction with non-transfected RBL cells. Furthermore, 
RBL cells transfected with human CD9 were also used because previous studies have shown 
that treatment of RBL cell transfected with human CD9 with anti-human CD9 antibodies was 
enough to stimulate degranulation and it was hypothesised that EC2 domains might display a 
similar outcome (Higginbottom et al., 2000a). 
Despite RBL-2H3 cells originating from basophils, they are frequently used as a model for mast 
cells and degranulation. This is because they share a number of mast cell properties, for 
example they express the mast cell proteins rat mast cell protease II and c-Kit (albeit a 
constitutively active variant) (Mol et al., 2004; Passante and Frankish, 2009; Seldin et al., 
1985). Furthermore, they are straightforward to culture and forgo timely isolation methods 
used for primary mast cells (which usually result in low cell numbers) (Siebenhaar et al., 2014). 
As mentioned previously (Section 1.2.1), mast cells display heterogeneity and their properties 
can differ significantly according to the stimuli they receive from their surrounding 
environment. For this reason it is difficult to take a property displayed by one subset of mast 
cells investigated in vitro and ascribe that to other mast cell populations (Galli et al., 2005). 
However, when considering IgE mediated release, RBL-2H3 cells display a characteristic bell-
shaped dose-response curve and are considered a reliable model for early screens of this 
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particular process (Passante et al., 2009).Being of Rat origin these cells endogenously express 
rat tetraspanin family members, this may preclude interaction with the recombinant human 
EC2 domains being used here, however, previous studies have shown that tetraspanins from 
one species can interact with cells from another (Zhu et al., 2002)(Our group, unpublished 
data). Furthermore, rat and human EC2 domains have fairly similar homology (64.6-86.8% 
identity) and the EC2 domains of rat CD63 EC2 (which shows the most variation) is also being 
used to see if rat EC2 domains show greater effects on degranulation.  Here, the degree of 
degranulation has been tracked through the release of β-hexosaminidase. The function of this 
enzyme in the degranulation response is unknown; however it is released in parallel to 
histamine and can be easily quantified by monitoring the breakdown of its substrate (Passante 
et al., 2009).  
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4.2 Results 
4.2.1 Expression of tetraspanins on RBL-2H3 cells 
Before investigating the effects of recombinant EC2 domains on RBL-2H3 cells, the level of 
tetraspanin expression on the cell surface was established by flow cytometry using 
tetraspanin-specific monoclonal antibodies according to section 2.2.1.9. In Figure 4.1a the 
median fluorescence intensity (MFI) of the resultant populations are shown relative to their 
respective isotype control antibodies (RFI), giving an indication of the level of surface 
expression, whilst in Figure 4.1b the “percentage positive of parent” is displayed and indicates 
how many cells in the overall population are expressing a specific tetraspanin. Figure 4.1c 
shows how gates are generating following an expression assay, with isotype control cells being 
used as negative populations to establish a positive gate to the right hand side, therefore any 
cells which have a higher fluorescence than the negative control cells and are farther to the 
right will be included in the positive gate. CD9 shows no expression on either plot which 
corroborates previously reported results (Higginbottom et al., 2000a). CD151 shows relatively 
low expression levels on a small population of cells (18%). However, whilst the other 
antibodies used were specific for rat tetraspanins, the only mAb available for CD151 was 
raised against human CD151. Although it is reported cross-react with the rat tetraspanin by 
the suppliers, this may be partial and so not reflect the true levels of expression. CD81 has the 
highest level of surface expression and is expressed on nearly all RBL-2H3 cells (96%). Finally, 
CD63 was found to be expressed on the majority of cells (82%) however it has relatively low 
intensity, which is most likely due to its predominantly intracellular expression (Boucheix and 
Rubinstein, 2001).  
 Overall expression levels were also analysed qualitatively via fluorescent microscopy in which 
cells were fixed and permeabilized before being stained with primary anti-tetraspanin 
antibodies or isotype controls (Section 2.2.1.9). (Figure 4.2). In each instance random fields 
depict expression of each tetraspanin on RBL-2H3 cells along with their respective isotype 
controls. Because the cells have been permeabilized, images represent the entire cellular 
content, as such CD63 shows up with more vivid staining than would be expected from flow 
cytometry. CD9 again shows no expression whilst CD151 and CD81 have moderate staining. 
Human CD9 transfected RBL-2H3 cells were also included which stained vividly indicating high 
transfection efficiency, which again would corroborate previous reports (Higginbottom et al., 
2000a) 
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a) b) 
Figure 4.1: Flow cytometry of RBL-2H3 surface expression of four tetraspanin members. Expression of 
tetraspanin on the RBL-2H3 cell surface was analysed by flow cytometry according to section 2.2.1.18. 
Briefly, RBL-2H3 cells were incubated with primary anti-tetraspanin antibodies (Table 2.2), appropriate 
isotype control antibodies or BBN alone for one hour. Cells were washed and stained with secondary 
FITC conjugated antibodies before cells were analysed on an Attune Autosampler. (a) Background values 
(buffer alone) were removed from isotype control and anti-tetraspanin values. MFIs of anti-tetraspanin 
values are shown relative to isotype control values as relative fluorescence intensitry (RFI) (b) Control 
gates were set based on isotype control populations and used to define positive cells in samples where 
anti-tetraspanin antibodies were used. (c) 10000 events are collected per treatment and displayed as cell 
side scatter vs fluorescence. Positive gates were made which exclude cells from the untreated control. 
For gating of each antibody please see appendix Figure 7.5.  Data points are mean ± standard error of the 
mean (SEM) from a minimum of three repeats carried out in duplicate. 
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Figure 4.2: Immunofluorescence microscopy on permeabilized RBL-2H3 cells to check for tetraspanin expression. RBL-2H3 expression of tetraspanins (both on the 
cell surface and intracelluarly) was visualised according to section 2.2.1.9, Briefly, RBL-2H3 cells were stained with the relevant anti-tetraspanin monoclonal 
antibodies (or isotype control antibodies) followed by secondary FITC-conjugated antibodies. Random fields were photographed for each population using a Nikon 
A1 confocal fluorescence microscope at 10x objective. Images are representative of two experiments carried out in duplicate  
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4.2.2 Effects of pre-incubation with EC2-GST fusion proteins on 
degranulation 
In initial experiments examining the effect of recombinant tetraspanin EC2-GST fusion proteins 
on degranulation, RBL-2H3 cells that had been pre-sensitised with mouse anti-DNP IgE 
overnight as described in 2.2.1.5, were pre-incubated with various recombinant tetraspanin 
EC2 domains for one hour prior to stimulating degranulation. A concentration of 500 nM of 
recombinant protein was used because this concentration shows clear activity in a number of 
other functional assays (Green et al., 2011; Parthasarathy et al., 2009). Despite CD9 not being 
expressed on these cells, recombinant CD9 EC2 was also used to see if homotypic interactions 
are required for an effect to be displayed. Because the EC2 domains are tagged with GST, and 
contain LPS (as a result of the E. coli used to express them) RBL-2H3 cells were also pre-
incubated with recombinant GST (produced in the same manner as the EC2 domains) and LPS 
as negative controls. Dinitrophenol conjugated to Human Serum Albumin (DNP-HSA) was used 
as a multivalent cross-linking reagent and in each case, conditions were run in triplicate and a 
minimum of three biological repeats were carried out. The resultant graphs have a bell shaped 
profile because at higher antigen concentrations, the IgE receptors are not as frequently cross-
linked by one antigen molecule and are instead bound by separate molecules. To account for 
differences in degranulation efficiency between cells, comparisons were only made between 
conditions on the same 96-well plate (shown on the same graphs). The raw data was 
normalised to the maximum release given when the cells were not pre-treated with 
recombinant protein or LPS, allowing for more direct comparisons by accounting for 
differences in plating density and changes in degranulation efficiency over time. In each 
experiment the amount of release induced by cross-linking was also related to the total 
cellular β-hexosaminidase which was determined by lysis with Triton X-100 (Figure 4.3d and 
4.3e) and if maximum DNP concentrations with no pre-treatment did not induce at minimum 
of 20% release, the cells were deemed inefficient and results were excluded. The amplitude 
and mean DNP of each condition was compared within each experiment using a one-way 
ANOVA. This represents the maximum amount of β-hexosaminidase released upon 
degranulation and amount of DNP required to cause maximal release respectively.  
Interestingly, one hour pre-treatment of the RBL-2H3 cells with any of the EC2-GST fusion 
proteins, GST alone or LPS had no effect on the maximal β-hexosaminidase release or DNP 
required to cause maximal release (Figure 4.3). The way in which EC2 domains are able to 
impart their effects is still unknown and it was considered that whilst the antibody treatment 
previously described (section 1.3) shows an effect after just one hour of treatment, this length 
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of time may not be sufficient for recombinant EC2 domains to modulate RBL-2H3 activity. 
Furthermore, tetraspanins have been associated with the high affinity IgE receptor and 
although anti-CD63 mAbs did not interfere with IgE binding (Kitani et al., 1991) it is possible 
that EC2 domains may affect initial stages of IgE priming. It was therefore decided to apply IgE 
and EC2 domains to the RBL-2H3 cells simultaneously, 16 hours before degranulation  
Similarly to one hour pre-incubation, overnight treatment with the EC2 domains also showed 
no activity on maximal degranulation or the concentration of DNP required for maximal 
release (Figure 4.4). This indicates that the EC2 domains do not interfere with IgE binding to 
the high affinity IgE receptor and that sustained exposure to the recombinant EC2 domains is 
also unable to modulate degranulation.  
4.2.3 Effect of anti-CD63 antibody AD1 and higher EC2 
concentrations on degranulation 
In prior studies which monitor the effect of monoclonal antibody treatment on degranulation, 
serotonin and histamine have been used as a marker for degranulation. Although β-
hexosaminidase is released in parallel with histamine it was considered that changes in the 
experimental method may affect the ability of such a screen to effectively display inhibition or 
enhancement of degranulation. In an attempt to reproduce the results previously documented 
by Kitani et al. (1991) RBL-2H3 cells were pre-incubated with the same anti-CD63 antibody 
used by Kitani and co-workers, AD1. The effects of anti-CD63 were quite apparent (Figure 4.5) 
and when results were compared by a one way ANOVA a significant (P<0.005) decrease in the 
amount of β-hexosaminidase released by the cells was observed. This indicated that the 
method being used should be sufficient to display any modulating effects that the 
recombinant EC2 domains may be having. Kitani et al. (1991) also reported that a high 
concentration (100µg/ml) of antibody was required to see this significant decrease in 
degranulation and when used at a lower concentration (10 µg/ml) (Figure 4.6) only a slight and 
non-significant decrease was exhibited. It was therefore considered that a higher 
concentration of EC2 domains may be required in order to affect a response. Consequently, 
RBL-2H3 cells were incubated with a threefold higher concentration (1.5µM as opposed to 
500nM) of recombinant EC2 protein, GST and LPS, for one hour. However, again there was no 
significant change in degranulation under any of these experimental conditions (Figure 4.7). 
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Figure 4.3: DNP stimulated degranulation following one hour pre-incubation with recombinant tetraspanin EC2 domains. RBL-2H3 cells that had been pre-sensitised 
with mouse anti-DNP IgE overnight as described in 2.2.1.5 were treated with 500nM GST-EC2 fusion proteins, GST alone, LPS or release buffer only (RB) for one hour 
prior to stimulating degranulation with a range of concentrations of DNP-HSA. β-hexosaminidase release was determined as described in 2.2.1.5 by measuring 
absorbance at 405 nm. Background absorbance values were removed from test values which in (a, b and c) were then normalised to the highest amount of 
degranulation seen when stimulating degranulation with antigen alone. (d+e) Values are shown in relation to the total cellular β-hexosaminidase determined by lysis 
with 1% TritonX-100. Data points are mean ± standard error of the mean (SEM) from three repeats carried out in duplicate. Amplitude and mean values were 
compared by one way ANOVA. 
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 Figure 4.4: DNP stimulated degranulation following 16 hour pre-incubation with recombinant 
tetraspanin EC2 domains. (a) RBL-2H3 cells were treated with 500 nM of the GST-EC2 fusion proteins, 
GST alone, or release buffer only for 16 hours along with anti-DNP IgE prior to stimulating 
degranulation with a range of concentrations of DNP-HSA. Background absorbance values were 
subtracted from test values which were then normalised to the highest amount of degranulation seen 
when stimulating degranulation with antigen alone. (b) The highest amount of degranulation seen with 
each treatment (amplitude values) were compared by one way ANOVA.  Data points are mean ± 
standard error of the mean (SEM) from four repeats carried out in duplicate. 
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Figure 4.5: DNP stimulated degranulation following one hour pre-incubation with anti-CD63 antibody AD1 (100µg/ml). (a) RBL-2H3 cells pre-sensitised with 
mouse IgE anti-DNP were treated with monoclonal anti-rat CD63 antibody (AD1) at 100 µg/ml, isotype control antibody (100 µg/ml) (JC-1) or release buffer for 
one hour prior to stimulating degranulation with a range of concentrations of DNP-HSA. Background absorbance values were subtracted from test values which 
were then normalised to the highest level of degranulation seen when stimulating degranulation with antigen alone. (b) For each condition the mean DNP 
concentrations (which shows how much DNP was required for maximum release) were compared by one way ANOVA (c) The amplitudes (representing the 
maximum degranulation) were also compared by one way ANOVA. Data points are mean ± standard error of the mean (SEM) from three repeats carried out in 
duplicate. 
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Figure 4.6 DNP Stimulated degranulation following one hour pre-incubation with anti-CD63 antibody 
AD1 (10µg/ml). (a) RBL-2H3 cells pre-sensitised with mouse IgE anti-DNP were treated with anti-CD63 
antibody (AD1) (10 µg/ml) , isotype control antibody (10 µg/ml) or release buffer for 1 hour prior to 
stimulating degranulation with a range of concentrations of DNP-HSA. Background absorbance values 
were subtracted from test values which were then normalised to the highest level of degranulation 
seen when stimulating degranulation with antigen alone. (b) For each condition the mean DNP 
concentrations (which shows how much DNP was required for maximum release) were compared by 
one way ANOVA (c) The amplitudes (representing the maximum degranulation) were also compared by 
one way ANOVA. Data points are mean ± standard error of the mean (SEM) from three repeats carried 
out in duplicate. 
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Figure 4.7: DNP stimulated degranulation following one hour pre-incubation with 1.5µM 
recombinant tetraspanin EC2 domains. (a+b) RBL-2H3 cells pre-sensitised with mouse IgE anti-DNP 
were treated with 1.5 µM GST-EC2 fusion proteins, GST alone, LPS or release buffer for 16 hours prior 
to stimulating degranulation with a range of concentrations of DNP-HSA. Background absorbance 
values were subtracted from test values which were then normalised to the highest amount of 
degranulation seen when stimulating degranulation with antigen alone (c) maximum degranulation 
values were compared via one way ANOVA. Data points are mean ± standard error of the mean (SEM) 
from three repeats carried out in duplicate. 
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4.2.4 Effects of tetraspanin EC2 domains on anti-IgE induced 
degranulation  
DNP-HSA Is commonly used to stimulate degranulation as it is a multivalent antigen, easily 
able to cross-link FcεRI bound anti-DNP IgE. However, this may not be ideal when looking at 
subtle effects involving less extensive cross-linking of the FcεRI. It was considered that the 
potential effects of the tetraspanins EC2 domains might be being masked by the extensive 
cross-linking induced by DNP-HSA.  
To investigate the effects of the tetraspanin EC2s on degranulation triggered by a lower 
valency molecule, an IgE specific monoclonal antibody was selected as this bivalent antibody 
would still be able to cross-link IgE bound to FcεRI, but each antibody molecule should only 
cross-link two receptors on the cell surface. To determine the suitability of this approach, 
preliminary FACS analysis was undertaken to ensure that the IgE specific IgG antibody was able 
to bind to the IgE when it was bound to the high affinity IgE receptor. Figure 4.8a shows low 
levels of non-specific binding of both the isotype control and the anti-IgE antibody (probably 
through Fcγ receptor binding); however the majority of anti-IgE binding takes place when cells 
are primed with IgE, indicating that this antibody is suitable for cross-linking. RBL-2H3 cells 
pre-sensitised with IgE were treated (as previously) with EC2 proteins for one hour. A range of 
concentrations of anti-IgE mAb were used to stimulate degranulation and the results are 
shown in Figure 4.8a. The anti-IgE antibody was able to trigger degranulation to a similar 
extent as DNP-HSA, with ~40% maximal degranulation being exhibited relative to the total 
cellular β-hexosaminidase (Data not shown), but again no significant effect was seen with the 
tetrasapnin EC2 proteins on maximal degranulation or the amount of IgG required causing 
maximal degranulation.  
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Figure 4.8: Anti-IgE stimulated degranulation following one hour pre-incubation with recombinant 
tetraspanin EC2 domains (a) RBL-2H3 cells were plated overnight with or without the addition of anti-
DNP IgE. The following day cells were washed and probed with an anti-IgE monoclonal antibody or 
isotype control antibody. After incubating for one hour, cells were washed and incubated with a 
secondary FITC labelled anti-IgG antibody, cells were then washed and analysed via flow cytometry. For 
percentage positive values see appendix Figure 7.6 (b) RBL-2H3 cells pre-sensitised with mouse IgE 
anti-DNP were treated with 500 nm GST-EC2 fusion proteins, GST alone, LPS or release buffer for one 
hour prior to stimulating degranulation with a range of concentrations of anti-IgE mAb. Background 
absorbance values were subtracted from test values which were then normalised to the highest 
amount of degranulation. Data points are mean ± standard error of the mean (SEM) from three repeats 
carried out in duplicate. 
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4.2.5 Effect of rat CD63 EC2 domain on degranulation 
Previous studies using EC2 domains have reported differences when using the EC2 domains 
from one species or another. For example Takeda et al. (2003) saw an inhibitory effect of 
human CD9 EC2 on monocyte fusion however mouse CD9 EC2 had no effect. Similarly 
Higginbottom et al. (2003) demonstrated that in contrast to human CD9 EC2, mouse CD9 EC2 
is unable to inhibit sperm oocyte binding. Being as RBL-2H3 cells are of rat origin, it was 
considered that the human tetraspanin EC2 domains used thus far may not be able to 
compete with endogenous tetraspanins. It was therefore decided to use a rat homologue for 
comparison. As time and expense constraints made it difficult to produce rat variants of each 
of the tetraspanins, it was instead decided to produce one rat EC2 domain for preliminary 
investigations. The EC2 domain of CD63 was selected as a candidate for expression because of 
the tetraspanins under investigation, this member shows the most variation between species 
(65% identity vs 84-87%, see Appendix Figure 7.2) so is perhaps more likely to exhibit a 
difference between orthologues. Moreover, there is more evidence for CD63 involvement in 
degranulation than the other three members. Once the recombinant EC2 was produced 
(Section 3.2.5) it was used to pre-treat RBL-2H3 cells for one hour prior to stimulating 
degranulation as previously described. Although there is a slight increase in the maximal 
degranulation (Figure 4.9) this is not significant which suggests that the use of human 
tetraspanin EC2 domains is not the reason for a lack of apparent effect of EC2 domains.  
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Figure 4.9: DNP stimulated degranulation following one hour pre-incubation with 
recombinant rat CD63 EC2 (a) RBL-2H3 cells pre-sensitised with mouse IgE anti-DNP were 
pre-incubated with rat-CD63 EC2 (rCD63), GST or release buffer alone for one hour before 
stimulating degranulation with a range of concentrations of DNP-HSA. Background 
absorbance values were subtracted from test values which were then normalised to the 
highest level of degranulation seen when stimulating degranulation with antigen alone. (b) 
Amplitude values were plotting on a column graph and compared via one way ANOVA. Data 
points are mean ± standard error of the mean (SEM) from three repeats carried out in 
duplicate. 
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4.2.6 Effects of CD9 EC2 on degranulation of human CD9 
transfected RBL-2H3 cells 
Although CD9 it not expressed in RBL-2H3 (Figure 4.1), it has previously been implicated in 
activation of both eosinophils and platelets (Kim et al., 1997; Qi et al., 1996). Moreover, a 
panel of antibodies directed towards human CD9 were shown to induce degranulation in 
human CD9 transfected RBL cells. In said studies the Fc region was shown to be critical for 
mAbs to impose their effects (Higginbottom et al., 2000a). Here it was hypothesised that the 
alternate mode of action of recombinant EC2 domains might enable further dissection of CD9s 
interaction with the high affinity IgE receptor. Human CD9 transfected RBL cells were 
incubated with CD9 EC2 for one hour prior to stimulating degranulation. Although there is a 
slight increase in degranulation this was not significant when compared to the GST control 
(Figure 4.10a). Furthermore, when using an anti IgE antibody to stimulate degranulation there 
was no change in the degranulation profile (Figure 4.10c). 
Peptides corresponding to different regions of the CD9 EC2 domain (Appendix Figure 7.4) have 
previously been shown to be functionally active and in some circumstances show activity at 
lower concentrations than the entire EC2 domains (D. Cozens, unpublished data). Two such 
peptides which are active in preventing bacterial adhesion (D. Cozens, unpublished data) were 
used to examine effects on degranulation. Scrambled versions of the peptides were also used 
as a negative control. RBL cells were pre-treated with 500 nM of each peptide and scrambled 
control for one hour before stimulating degranulation with either DNP or anti-IgE mAb. Again 
no significant effect was seen with any treatment (Figure 4.11).  
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Figure 4.10: Degranulation of human CD9 transfected RBL cells following pre-incubation 
with recombinant CD9 EC2. Human CD9 transfected RBL cells sensitised with IgE were pre-
treated for one hour with CD9-EC2, GST or release buffer alone before being stimulated to 
degranulate with (a) DNP or (b) an anti-IgE mAb. (c) Amplitude values collected when using 
DNP to stimulate degranulation were compared via one way ANOVA. Data points are mean ± 
standard error of the mean (SEM) from a four repeats carried out in duplicate 
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Figure 4.11: DNP and anti-IgE stimulated degranulation following one hour pre-incubation 
with CD9 EC2 peptides. Human CD9-transfected RBL-2H3 cells sensitised with IgE were pre-
incubated with 500 nm of CD9 EC2 peptide, scrambled control peptide or release buffer only 
for one hour prior to stimulating degranulation with either various concentrations of (a) DNP-
HSA or (b) anti-IgE mAb. Work carried out in part by W. Hazelton and E. McKeefry, data 
analysed by the author. Data points are mean ± standard error of the mean (SEM) from three 
repeats carried out in duplicate. 
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4.2.7 Effects of EC2 domains on cell adhesion 
Previous reports have shown that RBL-2H3 cells which are adhered to different substrates are 
able to degranulate to a greater extent than non-adhered RBL-2H3 cells (Apgar, 1997; Hamawy 
et al., 1992). The exact mechanism linking degranulation and adhesion is currently unknown 
however the “augmented degranulation” was shown to result from cell spreading rather than 
adhesion alone. Integrin binding of ECM components is primarily responsible for cellular 
adhesion and spreading (Hynes, 1992) and is therefore thought to contribute to increased 
degranulation. Several tetraspanins are known to have primary associations with various 
integrins, for instance one of the most studied primary interactions is between CD151 and 
integrin α3β1 (Yauch et al., 1998), CD81 regulates VLA-4 and VLA-5 adhesion strengthening 
(Feigelson et al., 2003) and CD63 binds to integrin VLA-3 and VLA-6 (Berditchevski et al., 1995). 
Antibodies towards CD63 are able to inhibit both adhesion and degranulation, supposedly by 
down-regulation of the GAB-2, PI3K signalling pathway common to both processes. Initial 
suggestions were that this occurs through antibody blocking of integrin-ECM interaction, 
disruption of membrane complexes or antibody sequestering of CD63 and its associated 
signalling molecules (Kraft et al., 2005). Later studies exhibited reduced degranulation in CD63 
knock out bone marrow derived mast cells (BMMC); being suspension cells this favoured the 
later hypothesis. CD9 EC2 domains have similarly been able to reduce adhesion (although in 
endothelial cells), however from this work it is evident that they are unable to alter 
degranulation. Due to the relatively undefined relationship between degranulation and 
adhesion it was also decided to carry out an initial screen to see if the EC2 domains are able to 
alter RBL-2H3 adhesion properties. 
An sulforhodamine B (SRB) colorometic assay (Skehan et al., 1990) was carried out as in 
section 2.2.1.17 to determine levels of cellular adhesion following EC2 treatment. Briefly, RBL 
cells were treated overnight with 500 nm or 1.5 µm of each recombinant EC2 domain, with 
GST and PBS being used as negative controls. Non-adherent cells were removed by washing 
and cells were then fixed and cellular protein remaining in the wells was stained with 
sulforhodamine B. The absorbance at 570nm thus relates to the number of remaining 
adherent cells. A one-way ANOVA was used to compare readings from each condition and 
none of the recombinant EC2 treatments (or controls) resulted in a significant reduction in 
cellular protein within the wells when used at either concentration. This initial screen indicates 
that EC2 domains are not significantly affecting adhesion or viability of the cells, however, 
more rigorous methods with differentiate between adhesion and viability may be desirable in 
future. 
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Figure 4.12: RBL-2H3 adhesion following overnight treatment with recombinant EC2 
domains. RBL-2H3 cells were pre-incubated with 500 nm or 1500nm EC2 protein, GST or PBS 
only for 16 hours. After washing an SRB colorometric assay was carried out as in section 
2.2.1.17, where absorbance at 570nm relates to the number of remaining adherent cells. 
Data points are mean ± standard error of the mean (SEM) from three repeats performed in 
triplicate. Values were compared by one-way ANOVA. 
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4.3 Discussion 
There have been many reports of tetraspanins association with FcɛRI or involvement in 
degranulation, for instance CD9 and CD81 both co-localize and co-immunoprecipitate with 
FcɛRI (Higginbottom et al., 2000a; Peng et al., 2011). In addition, CD151 knockout mice show 
increased pro-inflammatory cytokine production upon mast cell activation and CD63 knock out 
BMMC have significantly reduce degranulation in response to IgE cross-linking (Abdala-
Valencia et al., 2015; Kraft et al., 2013). On a number of occasions anti-tetraspanin monoclonal 
antibodies have been shown to affect the IgE-mediated degranulation response in RBL-2H3 
cells. Kitani et al. (1991) used an anti-CD63 antibody (AD1) which significantly reduced 
degranulation when used at a high concentration (a result which has been reproduced here). 
Fleming et al. (1997) later showed a similar effect when pre-incubating with an anti-CD81 
antibody, and also observed effects with the antibody on mast cells in vivo. More recently 
Kraft et al. (2005) also showed that an anti-CD63 mAb inhibited degranulation and linked this 
to its capacity to reduce cellular adhesion to various extracellular matrix components. RBL cells 
transfected with human CD63 were stimulated to degranulate in response to certain anti 
human-CD63 mAbs (Smith et al., 1995). Likewise, Higginbottom et al. (2000a) showed that 
human CD9 transfected RBL cells could be stimulated to degranulate in response to certain 
(mouse IgG1) anti-human CD9 antibodies; this response required CD9 cross linking along with 
the antibody Fc domain, which appeared to interact with the FcɛRI receptor. With these 
observations in mind it has been speculated that FcεRI may be within a TEM where separate 
FcεRI molecules are clustered to enable more efficient cross linking upon antigen encounter. 
Several studies have been complicated by intrinsic antibody properties, such as Fc receptor 
interaction, target protein cross-linking, along with their propensity to cross-link tetraspanin 
partner proteins also (Wright et al., 2004). Recombinant EC2 domains may therefore be useful 
alternative tools to discover more about tetraspanins functions in degranulation. In some 
cases, treatment with these recombinant proteins can result in a similar outcome to their 
respective monoclonal antibodies, whilst in other instances different effects are observed. 
Thus Takeda et al. (2003) found that anti-CD9 antibodies promoted monocyte fusion whilst 
recombinant CD9 EC2 inhibited fusion, a finding which was corroborated by our group 
(Parthasarathy et al., 2009). On the other hand CD81 mAbs and recombinant CD81 EC2 both 
inhibited sperm egg fusion (Higginbottom et al., 2003; Takahashi et al., 2001). The manner in 
which EC2 domains function is not fully understood, although several groups suggest that the 
they are able to compete with endogenous EC2 domains for binding of various receptors and 
in doing so disrupt signalling pathways (Barreiro et al., 2008; Zhu et al., 2002). Their disruptive 
effect could be in the context of TEMs where multiple interactions with both tetraspanins and 
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partner proteins lead to an ordered structure within the membrane. If FcɛRI is located within a 
TEM then EC2 domains may lead to decreased clustering of the receptors and therefore 
reduce cross-linking and degranulation. Alternatively recombinant EC2 domains could reduce 
associations with other downstream signalling molecules which might be present in TEMs such 
as several membrane bound adaptor proteins. Moreover, previous studies have linked levels 
of degranulation to cellular adhesion (Kraft et al., 2005) and because recombinant EC2 
domains have previously been shown to alter endothelial adhesion properties (Barreiro et al., 
2005, 2008) it is also conceivable that they could affect degranulation by altering RBL-2H3 
adhesion. 
Expression assays using EC2-specific monoclonal antibodies confirmed the presence of the 
relevant tetraspanins on RBL-2H3 cells (including CD9 on human CD9 transfected cells) (Figure 
4.2). However, initial degranulation assays indicated that recombinant EC2-GST fusion proteins 
were unable to affect IgE-mediated degranulation (Figure 4.3). Interestingly, LPS was also 
shown not to alter degranulation despite expression of TLR-4 on RBL-2H3 cells, however RBL-
2H3 insensitivity towards LPS has previously been reported and suggested to be due to 
absence of CD14 which is required for downstream signalling (Bieneman et al., 2005; Passante 
and Frankish, 2009). To make any potential effects of EC2 pre-incubation more pronounced, 
higher concentrations of recombinant EC2 domains and longer periods of incubation were 
used, however no effect on degranulation was observed (Figure 4.4, 4.7). It was speculated 
that perhaps the high valency of the DNP-HSA antigen (30-40 DNP moieties per HSA) used to 
trigger degranulation might mask any potential disruption of FcεRI within TEM caused by 
recombinant EC2 domains. For this reason it was decided to use a monoclonal anti-IgE as a 
cross-linking reagent, with lower valency. However, despite this hypothetically more sensitive 
approach the recombinant EC2 domains again had no significant effect on RBL-2H3 
degranulation (Figure 4.8).  
The tetraspanins are generally well conserved across species, with these particular members 
being 65-85% conserved between rat and human (Appendix Figure 7.2). Additionally, previous 
work have shown that recombinant human EC2 domains have been able to affect cells from 
other species, for instances reducing fusion of mouse macrophages (Figure 5.6) and in some 
instances tetraspanin knockout phenotypes can be restored using mRNA of tetraspanins from 
a different species (Zhu et al., 2002). However, some reports have suggested a level of species 
specificity, for example, human CD81 EC2 could inhibit HCV infection of human liver cells 
whereas rat and mouse could not (Flint et al., 2006). This is presumably due to either 
tetraspanin-tetraspanin or tetraspanin-partner interactions requiring regions of the EC2 
domain which vary between species. It is therefore possible that the use of human 
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recombinant EC2 domains here limited the amount of interaction with the endogenous rat 
proteins, thereby precluding any effect on degranulation. To address this, recombinant rat 
CD63 EC2 was generated as described in 3.2.5 , this particular member was chosen as it is the 
most divergent of the tetraspanins under investigation and has the largest body of evidence 
for involvement in degranulation. It was hoped that the use of recombinant rat CD63 may 
overcome this, however no modulation of degranulation was exhibited by the rat variant of 
CD63 EC2 (Figure 4.9).  
Due to the lack of CD9 in RBL-2H3 cells, human CD9 transfected cells were used to investigate 
the role of this particular tetraspanin. This cell line was previously shown to degranulate in 
response to anti-CD9 mAbs with no other stimulus (Higginbottom et al., 2000a) and an 
association between the human CD9 and FcεRI was suggested. However, when pre-incubating 
with CD9-EC2 then stimulating degranulation with DNP or anti-IgE there was no significant 
effect on degranulation (Figure 4.10). CD9/CD81 chimeras have shown that certain areas of 
the recombinant EC2 domains are more important than other for their functional effects in 
other assays (Hulme et al., 2014) and the use of short synthetic peptides corresponding to 
different regions of the CD9 EC2 domain have in some cases shown greater efficacy than the 
full recombinant EC2 domain (D. Cozens unpublished observations). This is purportedly 
because their small size enables easier intercalation where the larger EC2-GST fusion proteins 
may be sterically hindered. Furthermore, these short synthetic peptides have the advantage of 
not being synthesised in E. coli, therefore should not contain any LPS contamination making 
them amenable to use in LPS sensitive assays. However, in this assay the selected peptides 
also have no significant effect on degranulation (Figure 4.11). It is interesting that the 
recombinant EC2 treatments did not affect degranulation, as they have displayed an effect in 
an number of other functional assays in our group (Figures 5.1, 5.6), yet there are a number of 
possible reasons as to why this is this case, some of which will be discussed here.  
Firstly, It is possible that in previous reports of EC2-GST activity, the recombinant protein are 
not intercalating within the TEM giving a general disrupting effect as hypothesised (Barreiro et 
al., 2008; Parthasarathy et al., 2009; Zhu et al., 2002), but are operating by a different 
mechanism. For example, they could be disrupt specific interactions between tetraspanins and 
partner proteins, leading to a change in cell behaviour. This mechanism may not be applicable 
to FcεRI signalling if tetraspanins and FcεRI do not directly interact. Although co-
immunoprecipitation and antibody studies suggest interaction between a number of 
tetraspanins and FcεRI (Kraft et al., 2005; Peng et al., 2011) it is possible that these are 
secondary or even tertiary interactions rather than FcεRI being primary tetraspanin partner. 
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Secondly, although the IgE receptor appears to interact with a number of tetraspanins, there is 
the potential that it is not within a TEM. Tetraspanins are dynamic within the membrane and 
their inclusion within a TEM is transient, it is therefore possible that the interaction with FcεRI 
is not in the context of a TEM (Espenel et al., 2008). This would mean that the proposed 
general disruption of a TEM caused by EC2 treatment would not affect FcεRI distribution and 
therefore degranulation. EC2 domains might still be expected to disrupt FcεRI interactions 
with their respective tetraspanins, but due to limited understanding of tetraspanin 
involvement in this signalling pathway it is not clear what effect this would have. It is plausible 
that the anti-tetraspanin monoclonal antibodies are able to modulate activity due to their high 
affinity binding to their target protein, whilst EC2 domains are likely to bind with much lower 
affinity and may therefore require TEM involvement for effects to be displayed. 
A number of previous reports have provided evidence for lipid raft involvement in IgE 
mediated signalling, for instance, FcεRI has been isolated from low density Triton X-100 
resistant microdmains which are characteristic of lipid rafts (Field et al., 1995). Moreover, 
cholesterol depletion, which is known to disrupt lipid rafts and to a lesser extent TEMs, stops 
FcεRI partitioning into the detergent resistant fraction, reduces its tyrosine phosphorylation 
(the first step in its activation) and its association with the tyroskine kinase Lyn (which is 
responsible for initial signal transduction)(Kato et al., 2003; Sheets et al., 1999). Additionally, 
Lyn isolated from the detergent soluble fraction was shown to have a fourfold lower activity 
than “raft-associated” Lyn, which is suggested to be because of exclusion of specific 
phosphatase enzymes from lipid rafts (Young et al., 2003). TEMs and lipid rafts are often 
viewed as distinct microdomains so the involvement of FcεRI with lipid rafts may limit the 
possibility its presence within a TEM. On the other hand, it is not clear if these microdomains 
are mutually exclusive, indeed there has been certain examples of coalescence between the 
two (Hogue et al., 2011) so this might not definitively exclude FcεRI from TEMs. 
Finally, these results could indicate that intercalation of recombinant EC2 domains into the 
TEM is insufficient to disrupt IgE receptor signalling. In studies where EC2 domains do exhibit 
an effect, for example in membrane fusion and bacterial adhesion (Green et al., 2011; 
Parthasarathy et al., 2009), TEMs may play a more sophisticated role, perhaps coordinating a 
complex interplay between separate signalling molecules rather than the proposed function 
here of holding equivalent receptors within a defined area. This more elaborate role could be 
more easily disturbed by the EC2 treatment.  
The results here suggest that the EC2 domains do not have any therapeutic application with 
regards to mast cell activation. However, these negative data have enabled speculation into 
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tetraspanin association with FcεRI and possible mechanisms of recombinant EC2 domain 
activity. It is important to note that the suggested reasons for lack of activity are speculative 
and further work would be required to confirm any of the proposed explanations. For instance 
using a defined ECM component to which the cells could adhere during degranulation may 
give more information about potential reduction in adhesion caused by the EC2 domains. 
Nearest neighbour analysis was previously used to see if the spacing of two adhesion receptors 
was altered following CD9 EC2 treatment of endothelial cells (Barreiro et al., 2008). This 
involves immune-gold labelling and scanning electron microscopy to identify the receptors 
under investigation followed by statistical analysis of their location in respect to one another. 
A similar method could be undertaken following treatment of RBL cells with recombinant EC2 
domains to show more definitively if they are able to alter the spacing of the IgE receptor.  
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Chapter 5: Physical studies of 
tetraspanin EC2 domains 
5.1 Introduction 
Recombinant tetraspanin EC2 domains exhibit activity in a number of functional assays, such 
as inhibiting cell:cell fusion, viral infection and bacterial adhesion to cells (Barreiro et al., 2008; 
Green et al., 2011; Ho et al., 2006; Parthasarathy et al., 2009; Rajesh et al., 2012; Takeda et al., 
2003; Zhu et al., 2002). It is still not completely clear how the EC2 domains impart their effects, 
although it has been commonly suggested that they intercalate into and disrupt existing TEMs 
(Barreiro et al., 2008; Green et al., 2011; Ho et al., 2006). Since they show activity in so many 
processes associated with tetraspanins, it was somewhat surprising that several recombinant 
EC2 domains were unable to modulate degranulation in RBL-2H3 cells, as described in the 
previous chapter. Some studies have shown that recombinant EC2 domains only bind to 
specific cells (regardless of whether the respective tetraspanin is expressed) (Kelid et al., 2001), 
or to cells under specific conditions (Parthasarathy et al., 2009), suggesting  interactions with 
surface molecules present only on specific cell types or that are upregulated during certain 
processes. The first aim of this chapter was to investigate the binding of EC2 domains to RBL-
2H3 cells and to the human epithelial cell line, HEC-1B this experiment was carried out due to 
the hypothesis that the EC2 domains may have to bind the cells in order to impart an effect. 
The latter was chosen as EC2 domains have been shown to significantly reduce bacterial 
adhesion to these cells by a mechanism proposed to involve disruption of “adhesion 
platforms” on the epithelial surface (Green et al., 2011). 
As mentioned previously (Chapter 3), a potential problem of using recombinant proteins 
produced in bacteria is that they may be contaminated with endotoxin (LPS), a component of 
the bacterial cell wall which can affect mammalian cell behaviour by inducing signalling 
through the TLR4 receptor (Bausinger et al., 2002; Wakelin et al., 2006). An interest of our 
group has been the role of tetraspanins in the fusion of monocytes/macrophages to form 
multinucleated giant cells (Hulme et al., 2014; Parthasarathy et al., 2009). Recombinant EC2 
proteins representing CD9 and CD63 inhibited Concanavalin A (ConA)-induced giant cell 
formation from monocytes in vitro, whereas CD81 EC2 and mutated versions of CD9 EC2 were 
inactive (Hulme et al., 2014; Parthasarathy et al., 2009; Takeda et al., 2003). Some workers 
have indicated that monocyte/macrophage fusion is inhibited by LPS, which is present in the 
EC2 preparations (Takashima et al., 1993) (Fanaei, 2013), whereas others have shown no 
effect of LPS (Parthasarathy et al., 2009). Our group has recently started to investigate the role 
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of tetraspanin proteins in fusion induced by the bacterium Burkholderia thaillandensis. This 
non-pathogenic, gram-negative bacterium is used as a model of the pathogen Burkholderia 
pseudomallei which is the causative agent of mellioidosis, a potentially fatal disease 
comprising a broad array of clinical manifestations affecting animals and humans 
predominantly in Australia and South-East Asia (Boddey et al., 2007; Kespichayawattana et al., 
2000). B. pseudomallei is thought to induce cell fusion as a means of spreading within an 
infected host and in doing so forms large multinucleate giant cells containing many 
intracellular bacteria. Interestingly the bacteria is resistant to killing by phagocytes due to its 
ability to escape the phagosome into the cytoplasm, and has been shown to induce giant cell 
formation in both phagocytic and non-phagocytic cells both in vivo and in vitro 
(Kespichayawattana et al., 2000). Recombinant EC2 proteins generated as part of this project 
were found to inhibit B thaillandensis fusion by co-worker Atiga Elgawidi. The second aim of 
this chapter was therefore to determine LPS contamination levels in the EC2 proteins to see if 
there was any correlation with inhibitory activity. The levels of LPS present might also be 
relevant to other cell functional studies and would inform the inclusion of appropriate controls 
or the need to reduce endotoxin contamination.  
Rajesh et al. (2012) have used CD spectroscopy to show that their bacterially expressed CD81 
EC2 has a characteristic α-helical content consistent with that found in the CD81 crystal 
structure (Kitadokoro et al., 2001). However, differences in expression methodology (for 
instance different vectors, EC2 boundaries and expression conditions) mean these findings 
may not be readily applicable to the EC2 domains produced by our group. Moreover, some of 
the EC2 domains produced by our group contain a greater number of putative disulphide 
bonds than CD81 which attribute them with a more complex folding structure making them 
more liable to misfold (Qiu et al., 1998). The principle of circular dichroism is based on chiral 
molecules (including 19 out of 20 amino acids) capacity to absorb left-handed and right-
handed circularly polarised light to different extents. This difference in absorbance measured 
over a range of wavelengths is known as circular dichroism spectroscopy and in proteins is 
mainly influenced by the macromolecules overarching structure rather than the absorbance of 
its constituent residues. A protein secondary structure (i.e. its α-helical and β-sheet content) 
can be calculated based on its absorbance in the far UV region (190-260nm) as these particular 
structural features have a characteristic absorbance profile at these wavelengths (Greenfield, 
2007). Online software, such as Dichroweb, use algorithms to give an estimation of the overall 
secondary structure by comparing its absorbance profile to those gained when using reference 
proteins that contain alpha helix and beta sheet character. CD spectroscopy is often utilised to 
learn more about a proteins secondary structure but can also be used to track a protein 
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denaturation over time. In contrast to NMR and X-ray crystallography, CD spectroscopy is a 
low resolution method but has fewer requirements in terms of protein sample and time 
investment (Kelly et al., 2005) .  The final aim of this chapter was to use CD spectroscopy to 
determine more definitively if the EC2 domains produced by our group are correctly folded; 
however the GST tag within the recombinant fusion proteins makes up a large proportion of 
the overall recombinant EC2 domains (around 26kDa of the 36kDa proteins) and it too has a 
secondary structure. This could lead to difficulties when attempting to discern between 
readings contributed by the tag and by the protein under investigation. It was therefore 
necessary to first remove the GST prior to analysis (Kelly et al., 2005). Removal of the tag may 
also be desirable for later structural or functional studies in which effects of the GST tag must 
be negated.  
5.2 Results 
5.2.1 Binding of recombinant EC2 domains  
To examine their cellular specificity, binding of the EC2 domains to two cell lines, HEC-1B cells, 
and RBL-2H3 cells, was investigated. As described in Chapter 4, the EC2 domains have yet to 
show any activity on RBL-2H3 cells, however, CD9, CD63 and CD151 EC2 domains have been 
demonstrated to reduce bacterial adhesion to HEC-1B cells (Green et al., 2011) and using the 
EC2 proteins generated during this project we were able to reproduce this effect (CD151 was 
also shown to have an inhibitory role, however this affect was not tested here) (Figure 5.1). 
Thus in the presence of CD9, CD63 and CD151 EC2 there is a significant reduction in both 
number of number of bacteria per 100 cells and the number of infected cells, whilst CD81 EC2 
had no such effect. Importantly, both cell lines express some of the tetraspanins under 
investigation, with the notable exception of CD9 in RBL-2H3 cells (Figure 4.1) and the relatively 
low expression of CD151 in Hec-1B cells (Figure 5.1b).  
Initial attempts to dissect EC2 binding were indirect, using an anti-GST antibody as a means of 
quantifying the amount of bound EC2 protein (2.2.1.6). In brief, RBL cells were incubated with 
EC2-GST fusion proteins, then the cells were washed, fixed and then incubated with a FITC 
conjugated anti-GST antibody before being washed again and analysed by flow cytometry. 
Cells which were not incubated with an initial GST containing protein (no treatment, 
Figure5.2a) still exhibited high MFI readings (around 56% of the overall MFI) which are most 
likely due to non-specific or Fc receptor binding by the fluorescent anti-GST antibody. A clearer 
picture could be seen when this background was removed from the original values (Figure 
5.2b) and showed each concentration of the tetraspanin proteins had slightly more binding 
over the equivalent GST only control. However, GST binding was unexpectedly high and when 
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the MFI values of the cells which were incubated with the highest protein concentrations were 
compared by one-way ANOVA, only the CD81 treatment showed a significant (P <0.05) 
increase over GST (Figure 5.2c).  
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Figure 5.1: Effect of recombinant tetraspanin EC2 domains on N. meningitidis adhesion to HEC-1B 
cells and expression of several tetraspanins on the HEC-1B cell surface. (a+b) Bacterial adhesion 
assay carried out by D. Cozens. Briefly, Hec-1b cells were seeded on coverslips and blocked using 
bovine serum abumin (BSA). The cells were then washed and treated with recombinant GST fusion 
proteins for 30 minutes. Excess protein was removed by washing and the cells were then incubated 
with bacteria (MOI 300) for 60 minutes. Cells were washed and fixed then treated with anti-
miningococci antibodies followed by FITC-labelled secondary antibodies in order to visualize external 
bacteria. Nuclear DNA was stained with DAPI and coverslips were then mounted, slides were 
visualised and 100 cells were counted along with the number of associated bacteria. Results are 
from four biological repeats displayed as means ± standard error values. Significance is shown 
relative to the GST control *** = P<0.001, **** = P<0.0001 (c) Tetraspanin expression on HEC-1B 
cells was analysed according to section 2.2.1.9  carried out by F. Ali. MFI readings of cells probed 
with anti-tetraspanin antibodies or an isotype control antibody (JC-1) are displayed. (d) Example of 
gating used in Flow cytometry to determine expression of tetraspanins on HEC-1B cells. Data points 
are mean ± standard error of the mean (SEM) from three repeats carried out in duplicate. 
 
b) a) 
c) 
G
S
T
C
D
9
C
D
6
3
C
D
8
1
0
5 0
1 0 0
1 5 0
%
 c
h
a
n
g
e
 i
n
 i
n
fe
c
te
d
H
E
C
-1
B
  
c
e
ll
s
****
***
G
S
T
C
D
9
C
D
6
3
C
D
8
1
0
5 0
1 0 0
1 5 0
%
 c
h
a
n
g
e
 i
n
 o
r
g
a
n
is
m
s
 p
e
r
 1
0
0
 c
e
ll
s
****
****
d) 
Chapter 5: Physical studies of tetraspanin EC2 domains  
149 
  
  
Figure 5.2: Indirect analysis of EC2 binding to RBL-2H3 cells via flow cytometry. EC2 domains were 
incubated with RBL-2H3 cells for one hour, after which time they were fixed and incubated with a 
FITC labelled anti-GST antibody. Binding was analysed by flow cytometry (a) Original MFI values (b) 
MFI with background reading subtracted (c) one way ANOVA used to compare readings when using 
the highest concentration of recombinant EC2 domains. Results are means ± standard error from 
four experiment performed in triplicate * = P <0.05. 
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It was considered that the high level of non-specific/Fc receptor antibody binding might be masking 
much of the EC2 interaction, therefore a more direct method for assessing binding was used next 
(Section 2.2.1.7). Firstly recombinant EC2 domains and GST were fluorescently labelled with 
Alexa488 (Section 2.2.3.16) and the efficiency of labelling (representing the number of molecules of 
fluorescent dye per protein) was calculated to allow corrections to be made based on differences in 
labelling (Table 5.1). These proteins were incubated with the RBL-2H3 or HEC-1B cells, and after 
thoroughly washing, the cells were analysed by flow cytometry (Figure 5.3). Curves were generated 
to examine the binding profile of each protein (Figure 5.4) and the amount of binding exhibited by 
the EC2 domains at each concentration was analysed relative to the equivalent concentration GST 
control (Figure 5.4).  
In RBL-2H3 cells, at higher recombinant protein concentrations (above 300 mM) each EC2 domain 
exhibited significantly higher binding than the equivalent GST control and CD81 EC2 showed 
significance at even lower concentrations (Figure 5.4), suggesting that the indirect analysis identified 
this EC2 domains due to its higher degree of binding. The binding of EC2 domains to HEC-1B cells, 
although higher than RBL-2H3 cells in terms of total MFI, does not show as clear significance in 
relation to the GST control due to the higher amount of GST interaction (Figure 5.4). Furthermore, 
CD151 binding is not significantly higher than GST at any of the concentrations tested. Interestingly, 
the MFI values do not correlate with the expression of the respective tetraspanins, for instance the 
highest MFI readings with HEC-1B cells were given for incubation with CD9, despite CD81 being the 
most highly expressed, and CD9 gave similarly high readings when incubated with RBL-2H3 cells 
despite CD9 not being expressed on these cells (Figure 4.1). Furthermore, the binding pattern does 
not relate to the degree of protein labelling, and the very similar DOL values would also suggest that 
this is not responsible the different MFI values seen. Unfortunately it was not possible to attain high 
enough concentrations of labelled proteins to determine if binding could be saturated so these 
results do not show the complete binding profile of each recombinant EC2 domain and EC50s could 
not be calculated which made comparisons between cell types difficult. The MFI values of EC2 
treated HEC-1b cells were greater than those of the RBL-2H3 cells suggesting a higher amount of 
overall EC2 binding to this cell type; however GST binding was also higher so there could be a non-
specific contribution to the EC2 binding to these cells. 
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Protein name DOL 
GST 3.295 
CD9 EC2 3.629 
CD63 EC2 4.327 
CD81 EC2 4.628 
CD151 EC2 3.827 
Figure 5.3: Scatter plots representative of untreated and labelled GST and CD81 EC2 treated RBL-
2H3 cells. Following 40 minute incubation with labelled proteins, RBL cells were washed and then 
analysed by flow cytometry. To calculate % positive, negative control gates were established using 
non-treated cells and applied to cells which had been treated with the various EC2 domains. Scatter 
plots are one method of depicting the data with the percentage values being transferred to a line 
graph for easier comparison at multiple protein concentrations (Figure 5.4) 
Table 5.1: Degree of labelling of recombinant proteins. Recombinant proteins were labelled 
with Alexa488 and the degree of labelling calculated according to section 2.2.3.16. 
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Figure 5.4: Direct analysis of EC2 binding to HEC-1B cells and RBL-2H3 cells via flow cytometry. Fluorescently labelled EC2 domains were incubated 
with RBL-2H3 cells or HEC-1B cells for 40minutes before cells were washed and analysed by flow cytometry. Results for both cell types are displayed as 
(a+b) MFI which was determined by removing background MFI values from those attained from treated cells and (c+d) % positive cells when compared 
to control cells (determined according to Figure 5.3). Data points are mean ± standard error of the mean (SEM) representative of a minimum of two 
repeats performed in triplicate. 
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Although there is a dose dependent increase in binding of the recombinant proteins and a 
clear distinction between levels of GST and EC2 binding, it is not clear if the binding is specific 
(i.e. if they are binding to specific surface proteins). To determine if this was the case, 
competitions assays were performed where the cells were first incubated with a range of 
concentrations of unlabelled EC2 protein, before a binding assay was carried out using a fixed 
concentration of labelled protein. Labelled proteins were used at concentrations that gave half 
maximal binding in the previous binding assays, whilst unlabelled proteins were used at an 
initial ten-fold higher concentration in an effort to maximise any inhibitory effects. There was a 
notable decrease in MFI values of RBL-2H3 cells when treated with increasing concentrations 
of both CD9 and CD63 proteins (Figure 5.5a) suggesting some specific nature to the binding. 
However, readings for HEC-1B cells showed a greater amount of variation but, due to time 
constraints the binding of CD9 and CD151 could not be examined further.  
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Figure 5.5: Competitive binding of labelled and unlabelled EC2 domains to RBL-2H3 cells and 
HEC-1B cells. Cells were incubated with an excess of unlabelled recombinant EC2 domains for 
15minutes to saturate any specific binding sites which may be present. Cells were then treated 
with labelled EC2 domains at a concentration which gave half maximal signal in binding 
experiments (Figure 5.4) for 40 minutes. Cells were then washed and analysed by flow cytometry 
(a) MFI of RBL-2H3 cells incubated with CD63 and CD9 EC2 (b) MFI of HEC-1B cells treated with 
CD9 and CD63. Data points are mean ± standard error of the mean (SEM) and representative of a 
minimum of three repeats performed in triplicate. 
a) 
b) 
-1 .5 -1 .0 -0 .5 0 .0 0 .5
-2 0 0
0
2 0 0
4 0 0
6 0 0
R B L -2 H 3  M F I
 lo g  [u n la b e lle d  p ro te in ]  M
M
F
I
G ST
C D 9
C D 6 3
-2 .0 -1 .5 -1 .0 -0 .5 0 .0 0 .5
0
2 0 0
4 0 0
6 0 0
8 0 0
1 0 0 0
H E C -1 B  M F I
lo g  [u n la b e lle d  p ro te in ]  M
M
F
I
G ST
C D 9
C D 6 3
Chapter 5: Physical studies of tetraspanin EC2 domains  
 
155 
  
5.2.2 Effect of recombinant EC2 domains on B. thaillandensis 
induced cell fusion and correlation with LPS levels 
B. thaillandensis induced fusion of the mouse macrophage cell line J774.2 was studied by A. 
Elgawidi as described in section 2.2.1.16 (data analysed by the author). Although J774.2 cells 
are a murine macrophage cell line, the human EC2 domains display high identity to the mouse 
orthologues (Appendix Figure 7.3) and human CD9 has previously been shown to compensate 
for the loss of its mouse counterpart (Zhu et al., 2002). Cells were treated with various 
recombinant EC2 domains prior to infection with B. thaillandensis and after allowing fusion to 
take place, the number of giant cells and the number of nuclei within giant cells were 
determined. The average size of the resultant giant cells is displayed as the typical number of 
nuclei within a giant cell and the fusion index represents the number of nuclei within giant 
cells in relation to the total number of nuclei. To account for variation between experiments 
(for instance slightly different plating densities), both results are normalised to the values seen 
in cells with no pre-treatment but non-normal values ranging from 6-20 nuclei per cell with 10-
60% of cells taking part in fusion. Giant cell size is significantly decreased when pre-treating 
the cells with CD9-EC2 and CD63-EC2, with no decrease being exhibited after CD151-EC2 or 
Tspan 2-EC2 treatment (Figure 5.6a). Similarly CD9 and CD63 are also able to significantly 
reduce fusion index, whilst CD151 and Tspan2 showed no affect (Figure 5.6b). Moreover, as 
only two of the four tetraspanins studied were able to reduce fusion, it suggests a specific 
involvement of these tetraspanin members in the process. To confirm that LPS was not the 
active constituent, the amount of LPS within the proteins was determined (2.2.3.12) and 
correlated to the inhibitory effect that each protein has on fusion.  
Figure 5.7a shows that amounts of LPS varies between different EC2 domains, and it is also 
interesting to note that different preparations of the same EC2 domain, made under the same 
conditions, can exhibit varied LPS levels (as can be seen when comparing CD9(1) with CD9(2) 
and CD63(1) with CD63(2)). The amount of LPS within a sample does not correlated with its 
effect on either fusion index or average MNGC size, and it is clear that in each instance there is 
no relationship between the amount of LPS within a sample and its effect on either parameter. 
This result indicates that, in this instance, the inhibitory effect of the recombinant proteins on 
MNGC formation relates to the specific EC2 protein rather than any activity of LPS. 
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Figure 5.6: Recombinant tetraspanin EC2 domains effect on B. thailandensis induced fusion of 
J774.2 cells. J774.2 cells were treated with 500nM of various EC2 or GST alone for one hour prior 
to infection with B. thailandensis. After infection, external bacteria were killed and cells were 
allowed to fuse overnight after which they were fixed and stained with Giemsa solution. 10 
random fields were taken from each condition and nuclei were counted. Results were normalised 
and are displayed as (a) MNGC size which indicates the average number of nuclei within a giant 
cell and (b) Fusion index which represents the proportion of nuclei found within giant cells. 
Results are means ± standard error from three experiment performed in triplicate, values were 
compared to the GST control by one way ANOVA with Holm-Sidak’s multiple comparison 
correction * = P<0.05, ** = P<0.001, **** = P<0.0001. 
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Figure 5.7: LPS content of recombinant EC2 domains and correlation to effect on giant cell 
formation. (a) LPS content of recombinant proteins was determined using a Pierce LAL 
endotoxin quantification kit. CD9 (2) and GST (2) were produced by a previous lab member and 
CD63 (2) indicates CD63 produced from a separate round of purification than that which made 
CD63 (1). (b) The amount of LPS within a recombinant protein preparation plotted against the 
amount which it reduced MNGC size (c) As in (b) but plotted against EC2 ability to reduce cell 
fusion. Data points are mean ± standard error of the mean (SEM) from a minimum of two 
repeats carried out in duplicate. 
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5.2.3 Recombinant EC2 cleavage and CD spectra 
5.2.3.1 Optimisation of EC2-GST cleavage 
To enable CD spectra to be attained from the EC2 proteins without interference of the large 
GST tag, the tag first had to be removed. The inclusion of a cleavage site in the vector enables 
removal through incubation with thrombin, and the flexible glycine linker within the pGEX-KG 
vector is thought to enable cleavage to take place more efficiently (Guan and Dixon, 1991). 
Previous students utilised a batch method of cleavage described in section 2.2.3.13, where 
proteins are incubated with glutathione Sepharose beads cleaved and separated from the 
beads by centrifugation. Recovery from this method of cleavage was reported to be only 5% 
however (Hulme, 2010), so efforts were undertaken to improve the experimental design.  
According to manufacturer’s guidelines (GE healthcare), one unit of thrombin, cleaves 100 µg 
of protein when incubated for 16 hours at 22:C, however this is subject to change based on 
the target protein. Here, CD9 EC2-GST was cleaved using 0.5, 1 and 1.5 units of thrombin; 
additionally, a range of incubation times were used to determine which was most favourable. 
The protein attained from each cleavage condition was analysed by SDS PAGE followed by 
Coomassie staining (Figure5.8a) or Western blotting (Figure5.8b). Densitometry analysis of the 
anti-CD9 Western blot indicated that overnight incubation using one unit of thrombin resulted 
in the highest yield of cleaved protein. However, Coomassie staining of the cleaved protein 
(Figure 5.8a) shows bands at both 37 kDa and 26 kDa indicating both uncleaved protein and 
cleaved, free GST in the final sample. A proteins purity of 95% (as determined by Coomassie 
staining) is recommended for CD spectroscopy (Kelly et al., 2005), so it was therefore 
important to try to remove these unwanted proteins from the final samples. Repeat 
incubation with glutathione Sepharose beads followed by centrifugation reduced the amount 
of contaminating protein (data not shown); however contaminants still represented over 5% of 
the final sample. It is likely that these bands are a result of some of the glutathione Sepharose 
beads transferring into the final solution (despite using gel loading tips). It was not possible to 
quantify how much of the bead fraction had transferred into the final sample so comparison of 
cleavage efficiency between test conditions was not reliable. During later attempts at batch 
cleavage, these contaminating bands were still visible, so a column method of purification was 
subsequently employed, which should eliminate the transfer of Sepharose beads. The column 
cleavage method was carried out as in section 2.2.3.14, and the length of incubation with the 
thrombin was again adjusted. Western blot analysis (Figure 5.9c) followed by densitometry 
showed that overnight incubation resulted in the highest amount of cleaved CD9 protein. 
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Figure 5.8: Optimisation of EC2-GST cleavage using a batch method. CD9-EC2 GST fusion 
protein was cleaved using three different concentration of thrombin and four different 
incubation times according to the batch cleavage method (Section 2.2.3.13). Lanes one and 
two show the original uncleaved sample and the protein removed from the beads 
following an initial wash respectively. (a) Coomassie stain of the resultant cleaved proteins 
(b) Western blot probed with an anti-CD9 monoclonal antibody. 
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Western blot 
1 2 
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CD9-GST 
Cleaved CD9 
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Figure 5.9: Effect of incubation time for EC2-GST cleavage using the column method. On column 
cleavage of CD9-EC2-GST fusion proteins was carried out (section 2.2.3.14) using one unit of 
thrombin with varied incubation times as indicated. Lanes one and two show the proteins which 
did not bind to the beads and the initial wash before cleavage. (a) Coomassie stain following 
cleavage (b) anti-GST Western blot following cleavage (c) anti-CD9 Western blot following cleavage. 
1 = Cleavage fraction one, 2 = Cleavage fraction two, 3 = Wash following cleavage, 4 = Protein 
remaining on Glutathione sepharose beads.  
a) 
b) 
c) 
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Figures 5.9a and 5.9c (Lane 4) indicate that some of the cleaved protein remains attached to 
the glutathione Sepharose beads so in an attempt reduce the non-specific associations 
between the proteins and beads, a higher concentration of NaCl was used, along with 0.1% 
Triton X-100. A higher quantity of thrombin was also used (1.5 units) to see if this improved 
protein yields. When comparing the first cleavage fraction of Figure 5.10 (Lane 3) a thicker 
band can be observed when using 1.5 units of thrombin as opposed 1 unit, with densitometry 
analysis indicating around a three-fold improvement. Interestingly, almost no protein is visible 
in the cleaved fraction when using a higher amount of NaCl and Triton X-100 (Figure 5.10c), 
perhaps due to the protein precipitating out of solution due to the higher salt concentration. 
5.2.3.2 CD spectroscopy 
Once the optimum cleavage conditions had been established (16 hour incubation with 1.5 
units of thrombin and standard PBS salt concentration (137 mM)), the purified tetraspanin 
EC2-GST fusion proteins were cleaved prior to CD spectroscopy analysis. Each of the cleaved 
proteins were quantified by Bradford assays (Section 2.2.3.10) and analysed by Coomassie 
staining and Western blotting using anti-tetraspanin antibodies (Figure 5.11). Coomassie 
staining indicates no contaminating protein in the cleavage fraction and similarly no GST was 
detected in cleaved fractions of CD9 and CD81 by Western blot analysis. Bands are present at 
~10 kDa in anti-CD9, anti-CD81 and anti-CD151 Western blots, however there are no such 
bands displayed in the anti-CD63 Western blots. Spectra attained for CD9 and CD81 are 
displayed in Figure 5.12; readings were deconvoluted using the online software DICHROWEB 
using the SELCON3 and CONTIN algorithms. Secondary structure predictions were averaged 
from the two algorithms, however relatively high NRMSD values indicate that secondary 
predictions may not be as accurate as desired (perhaps resulting from difficulty in accurately 
estimating protein concentrations at such low values). However, an estimated 52% α-helical 
content of CD81 is comparable to the 58% previously reported (Rajesh et al., 2012) and the 
spectra for both CD9 and CD81 have a characteristic α-helical shape with minima at 208 nm 
and 222 nm which are expected for these proteins, suggesting that the estimated readings are 
somewhat reliable. Despite optimising cleavage and repeated cleavage attempts, quantities of 
cleaved CD63 and CD151 were still poor and not sufficiently concentrated to give acceptable 
spectra. After optimisation, cleavage efficiency of CD9-EC2 was ~50%, a tenfold increase over 
that reported by previous lab members. However CD63-EC2 exhibited a cleavage efficiency of 
~20% and its UV absorbance readings, and that of CD151 displayed light scattering which 
indicates protein aggregates. It is possible that removal of the GST tag reduced the solubility of 
the proteins and in the 6-cys containing EC2 domains this has a more pronounced effect which 
could lead to them precipitating out of solution (Terpe, 2003).  
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Figure 5.10: Effect of increased thrombin and increased NaCl on EC2-GST cleavage. On column 
cleavage (2.2.3.14) of CD9-EC2-GST fusion protein was carried out overnight using 1 or 1.5 units of 
thrombin or 1 unit of thrombin with 0.5M NaCl and 0.1% Triton X-100. 1= Protein not bound to 
beads, 2= Wash prior to cleavage, 3= Cleavage fraction one, 4= Cleavage fraction two, 5= Protein 
remaining on beads after cleavage.  
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Figure 5.11: On column cleavage of several recombinant EC2-GST fusion proteins. On column 
cleavage (2.2.3.14) of CD9, CD63 and CD81 and CD151 EC2 GST fusion proteins was carried out 
overnight using 1.5 units of thrombin. Samples following cleavage were analysed by SDS-PAGE 
followed by Coomassie staining or Western blotting using relevant anti-tetraspanin monoclonal 
antibodies or an anti-GST antibody (as CD spectra could not be attained for CD63 and CD151, anti-
GST blots were not carried out on them). 1= Protein remaining on beads following cleavage, 2= 
Protein not bound to beads, 3= Cleavage fraction one, 4= Cleavage fraction two. 
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Structural 
Feature 
Estimated 
Percentage 
α-helix 52 
Β-sheet 5 
Turns 18 
Unordered 25 
Total 100 
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Figure 5.12: Far UV CD spectra for CD9-EC2 and CD81-EC2. CD spectroscopy was carried out on 
CD9 and CD81 EC2 according to section 2.2.3.15. Estimated secondary structure percentages are an 
average of those given by SELCON3 and CONTIN analysis programs used by DICHOWEB with 
average RMSD values of 0.115 for CD9 estimations and 0.179 for CD81. Graphs are representative 
of two repeats.  
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5.3 Discussion 
5.3.1 Recombinant EC2 binding 
Following on from previous results which demonstrated that the recombinant EC2 domains do 
not affect degranulation (Chapter 4), it was considered that the EC2 proteins may not be able 
to bind to RBL-2H3 cells. The binding of recombinant EC2 domains to specific cell types but not 
others was demonstrated by Kelid et al. (2001) who showed that CD81 EC2 bound to neurons, 
but not astrocytes, despite the latter expressing endogenous CD81 also. Furthermore, 
Parthasarathy et al. (2009) demonstrated that recombinant CD63 EC2 binding to monocytes 
only took place once the cells were stimulated with ConA. In this chapter the binding of EC2 
domains to two cell lines, HEC-1B and RBL-2H3 cells, was compared. In chapter 4 it was 
considered that EC2 domains may disrupt TEMs on the RBL-2H3 surface and in doing so disrupt 
IgE signalling; however this was shown not be the case. On the other hand, recombinant CD9, 
CD63 and CD81 EC2 domains did affect bacterial adhesion to Hec-1B cells, where they are 
suggested to function, through disruption of TEMs acting as “adhesion platforms” containing 
receptors for meningococcal attachment (Green et al., 2011).   
Initial experiments monitored binding to RBL-2H3 cells indirectly using a fluorescent anti-GST 
antibody; however, non-specific antibody binding was high and accounted for a large 
proportion of the detected signal. The majority of recombinant EC2 binding was similar to that 
of the GST control, with the exception of CD81, which was significantly higher. However, there 
were concerns that the high levels of binding exhibited by the anti-GST antibody itself may 
have been masking a large proportion of the interaction so directly labelled EC2 proteins were 
utilised in later experiments. In these assays, the higher concentrations of each EC2 domain 
bound to both cell types significantly more than the corresponding GST control, with the 
exception of CD151 to HEC-1B cells. As previously reported (Kelid et al., 2001), homotypic 
interactions do not seem to be required for recombinant EC2 binding to a specific cell, as 
evidenced by recombinant CD9 EC2 binding to RBL-2H3 cells which do not express CD9. In 
contrast, CD151 exhibits poor binding to HEC-1B cells (which do not express CD151) suggesting 
homotypic interactions may be involved in some circumstances. Moreover, the amount EC2 
binding to RBL-2H3 cells does not correlate to the homology displayed between the rat and 
human orthologous; for instance CD151 has the highest homology (86.8% identity) and yet the 
lowest degree of binding. Direct comparisons of EC2 binding to the different cell types is 
difficult due to higher level of GST binding seen with the HEC-1B cells. However, the low 
binding values for CD151 EC2 on HEC-1b cells are surprising, as recombinant CD151 EC2 was 
previously shown to significantly decrease bacterial adhesion to these cells (albeit with a 
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different recombinant protein preparation). This could mean that binding is not required for 
modulation of cellular activity, alternatively the interaction is such that it cannot be identified 
in this fashion, for example if it is more transient. Moreover, CD81 shows high binding to HEC-
1b cells and yet does not alter bacterial adhesion, perhaps suggesting a different manner of 
interaction to the other EC2 domains. 
Competitive binding experiments were undertaken using an excess of unlabelled GST-EC2 
protein in an attempt to determine the specificity of EC2 interaction with the cells. Labelled 
CD9 and CD63 EC2 binding to RBL-2H3 cells diminishes slightly with increasing concentrations 
of unlabelled EC2 protein which may indicate binding to a specific saturable “receptor”. 
However, it has yet to be determined if the same response is seen when using an excess of 
control protein such as GST. Competitive binding experiments using HEC-1B cells exhibited 
much higher variation, which may have arisen from inaccuracies when using small volumes of 
labelled protein, or prolonged storage of the labelled proteins, leading to their deterioration 
(e.g. possible aggregate formation or the label dissociating from the proteins). Interestingly the 
binding of the labelled GST protein to HEC-1B cells does not show as much variation, perhaps 
suggesting an intrinsic property of the EC2 domains which is contributing to the varied nature 
of the results. For example, if the EC2 domains are intercalating into TEMs then this type of 
cellular binding may not be easily saturated and therefore MFI values would not decrease 
when higher concentrations of unlabelled proteins are applied to the cells. Moreover, it is 
possible that the EC2 domains form dimers or even multimers which may impact upon the 
binding values. After further refinement it would be desirable to determine if binding of 
labelled protein could be reduced using an excess of the same protein. It would also be 
necessary to use an excess of control protein (GST for example) to show that any inhibition in 
binding was due to binding sites being occupied. It would also be possible to use an excess of 
other tetraspanin EC2 domains to see if the binding of one tetraspanin can be inhibited using 
another member. 
5.3.2 LPS contamination of recombinant EC2 domains 
Many recombinant proteins are produced in E. coli because of its relative simplicity, high yields 
and established methods. However the end product inherently contains a number of 
contaminating bacterial components such as LPS. Under normal in vivo conditions, when an 
immune cell encounters LPS, it is a signal of infection and the cell responds by producing 
cytokines and inflammatory mediators. In an in vitro setting, immune cells respond similarly, 
and depending on the process under investigation these changes can have a pronounced 
effect on cellular behaviour. In certain instances the effect of endotoxin contamination has 
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been confused with that of a recombinant protein under investigation. For instance, 
recombinant heat shock protein 70 (HSP70) was thought to induce TNFα production but this 
property was later attributed to the contaminating endotoxin (Gao and Tsan, 2003). A number 
of methods have been described to reduce the levels of LPS within a sample, however none 
are able to completely remove it (Wakelin et al., 2006). Alternatively, agents can be added to 
neutralise the endotoxin such as PMB (Polymyxin B) which binds to the lipid A portion, 
however this can also stimulate cytokine production (Damais et al., 1987). 
Tetraspanins have been implicated in a number of cellular fusion events including; viral 
induced syncytium formation (Weng et al., 2009), sperm-egg fusion (Rubinstein et al., 2006; 
Zhu et al., 2002), muscle cell fusion (Tachibana and Hemler, 1999) and monocyte fusion 
(Parthasarathy et al., 2009; Takeda et al., 2003). In several of these scenarios it is thought that 
tetraspanins function by regulating associated fusogenic proteins, for example, restricting the 
access of viral fusion proteins to cell-cell junctions (Singethan et al., 2008). Recombinant EC2 
domains have displayed activity in a number of fusion events and as such have been used to 
investigate tetraspanin involvement. However, LPS contamination of the recombinant EC2 
domains has recently been shown to affect ConA and RankL induced fusion of monocytes cells 
(Fanaei, 2013) and as the mode of action of EC2 domains is yet to be determined, it is 
important to show that LPS is not the active component in each functional assay that they are 
used. More recently recombinant EC2 domains have been shown to modulate levels of 
macrophage fusion induced by B. thailandensis. Reduction of fusion in this manner is not a 
result of reduced bacterial adhesion (A. Elgawidi, unpublished data) and the mechanism of 
action of the EC2 proteins is instead suggested to be due to interference with tetraspanin 
regulation of fusogenic proteins. Although control experiments using pure LPS showed no 
effects (Atiga Elgawidi, personal communication), it was deemed important to correlate the 
levels of LPS within the proteins to their effect on this kind of fusion (Figure 5.6). Importantly 
there was no trend between the amount of LPS within the sample and the resultant MNGC 
size or fusion index, and there was similarly no correlation with their effects on bacterial 
adhesion thus indicating that endotoxin was not the contributing factor. However, it is 
important to note that this can only be considered the case within these particular 
experiments as others assays may be more sensitive to the endotoxin contaminant. It is 
interesting that some previous work indicated that LPS had an effect on ConA induced fusion 
of primary monocytes whilst it does not affect B. thailandensis induced fusion of the mouse 
macrophage cell line. It is possible that the use of a cell lines rather than primary cells was 
responsible for the difference in LPS sensitivity, alternatively (and perhaps more likely), the 
bacterial induced cell fusion may not be sensitive to the presence of LPS because LPS is 
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inherently in the system due to the incubation with bacteria. Interestingly, the same EC2 
domain produced from different rounds of expression and purification had differing levels of 
LPS, suggesting that the amount of LPS within a sample is not dependent on an inherent 
property of the EC2 domain but rather slight differences in its expression and purification. 
Additionally, previous work (Chapter 3, Figure 3.17) displayed no difference in endotoxin levels 
between CD9 EC2 purified by batch or column method suggesting that LPS levels are more 
influenced by slight differences growth, harvesting and lysis of the bacterial cultures rather 
than downstream purification. This result also emphasises the importance of separate LPS 
quantifications for EC2 domains produced from different rounds of purification. In future it 
may be desirable to utilise an E. coli system such as ClearColi® which expresses a modified 
version of LPS (Lipid IVA) which does not illicit an immune response in human cells (Mamat et 
al., 2015). This however would not be appropriate for experiments such as these, where 
mouse cells are utilised and as of yet there is no stain available which contains the 
modification found in Rosetta-gami which makes them appropriate for EC2 expression. 
Alternatively there are methods of LPS removal or reduction which could be implemented 
when lower levels or no LPS is required (Reichelt et al., 2006). 
The functional effects described for the EC2 domains in this chapter (both on bacterial 
adhesion to HEC-1B cells and fusion events in J774.2 cells) show that the recombinant proteins 
produced during the present work do have biological activity in some systems despite them 
not affecting RBL-2H3 degranulation. Furthermore, their ability to modulate events in the 
mouse macrophage cell line demonstrates that homology between tetraspanin ortholgues is 
such that the human EC2 domains are active on rodent cells. 
5.3.3 CD spectroscopy of recombinant EC2 domains 
CD spectroscopy has been used by Rajesh et al. (2012) to show that the CD81-EC2 which they 
produced had 58% α-helical content, similar to that reported from the CD81 crystal structure. 
Properties of EC2 proteins produced by one group are not readily transferred to those 
produced by another due to changes in the expression procedure. Indeed EC2 domains from 
different groups can have different efficacy, for example recombinant CD9 EC2 used by Zhu et 
al. (2002) shows inhibitory effect on sperm egg fusion at 250 µg/ml whereas Higginbottom et 
al. (2003) showed an effect at 0.1µg/ml which the authors suggest is due to different folding 
states of the recombinant proteins. Thus far our group has solely used antibody-based 
methods (e.g. Western blots) to confirm correct folding of the EC2 domains; however, this only 
confirms that the antibody binding region is correctly folded and a band on a Western blot 
could be displayed from only a small proportion of the sample having the correct folding 
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pattern. It was therefore desirable to undertake CD spectroscopy on our proteins to 
investigate their secondary structure characteristics; however the GST tag had to first be 
removed. Previous lab members reported low cleavage efficiencies (5%) and unstable products 
when attempting to remove the GST tag from CD9 (Hulme, 2010) so initial efforts went into 
optimising cleavage and focused on a batch method which would enable recovery of cleaved 
proteins in a small sample volume and therefore potentially higher concentrations. The 
resulting cleavage products contained both uncleaved EC2-GST fusion proteins and free GST, 
presumably from transfer of some glutathione Sepharose beads into the cleavage fraction; 
moreover, these contaminants were present in subsequent cleavage attempts and could not 
be removed by repeated glutathione incubation. In an effort to prevent these proteins being 
introduced into the cleaved fraction, on-column cleavage was next used. Fortunately this 
method resulted in much cleaner cleavage products with none of the undesired protein bands 
apparent in Coomassie stained gels and no GST containing proteins in the cleaved proteins (as 
determined by Western blot). Length of incubation with thrombin and the amounts of 
thrombin used were altered and a cleavage efficiency of ~50% was attained for CD9 EC2. On 
the other hand, cleavage of CD63 was around 20% efficient and the resulting concentrations of 
both CD63 and CD151 were low. It is possible that these proteins were more susceptible to 
non-specific degradation by thrombin; alternatively, their solubility could have been adversely 
affected by the removal of GST leading to aggregation (which might explain the high light 
scattering following cleavage). In future experiments, higher initial concentrations could be 
used to attain more cleavage protein or further optimisation could be undertaken, for example 
altering buffer conditions to aid with protein solubility. Inclusion of a His tag at the 3’ end of 
EC2 constructs may also be beneficial as it would enable efficient purification of EC2 domain 
following cleavage.  
Unfortunately the low recovery of CD63 and CD151 following cleavage meant that spectra for 
these two proteins could not be gathered. CD spectra were attained for CD9 and CD81, 
however, and the online program DichroWeb was used to estimate the percentage secondary 
structure for each protein. Relatively high NRMSD values (>0.1) suggest that the secondary 
structure predictions may not be reliable (Whitmore and Wallace, 2008), however 52% 
predicated α-helical content of CD81-EC2 is comparable to the 58% reported elsewhere 
(Rajesh et al., 2012) and the spectra do have a characteristic α-helical shape giving confidence 
in the correct folding of the CD9 and CD81 EC2 domains. Given that CD63 and CD151 contain 
six di-sulphide bonds and potentially a more complex structure it would useful to attain 
spectra for these EC2 domains too as there is theoretically a greater incidence of misfolding. 
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Spectra of CD63 would also enable comparisons to be made between the human rat-CD63 EC2 
domains produced previously to see if the predicted secondary structure differences.  
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Chapter 6: General discussion  
6.1 General discussion  
It has been reiterated throughout this thesis that the tetraspanin family of proteins are 
important in a multitude of processes and yet our understanding of the functions of individual 
members is limited. The EC2 domains in the form of recombinant proteins have already 
proven useful tools in assessing tetraspanin function (Barreiro et al., 2008; Green et al., 2011; 
Ho et al., 2006; Parthasarathy et al., 2009; Zhu et al., 2002). Initial work in this study involved 
the attempted expression of EC2s from selected tetraspanins in mammalian and insect cells, 
with the aim of producing reagents which would more closely resemble the corresponding 
region of native tetraspanin proteins. Difficulties were encountered in producing the proteins 
in eukaryotic cells so later work focused on expression and optimisation of expression in 
bacteria. The effects of the EC2 proteins on IgE mediated degranulation were then 
investigated using the RBL-2H3 cell line as a model system. Although a number of studies have 
linked tetraspanins to IgE mediated degranulation (Fleming et al., 1997; Kitani et al., 1991; 
Köberle et al., 2012; Kraft et al., 2005, 2013; Peng et al., 2011; Smith et al., 1995), their role 
within this process remains unknown and this is the first time the recombinant EC2 domains 
have been used to assess their involvement. Finally, efforts were made to characterise the 
protein in terms of LPS content, folding and cellular binding capacity. 
Chapter 3 focused primarily on EC2 expression in eukaryotic systems (specifically CHO, HEK-
293 and SF9 cells). The desire for these eukaryotic recombinant EC2 domains stemmed from 
the inherent downsides found in the bacterially expressed EC2 domains which include: 
A. Suggestions of incorrect protein folding due to antibodies which were raised against 
these proteins not recognizing the native tetraspanins (Jiraviriyakul, 2010) (Azorsa et 
al., 1999). 
B. Lack of glycosylation, a modification which is required for some tetraspanin function 
(Ono et al., 2000; Ranjan et al., 2014). 
C. LPS contamination resulting from the use of E. coli as a host for expression rendering 
the proteins unsuitable for some functional assays. 
Not only would eukaryotic expression of the EC2 domains overcome these issues but it would 
also enable comparisons to be made between EC2 domains produced in different hosts. For 
instance, the functional relevance of glycosylation could be examined by carrying out 
functional assays in paralleled with glycosylated and de-glycosylated proteins. The structural 
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differences could also be inspected, perhaps by CD spectroscopy experiments similar to those 
carried out previously to compare CD81 expressed in prokaryotic and eukaryotic systems 
(Rajesh et al., 2012). Moreover, comparisons between the structures of tetraspanins with 
higher cysteine numbers would give an indication as to how well bacterial systems cope with 
the folding of these proteins. Some tetraspanin EC2 domains which contain six to eight 
cysteines (e.g. Tspan-4, Tspan-5, Tspan-8 and Tspan-31) and therefore have 3-4 potential di-
sulphide bonds and more complex folding structures, give extremely low yields when 
expressed in bacteria. This is suggested to arise from aggregation caused by misfolding within 
the reducing environment of the E. coli cytoplasm (Fanei, 2013). This limits the tools available 
to study these particular family members, which is compounded in some cases by the lack of 
monoclonal antibodies towards the native proteins. Furthermore, tetraspanins which contain 
8 cysteine residues within the EC2 are becoming increasingly appreciated as a subdivision of 
the tetraspanin family with some conserved properties (Dornier et al., 2012), making reagents 
for assessing their function ever more desirable. The improved folding associated with 
eukaryotes means they are more likely to be able to produce the required recombinant EC2 
domains, which are not only useful functional tools in themselves but may also be used as 
antigens to produce monoclonal antibodies which recognise the native proteins.  
Although there are benefits to eukaryotic expression, multiple attempts at producing the 
recombinant EC2 domains in these systems did not yield the desired product. It is difficult to 
define where the problem in mammalian expression arose, but PCR experiments showed that 
the DNA was integrated into the host genome and that the cells were producing EC2 encoding 
mRNA. it is possible that the issue was with the coding RNA itself; for example if the RNA 
product was poorly processed due to its short size (Ntini et al., 2013). Alternatively, problems 
may have arisen if overexpression of the EC2 domains was toxic to the host cells. Indeed only 
one other group have expressed the EC2 domains in a mammalian host and a transient form of 
expression was used (Rajesh et al., 2012), which may suggest an inherent property of the EC2 
domains that makes them difficult to express. 
With regards to bacterial expression, each of the investigated tetraspanins (CD9, CD63, CD81 
and CD151) were expressed and recognised by their respective antibodies and efforts were 
made to optimise the amount of soluble protein recovered by altering IPTG levels and length 
of time temperature used for induction. The four tetraspanins were selected based on their 
involvement in IgE mediated signalling, with at least two of these (CD9 and CD81) being co-
immunoprecipitated with the high affinity IgE receptor itself (Abdala-Valencia et al., 2015; 
Fleming et al., 1997; Higginbottom et al., 2000a; Kraft et al., 2005; Peng et al., 2011). Since 
several tetraspanins have been implicated in IgE mediated degranulation, it was theorised that 
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they might regulate FcεRI activity due to its presence within a TEM. Recombinant EC2 domains 
have been suggested to affect various processes through disruption of TEMs (Barreiro et al., 
2008; Green et al., 2011; Parthasarathy et al., 2009). Therefore, as described in Chapter 4, the 
recombinant EC2 domains were utilised in in an effort to further understand tetraspanin 
involvement in degranulation and as an initial investigation into any therapeutic application.  
After extensive investigation, it was shown that EC2 domains do not affect IgE mediated 
degranulation in RBL-2H3 cells. Several hypotheses were suggested as to why these results 
were seen, with focus on (a) our understanding of tetraspanins involvement in IgE signalling, 
and (b) the mechanism of recombinant EC2 domain activity. Firstly, it was proposed that 
although FcεRI interacts with tetraspanins, the receptor may not be found within a TEM. The 
possible involvement of lipid-rafts in IgE mediated signalling may also indicate this as the 
microdomains are often seen as distinct regions. However, this could be a rare instance of 
coalescence between the microdomains. Alternatively, as tetraspanins are dynamic in the 
membrane and are not restricted to TEMs (Espenel et al., 2008), the association with FcεRI 
could be outside of a TEM environment. Moreover, the reports of tetraspanin association 
(Peng et al., 2011) with FcεRI may not indicate direct, primary associations and may instead 
allude to more distal interactions through a common partner protein. It is possible that the 
inhibitory effects on IgE degranulation observed using anti-tetraspanin monoclonal antibodies 
are due to higher affinity for their target proteins whereas the recombinant EC2 proteins may 
require interactions with clustered partners in the context of a TEM to illicit a response. 
If it is assumed that FcεRI is within a TEM then either recombinant EC2 domains do not disrupt 
the TEM as initially speculated (Figure 6,1b), or they do not disrupt the TEM to a high enough 
extent to affect FcεRI signalling. Evidence that recombinant EC2 domains disrupt TEMs 
includes their ability to modulate TEM involving process (Ho et al., 2006; Takeda et al., 2003; 
Zhu et al., 2002) and increased spacing and diffusion rates of TEM associated component when 
treating cells with recombinant EC2 domains. Also, treatment with CD9-EC2 not only affects 
the diffusion of endogenous CD9 but also endogenous CD151 suggesting a broader effect on 
TEMs dynamics (Barreiro et al., 2005). With this limited information it is conceivable that the 
recombinant proteins could function in other ways, for instance it has also been suggested 
that they may compete for binding with tetraspanin partner proteins which may have more 
specific outcomes (Figure 6.1c) (Higginbottom et al., 2003; Parthasarathy et al., 2009; Zhu et 
al., 2002).  
In Chapter 5, several properties of recombinant EC2 domains were examined in an effort to 
shed more light on how they function. Firstly the binding of recombinant EC2 domains to two 
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cell lines was examined (RBL-2H3 and HEC-1B). In both instances the binding of the 
recombinant EC2 domains was greater than that of the GST control protein (with the 
exception of CD151 to HEC-1B cells), indicating that the labelled recombinant proteins do 
indeed bind to the cells. The binding patterns did not correlate with degree of labelling of the 
recombinant proteins and, in the case of binding to RBL-2H3 cells, there was no relationship 
between the binding and homology between human and rat orthologues, suggesting that the 
differences in binding were an inherent property of the EC2 proteins. The overall level of 
binding of the recombinant proteins (indicated by the total MFI values) were greater for HEC-
1B cells than those displayed by RBL-2H3; however GST binding was also higher, so it is likely 
that there is some contribution from non-specific association making direct comparisons 
difficult. In competitive binding assays, the binding of labelled CD9 and CD63 to RBL-2H3 cells 
diminished with increasing concentrations of unlabelled protein, indicating that the binding 
was to a saturable binding partner at the cells surface. On the other hand, labelled CD9 and 
CD63 binding to HEC-1B cells did not decrease in the same way. The HEC-1B MFI values also 
show a higher degree of variation between experiments compared to the GST control, which 
could be due to technical issues; however it is possible that the increased variation and lack of 
inhibition of binding are a result of different binding properties (for instance intercalation into 
the TEM).  
LPS levels in the recombinant proteins were later measured and were then correlated to their 
effects on monocyte fusion induced by the bacterium B. thailandensis. The lack of relation 
between activity and LPS content confirmed that LPS was not the active component in 
recombinant protein preparations in this instance, although this cannot be said definitively for 
each assay in which they are used. It was also noted that the amount of LPS within the 
recombinant proteins varied between rounds of purification suggesting that levels of LPS are 
not dictated by the particular recombinant protein being expressed but are determined by 
variations in expression and purification procedures. 
 Finally, the secondary structures of the tetraspanins were investigated using CD spectroscopy. 
This attributed both CD9 and CD81 with a predominantly α-helical structure which is as 
expected from these proteins (Kitadokoro et al., 2001) suggesting they are correctly folded in 
the most part. Unfortunately, spectra for CD63 and CD151 could not be attained due to 
insufficient protein yields following cleavage. 
   
1
7
5 
Figure 6.1: Diagrammatic representation of the proposed mechanisms of EC2 action. (a) Under normal circumstances Partner proteins are normally held in an 
ordered fashion in close proximity within a TEM. (b) Recombinant EC2 domains added exogenously bind and intercalate between tetraspanins on the cell surface 
which leads to general disruption of the ordered TEM structure and decreased partner protein clustering, resulting in downstream physiological effects. (c) 
Recombinant EC2 domains added exogenously bind to partner proteins therefore preventing the binding of exogenous tetraspanins and stopping any specific effects 
which result from these interactions.  
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6.2 Future directions 
6.2.1 Improved expression systems 
Production of mammalian EC2 domains is still a desirable prospect despite time constraints 
meaning that attempts to attain these proteins had to be halted. Future efforts could be made 
accounting for the issues which have been suggested here. For example, a tightly regulated 
inducible mammalian promoter or transient gene expression could be utilised to circumvent 
issues with potential toxic effects of EC2 domain overexpression (Wurm, 2004). On the other 
hand, being as yeast do not express endogenous tetraspanins, these may be resistant to the 
potential cytotoxic effects of the EC2 domains and may therefore be an attractive alternative 
host which is able to glycosylate the proteins they produce. Indeed, Pishia pastoris has 
previously been used for the expression of full length CD81 (Jamshad et al., 2008). To prevent 
the possible issues with shorter RNA products new expression constructs including an epitope 
tag and cleavage site could be generated (similar to those previously used successfully for 
CD63 expression (Jiraviriyakul, 2010 ).  
In chapter 3 some elements of the bacterial expression were altered to favour higher 
recombinant EC2 yields, but there are numerous other changes which could be implemented 
to enable easier downstream processing and potentially give higher protein yields. Firstly, (as 
previously suggested) the inclusion of both a GST and His tag would enable two step 
purification which would aid in the removal of lower molecular weight (presumably truncated) 
proteins from the initial preparations. A second affinity tag would also allow for purification 
following cleavage of the bulky GST tag, moreover, because a His tag is not reliant on tertiary 
structure for affinity purification, it would enable purification following denaturation of 
inclusion bodies if this was considered in future. Other protein tags could be utilised which are 
suggested to aid in fusion protein solubility to a greater extent than GST, for instance maltose 
binding protein (MBP) which can also function as an affinity tag (Esposito and Chatterjee, 
2006). Alternatively, a leader sequence could be included to enable periplasmic expression 
with the hopes of producing more soluble proteins in the non-reducing environment of the 
pariplasmic space.    
The choice of bacterial host might also be altered. Rosetta-gami cells do contain modifications 
which are beneficial for expression of tetraspanin EC2 domains, however there may be other 
commercial strains of E. coli which offer distinct advantages. For instance, SHuffle cells which 
have similar modifications to Rosetta-gami but have the added benefit of the disulphide bond 
isomerase DsbC being constitutively expressed and retained in the cytoplasm, which aids in 
the folding of the disulphide containing proteins (Kurokawa et al., 2000). Yields of recombinant 
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EC2 proteins from Rosetta-gami and Shuffle cells were previously compared (Fanei, 2013) and 
SHuffle cells were found to give higher yields; however the amount of LPS in the preparations 
was consistently higher also. That being said, in LPS sensitive assays, even a small amount of 
protein can modulate cellular activity (Gao and Tsan, 2003) so unless LPS can be completely 
removed from the preparations the cost of increased LPS contamination may be worthwhile 
for higher protein yields. When considering experiments which would be altered by the 
inclusion of LPS, it may be favourable to utilise the ClearColi® strain of E. coli. These cells do 
not have the adaptations found in Rosetta-gami so would presumably give a lower proportion 
of soluble protein; however they have modified LPS which does not illicit a response in human 
immune cells which may enable the recombinant proteins to be used in more assays (Mamat 
et al., 2015). It seems that one could make a selection of bacterial strain based on the 
application of the resultant protein, for example a different systems could be used when a 
higher quantity of protein is required or when LPS is a concern.  
6.2.2 Tetraspanin involvement in IgE signalling 
Since little is known about tetraspanin involvement in degranulation and the mode of action of 
EC2 domains is ambiguous, it is difficult to speculate on the implications of the results 
obtained here. However, improved understanding of one unknown will enable greater 
interpretation of the data herein. For example, if the EC2 domains are proven more 
definitively to disrupt TEMs, than one could say with more conviction that the IgE receptor is 
not located within a tetraspanin enriched microdomain. Alternatively, if further studies did 
show that FcεRI partitioned into tetraspanin enriched microdomain, then it is likely that the 
recombinant EC2 do not disrupt TEMS. Mast cell lysis with different strengths of detergent 
followed by co-immunoprecipitation using anti-tetraspanin antibodies may help to determine 
the extent of tetraspanins FcεRI interaction (i.e. if they are primary direct interactions or not). 
It may also be desirable to study the association of tetraspanins with the high affinity IgE 
receptor during different phases of mast cell activation, to determine if they associate with 
one another following RBL-2H3 activation for example. FcεRI is thought to partition into lipid 
rafts following activation (Field et al., 1995) so association of the receptor with tetraspanins at 
this point may indicate an overlap between the two types of microdomain (which could be 
examined further by sucrose density centrifugation). 
Deletion of specific genes may prove a more direct method of determining what effects 
disruption of the TEM has on degranulation. Although single deletions show mild phenotypes, 
multiple genes could be knocked down via RNAi of removed through CRISPR. Future work 
could also focus on other steps in the degranulation pathway, for instance effects on calcium 
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influx and alteration in cytokine production rather than focusing on the extent of granule 
release. Indeed CD151-/- ex-vivo mast cells shows enhanced expression of proinflamatory 
cytokines despite no changes in degranulation (Abdala-Valencia et al., 2015). With this in 
mind, tetraspanin gene disruption followed by cytokine profiling may be advantageous. This 
more general approach would be useful in characterising the family as a whole, not just its 
specific involvement in IgE mediated degranulation. For example micro-array analysis could 
display which processes specific tetraspanins are required for, it is possible that a tetraspanin 
database could allow tetraspanins functional properties to be related to their physical 
structure more readily.   
6.2.3 EC2 mode of action 
Further analysis of EC2 mode of action would allow results to be deciphered more readily. CD 
spectroscopy is useful for analysing the proteins secondary structure but further physical 
characterisation may be helpful also. For example, CD81 EC2 crystallised as a dimer 
(Kitadokoro et al., 2001), and it would be interesting to determine if the other EC2 domains 
exist in a dimerised state and may inform more about how they function. This could be 
achieved using native PAGE or size exclusion chromatography (although the GST tag would 
have to be removed first at this dimerises naturally). As previously mentioned, Barreiro et al. 
used “nearest neighbour analysis” to show that the EC2 domains were able to affect the 
spacing or diffusion of two TEM associated proteins. If the same technique were applied to 
other instances where EC2 domains modulate cell function (for instance bacterial adhesion or 
cell fusion) it may be possible to say that the EC2 domains routinely affect TEM associated 
proteins. Alternatively, high resolution microscopy could be used to analyse the distribution of 
GFP labelled/ antibody stained partner proteins (e.g. FcεRI) before and after recombinant EC2 
treatment to determine if the proteins alter distribution or diffusion of partner proteins. 
Initial attempts were made to examine the binding of recombinant EC2 domains to cells and 
now the methods for EC2 labelling and binding have been established it may be possible to 
look at this further. Firstly the nature of binding could be established i.e. whether it can be 
inhibited by the corresponding unlabelled tetraspanins and/or by other tetraspanin proteins 
which may be competing for the same site. It may then be possible to establish what is 
required for binding to the cell surface. It has been indicated here and elsewhere (Kelid et al., 
2001) that homotypic interactions are not required; it would be useful to determine if 
association with other tetraspanin family members is necessary. Visualisation of binding may 
be useful also and initial attempts were made at analysing binding microscopically; perhaps in 
future endeavours expression of fluorescently-tagged tetraspanin proteins at the cell surface 
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followed by binding assays may give an indication as to any co-localisation between 
endogenous and exogenous tetraspanins. Co-immunoprecipitation or GST pull downs might 
help identify interacting proteins, however previous pull-down experiments were unsuccessful 
(our group, unpublished data).  Cell-free methods maybe more sensitive in identifying specific 
tetraspanin binding partners, for example, Biacore could be used to generate dissociation 
constants which may provide a more accurate read as to whether a binding partner is primary 
secondary or tertiary (Phizicky and Fields, 1995). 
Although targeting of tetraspanins using EC2 domains may not be applicable in the context of 
reduction of degranulation they may be a viable target for other therapeutic areas. It has been 
proposed that TEMs enable the formation of adhesion platforms which in turn allow microbial 
infection (Green et al., 2011). Disruption of TEMs using recombinant EC2 domains reduced 
bacterial adhesion to endothelial cells and has been proposed as an antimicrobial treatment 
which offers the advantage of not targeting the microbe itself, therefore resistance is less 
likely to arise due to selection pressure   (Green et al., 2011; Hassuna et al., 2009). Instances of 
direct pathogen–tetraspanin association may not be as readily disrupted by EC2 treatment 
however, as CD81 EC2s were unable to reduce HCV infection where as anti-CD81 mAbs and 
siRNA knockdown of CD81 did (Molina et al., 2008) therefore disruption of TEM function by 
siRNA may be beneficial when targeting specific tetraspanins which are known to take place in 
disease. The involvement of various tetraspanins in tumour progression also raises the 
possibility of targeting tetraspanins for treatment of cancer. For example high levels of CD151 
expression are linked with a poor prognosis in lung and prostate cancer and mouse xenograft 
models with mutated CD151 show reduced tumour growth (Yang et al., 2008). Anti-CD151 
mAbs have also been shown to reduce tumour cell metasitasis (Kohno et al., 2002) and 
recently an anti-CD37 antibody called Otlertuzumab has entered clinical trials for treatment of 
non-hodgkin lymphoma (NHL).  Otlertuzumab induces apoptosis in the bound cell by signalling 
through CD37 which increases the levels of the pro-apoptotic protein BIM (Pagel et al., 2014). 
Due to CD37s restricted expression in B-cells this offers a directed approach to treat B-cell 
malignancies. Other mAbs have shown promise in in-vivo models for instance and CD81 mAbs 
results in increased recovery from spinal injury and an anti-CD9 mAb reduced colon carcinoma 
growth (Ovalle et al., 2007). It is possible that the antibodies have a stronger more directed 
effect than the EC2 domains due to their specific and high affinity binding towards one 
tetraspanin, however EC2 domains may prove to be a valuable therapeutic with a more 
general disputing effect (Hemler, 2008).  
Although EC2 domains have proven useful in determining tetraspanin function several 
instances, they do have a number of limitations. In addition to effects seen due to bacterial 
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contaminants in the final preparations, they are also difficult to produce in high quantities due 
to a propensity to stick to plastic ware and the amount of miss folding due to large numbers of 
disulphide bonds. Another concern is their unknown mode of action making elucidation of 
results challenging, furthermore, EC2 domains represent only one form of tetraspanin EC2 
domain whereas native tetraspanins may be more homogenous, for instance CD9 has 13 splice 
variants and CD63 has 16.  
Chapter 6: General discussion and future direction 
181 
  
Bibliography 
 
Abdala-Valencia, H., Bryce, P.J., Schleimer, R.P., Wechsler, J.B., Loffredo, L.F., Cook-Mills, J.M., 
Hsu, C.-L., and Berdnikovs, S. (2015). Tetraspanin CD151 Is a Negative Regulator of FcεRI-
Mediated Mast Cell Activation. J. Immunol. 
Abidi, F.E. (2002). A novel 2 bp deletion in the TM4SF2 gene is associated with MRX58. J. Med. 
Genet. 39, 430–433. 
Abraham, S.N., and Malaviya, R. (1997). Mast cells in infection and immunity. Infect. Immun. 
65, 3501–3508. 
Abraham, S.N., and St John, A.L. (2010). Mast cell-orchestrated immunity to pathogens. Nat. 
Rev. Immunol. 10, 440–452. 
Altmann, F., Staudacher, E., Wilson, I.B.H., and März, L. (1999). Insect cells as hosts for the 
expression of recombinant glycoproteins. Glycoconj. J. 16, 109–123. 
Andrews, P.W., Knowles, B.B., and Goodfellow, P.N. (1981). A human cell-surface antigen 
defined by a monoclonal antibody and controlled by a gene on chromosome 12. Somatic Cell 
Genet. 7, 435–443. 
Apgar, J.R. (1997). Increased degranulation and phospholipase A 2 , C , and D activity in RBL 
cells stimulated through FcεR1 is due to spreading and not simply adhesion. J. Cell Sci. 110, 
771–780. 
Arpin, M., Chirivino, D., Naba, A., and Zwaenepoel, I. (2011). Emerging role for ERM proteins in 
cell adhesion and migration. Cell Adh. Migr. 5, 199–206. 
Asai, K., Kitaura, J., Kawakami, Y., Yamagata, N., Tsai, M., Carbone, D.P., Liu, F.T., Galli, S.J., and 
Kawakami, T. (2001). Regulation of mast cell survival by IgE. Immunity 14, 791–800. 
Azorsa, D.O., Hyman, J. a, and Hildreth, J.E. (1991). CD63/Pltgp40: a platelet activation antigen 
identical to the stage-specific, melanoma-associated antigen ME491. Blood 78, 280–284. 
Azorsa, D.O., Moog, S., Cazenave, J.P., and Lanza, F. (1999). A general approach to the 
generation of monoclonal antibodies against members of the tetraspanin superfamily using 
recombinant GST fusion proteins. J. Immunol. Methods 229, 35–48. 
Balbás, P. (2001). Understanding the art of producing protein and nonprotein molecules in 
Escherichia coli. Mol. Biotechnol. 19, 251–267. 
Baneyx, F. (1999). Recombinant protein expression in Escherichia coli. Curr. Opin. Biotechnol. 
10, 411–421. 
Baneyx, F., and Mujacic, M. (2004). Recombinant protein folding and misfolding in Escherichia 
coli. Nat. Biotechnol. 22, 1399–1408. 
Bari, R., Zhang, Y.H., Zhang, F., Wang, N.X., Stipp, C.S., Zheng, J.J., and Zhang, X. a (2009). 
Transmembrane interactions are needed for KAI1/CD82-mediated suppression of cancer 
invasion and metastasis. Am. J. Pathol. 174, 647–660. 
Barnes, L.M., Bentley, C.M., and Dickson, A.J. (2003). Stability of protein production from 
recombinant mammalian cells. Biotechnol. Bioeng. 81, 631–639. 
Barreiro, O., Yáñez-Mó, M., Sala-Valdés, M., Gutiérrez-López, M.D., Ovalle, S., Higginbottom, 
A., Monk, P.N., Cabañas, C., and Sánchez-Madrid, F. (2005). Endothelial tetraspanin 
microdomains regulate leukocyte firm adhesion during extravasation. Blood 105, 2852–2861. 
Barreiro, O., Zamai, M., Yáñez-Mó, M., Tejera, E., López-Romero, P., Monk, P.N., Gratton, E., 
Caiolfa, V.R., and Sánchez-Madrid, F. (2008). Endothelial adhesion receptors are recruited to 
Chapter 6: General discussion and future direction 
182 
  
adherent leukocytes by inclusion in preformed tetraspanin nanoplatforms. J. Cell Biol. 183, 
527–542. 
Bausinger, H., Lipsker, D., Ziylan, U., Manié, S., Briand, J.P., Cazenave, J.P., Muller, S., Haeuw, 
J.F., Ravanat, C., de la Salle, H., et al. (2002). Endotoxin-free heat-shock protein 70 fails to 
induce APC activation. Eur. J. Immunol. 32, 3708–3713. 
Beaven, M. a. (2009). Our perception of the mast cell from Paul Ehrlich to now. Eur. J. 
Immunol. 39, 11–25. 
Beckwith, K. a., Byrd, J.C., and Muthusamy, N. (2015). Tetraspanins as therapeutic targets in 
hematological malignancy: a concise review. Front. Physiol. 6, 1–13. 
Berditchevski, F., and Odintsova, E. (2007). Tetraspanins as regulators of protein trafficking. 
Traffic 8, 89–96. 
Berditchevski, F., Bazzoni, G., and Hemler, M.E. (1995). Specific association of CD63 with the 
VLA-3 and VLA-6 integrins. J. Biol. Chem. 270, 17784–17790. 
Berditchevski, F., Gilbert, E., Griffiths, M.R., Fitter, S., Ashman, L., and Jenner, S.J. (2001). 
Analysis of the CD151∙α3β1 Integrin and CD151∙Tetraspanin Interactions by Mutagenesis. J. 
Biol. Chem. 276, 41165–41174. 
Berditchevski, F., Odintsova, E., Sawada, S., and Gilbert, E. (2002). Expression of the 
palmitoylation-deficient CD151 weakens the association of alpha 3 beta 1 integrin with the 
tetraspanin-enriched microdomains and affects integrin-dependent signaling. J. Biol. Chem. 
277, 36991–37000. 
Bessette, P.H., Aslund, F., Beckwith, J., and Georgiou, G. (1999). Efficient folding of proteins 
with multiple disulfide bonds in the Escherichia coli cytoplasm. Proc. Natl. Acad. Sci. U. S. A. 96, 
13703–13708. 
Bieneman, A.P., Chichester, K.L., Chen, Y.H., and Schroeder, J.T. (2005). Toll-like receptor 2 
ligands activate human basophils for both IgE-dependent and IgE-independent secretion. J. 
Allergy Clin. Immunol. 115, 295–301. 
Blank, U., Falcone, F.H., and Nilsson, G. (2013). The history of mast cell and basophil research - 
Some lessons learnt from the last century. Allergy Eur. J. Allergy Clin. Immunol. 68, 1093–1101. 
Boddey, J. a., Day, C.J., Flegg, C.P., Ulrich, R.L., Stephens, S.R., Beacham, I.R., Morrison, N. a., 
and Peak, I.R. a (2007). The bacterial gene lfpA influences the potent induction of calcitonin 
receptor and osteoclast-related genes in Burkholderia pseudomallei-induced TRAP-positive 
multinucleated giant cells. Cell. Microbiol. 9, 514–531. 
Boesze-Battaglia, K., Goldberg, A.F.X., Dispoto, J., Katragadda, M., Cesarone, G., and Albert, 
A.D. (2003). A soluble peripherin/Rds C-terminal polypeptide promotes membrane fusion and 
changes conformation upon membrane association. Exp. Eye Res. 77, 505–514. 
Boon, C.J.F., den Hollander, A.I., Hoyng, C.B., Cremers, F.P.M., Klevering, B.J., and Keunen, 
J.E.E. (2008). The spectrum of retinal dystrophies caused by mutations in the peripherin/RDS 
gene. Prog. Retin. Eye Res. 27, 213–235. 
Borriello, F., Granata, F., Varricchi, G., Genovese, A., Triggiani, M., and Marone, G. (2014). 
Immunopharmacological modulation of mast cells. Curr. Opin. Pharmacol. 17C, 45–57. 
Boucheix, C., and Rubinstein, E. (2001). Tetraspanins. C. Cell. Mol. Life Sci. 58, 1189–1205. 
Boucheix, C., Benoit, P., Frachet, P., Billard, M., Worthington, R.E., Gagnon, J., and Uzan, G. 
(1991). Molecular cloning of the CD9 antigen: A new family of cell surface proteins. J. Biol. 
Chem. 266, 117–122. 
Bradford, M.M. (1976). A rapid and sensitive method for the quantitation of microgram 
quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72, 248–254. 
Brandt, E.B., Strait, R.T., Hershko, D., Wang, Q., Muntel, E.E., Scribner, T. a, Zimmermann, N., 
Chapter 6: General discussion and future direction 
183 
  
Finkelman, F.D., and Rothenberg, M.E. (2003). Mast cells are required for experimental oral 
allergen – induced diarrhea. J. Clin. Invest. 112. 
Brinkmann, U., Mattes, R.E., and Buckel, P. (1989). High-level expression of recombinant genes 
in Escherichia coli is dependent on the availability of the dnaY gene product. Gene 85, 109–
114. 
Britain, G., Reserved, A.R., and Press, P. (1991). Production Scale Insect Cell Culture. 
Biotechnol. Adv. 9, 51–58. 
Brown, M. a, Pierce, J.H., Watson, C.J., Falco, J., Ihle, J.N., and Paul, W.E. (1987). B cell 
stimulatory factor-1/interleukin-4 mRNA is expressed by normal and transformed mast cells. 
Cell 50, 809–818. 
Buchner, J., and Rudolph, R. (1991). Routes to active proteins from transformed 
microorganisms. Curr. Opin. Biotechnol. 2, 532–538. 
Cannon, K.S., and Cresswell, P. (2001). Quality control of transmembrane domain assembly in 
the tetraspanin CD82. EMBO J. 20, 2443–2453. 
Cao, S.S., and Kaufman, R.J. (2012). Unfolded protein response. Curr. Biol. 22, R622–R626. 
Carrió, M.M., and Villaverde,  a. (2002). Construction and deconstruction of bacterial inclusion 
bodies. J. Biotechnol. 96, 3–12. 
Caughey, G.H. (2007). Mast cell tryptases and chymases in inflammation and host defense. 
Immunol. Rev. 217, 141–154. 
Chang, T.W. (2000). The pharmacological basis of anti-IgE therapy. Nat. Biotechnol. 18, 157–
162. 
Charrin, S., Manié, S., Oualid, M., Billard, M., Boucheix, C., and Rubinstein, E. (2002). 
Differential stability of tetraspanin/tetraspanin interactions: role of palmitoylation. FEBS Lett. 
516, 139–144. 
Charrin, S., Manié, S., Billard, M., Ashman, L., Gerlier, D., Boucheix, C., and Rubinstein, E. 
(2003a). Multiple levels of interactions within the tetraspanin web. Biochem. Biophys. Res. 
Commun. 304, 107–112. 
Charrin, S., Manié, S., Thiele, C., Billard, M., Gerlier, D., Boucheix, C., and Rubinstein, E. 
(2003b). A physical and functional link between cholesterol and tetraspanins. Eur. J. Immunol. 
33, 2479–2489. 
Charrin, S., le Naour, F., Silvie, O., Milhiet, P.-E., Boucheix, C., and Rubinstein, E. (2009). Lateral 
organization of membrane proteins: tetraspanins spin their web. Biochem. J. 420, 133–154. 
Charrin, S., Jouannet, S., Boucheix, C., and Rubinstein, E. (2014). Tetraspanins at a glance. J. 
Cell Sci. 1–8. 
Chen, E.H., Grote, E., Mohler, W., and Vignery, A. (2007). Cell-cell fusion. FEBS Lett. 581, 2181–
2193. 
Choi, J.H., and Lee, S.Y. (2004). Secretory and extracellular production of recombinant proteins 
using Escherichia coli. Appl. Microbiol. Biotechnol. 64, 625–635. 
Claas, C., Stipp, C.S., and Hemler, M.E. (2001). Evaluation of Prototype Transmembrane 4 
Superfamily Protein Complexes and Their Relation to Lipid Rafts. J. Biol. Chem. 276, 7974–
7984. 
Clarke, G., Goldberg,  a F., Vidgen, D., Collins, L., Ploder, L., Schwarz, L., Molday, L.L., Rossant, 
J., Szél,  a, Molday, R.S., et al. (2000). Rom-1 is required for rod photoreceptor viability and the 
regulation of disk morphogenesis. Nat. Genet. 25, 67–73. 
Crew, V.K., Burton, N., Kagan, A., Green, C. a., Levene, C., Flinter, F., Brady, R.L., Daniels, G., 
and Anstee, D.J. (2004). CD151, the first member of the tetraspanin (TM4) superfamily 
Chapter 6: General discussion and future direction 
184 
  
detected on erythrocytes, is essential for the correct assembly of human basement 
membranes in kidney and skin. Blood 104, 2217–2223. 
Curti, E., Kwityn, C., Zhan, B., Gillespie, P., Brelsford, J., Deumic, V., Plieskatt, J., Rezende, W.C., 
Tsao, E., Kalampanayil, B., et al. (2013). Expression at a 20L scale and purification of the 
extracellular domain of the Schistosoma mansoni TSP-2 recombinant protein: A vaccine 
candidate for human intestinal schistosomiasis. Hum. Vaccines Immunother. 9, 2342–2350. 
Dalton, A.C., and Barton, W. a (2014). Over-expression of secreted proteins from mammalian 
cell lines. Protein Sci. 23, 517–525. 
Damais, C., Jupin, C., Parant, M., and Chedid, L. (1987). Induction of human interleukin-1 
production by polymyxin B. J Immunol Methods 101, 51–56. 
Demain, A.L., and Vaishnav, P. (2009). Production of recombinant proteins by microbes and 
higher organisms. Biotechnol. Adv. 27, 297–306. 
Deng, J., Yeung, V.P., Tsitoura, D., DeKruyff, R.H., Umetsu, D.T., and Levy, S. (2000). Allergen-
induced airway hyperreactivity is diminished in CD81-deficient mice. J. Immunol. 165, 5054–
5061. 
DeSalle, R., Mares, R., and Garcia-España, A. (2010). Evolution of cysteine patterns in the large 
extracellular loop of tetraspanins from animals, fungi, plants and single-celled eukaryotes. 
Mol. Phylogenet. Evol. 56, 486–491. 
Dombrowicz, D., Flamand, V., Brigman, K.K., Koller, B.H., and Kinet, J.P. (1993). Abolition of 
anaphylaxis by targeted disruption of the high affinity immunoglobulin E receptor alpha chain 
gene. Cell 75, 969–976. 
Don, R.H., Cox, P.T., Wainwright, B.J., Baker, K., and Mattick, J.S. (1991). “Touchdown” PCR to 
circumvent spurious priming during gene amplification. Nucleic Acids Res. 19, 4008. 
Dornier, E., Coumailleau, F., Ottavi, J.-F., Moretti, J., Boucheix, C., Mauduit, P., Schweisguth, F., 
and Rubinstein, E. (2012). TspanC8 tetraspanins regulate ADAM10/Kuzbanian trafficking and 
promote Notch activation in flies and mammals. J. Cell Biol. 199, 481–496. 
Draber, P., Halova, I., Levi-Schaffer, F., and Draberova, L. (2012). Transmembrane adaptor 
proteins in the high-affinity IgE receptor signaling. Front. Immunol. 2, 1–11. 
Ehrlich, P. (1879). Uber die specifischen granulationen des Blutes. 
El-Agamy, D.S. (2012). Targeting c-kit in the therapy of mast cell disorders: Current update. 
Eur. J. Pharmacol. 690, 1–3. 
Ellerman, D.A., Ha, C., Primakoff, P., Myles, D.G., and Dveksler, G.S. (2003). Direct binding of 
the ligand PSG17 to CD9 requires a CD9 site essential for sperm-egg fusion. Mol. Biol. Cell 14, 
5098–5103. 
Eshhar, Z., Ofarim, M., and Waks, T. (1980). Generation of hybridomas secreting murine 
reaginic antibodies of anti-DNP specificity. J. Immunol. 124, 775–780. 
Espenel, C., Margeat, E., Dosset, P., Arduise, C., Le Grimellec, C., Royer, C.A., Boucheix, C., 
Rubinstein, E., and Milhiet, P.-E. (2008). Single-molecule analysis of CD9 dynamics and 
partitioning reveals multiple modes of interaction in the tetraspanin web. J. Cell Biol. 182, 
765–776. 
Esposito, D., and Chatterjee, D.K. (2006). Enhancement of soluble protein expression through 
the use of fusion tags. Curr. Opin. Biotechnol. 17, 353–358. 
Fanaei, M., Monk, P.N., and Partridge, L.J. (2011). The role of tetraspanins in fusion. Biochem. 
Soc. Trans. 39, 524–528. 
Feigelson, S.W., Grabovsky, V., Shamri, R., Levy, S., and Alon, R. (2003). The CD81 Tetraspanin 
Facilitates Instantaneous Leukocyte VLA-4 Adhesion Strengthening to Vascular Cell Adhesion 
Molecule 1 (VCAM-1) under Shear Flow. J. Biol. Chem. 278, 51203–51212. 
Chapter 6: General discussion and future direction 
185 
  
Ferrer, M., Chernikova, T.N., Timmis, K.N., and Golyshin, P.N. (2004). Expression of a 
Temperature-Sensitive Esterase in a Novel Chaperone-Based Escherichia coli Strain Expression 
of a Temperature-Sensitive Esterase in a Novel Chaperone-Based Escherichia coli Strain. 70, 
4499–4504. 
Field, K.A., Holowka, D., and Baird, B. (1995). Fc epsilon RI-mediated recruitment of p53/56lyn 
to detergent-resistant membrane domains accompanies cellular signaling. Proc. Natl. Acad. 
Sci. 92, 9201–9205. 
Finn, G.K., Kurz, B.W., Cheng, R.Z., and Shmookler Reis, R.J. (1989). Homologous plasmid 
recombination is elevated in immortally transformed cells. Mol. Cell. Biol. 9, 4009–4017. 
Fleming, T.J., Donnadieu, E., Song, C.H., Laethem, F. Van, Galli, S.J., and Kinet, J.-P. (1997). 
Negative Regulation of FcεRI-mediated  Degranulation by CD81. J. Exp. Med. 186, 1307–1314. 
Flint, M., von Hahn, T., Zhang, J., Farquhar, M., Jones, C.T., Balfe, P., Rice, C.M., and McKeating, 
J. a (2006). Diverse CD81 proteins support hepatitis C virus infection. J. Virol. 80, 11331–11342. 
Foster, L.J., De Hoog, C.L., and Mann, M. (2003). Unbiased quantitative proteomics of lipid 
rafts reveals high specificity for signaling factors. Proc. Natl. Acad. Sci. U. S. A. 100, 5813–5818. 
Galli, S.J., Nakae, S., and Tsai, M. (2005). Mast cells in the development of adaptive immune 
responses. Nat. Immunol. 6, 135–142. 
Gao, B., and Tsan, M.-F. (2003). Endotoxin contamination in recombinant human heat shock 
protein 70 (Hsp70) preparation is responsible for the induction of tumor necrosis factor alpha 
release by murine macrophages. J. Biol. Chem. 278, 174–179. 
Garman, S.C., Kinet, J.P., and Jardetzky, T.S. (1998). Crystal structure of the human high-affinity 
IgE receptor. Cell 95, 951–961. 
Gartlan, K.H., Wee, J.L., Demaria, M.C., Nastovska, R., Chang, T.M., Jones, E.L., Apostolopoulos, 
V., Pietersz, G. a, Hickey, M.J., van Spriel, A.B., et al. (2013). Tetraspanin CD37 contributes to 
the initiation of cellular immunity by promoting dendritic cell migration. Eur. J. Immunol. 43, 
1208–1219. 
Genovese,  a., Bouvet, J.P., Florio, G., Lamparter-Schummert, B., Bjorck, L., and Marone, G. 
(2000). Bacterial immunoglobulin superantigen proteins A and L activate human heart mast 
cells by interacting with immunoglobulin E. Infect. Immun. 68, 5517–5524. 
Ghildyal, N., Mcneil, H.P., Gurish, M.F., Austen, K.F., and Stevens, R.L. (1992). Transcriptional 
Regulation of the Mucosal Mast Cell-specific Protease Gene, MMCP-8,. Mol. Biol. 267, 8473–
8477. 
Gorman, C.M., Howard, B.H., and Reeves, R. (1983). Expression of recombinant plasmids in 
mammalian cells is enhanced by sodium butyrate. Nucleic Res. 1, 7631–7648. 
Green, L.R., Monk, P.N., Partridge, L.J., Morris, P., Gorringe, A.R., and Read, R.C. (2011). 
Cooperative role for tetraspanins in adhesin-mediated attachment of bacterial species to 
human epithelial cells. Infect. Immun. 79, 2241–2249. 
Greenfield, N. (2007). Using circular dichroism spectra to estimate protein secondary 
structure. Nat. Protoc. 1, 2876–2890. 
Guan, K.L., and Dixon, J.E. (1991). Eukaryotic proteins expressed in Escherichia coli: an 
improved thrombin cleavage and purification procedure of fusion proteins with glutathione S-
transferase. Anal. Biochem. 192, 262–267. 
Gurish, M.F., and Boyce, J. a. (2006). Mast cells: Ontogeny, homing, and recruitment of a 
unique innate effector cell. J. Allergy Clin. Immunol. 117, 1285–1291. 
Guruprasad, K., Reddy, B. V, and Pandit, M.W. (1990). Correlation between stability of a 
protein and its dipeptide composition: a novel approach for predicting in vivo stability of a 
protein from its primary sequence. Protein Eng. 4, 155–161. 
Chapter 6: General discussion and future direction 
186 
  
Hamawy, M.M., Oliver, C., Mergenhagen, S.E., and Siraganian, R.P. (1992). Adherence of rat 
basophilic leukemia (RBL-2H3) cells to fibronectin-coated surfaces enhances secretion. J. 
Immunol. 149, 615–621. 
Harvima, I.T., Levi-Schaffer, F., Draber, P., Friedman, S., Polakovicova, I., Gibbs, B.F., Blank, U., 
Nilsson, G., and Maurer, M. (2014). Molecular targets on mast cells and basophils for novel 
therapies. J. Allergy Clin. Immunol. 134, 530–544. 
Hassuna, N., Monk, P.N., Moseley, G.W., and Partridge, L.J. (2009). Strategies for targeting 
tetraspanin proteins: potential therapeutic applications in microbial infections. BioDrugs 23, 
341–359. 
Hemler, M.E. (1990). VLA proteins in the integrin family: structures, functions, and their role 
on leukocytes. Annu. Rev. Immunol. 8, 365–400. 
Hemler, M.E. (2001). Specific tetraspanin functions. J. Cell Biol. 155, 1103–1107. 
Hemler, M.E. (2003). Tetraspanin proteins mediate cellular penetration, invasion, and fusion 
events and define a novel type of membrane microdomain. Annu. Rev. Cell Dev. Biol. 19, 397–
422. 
Hemler, M.E. (2005). Tetraspanin functions and associated microdomains. Nat. Rev. Mol. Cell 
Biol. 6, 801–811. 
Hemler, M.E. (2008). Targeting of tetraspanin proteins--potential benefits and strategies. Nat. 
Rev. Drug Discov. 7, 747–758. 
Hemler, M.E. (2013). Tetraspanin proteins promote multiple cancer stages. Nat. Rev. Cancer 
14, 49–60. 
Henz, B.M., Maurer, M., Lippert, U., Worm, M., and Babina, M. (2001). Mast cells as initiators 
of immunity and host defense. Exp. Dermatol. 10, 1–10. 
Higginbottom,  a, Wilkinson, I., McCullough, B., Lanza, F., Azorsa, D.O., Partridge, L.J., and 
Monk, P.N. (2000a). Antibody cross-linking of human CD9 and the high-affinity 
immunoglobulin E receptor stimulates secretion from transfected rat basophilic leukaemia 
cells. Immunology 99, 546–552. 
Higginbottom, A., Quinn, E.R., Kuo, C.C., Flint, M., Wilson, L.H., Bianchi, E., Nicosia, A., Monk, 
P.N., McKeating, J. a, and Levy, S. (2000b). Identification of amino acid residues in CD81 critical 
for interaction with hepatitis C virus envelope glycoprotein E2. J. Virol. 74, 3642–3649. 
Higginbottom, A., Takahashi, Y., Bolling, L., Coonrod, S. a., White, J.M., Partridge, L.J., and 
Monk, P.N. (2003). Structural requirements for the inhibitory action of the CD9 large 
extracellular domain in sperm/oocyte binding and fusion. Biochem. Biophys. Res. Commun. 
311, 208–214. 
Ho, S.-H., Martin, F., Higginbottom, A., Partridge, L.J., Parthasarathy, V., Moseley, G.W., Lopez, 
P., Cheng-Mayer, C., and Monk, P.N. (2006). Recombinant extracellular domains of tetraspanin 
proteins are potent inhibitors of the infection of macrophages by human immunodeficiency 
virus type 1. J. Virol. 80, 6487–6496. 
Ho, S.N., Hunt, H.D., Horton, R.M., Pullen, J.K., and Pease, L.R. (1989). Site-directed 
mutagenesis by overlap extension using the polymerase chain reaction. Gene 77, 51–59. 
Hogue, I.B., Grover, J.R., Soheilian, F., Nagashima, K., and Ono, A. (2011). Gag Induces the 
Coalescence of Clustered Lipid Rafts and Tetraspanin-Enriched Microdomains at HIV-1 
Assembly Sites on the Plasma Membrane. J. Virol. 85, 9749–9766. 
Hong, H., Kitaura, J., Xiao, W., Horejsi, V., Ra, C., Lowell, C. a, Kawakami, Y., and Kawakami, T. 
(2007). The Src family kinase Hck regulates mast cell activation by suppressing an inhibitory Src 
family kinase Lyn. Blood 110, 2511–2519. 
Hotta, H., Ross, A.H., Huebner, K., Isobe, M., Wendeborn, S., Chao, M. V, Ricciardi, R.P., 
Chapter 6: General discussion and future direction 
187 
  
Tsujimoto, Y., Croce, C.M., and Koprowski, H. (1988). Molecular Cloning and Characterization 
of an Antigen Associated with Early Stages of Melanoma Tumor Progression. Cancer Reseach 
48, 2955–2962. 
Huang, M.M., Indik, Z., Brass, L.F., Hoxie, J. a, Schreiber,  a D., and Brugge, J.S. (1992). 
Activation of Fc gamma RII induces tyrosine phosphorylation of multiple proteins including Fc 
gamma RII. J. Biol. Chem. 267, 5467–5473. 
Huang, S., Yuan, S., Dong, M., Su, J., Yu, C., Shen, Y., Xie, X., Yu, Y., Yu, X., Chen, S., et al. (2005). 
The phylogenetic analysis of tetraspanins projects the evolution of cell-cell interactions from 
unicellular to multicellular organisms. Genomics 86, 674–684. 
Huang, S., Tian, H., Chen, Z., Yu, T., and Xu, A. (2010). The evolution of vertebrate tetraspanins: 
gene loss, retention, and massive positive selection after whole genome duplications. BMC 
Evol. Biol. 10, 306. 
Hulme, R.S., Higginbottom, A., Palmer, J., Partridge, L.J., and Monk, P.N. (2014). Distinct 
Regions of the Large Extracellular Domain of Tetraspanin CD9 Are Involved in the Control of 
Human Multinucleated Giant Cell Formation. PLoS One 9, e116289. 
Hynes, R.O. (1992). Integrins: versatility, modulation, and signaling in cell adhesion. Cell 69, 
11–25. 
Irani,  a a, Schechter, N.M., Craig, S.S., DeBlois, G., and Schwartz, L.B. (1986). Two types of 
human mast cells that have distinct neutral protease compositions. Proc. Natl. Acad. Sci. U. S. 
A. 83, 4464–4468. 
Ishizaka, K., Ishizaka, T., and Alerts, E. (1967). Identification of γ E-Antibodies as a Carrier of 
Reaginic Activity. J. Immunol. 99, 1187–1198. 
Ishizaka, K., Tomioka, H., and Ishizaka, T. (1970). Mechanisms of passive sensitization. I. 
Presence of IgE and IgG molecules on human leukocytes. J. Immunol. 105, 1459–1467. 
Iwai, K., Ishii, M., Ohshima, S., Miyatake, K., and Saeki, Y. (2007). Expression and function of 
transmembrane-4 superfamily (tetraspanin) proteins in osteoclasts: reciprocal roles of Tspan-5 
and NET-6 during osteoclastogenesis. Allergol. Int. 56, 457–463. 
Jamshad, M., Rajesh, S., Stamataki, Z., McKeating, J. a, Dafforn, T., Overduin, M., and Bill, R.M. 
(2008). Structural characterization of recombinant human CD81 produced in Pichia pastoris. 
Protein Expr. Purif. 57, 206–216. 
Jankowski, S.A., Mitchell, D.S., Smith, S.H., Trent, J.M., and Meltzer, P.S. (1994). SAS, a gene 
amplified in human sarcomas, encodes a new member of the transmembrane 4 superfamily of 
proteins. Oncogene 9, 1205–1211. 
Jayapal, K., Wlaschin, K., Hu, W., and Yap, G. (2007). Recombinant protein therapeutics from 
CHO cells-20 years and counting. Chem. Eng. Prog. 103, 40–47. 
Jegou, A., Ziyyat, A., Barraud-Lange, V., Perez, E., Wolf, J.P., Pincet, F., and Gourier, C. (2011). 
CD9 tetraspanin generates fusion competent sites on the egg membrane for mammalian 
fertilization. Proc. Natl. Acad. Sci. 108, 10946–10951. 
Jenkins, N., and Curling, E.M. a (1994). Glycosylation of recombinant proteins: Problems and 
prospects. Enzyme Microb. Technol. 16, 354–364. 
Joly, J.C., and Swartz, J.R. (1994). Protein folding activities of Escherichia coli protein disulfide 
isomerase. Biochemistry 33, 4231–4236. 
Jung, K.-K., Liu, X.-W., Chirco, R., Fridman, R., and Kim, H.-R.C. (2006). Identification of CD63 as 
a tissue inhibitor of metalloproteinase-1 interacting cell surface protein. EMBO J. 25, 3934–
3942. 
Junge, H.J., Yang, S., Burton, J.B., Paes, K., Shu, X., French, D.M., Costa, M., Rice, D.S., and Ye, 
W. (2009). TSPAN12 Regulates Retinal Vascular Development by Promoting Norrin- but Not 
Chapter 6: General discussion and future direction 
188 
  
Wnt-Induced FZD4/??-Catenin Signaling. Cell 139, 299–311. 
Kaji, K., Oda, S., Shikano, T., Ohnuki, T., Uematsu, Y., Sakagami, J., Tada, N., Miyazaki, S., and 
Kudo,  a (2000). The gamete fusion process is defective in eggs of Cd9-deficient mice. Nat. 
Genet. 24, 279–282. 
Kalesnikoff, J., Huber, M., Lam, V., Damen, J.E., Zhang, J., Siraganian, R.P., and Krystal, G. 
(2001). Pathways in Mast Cells that Lead to Cytokine Production and Cell Survival. 14, 801–
811. 
Kaplan, W., Hüsler, P., Klump, H., Erhardt, J., Sluis-Cremer, N., and Dirr, H. (1997). 
Conformational stability of pGEX-expressed Schistosoma japonicum glutathione S-transferase: 
a detoxification enzyme and fusion-protein affinity tag. Protein Sci. 6, 399–406. 
Kato, N., Nakanishi, M., and Hirashima, N. (2003). Cholesterol depletion inhibits store-
operated calcium currents and exocytotic membrane fusion in RBL-2H3 cells. Biochemistry 42, 
11808–11814. 
Kawakami, T., and Galli, S.J. (2002). Regulation of mast-cell and basophil function and survival 
by IgE. Nat. Rev. Immunol. 2, 773–786. 
Kazarov, A.R., Yang, X., Stipp, C.S., Sehgal, B., and Hemler, M.E. (2002). An extracellular site on 
tetraspanin CD151 determines α3 and α6 integrin-dependent cellular morphology. J. Cell Biol. 
158, 1299–1309. 
Kelid, S., Levy, S., Suarez, C., and Weinstein, D.E. (2001). CD81 regulates neuron-induced 
astrocyte cell-cycle exit. Mol. Cell. Neurosci. 17, 551–560. 
Kelly, S.M., Jess, T.J., and Price, N.C. (2005). How to study proteins by circular dichroism. 
Biochim. Biophys. Acta 1751, 119–139. 
Kespichayawattana, W., Rattanachetkul, S., Wanun, T., Utaisincharoen, P., and Sirisinha, S. 
(2000). Burkholderia pseudomallei induces cell fusion and actin-associated membrane 
protrusion: A possible mechanism for cell-to-cell spreading. Infect. Immun. 68, 5377–5384. 
Kim, J., Cleich, G.J., and Kita, H. (1997). Roles of CD9 Molecules in Survival and Activation of 
Human Eosinophils. Culture 7. 
Kim, J.Y., Kim, Y.G., and Lee, G.M. (2012). CHO cells in biotechnology for production of 
recombinant proteins: Current state and further potential. Appl. Microbiol. Biotechnol. 93, 
917–930. 
Kitadokoro, K., Bordo, D., Galli, G., Petracca, R., Falugi, F., Abrignani, S., Grandi, G., and 
Bolognesi, M. (2001). CD81 extracellular domain 3D structure: insight into the tetraspanin 
superfamily structural motifs. EMBO J. 20, 12–18. 
Kitani, S., Berenstein, E., Mergenhagen, S., Tempstg, P., and Siraganian, R.P. (1991). A Cell 
Surface Glycoprotein of Rat Basophilic Leukemia Cells Close to the High Affinity IgE Receptor ( 
FcrRI ). J. Biol. Chem. 266, 1903–1909. 
Knol, E.F., Mul, F.P., Jansen, H., Calafat, J., and Roos, D. (1991). Monitoring human basophil 
activation via CD63 monoclonal antibody 435. J. Allergy Clin. Immunol. 88, 328–338. 
Köberle, M., Kaesler, S., Kempf, W., Wölbing, F., and Biedermann, T. (2012). Tetraspanins in 
mast cells. Front. Immunol. 3, 106. 
Kohno, M., Hasegawa, H., Miyake, M., Yamamoto, T., and Fujita, S. (2002). CD151 enhances 
cell motility and metastasis of cancer cells in the presence of focal adhesion kinase. Int. J. 
Cancer 97, 336–343. 
Kopito, R.R. (2000). Aggresomes, inclusion bodies and protein aggregation. Trends Cell Biol. 10, 
524–530. 
Kovalenko, O. V, Yang, X., Kolesnikova, T. V, and Hemler, M.E. (2004). Evidence for specific 
tetraspanin homodimers: inhibition of palmitoylation makes cysteine residues available for 
Chapter 6: General discussion and future direction 
189 
  
cross-linking. Biochem. J. 377, 407–417. 
Kovalenko, O. V, Metcalf, D.G., DeGrado, W.F., and Hemler, M.E. (2005). Structural 
organization and interactions of transmembrane domains in tetraspanin proteins. BMC Struct. 
Biol. 5, 11. 
Kraft, S., Fleming, T., Billingsley, J.M., Lin, S.-Y., Jouvin, M.-H., Storz, P., and Kinet, J.-P. (2005). 
Anti-CD63 antibodies suppress IgE-dependent allergic reactions in vitro and in vivo. J. Exp. 
Med. 201, 385–396. 
Kraft, S., Jouvin, M.-H., Kulkarni, N., Kissing, S., Morgan, E.S., Dvorak, A.M., Schröder, B., Saftig, 
P., and Kinet, J.-P. (2013). The Tetraspanin CD63 Is Required for Efficient IgE-Mediated Mast 
Cell Degranulation and Anaphylaxis. J. Immunol. 
Krämer, B., Schulte, D., Körner, C., Zwank, C., Hartmann, A., Michalk, M., Söhne, J., Langhans, 
B., Nischalke, H.-D., Coenen, M., et al. (2009). Regulation of NK cell trafficking by CD81. Eur. J. 
Immunol. 39, 3447–3458. 
Kropshofer, H., Spindeldreher, S., Röhn, T. a, Platania, N., Grygar, C., Daniel, N., Wölpl,  a, 
Langen, H., Horejsi, V., and Vogt,  a B. (2002). Tetraspan microdomains distinct from lipid rafts 
enrich select peptide-MHC class II complexes. Nat. Immunol. 3, 61–68. 
Kulczycki, A., Isersky, C., and Metzger, H. (1974). The interaction of IgE with rat basophilic 
leukemia cells. I. Evidence for specific binding of IgE. J. Exp. Med. 139, 600–616. 
Kulka, M., Sheen, C.H., Tancowny, B.P., Grammer, L.C., and Schleimer, R.P. (2008). 
Neuropeptides activate human mast cell degranulation and chemokine production. 
Immunology 123, 398–410. 
Kunder, C. a, St John, A.L., Li, G., Leong, K.W., Berwin, B., Staats, H.F., and Abraham, S.N. 
(2009). Mast cell-derived particles deliver peripheral signals to remote lymph nodes. J. Exp. 
Med. 206, 2455–2467. 
Kurokawa, Y., Yanagi, H., and Yura, T. (2000). Overexpression of protein disulfide isomerase 
DsbC stabilizes multiple-disulfide-bonded recombinant protein produced and transported to 
the periplasm in Escherichia coli. Appl. Environ. Microbiol. 66, 3960–3965. 
Lammerding, J., Kazarov, A.R., Huang, H., Lee, R.T., and Hemler, M.E. (2003). Tetraspanin 
CD151 regulates 6 1 integrin adhesion strengthening. Proc. Natl. Acad. Sci. 100, 7616–7621. 
Larrick, J.W., and Thomas, D.W. (2001). Producing proteins in transgenic plants and animals. 
Curr. Opin. Biotechnol. 12, 411–418. 
Latysheva, N., Muratov, G., Rajesh, S., Padgett, M., Hotchin, N. a, Overduin, M., and 
Berditchevski, F. (2006). Syntenin-1 is a new component of tetraspanin-enriched 
microdomains: mechanisms and consequences of the interaction of syntenin-1 with CD63. 
Mol. Cell. Biol. 26, 7707–7718. 
Lee, J.H., Kim, J.W., Kim, D.K., Kim, H.S., Park, H.J., Park, D.K., Kim, A.-R., Kim, B., Beaven, M. a, 
Park, K.L., et al. (2011). The Src family kinase Fgr is critical for activation of mast cells and IgE-
mediated anaphylaxis in mice. J. Immunol. 187, 1807–1815. 
Levy, R., Weiss, R., Chen, G., Iverson, B.L., and Georgiou, G. (2001). Production of correctly 
folded Fab antibody fragment in the cytoplasm of Escherichia coli trxB gor mutants via the 
coexpression of molecular chaperones. Protein Expr. Purif. 23, 338–347. 
Lin, S., Cicala, C., Scharenberg, A.M., and Kinet, J.P. (1996). The FceRI beta subunit functions as 
an amplifier of FceRI gamma-mediated cell activation signals. Cell 85, 985–995. 
von Lindern, J.J., Rojo, D., Grovit-Ferbas, K., Yeramian, C., Deng, C., Herbein, G., Ferguson, 
M.R., Pappas, T.C., Decker, J.M., Singh, A., et al. (2003). Potential Role for CD63 in CCR5-
Mediated Human Immunodeficiency Virus Type 1 Infection of Macrophages. J. Virol. 77, 3624–
3633. 
Chapter 6: General discussion and future direction 
190 
  
Lineberry, N., Su, L., Soares, L., and Fathman, C.G. (2008). The single subunit transmembrane 
E3 ligase gene related to anergy in lymphocytes (GRAIL) captures and then ubiquitinates 
transmembrane proteins across the cell membrane. J. Biol. Chem. 283, 28497–28505. 
Lipski, S., Grabbe, J., and Henz, B.M. (1996). Absence of MHC class II antigen on mast cells at 
sites of inflammation in human skin. Exp. Dermatol. 5, 120–124. 
Liu, L., He, B., Liu, W.M., Zhou, D., Cox, J. V, and Zhang, X. a (2007). Tetraspanin CD151 
promotes cell migration by regulating integrin trafficking. J. Biol. Chem. 282, 31631–31642. 
Loewen, C.J.R., and Molday, R.S. (2000). Disulfide-mediated Oligomerization of Peripherin / 
Rds and Rom-1 in Photoreceptor Disk Membranes. J. Biol. Chem. 275, 5370–5378. 
Macauley-Patrick, S., Fazenda, M.L., McNeil, B., and Harvey, L.M. (2005). Heterologous protein 
production using the Pichia pastoris expression system. Yeast 22, 249–270. 
Maecker, H.T., Todd, S.C., and Levy, S. (1997). The tetraspanin superfamily: molecular 
facilitators. FASEB J. 11, 428–442. 
Malaviya, R., Twesten, N.J., Ross, E. a, Abraham, S.N., and Pfeifer, J.D. (1996). Mast cells 
process bacterial Ags through a phagocytic route for class I MHC presentation to T cells. J. 
Immunol. 156, 1490–1496. 
Malaviya, R., Gao, Z., Thankavel, K., van der Merwe, P. a, and Abraham, S.N. (1999). The mast 
cell tumor necrosis factor alpha response to FimH-expressing Escherichia coli is mediated by 
the glycosylphosphatidylinositol-anchored molecule CD48. Proc. Natl. Acad. Sci. U. S. A. 96, 
8110–8115. 
Mamat, U., Wilke, K., Bramhill, D., Schromm, A.B., Lindner, B., Kohl, T.A., Corchero, J.L., 
Villaverde, A., Schaffer, L., Head, S.R., et al. (2015). Detoxifying Escherichia coli for endotoxin-
free production of recombinant proteins. Microb. Cell Fact. 14, 1–15. 
Marbach, A., and Bettenbrock, K. (2012). Lac operon induction in Escherichia coli: Systematic 
comparison of IPTG and TMG induction and influence of the transacetylase LacA. J. Biotechnol. 
157, 82–88. 
Martin, F., Roth, D.M., Jans, D.A., Pouton, C.W., Monk, P.N., Moseley, G.W., and Partridge, L.J. 
(2005). Tetraspanins in Viral Infections : a Fundamental Role in Viral Biology ? J. Virol. 79, 
10839–10851. 
Masciopinto, F., Campagnoli, S., Abrignani, S., Uematsu, Y., and Pileri, P. (2001). The small 
extracellular loop of CD81 is necessary for optimal surface expression of the large loop, a 
putative HCV receptor. Virus Res. 80, 1–10. 
Masciopinto, F., Giovani, C., Campagnoli, S., Galli-Stampino, L., Colombatto, P., Brunetto, M., 
Yen, T.S.B., Houghton, M., Pileri, P., and Abrignani, S. (2004). Association of hepatitis C virus 
envelope proteins with exosomes. Eur. J. Immunol. 34, 2834–2842. 
Metcalfe, D.D. (2008). Mast cells and mastocytosis. Blood 112, 946–956. 
Metcalfe, D., Baram, D., and Mekori, Y. (1997). Mast cells. Physiol. Rev. 77, 1033–1079. 
Metcalfe, D.D., Peavy, R.D., and Gilfillan, A.M. (2009). Mechanisms of mast cell signaling in 
anaphylaxis. J. Allergy Clin. Immunol. 124, 639–646. 
Metz, M., Piliponsky, A.M., Chen, C.-C., Lammel, V., Abrink, M., Pejler, G., Tsai, M., and Galli, 
S.J. (2006). Mast cells can enhance resistance to snake and honeybee venoms. Science 313, 
526–530. 
Miller, B.J., Georges-Labouesse, E., Primakoff, P., and Myles, D.G. (2000). Normal fertilization 
occurs with eggs lacking the integrin ??6??1 and is CD9-dependent. J. Cell Biol. 149, 1289–
1295. 
Min, G., Stolz, M., Zhou, G., Liang, F., Sebbel, P., Stoffler, D., Glockshuber, R., Sun, T.-T., Aebi, 
U., and Kong, X.-P. (2002). Localization of uroplakin Ia, the urothelial receptor for bacterial 
Chapter 6: General discussion and future direction 
191 
  
adhesin FimH, on the six inner domains of the 16 nm urothelial plaque particle. J. Mol. Biol. 
317, 697–706. 
Min, G., Wang, H., Sun, T.-T., and Kong, X.-P. (2006). Structural basis for tetraspanin functions 
as revealed by the cryo-EM structure of uroplakin complexes at 6-A resolution. J. Cell Biol. 173, 
975–983. 
Mol, C.D., Dougan, D.R., Schneider, T.R., Skene, R.J., Kraus, M.L., Scheibe, D.N., Snell, G.P., Zou, 
H., Sang, B.C., and Wilson, K.P. (2004). Structural basis for the autoinhibition and STI-571 
inhibition of c-Kit tyrosine kinase. J. Biol. Chem. 279, 31655–31663. 
Molina, S., Castet, V., Pichard-Garcia, L., Wychowski, C., Meurs, E., Pascussi, J.M., Sureau, C., 
Fabre, J.M., Sacunha, A., Larrey, D., et al. (2008). Serum-derived hepatitis C virus infection of 
primary human hepatocytes is tetraspanin CD81 dependent. J Virol 82, 569–574. 
Monk, P.N., and Partridge, L.J. (2012). Tetraspanins: gateways for infection. Infect. Disord. 
Drug Targets 12, 4–17. 
Moseley, G.W.G. (2005). Tetraspanin-Fc receptor interactions. Platelets 48, 40. 
Moseley, G.W., Elliott, J., Wright, M.D., Partridge, L.J., and Monk, P.N. (2003). Interspecies 
contamination of the KM3 cell line: implications for CD63 function in melanoma metastasis. 
Int. J. Cancer 105, 613–616. 
Muranova, T.A., Ruzheinikov, S.N., Higginbottom, A., Clipson, J.A., Blackburn, G.M., 
Wentworth, P., Datta, A., Rice, D.W., and Partridge, L.J. (2003). Crystallization of a 
carbamatase catalytic antibody Fab fragment and its complex with a transition-state analogue. 
Acta Crystallogr. Sect. D Biol. Crystallogr. 60, 172–174. 
Le Naour, F., Rubinstein, E., Jasmin, C., Prenant, M., and Boucheix, C. (2000). Severely reduced 
female fertility in CD9-deficient mice. Science 287, 319–321. 
Le Naour, F., André, M., Boucheix, C., and Rubinstein, E. (2006). Membrane microdomains and 
proteomics: lessons from tetraspanin microdomains and comparison with lipid rafts. 
Proteomics 6, 6447–6454. 
Di Nardo, A., Vitiello, A., and Gallo, R.L. (2003). Cutting edge: mast cell antimicrobial activity is 
mediated by expression of cathelicidin antimicrobial peptide. J. Immunol. 170, 2274–2278. 
Di Nardo, A., Yamasaki, K., Dorschner, R. a, Lai, Y., and Gallo, R.L. (2008). Mast cell cathelicidin 
antimicrobial peptide prevents invasive group A Streptococcus infection of the skin. J. 
Immunol. 180, 7565–7573. 
Nilsson, G., Johnell, M., Hammer, C.H., Tiffany, H.L., Nilsson, K., Metcalfe, D.D., Siegbahn,  a, 
and Murphy, P.M. (1996). C3a and C5a are chemotaxins for human mast cells and act through 
distinct receptors via a pertussis toxin-sensitive signal transduction pathway. J. Immunol. 157, 
1693–1698. 
Nishikata, H., Oliver, C., Mergenhagen, S.E., and Siraganian, R.P. (1992). The rat mast cell 
antigen AD1 (homologue to human CD63 or melanoma antigen ME491) is expressed in other 
cells in culture. J. Immunol. 149, 862–870. 
Nishizumi, H., and Yamamoto, T. (1997). Impaired tyrosine phosphorylation and Ca2+ 
mobilization, but not degranulation, in lyn-deficient bone marrow-derived mast cells. J. 
Immunol. 158, 2350–2355. 
Ntini, E., Järvelin, A.I., Bornholdt, J., Chen, Y., Boyd, M., Jørgensen, M., Andersson, R., Hoof, I., 
Schein, A., Andersen, P.R., et al. (2013). Polyadenylation site-induced decay of upstream 
transcripts enforces promoter directionality. Nat. Struct. Mol. Biol. 20, 923–928. 
O’Gorman, S., Fox, D.T., and Wahl, G.M. (1991). Recombinase-mediated gene activation and 
site-specific integration in mammalian cells. Science 251, 1351–1355. 
O’Mahony, L., Akdis, M., and Akdis, C. a. (2011). Regulation of the immune response and 
Chapter 6: General discussion and future direction 
192 
  
inflammation by histamine and histamine receptors. J. Allergy Clin. Immunol. 128, 1153–1162. 
Oba, M., and Tanaka, M. (2012). Intracellular Internalization Mechanism of Protein 
Transfection Reagents. Biol. Pharm. Bull. 35, 1064–1068. 
Ono, M., Handa, K., Withers, D. a., and Hakomori, S.I. (1999). Motility inhibition and apoptosis 
are induced by metastasis-suppressing gene product CD82 and its analogue CD9, with 
concurrent glycosylation. Cancer Res. 59, 2335–2339. 
Ono, M., Handa, K., Withers, D. a, and Hakomori, S. (2000). Glycosylation effect on membrane 
domain (GEM) involved in cell adhesion and motility: a preliminary note on functional alpha3, 
alpha5-CD82 glycosylation complex in ldlD 14 cells. Biochem. Biophys. Res. Commun. 279, 
744–750. 
Oren, R., Takahashi, S., Doss, C., Levy, R., and Levy, S. (1990). TAPA-1, the target of an 
antiproliferative antibody, defines a new family of transmembrane proteins. Mol. Cell. Biol. 10, 
4007–4015. 
Ortega, E., Schweitzer-Stenner, R., and Pecht, I. (1991). Kinetics of ligand binding to the type 1 
Fc epsilon receptor on mast cells. Biochemistry 30, 3473–3483. 
Ovalle, S., Guti??rrez-L??pez, M.D., Olmo, N., Turnay, J., Lizarbe, M.A., Majano, P., Molina-
Jim??nez, F., L??pez-Cabrera, M., Y????ez-M??, M., S??nchez-Madrid, F., et al. (2007). The 
tetraspanin CD9 inhibits the proliferation and tumorigenicity of human colon carcinoma cells. 
Int. J. Cancer 121, 2140–2152. 
Pagel, J.M., Spurgeon, S.E., Byrd, J.C., Awan, F.T., Flinn, I.W., Lanasa, M.C., Eisenfeld, A.J., 
Stromatt, S.C., and Gopal, A.K. (2014). Otlertuzumab (TRU-016), an anti-CD37 monospecific 
ADAPTIRTM therapeutic protein, for relapsed or refractory NHL patients. Br. J. Haematol. 1–8. 
Pan, Y., Brown, C., Wang, X., and Geisert, E.E. (2007). The developmental regulation of CD81 in 
the rat retina. Mol. Vis. 13, 181–189. 
Parravicini, V., Gadina, M., Kovarova, M., Odom, S., Gonzalez-Espinosa, C., Furumoto, Y., 
Saitoh, S., Samelson, L.E., O’Shea, J.J., and Rivera, J. (2002). Fyn kinase initiates complementary 
signals required for IgE-dependent mast cell degranulation. Nat. Immunol. 3, 741–748. 
Parthasarathy, V., Martin, F., Higginbottom, A., Murray, H., Moseley, G.W., Read, R.C., Mal, G., 
Hulme, R., Monk, P.N., and Partridge, L.J. (2009). Distinct roles for tetraspanins CD9, CD63 and 
CD81 in the formation of multinucleated giant cells. Immunology 127, 237–248. 
Passante, E., and Frankish, N. (2009). The RBL-2H3 cell line: Its provenance and suitability as a 
model for the mast cell. Inflamm. Res. 58, 737–745. 
Passante, E., Ehrhardt, C., Sheridan, H., and Frankish, N. (2009). RBL-2H3 cells are an imprecise 
model for mast cell mediator release. Inflamm. Res. 58, 611–618. 
Peng, W.M., Yu, C.F., Kolanus, W., Mazzocca,  a, Bieber, T., Kraft, S., and Novak, N. (2011). 
Tetraspanins CD9 and CD81 are molecular partners of trimeric FcɛRI on human antigen-
presenting cells. Allergy 66, 605–611. 
Petracca, R., Falugi, F., Galli, G., Norais, N., Rosa, D., Campagnoli, S., Burgio, V., Di Stasio, E., 
Giardina, B., Houghton, M., et al. (2000). Structure-function analysis of hepatitis C virus 
envelope-CD81 binding. J. Virol. 74, 4824–4830. 
Phizicky, E.M., and Fields, S. (1995). Protein-protein interactions: Methods for detection and 
analysis. Microbiological.Reviews 59, 94–123. 
Pileri, P., Uematsu, Y., Campagnoli, S., Galli, G., Falugi, F., Petracca, R., Weiner,  a J., Houghton, 
M., Rosa, D., Grandi, G., et al. (1998). Binding of hepatitis C virus to CD81. Science 282, 938–
941. 
Piliponsky, A.M., Chen, C.-C., Nishimura, T., Metz, M., Rios, E.J., Dobner, P.R., Wada, E., Wada, 
K., Zacharias, S., Mohanasundaram, U.M., et al. (2008). Neurotensin increases mortality and 
Chapter 6: General discussion and future direction 
193 
  
mast cells reduce neurotensin levels in a mouse model of sepsis. Nat. Med. 14, 392–398. 
Plaut, M., Pierce, J.H., Watson, C.J., Hanley-Hyde, J., Nordan, R.P., and Paul, W.E. (1989). Mast 
cell lines produce lymphokines in response to cross-linkage of Fc epsilon RI or to calcium 
ionophores. Nature 339, 64–67. 
Powner, D., Kopp, P.M., Monkley, S.J., Critchley, D.R., and Berditchevski, F. (2011). Tetraspanin 
CD9 in cell migration. Biochem. Soc. Trans. 39, 563–567. 
Pribluda, V.S., Pribluda, C., and Metzger, H. (1994). Transphosphorylation as the mechanism by 
which the high-affinity receptor for IgE is phosphorylated upon aggregation. Proc. Natl. Acad. 
Sci. U. S. A. 91, 11246–11250. 
Protty, M.B., Watkins, N. a, Colombo, D., Thomas, S.G., Heath, V.L., Herbert, J.M.J., Bicknell, R., 
Senis, Y. a, Ashman, L.K., Berditchevski, F., et al. (2009). Identification of Tspan9 as a novel 
platelet tetraspanin and the collagen receptor GPVI as a component of tetraspanin 
microdomains. Biochem. J. 417, 391–400. 
Qi, J.C., Wang, J., Mandadi, S., Tanaka, K., Roufogalis, B.D., Madigan, M.C., Lai, K., Yan, F., 
Chong, B.H., Stevens, R.L., et al. (2006). Human and mouse mast cells use the tetraspanin CD9 
as an alternate interleukin-16 receptor. Blood 107, 135–142. 
Qi, R., Ozaki, Y., Kuroda, K., Asazuma, N., Yatomi, Y., Satoh, K., Nomura, S., and Kume, S. 
(1996). Differential activation of human platelets induced by Fc gamma receptor II cross-
linking and by anti-CD9 monoclonal antibody. J. Immunol. 157, 5638–5645. 
Qiu, J., Swartz, J.R., and Georgiou, G. (1998). Expression of active human tissue-type 
plasminogen activator in Escherichia coli. Appl. Environ. Microbiol. 64, 4891–4896. 
Rajan, T. V. (2003). The Gell-Coombs classification of hypersensitivity reactions: A re-
interpretation. Trends Immunol. 24, 376–379. 
Rajesh, S., Sridhar, P., Tews, B.A., Fénéant, L., Cocquerel, L., Ward, D.G., Berditchevski, F., and 
Overduin, M. (2012). Structural basis of ligand interactions of the large extracellular domain of 
tetraspanin CD81. J. Virol. 86, 9606–9616. 
Ranjan, A., Bane, S.M., and Kalraiya, R.D. (2014). Glycosylation of the laminin receptor (α3β1) 
regulates its association with tetraspanin CD151: Impact on cell spreading, motility, 
degradation and invasion of basement membrane by tumor cells. Exp. Cell Res. 322, 249–264. 
Reber, L.L., and Frossard, N. (2014). Targeting mast cells in inflammatory diseases. Pharmacol. 
Ther. 142, 416–435. 
Reichelt, P., Schwarz, C., and Donzeau, M. (2006). Single step protocol to purify recombinant 
proteins with low endotoxin contents. Protein Expr. Purif. 46, 483–488. 
Riley, J.F., and West, G.B. (1953). The presence of histamine in tissue mast cells. J. Physiol. 120, 
528–537. 
Robb, L., Tarrant, J., Groom, J., Ibrahim, M., Li, R., Borobakas, B., and Wright, M.D. (2001). 
Molecular characterisation of mouse and human TSSC6: evidence that TSSC6 is a genuine 
member of the tetraspanin superfamily and is expressed specifically in haematopoietic organs. 
Biochim. Biophys. Acta 1522, 31–41. 
Roberts, L.J., Lewis, R.A., Oates, J.A., and Austen, K.F. (1979). Prostaglandin thromboxane, and 
12-hydroxy-5,8,10,14-eicosatetraenoic acid production by ionophore-stimulated rat serosal 
mast cells. Biochim. Biophys. Acta 575, 185–192. 
Rous, B.A.B., Reaves, B.B.J., Ihrke, G., Briggs, J.A.G., Gray, S.R., Stephens, D.J., Banting, G., and 
Luzio, J.P. (2002). Role of adaptor complex AP-3 in targeting wild-type and mutated CD63 to 
lysosomes. Mol. Biol. Cell 13, 1071–1082. 
Rubinstein, E., Naour, F. Le, Lagaudrière-Gesbert, C., Billard, M., Conjeaud, H., and Boucheix, C. 
(1996). CD9, CD63, CD81, and CD82 are components of a surface tetraspan network connected 
Chapter 6: General discussion and future direction 
194 
  
to HLA-DR and VLA integrins. Eur. J. Immunol. 26, 2657–2665. 
Rubinstein, E., Ziyyat, A., Wolf, J.P., Le Naour, F., and Boucheix, C. (2006). The molecular 
players of sperm-egg fusion in mammals. Semin. Cell Dev. Biol. 17, 254–263. 
Russell, D., Oldham, N.J., and Davis, B.G. (2009). Site-selective chemical protein glycosylation 
protects from autolysis and proteolytic degradation. Carbohydr. Res. 344, 1508–1514. 
Sala-Vald s, M.,  rsa,  . , Charrin, S., Rubinstein, E., Hemler, M.E., S nchez-Madrid, F., and 
Yáñez-Mó, M. (2006). EWI-2 and EWI-F link the tetraspanin web to the actin cytoskeleton 
through their direct association with ezrin-radixin-moesin proteins. J. Biol. Chem. 281, 19665–
19675. 
Sanyal, S., and Hawkins, R.K. (1981). Genetic interaction in the retinal degeneration of mice. 
Exp. Eye Res. 33, 213–222. 
Schäfer, T., Starkl, P., Allard, C., Wolf, R.M., and Schweighoffer, T. (2010). A granular variant of 
CD63 is a regulator of repeated human mast cell degranulation. Allergy 65, 1242–1255. 
Scholz, C.-J., Kurzeder, C., Koretz, K., Windisch, J., Kreienberg, R., Sauer, G., and Deissler, H. 
(2009). Tspan-1 is a tetraspanin preferentially expressed by mucinous and endometrioid 
subtypes of human ovarian carcinomas. Cancer Lett. 275, 198–203. 
Schwartz, L.B., Riedel, C., Caulfield, J.P., Wasserman, S.I., and Austen, K.F. (1981). Cell 
association of complexes of chymase, heparin proteoglycan, and protein after degranulation 
by rat mast cells. J. Immunol. 126, 2071–2078. 
Seigneuret, M. (2006). Complete predicted three-dimensional structure of the facilitator 
transmembrane protein and hepatitis C virus receptor CD81: conserved and variable structural 
domains in the tetraspanin superfamily. Biophys. J. 90, 212–227. 
Seigneuret, M., Delaguillaumie,  a, Lagaudrière-Gesbert, C., and Conjeaud, H. (2001). Structure 
of the tetraspanin main extracellular domain. A partially conserved fold with a structurally 
variable domain insertion. J. Biol. Chem. 276, 40055–40064. 
Seldin, D.C., Adelman, S., Austen, K.F., Stevens, R.L., Hein,  a, Caulfield, J.P., and Woodbury, 
R.G. (1985). Homology of the rat basophilic leukemia cell and the rat mucosal mast cell. Proc. 
Natl. Acad. Sci. U. S. A. 82, 3871–3875. 
Sheets, E.D., Holowka, D., and Baird, B. (1999). Critical role for cholesterol in Lyn-mediated 
tyrosine phosphorylation of FcepsilonRI and their association with detergent-resistant 
membranes. J. Cell Biol. 145, 877–887. 
Sheng, K.C., van Spriel, A.B., Gartlan, K.H., Sofi, M., Apostolopoulos, V., Ashman, L., and 
Wright, M.D. (2009). Tetraspanins CD37 and CD151 differentially regulate Ag presentation and 
T-cell co-stimulation by DC. Eur. J. Immunol. 39, 50–55. 
Shih, Y.-P., Kung, W.-M., Chen, J.-C., Yeh, C.-H., Wang, A.H.-J., and Wang, T.-F. (2002). High-
throughput screening of soluble recombinant proteins. Protein Sci. 11, 1714–1719. 
Shoham, T., Rajapaksa, R., Boucheix, C., Rubinstein, E., Poe, J.C., Tedder, T.F., and Levy, S. 
(2003). The tetraspanin CD81 regulates the expression of CD19 during B cell development in a 
postendoplasmic reticulum compartment. J. Immunol. 171, 4062–4072. 
Shoham, T., Rajapaksa, R., Kuo, C., Levy, S., and Haimovich, J. (2006). Building of the 
tetraspanin web: distinct structural domains of CD81 function in different cellular 
compartments. Mol. Cell. Biol. 26, 1373–1385. 
Shokri,  a, Sandén,  a M., and Larsson, G. (2003). Cell and process design for targeting of 
recombinant protein into the culture medium of Escherichia coli. Appl. Microbiol. Biotechnol. 
60, 654–664. 
Sibilano, R., Frossi, B., and Pucillo, C. (2014). Mast cell activation: A complex interplay of 
positive and negative signaling pathways. Eur. J. … 1–27. 
Chapter 6: General discussion and future direction 
195 
  
Siebenhaar, F., Falcone, F.H., Tiligada, E., Hammel, I., Maurer, M., Sagi-Eisenberg, R., and Levi-
Schaffer, F. (2014). The search for Mast Cell and Basophil models - Are we getting closer to 
pathophysiological relevance? Allergy n/a – n/a. 
Simons, F.E.R., and Simons, K.J. (2011). Histamine and H1-antihistamines: Celebrating a 
century of progress. J. Allergy Clin. Immunol. 128, 1139–1150.e4. 
Simons, K., and Ikonen, E. (1997). Functional rafts in cell membranes. Nature 387, 569–572. 
Singethan, K., Müller, N., Schubert, S., Lüttge, D., Krementsov, D.N., Khurana, S.R., Krohne, G., 
Schneider-Schaulies, S., Thali, M., and Schneider-schaulies, J. (2008). CD9 clustering and 
formation of microvilli zippers between contacting cells regulates virus-induced cell fusion. 
Traffic 9, 924–935. 
Skehan, P., Storeng, R., Scudiero, D., Monks,  a, McMahon, J., Vistica, D., Warren, J.T., Bokesch, 
H., Kenney, S., and Boyd, M.R. (1990). New colorimetric cytotoxicity assay for anticancer-drug 
screening. J. Natl. Cancer Inst. 82, 1107–1112. 
Smith, D.A., Monk, P.N., and Partridge, L.J. (1995). Antibodies against human CD63 activate 
transfected rat basophilic leukemia (RBL-2H3) cells. Mol. Immunol. 32, 1339–1344. 
van Spriel, A.B., and Figdor, C.G. (2010). The role of tetraspanins in the pathogenesis of 
infectious diseases. Microbes Infect. 12, 106–112. 
Stelekati, E., Bahri, R., D’Orlando, O., Orinska, Z., Mittrücker, H.W., Langenhaun, R., Glatzel, M., 
Bollinger, A., Paus, R., and Bulfone-Paus, S. (2009). Mast Cell-Mediated Antigen Presentation 
Regulates CD8+ T Cell Effector Functions. Immunity 31, 665–676. 
Stipp, C.S., Kolesnikova, T. V, and Hemler, M.E. (2003). Functional domains in tetraspanin 
proteins. Trends Biochem. Sci. 28, 106–112. 
Südhof, T.C., and Rothman, J.E. (2009). Membrane fusion: grappling with SNARE and SM 
proteins. Science 323, 474–477. 
Supajatura, V., Ushio, H., Nakao,  a, Akira, S., Okumura, K., Ra, C., and Ogawa, H. (2002). 
Differential responses of mast cell Toll-like receptors 2 and 4 in allergy and innate immunity. 
J.Clin.Invest. 109, 1351 – . 
Szöllósi, J., Horejsí, V., Bene, L., Angelisová, P., and Damjanovich, S. (1996). Supramolecular 
complexes of MHC class I, MHC class II, CD20, and tetraspan molecules (CD53, CD81, and 
CD82) at the surface of a B cell line JY. J. Immunol. 157, 2939–2946. 
Tachibana, I., and Hemler, M.E. (1999). Role of Transmembrane 4 Superfamily (TM4SF) 
Proteins CD9 and CD81 in Muscle Cell Fusion and Myotube Maintenance Isao. Cell 146, 893–
904. 
Takahashi, Y., Bigler, D., Ito, Y., and White, J.M. (2001). Sequence-specific interaction between 
the disintegrin domain of mouse ADAM 3 and murine eggs: role of beta1 integrin-associated 
proteins CD9, CD81, and CD98. Mol. Biol. Cell 12, 809–820. 
Takashima, T., Ohnishi, K., Tsuyuguchi, I., and Kishimoto, S. (1993). Differential regulation of 
formation of multinucleated giant cells from concanavalin A-stimulated human blood 
monocytes by IFN-gamma and IL-4. J. Immunol. 150, 3002–3010. 
Takeda, Y., Tachibana, I., Miyado, K., Kobayashi, M., Miyazaki, T., Funakoshi, T., Kimura, H., 
Yamane, H., Saito, Y., Goto, H., et al. (2003). Tetraspanins CD9 and CD81 function to prevent 
the fusion of mononuclear phagocytes. J. Cell Biol. 161, 945–956. 
Takeda, Y., Kazarov, A.R., Butterfield, C.E., Hopkins, B.D., Benjamin, L.E., Kaipainen, A., and 
Hemler, M.E. (2007). Deletion of tetraspanin Cd151 results in decreased pathologic 
angiogenesis in vivo and in vitro. Blood 109, 1524–1532. 
Tejera, E., Rocha-Perugini, V., López-Martín, S., Pérez-Hernández, D., Bachir, A.I., Horwitz, A.R., 
Vázquez, J., Sánchez-Madrid, F., and Yáñez-Mo, M. (2013). CD81 regulates cell migration 
Chapter 6: General discussion and future direction 
196 
  
through its association with Rac GTPase. Mol. Biol. Cell 24, 261–273. 
Terpe, K. (2003). Overview of tag protein fusions: from molecular and biochemical 
fundamentals to commercial systems. Appl. Microbiol. Biotechnol. 60, 523–533. 
Terpe, K. (2006). Overview of bacterial expression systems for heterologous protein 
production: From molecular and biochemical fundamentals to commercial systems. Appl. 
Microbiol. Biotechnol. 72, 211–222. 
Tham, T.N., Gouin, E., Rubinstein, E., Boucheix, C., Cossart, P., and Pizarro-Cerda, J. (2010). 
Tetraspanin CD81 is required for Listeria monocytogenes invasion. Infect. Immun. 78, 204–
209. 
Thomsen, P., Roepstorff, K., and Stahlhut, M. (2002). Caveolae Are Highly Immobile Plasma 
Membrane Microdomains, Which Are not Involved in Constitutive Endocytic Trafficking. Mol. 
Biol. Cell 13, 238–250. 
Todd, S.C., Doctor, V.S., and Levy, S. (1998). Sequences and expression of six new members of 
the tetraspanin/TM4SF family. Biochim. Biophys. Acta 1399, 101–104. 
Toru, H., Eguchi, M., Matsumoto, R., Yanagida, M., Yata, J., and Nakahata, T. (1998). 
Interleukin-4 promotes the development of tryptase and chymase double-positive human 
mast cells accompanied by cell maturation. Blood 91, 187–195. 
Trinchieri, G., and Sher, A. (2007). Cooperation of Toll-like receptor signals in innate immune 
defence. Nat. Rev. Immunol. 7, 179–190. 
Tsai, Y.C., Mendoza, A., Mariano, J.M., Zhou, M., Kostova, Z., Chen, B., Veenstra, T., Hewitt, 
S.M., Helman, L.J., Khanna, C., et al. (2007). The ubiquitin ligase gp78 promotes sarcoma 
metastasis by targeting KAI1 for degradation. Nat. Med. 13, 1504–1509. 
Tsitsikov, E.N., Gutierrez-Ramos, J.C., and Geha, R.S. (1997). Impaired CD19 expression and 
signaling, enhanced antibody response to type II T independent antigen and reduction of B-1 
cells in CD81-deficient mice. Proc. Natl. Acad. Sci. U. S. A. 94, 10844–10849. 
Unternaehrer, J.J., Chow, A., Pypaert, M., Inaba, K., and Mellman, I. (2007). The tetraspanin 
CD9 mediates lateral association of MHC class II molecules on the dendritic cell surface. Proc. 
Natl. Acad. Sci. U. S. A. 104, 234–239. 
Vichai, V., and Kirtikara, K. (2006). Sulforhodamine B colorimetric assay for cytotoxicity 
screening. Nat. Protoc. 1, 1112–1116. 
Wakelin, S.J., Sabroe, I., Gregory, C.D., Poxton, I.R., Forsythe, J.L.R., Garden, O.J., and Howie, 
S.E.M. (2006). “Dirty little secrets”-Endotoxin contamination of recombinant proteins. 
Immunol. Lett. 106, 1–7. 
Wang, H., Min, G., Glockshuber, R., Sun, T.T., and Kong, X.P. (2009). Uropathogenic E. coli 
Adhesin-Induced Host Cell Receptor Conformational Changes: Implications in Transmembrane 
Signaling Transduction. J. Mol. Biol. 392, 352–361. 
Wang, H.W., Tedla, N., Lloyd,  a R., Wakefield, D., and McNeil, P.H. (1998). Mast cell activation 
and migration to lymph nodes during induction of an immune response in mice. J. Clin. Invest. 
102, 1617–1626. 
Wang, H.-X., Kolesnikova, T. V, Denison, C., Gygi, S.P., and Hemler, M.E. (2011). The C-terminal 
tail of tetraspanin protein CD9 contributes to its function and molecular organization. J. Cell 
Sci. 124, 2702–2710. 
Wang, Y., Tong, X., Omoregie, E.S., Liu, W., Meng, S., and Ye, X. (2012). Tetraspanin 6 (TSPAN6) 
negatively regulates retinoic acid-inducible gene I-like receptor-mediated immune signaling in 
a ubiquitination-dependent manner. J. Biol. Chem. 287, 34626–34634. 
Waterhouse, R., Ha, C., and Dveksler, G.S. (2002). Murine CD9 is the receptor for pregnancy-
specific glycoprotein 17. J. Exp. Med. 195, 277–282. 
Chapter 6: General discussion and future direction 
197 
  
Weng, J., Krementsov, D.N., Khurana, S., Roy, N.H., and Thali, M. (2009). Formation of syncytia 
is repressed by tetraspanins in human immunodeficiency virus type 1-producing cells. J. Virol. 
83, 7467–7474. 
Westers, L., Westers, H., and Quax, W.J. (2004). Bacillus subtilis as cell factory for 
pharmaceutical proteins: A biotechnological approach to optimize the host organism. Biochim. 
Biophys. Acta - Mol. Cell Res. 1694, 299–310. 
Whitmore, L., and Wallace, B. a. (2008). Protein secondary structure analyses from circular 
dichroism spectroscopy: Methods and reference databases. Biopolymers 89, 392–400. 
Whitmore, L., and Wallace, B.A. (2004). DICHROWEB, an online server for protein secondary 
structure analyses from circular dichroism spectroscopic data. Nucleic Acids Res. 32, W668–
W673. 
Wildt, S., and Gerngross, T.U. (2005). The humanization of N-glycosylation pathways in yeast. 
Nat. Rev. Microbiol. 3, 119–128. 
Winterwood, N.E., Varzavand, A., Meland, M.N., Ashman, L.K., and Stipp, C.S. (2006). A critical 
role for tetraspanin CD151 in alpha3beta1 and alpha6beta4 integrin-dependent tumor cell 
functions on laminin-5. Mol. Biol. Cell 17, 2707–2721. 
Witherden, D. a, Boismenu, R., and Havran, W.L. (2000). CD81 and CD28 costimulate T cells 
through distinct pathways. J. Immunol. 165, 1902–1909. 
Woodbury, R.G., Miller, H.R., Huntley, J.F., Newlands, G.F., Palliser,  a C., and Wakelin, D. 
(1984). Mucosal mast cells are functionally active during spontaneous expulsion of intestinal 
nematode infections in rat. Nature 312, 450–452. 
Wright, M.D., Henkle, K.J., and Mitchell, G.F. (1990). An immunogenic Mr 23,000 integral 
membrane protein of Schistosoma mansoni worms that closely resembles a human tumor-
associated antigen. J. Immunol. 144, 3195–3200. 
Wright, M.D., Ni, J., and Rudy, G.B. (2000). The L6 membrane proteins--a new four-
transmembrane superfamily. Protein Sci. 9, 1594–1600. 
Wright, M.D., Moseley, G.W., and van Spriel,  a B. (2004). Tetraspanin microdomains in 
immune cell signalling and malignant disease. Tissue Antigens 64, 533–542. 
Wu, X.C., Lee, W., Tran, L., and Wong, S.L. (1991). Engineering a Bacillus subtilis expression-
secretion system with a strain deficient in six extracellular proteases. J. Bacteriol. 173, 4952–
4958. 
Wu, X.R., Medina, J.J., and Sun, T.T. (1995). Selective interactions of UPIa and UPIb, two 
members of the transmembrane 4 superfamily, with distinct single transmembrane-domained 
proteins in differentiated urothelial cells. J. Biol. Chem. 270, 29752–29759. 
Wu, X.R., Sun, T.T., and Medina, J.J. (1996). In vitro binding of type 1-fimbriated Escherichia 
coli to uroplakins Ia and Ib: relation to urinary tract infections. Proc. Natl. Acad. Sci. U. S. A. 93, 
9630–9635. 
Wu, X.-R., Kong, X.-P., Pellicer, A., Kreibich, G., and Sun, T.-T. (2009). Uroplakins in urothelial 
biology, function, and disease. Kidney Int. 75, 1153–1165. 
Wurm, F.M. (2004). Production of recombinant protein therapeutics in cultivated mammalian 
cells. Nat. Biotechnol. 22, 1393–1398. 
Xie, B., Zhou, G., Chan, S.Y., Shapiro, E., Kong, X.P., Wu, X.R., Sun, T.T., and Costello, C.E. 
(2006). Distinct glycan structures of uroplakins Ia and Ib: Structural basis for the selective 
binding of FimH adhesin to uroplakin Ia. J. Biol. Chem. 281, 14644–14653. 
Yadav, S., Shi, Y., and Wang, H. (2010). IL-16 effects on A549 lung epithelial cells: dependence 
on CD9 as an IL-16 receptor? J. Immunotoxicol. 7, 183–193. 
Yanez-Mó, M., Barreiro, O., Gonzalo, P., Batista, A., Megías, D., Genís, L., Sachs, N., Sala-Valdés, 
Chapter 6: General discussion and future direction 
198 
  
M., Alonso, M. a., Montoya, M.C., et al. (2008). MT1-MMP collagenolytic activity is regulated 
through association with tetraspanin CD151 in primary endothelial cells. Blood 112, 3217–
3226. 
Yáñez-Mó, M., Barreiro, O., Gordon-Alonso, M., Sala-Valdés, M., and Sánchez-Madrid, F. 
(2009). Tetraspanin-enriched microdomains: a functional unit in cell plasma membranes. 
Trends Cell Biol. 19, 434–446. 
Yang, H., Xiao, X., Li, S., Mai, G., and Zhang, Q. (2011). Novel TSPAN12 mutations in patients 
with familial exudative vitreoretinopathy and their associated phenotypes. Mol. Vis. 17, 1128–
1135. 
Yang, X., Claas, C., Kraeft, S.-K., Chen, L.B., Wang, Z., Kreidberg, J.A., and Hemler, M.E. (2002). 
Palmitoylation of tetraspanin proteins: modulation of CD151 lateral interactions, subcellular 
distribution, and integrin-dependent cell morphology. Mol. Biol. Cell 13, 767–781. 
Yang, X., Kovalenko, O. V, Tang, W., Claas, C., Stipp, C.S., and Hemler, M.E. (2004). 
Palmitoylation supports assembly and function of integrin-tetraspanin complexes. J. Cell Biol. 
167, 1231–1240. 
Yang, X.H., Richardson, A.L., Torres-Arzayus, M.I., Zhou, P., Sharma, C., Kazarov, A.R., Andzelm, 
M.M., Strominger, J.L., Brown, M., and Hemler, M.E. (2008). CD151 accelerates breast cancer 
by regulating α6 integrin function, signaling, and molecular organization. Cancer Res. 68, 
3204–3213. 
Yauch, R.L., Berditchevski, F., Harler, M.B., Reichner, J., and Hemler, M.E. (1998). Highly 
stoichiometric, stable, and specific association of integrin alpha3beta1 with CD151 provides a 
major link to phosphatidylinositol 4-kinase, and may regulate cell migration. Mol. Biol. Cell 9, 
2751–2765. 
Yaucht, R.L., Kazarov, A.R., Desai, B., Lee, R.T., and Hemler, M.E. (2000). Direct extracellular 
contact between integrin α3β1 and TM4SF protein CD151. J. Biol. Chem. 275, 9230–9238. 
Yoshida, T., Kawano, Y., Sato, K., Ando, Y., Aoki, J., Miura, Y., Komano, J., Tanaka, Y., and 
Koyanagi, Y. (2008). A CD63 mutant inhibits T-cell tropic human immunodeficiency virus type 1 
entry by disrupting CXCR4 trafficking to the plasma membrane. Traffic 9, 540–558. 
Young, R.J., Owens, R.J., Mackay, G. a, Chan, C.M., Shi, J., Hide, M., Francis, D.M., Henry,  a J., 
Sutton, B.J., and Gould, H.J. (1995). Secretion of recombinant human IgE-Fc by mammalian 
cells and biological activity of glycosylation site mutants. Protein Eng. 8, 193–199. 
Young, R.M., Holowka, D., and Baird, B. (2003). A lipid raft environment enhances Lyn kinase 
activity by protecting the active site tyrosine from dephosphorylation. J. Biol. Chem. 278, 
20746–20752. 
Zahn-Zabal, M., Kobr, M., Girod, P. a, Imhof, M., Chatellard, P., de Jesus, M., Wurm, F., and 
Mermod, N. (2001). Development of stable cell lines for production or regulated expression 
using matrix attachment regions. J. Biotechnol. 87, 29–42. 
Van Zelm, M.C., Smet, J., Adams, B., Mascart, F., Schandené, L., Janssen, F., Ferster, A., Kuo, 
C.C., Levy, S., Van Dongen, J.J.M., et al. (2010). CD81 gene defect in humans disrupts CD19 
complex formation and leads to antibody deficiency. J. Clin. Invest. 120, 1265–1274. 
Zemni, R., Bienvenu, T., Vinet, M.C., Sefiani,  a, Carrié,  a, Billuart, P., McDonell, N., Couvert, P., 
Francis, F., Chafey, P., et al. (2000). A new gene involved in X-linked mental retardation 
identified by analysis of an X;2 balanced translocation. Nat. Genet. 24, 167–170. 
Zhang, X. a, Kazarov, A.R., Yang, X., Bontrager, A.L., Stipp, C.S., and Hemler, M.E. (2002). 
Function of the tetraspanin CD151-alpha6beta1 integrin complex during cellular 
morphogenesis. Mol. Biol. Cell 13, 1–11. 
Zhou, G., Mo, W.J., Sebbel, P., Min, G., Neubert, T. a, Glockshuber, R., Wu, X.R., Sun, T.T., and 
Kong, X.P. (2001). Uroplakin Ia is the urothelial receptor for uropathogenic Escherichia coli: 
Chapter 6: General discussion and future direction 
199 
  
evidence from in vitro FimH binding. J. Cell Sci. 114, 4095–4103. 
Zhu, G.-Z., Miller, B.J., Boucheix, C., Rubinstein, E., Liu, C.C., Hynes, R.O., Myles, D.G., and 
Primakoff, P. (2002). Residues SFQ (173-175) in the large extracellular loop of CD9 are required 
for gamete fusion. Development 129, 1995–2002. 
Zhu, Y.Z., Luo, Y., Cao, M.M., Liu, Y., Liu, X.Q., Wang, W., Wu, D.G., Guan, M., Xu, Q.Q., Ren, H., 
et al. (2012). Significance of palmitoylation of CD81 on its association with tetraspanin-
enriched microdomains and mediating hepatitis C virus cell entry. Virology 429, 112–123. 
Zöller, M. (2009). Tetraspanins: push and pull in suppressing and promoting metastasis. Nat. 
Rev. Cancer 9, 40–55. 
Chapter 6: General discussion and future direction 
200 
  
Appendix 
 
Figure 7.1: Vector maps, Created in Snapgene 
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Primer Name Sequence Used in 
Hamster actin forward 5’ CCTCTATGCCAACACAGTGC 3’ CHO RT-PCR control 
Hamster actin reverse 5’ CCTGCTTGCTGATCCACATC 3’ CHO RT-PCR control 
Human actin forward 5’ TGACAGGATCGAGAAGGAGA 3’ HEK-293 RT-PCR control 
Human actin reverse 5’ CGCTCAGGAGGAGCAATG 3’ HEK-293 RT-PCR control 
Leader sequence forward 5’ TTGCGCGCTAGCCACCATGGAGACAGACACAC 3’ Flp-in cloning 
Leader sequence reverse 9 5’ CATCCTTGTGGTCACCAGTGGAACCTGGA 3’ Flp-in cloning 
Leader sequence reverse 151 5’ GCTGGTAGTAGTCACCAGTGGAACCTGGA 3’ Flp-in cloning 
Leader sequence reverseTspan5 5’ AGTCTTTGAAGTCACCAGTGGAACCTGGA 3’ Flp-in cloning 
CD9 forward 5’ CACTGGTGACCACAAGGATGAGGTGATTAAG 3’ Flp-in cloning 
CD9 reverse AgeI (CD9R1) 5’ TTGCGCACCGGTTTTATTGTCGAAGACCTCTTTG 3’ Flp-in cloning 
CD9 Reverse HindIII (CD9R2) 5’ TTGCGCAAGCTTCTATTTATTGTCGAAGACCTCTTTG 3’ Flp-in cloning 
CD151 Forward 5’ CACTGGTGACTACTACCAGCAGCTGAACAC 3’ Flp-in cloning 
CD151 reverse AgeI (CD151R1) 5’ TTGCGCACCGGTGTGCTCCTGGATGAAGGTC 3’ Flp-in cloning 
CD151 reverse HindIII (CD151R2) 5’ TTGCGCAAGCTTCTAGTGCTCCTGGATGAAGGTC 3’ Flp-in cloning 
Tspan5 Forward 5’ CACTGGTGACTTCAAAGACTGGATCAAAGACC 3’ Flp-in cloning 
Tspan5 Reverse AgeI (Tspan5R1) 5’ TTGCGCACCGGTATTGTCCTGCAACCACTTCTC 3’ Flp-in cloning 
Tspan5 Reverse HindIII (Tspan5R2) 5’ TTGCGCAAGCTTCTAATTGTCCTGCAACCACTTCTC 3’ Flp-in cloning 
CD9 Forward 5’ GCGCGCGATATCCACAAGGATGAGGTGATTAAG 3’ pCINEO cloning 
CD9 reverse 5’ GGGCCCTCTAGATCATTTATTGTCGAAGACCTCTTTG 3’ pCINEO cloning 
CD151 Forward 5’ GGGCCCGATATCTACTACCAGCAGCTGAACAC 3’ pCINEO cloning 
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CD151 Reverse 5’ GCGCGCTCTAGATCAGTGCTCCTGGATGAAGGTCTC 3’ pCINEO cloning 
CD9 EC2 forward 5’ GGATCCCACAAGGATGAGGTGATTAAG 3’ Insect expression 
CD9 EC2 forward HIS tag 5’ GGATCCCACCACCACCACCACCACCACAAGGATGAGGTGATTAAG 3’ Insect expression 
CD9 EC2 reverse 5’ GCGGCCGCTTTATTGTCGAAGACCTCTTTG 3’ Insect expression 
CD9 EC2 reverse His tag 5’ GCGGCCGCCACCACCACCACCACCACTTTATTGTCGAAGACCTCTTTG 3’ Insect expression 
CD9 full length forward 5’ GGATCCATGCCGGTCAAAGGAG 3’ Insect expression 
CD9 full length forward HIS tag 5’ GGATCCCACCACCACCACCACCACATGCCGGTCAAAGGAG 3’ Insect expression 
CD9 full length reverse 5’ GCGGCCGCCTAGACCATCTCGCGG 3’ Insect expression 
CD9 full length reverse His tag 5’ GCGGCCGCCACCACCACCACCACCACCTAGACCATCTCGCGG 3’ Insect expression 
Tspan5 EC2 forward 5’ GGATCCTTCAAAGACTGGATCAAAGAC 3’ Insect expression 
Tspan5 EC2 forward HIS tag 5’ GGATCCCACCACCACCACCACCACTTCAAAGACTGGATCAAAGAC 3’ Insect expression 
Tspan5 EC2 reverse 5’ GCGGCCGCATTGTCCTGCAACCACTTC 3’ Insect expression 
Tspan5 EC2 reverse His tag 5’ GCGGCCGCCACCACCACCACCACCACATTGTCCTGCAACCAC 3’ Insect expression 
Tspan5 full length forward 5’ GGATCCATGTCCGGGAAGC 3’ Insect expression 
Tspan5 full length forward HIS tag 5’ GGATCCCACCACCACCACCACCACATGTCCGGGAAGCAC 3’ Insect expression 
Tspan5 full length reverse 5’ GCGGCCGCCTACCAGCTCGCCCTG 3’ Insect expression 
Tspan5 full length reverse His tag 5’ GCGGCCGCCACCACCACCACCACCACCTACCAGCTCGCCCTG 3’ Insect expression 
Rat CD63 Forward 5’ ATTATTGAATTCTATTTAGAGACCAGGTGAAGTC 3’ Bacteria expression of Rat CD63 
Rat CD63 Reverse 5’ ATTATTAAGCTTTCAGTTCTTCCTCAGCCATGC 3’ Bacteria expression of Rat CD63 
CMV forward primer 5’ CGCAAATGGGCGGTAGGCGTG 3’ Sequencing primer 
BGH reverse primer 5’ TAGAAGGCACAGTCGAGG 3’ Sequencing primer 
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pGEX forward sequencing primer 5’ GAGCTGTTGACAATTAATCATCGG 3’ Sequencing primer 
pGEX reverse sequencing primer 5’ CCGGGAGCTGCATGTGTCAGAGG 3’ Sequencing primer 
 
Table 7.1: Primer sequences and there application  
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Figure 7.2 Rat and human EC2 alignment. Sequences aligned with ClustalW and highlighted using BoxShade. 
CD9 
 
Human    1 HKDEVIKEVQEFYKDTYNKLKTKDEPQRETLKAIHYALNCCGLAGGVEQFISDICPKKDVLETFTVKSCPDAIKEVFDNK 80 
Rat      1 HKDEVIKELQEFYKDTYQKLRNKDEPQRETLKAIHMALNCCGIAGGVEQFISDICPKKQVLESFQVKSCPDAIDEVFHSK 80 
85% identity 
 
 
CD63 
 
Human    1 FRDKVMSEFNNNFRQQMENYPKNNHTASILDRMQADFKCCGAANYTDWEKIPSMSKNRVPDSCCINVTVGCGINFNEKAIHKEGCVEKIGGWLRKN 96 
Rat      1 FRDQVKSEFSKSFQKQMQNYLTDNKTATILDKLQKENKCCGASNYTDWERIPGMAKDRVPDSCCINITVGCGNDFKESTIHTQGCVETIAAWLRKN 96 
 
 
64.6% identity 
 
CD81 
 
Human    1 NKDQIAKDVKQFYDQALQQAVVDDDANNAKAVVKTFHETLDCCGSSTLTALTTSVLKNNLCPSGSNIISNLFKEDCHQKIDDLFSGKLY 89 
Rat      1 NKDQIAKDVKQFYDQALQQAVMDDDANNAKAVVKTFHETLNCCGSNTLTTLTTAVLRNSLCPSSSNSFTQLLKEDCHQKIDELFSGKLY 89 
 
 
84.3% identity 
 
CD151 
 
Human    1 
YYQQLNTELKENLKDTMTKRYHQPGHEAVTSAVDQLQQEFHCCGSNNSQDWRDSEWIRSQEAGGRVVPDSCCKTVVALCGQRDHASNIYKVEGGCITKLETFIQEH 106 
Rat      1 
YYQQLNTELKENLKDTMIKRYHQSGHEGVTNAVDKLQQEFHCCGSNNSRDWRDSEWIRSGEADSRVVPDSCCKTVVTGCGKREHASNIYKVEGGCITKLESFIQEH 106 
 
86.8% identity 
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Figure 7.3: Mouse and human EC2 alignment. Sequences aligned with ClustalW and highlighted using BoxShade 
CD9 
Human    1 HKDEVIKEVQEFYKDTYNKLKTKDEPQRETLKAIHYALNCCGLAGGVEQFISDICPKKDVLETFTVKSCPDAIKEVFDNK 80 
mouse    1 HKDEVIKELQEFYKDTYQKLRSKDEPQRETLKAIHMALDCCGIAGPLEQFISDTCPKKQLLESFQVKPCPEAISEVFNNK 80 
77.5% identity 
CD63 
Human    1 FRDKVMSEFNNNFRQQMENYPKNNHTASILDRMQADFKCCGAANYTDWEKIPSMSKNRVP DSCCINVTVGCGINFNEKAIHKEGCVEKIGGWLRKN 96 
Mouse    1 FRDQVKSEFNKSFQQQMQNYLKDNKTATILDKLQKENNCCGASNYTDWENIPGMAKDRVP DSCCINITVGCGNDFKESTIHTQGCVETIAIWLRKN 96 
66.8% identity 
CD81 
Human    1 NKDQIAKDVKQFYDQALQQAVVDDDANNAKAVVKTFHETLDCCGSSTLTALTTSVLKNNLCPSGSNIISNLFKEDCHQKIDDLFSGKLY 
Mouse    1 NKDQIAKDVKQFYDQALQQAVMDDDANNAKAVVKTFHETLNCCGSNALTTLTTTILRNSLCPSGGNILTPLLQQDCHQKIDELFSGKLY 
80.9% identity 
CD151 
human    1 
YYQQLNTELKENLKDTMTKRYHQPGHEAVTSAVDQLQQEFHCCGSNNSQDWRDSEWIRSQEAGGRVVPDSCCKTVVALCGQRDHASNIYKVEGGCITKLETFIQEH 
mouse    1 
YYQQLNTELKENLKDTMVKRYHQSGHEGVSSAVDKLQQEFHCCGSNNSQDWQDSEWIRSGEADSRVVPDSCCKTMVAGCGKRDHASNIYKVEGGCITKLETFIQEH 
88.7% identity
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Figre 7.4 Sequence and region of CD9 EC2 peptides. Three letter amino acid sequences of the 
relevant CD9 peptides are displayed in the table whilst their positions are depicted in the 
schematic tetraspanin representation.  
 
 
 
 
 
 
 
 
  
  
Peptide name Peptide sequence 
8001:                     Ser Lys His Asp Glu Val Ile Lys Glu Val Gln Glu Phe Tyr  
8001 Scrambled: Glu Glu Val Lys Lys Phe Glu Ser Gln His Asp Ile Tyr Val 
8003:                   Gly Leu Ala Gly Gly Val Glu Gln Phe Ile Ser Asp Ile Ser 
8003 Scrambled: Ile Asp Ser Gly Phe Val Gly Gln Ile Ala Ser Gly Leu Glu 
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Figure 7.5 Example isotype gating used for checking tetraspanin expression on RBL-2H3 cells. For 
each anti-tetraspanin antibody gates were established based on the relevant isotype control 
antibody, MFI reading are also shown in figure 4.1 
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Figure 7.6 Scatter graphs showing percentage positive of IgE primed and Non-IgE primed RBL-2H3 
cells probed with an anti-IgE antibody. For each anti-tetraspanin antibody gates were established 
based on the relevant isotype control antibody, MFI reading are also shown in figure 4.1 
 
